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Direct allylic C––H functionalization of terminal olefin represents an orthogonal approach 
to traditional methods to build C––O, C––N and C—C bond due to less oxidation state 
manipulation and synthetic overhead. In particular, site, chemo- and stereoselective methods for 
Pd(II)-catalyzed allylic C––H amination exists. However, all these reactions proceed via near 
ligandless conditions (e.g. reversibly coordinating sulfoxide ligands) and require benzoquinone 
oxidant to coordinate to Pd metal to promote the functionalization step (known as “serial ligand 
catalysis). This mechanism with sulfoxide ligands renders catalyst deactivation and the ability to 
tune the functionalization step limited. This work describes the development of racemic sulfoxide-
oxazoline (SOX) ligands for Pd(II) catalyzed allylic C––H amination. By combining sulfoxide 
moiety, known for promoting heterolytic allylic C—H cleavage and oxazoline moiety, a stronger 
coordinating element that can keep the ligand associating with the Pd metal, we create a highly 
modular, oxidative stable ligand platform that is capable to support both Pd(II) and Pd(0) processes 
in allylic C––H amination.  
The first chapter of this dissertation describes the development of a general strategy for C–
–H to C––N coupling of sulfonamides with olefins via Pd(II)/ (±)-MeO-SOX catalysis. Due to the 
ubiquity of C—N bonds in natural products and pharmaceuticals, the cross-coupling of amines 
with hydrocarbons under fragment coupling conditions (1 equivalent) stands to significantly 
impacted chemical synthesis. Herein, we disclose a C(sp3)—N fragment coupling reaction between 
abundant terminal olefins and N-triflyl protected aliphatic and aromatic amines via Pd(II)/(±)-
MeO-SOX catalyzed intermolecular allylic C––H amination. A range of (56) allylic amines are 
furnished in good yields (avg. 76%) and excellent regio- and stereoselectivity (avg. >20:1 
linear:branched, >20:1 E:Z). For the first time, a variety of singly activated aromatic and aliphatic 
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nitrogen nucleophiles, including ones with stereochemical elements, can be used in fragment 
coupling stoichiometries for intermolecular C––H amination reactions. Mechanistic studies reveal 
that the SOX ligand framework is effective in promoting functionalization by supporting cationic 
p-allyl Pd intermediates. 
The second chapter of this dissertation describes the development of a Pd(II)/(±)-MeO-
SOX/2,5-dimethylbenzoquinone condition for intramolecular C––H amination that enables 
unprecedented access to anti-1,3 amino alcohols in good yields (33 substrates, avg. 66%) and high 
selectivities (avg. 10:1 dr).  Switching ligand to (±)-CF3-SOX using a less bulky quinone oxidant 
(BQ), the kinetic syn- 1,3 amino alcohol motif can be accessed in comparable yields and 
selectivities. Advantages of stereodivergent nature of this allylic C––H amination method are 
showcased in the synthesis of anti- and syn- 1,3-amino alcohol Vitamin D3 analogue intermediates 
in half the steps and higher overall yield of previous route. Moreover, all eight possible 
stereoisomers of a medicinally important chiral diamino alcohol core are generated from two chiral 
pool amino acids. Mechanistic studies revealed that the anti-oxazinanone is furnished through C—
H amination that furnishes the syn-isomer followed by Pd(0)-isomerization process promoted by 
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Complex, aliphatic amines are prominent structural elements in biologically active small 
molecules.1-3 In drug development, nearly half of all heteroatom derivatizations involve the 
formation of C(sp3)—N bonds.4 While robust and reliable, these reactions often proceed via 
coupling of amines and pre-functionalized compounds (e.g. N-alkylation, reductive amination and 
N-acylation-reduction) and necessitate unproductive synthetic steps to install and maintain those 
functionalities.4,5 An alternative approach requiring less synthetic overhead that may tolerate 
orthogonal functionality is coupling amines directly to hydrocarbons. Recent advances in 
hydroamination of a-olefins and symmetric internal olefins to furnish aliphatic amines underscore 
the advantages of such methods.6-13  Direct allylic C—H amination of a-olefins would provide an 
orthogonal approach that furnishes allylic amines where the olefin and functionalities prone to 
reduction are tolerated and may be further elaborated (vide infra). 
Impressive methods for allylic C—H aminations exist, however generally require doubly 
activated nitrogen sources (e.g. N-tosyl carbamates)14-25 or alkyl azides with limited scope26 that 
are not amenable to fragment coupling methods between complex terminal olefins and complex 
aliphatic amines.  For example, site, chemo- and E-selective Pd(II)-catalyzed reactions for 
intermolecular allylic C—H aminations of a-olefins all require use of N-tosyl carbamate 
nucleophiles (Figure 1).14-18,21-22,24 These reactions proceed via near ligandless conditions (e.g. 
reversibly coordinating sulfoxide ligands) that may lead to catalyst deactivation and do not 
                                               
a This chapter and the figures are adapted from “Ma, R.; White, M. C. J. Am. Chem. Soc. 2018, 




promote functionalization with nucleophiles less activated towards deprotonation. Mixed 
sulfoxide-oxazoline ligands (SOX),27,28 were recently reported for asymmetric allylic C—H 
oxidations to form enantioenriched isochromans via Pd(II)-catalysis.28 The uniformly high levels 
of asymmetric induction (>90% ee) observed with these ligands supports the hypothesis that they 
do not dissociate from the Pd metal during catalysis and thereby may be effective with more 
complex, alkyl amine nucleophiles.28 Herein we report the discovery of a novel (±)-MeO-SOX 
ligand (L-5) that works with Pd(II) acetate to promote the first allylic C—H amination fragment 
coupling method. This method enables complex terminal olefins (1.0 equiv.) to be coupled to 
bench-stable, easy-to-synthesize complex N-triflyl protected primary aliphatic amines29 (1.0 
equiv.) to afford allylic amines in good yields (56 examples, avg. 75%) and excellent regio- and 
stereoselectivity (>20:1 linear:branched, > 15:1 E:Z). 









































a, Previous methods all require use of doubly activated nitrogen sources (N-tosyl carbamate and etc.) and 
require additional steps to achieve complex difunctionalized amine products. b, Novel Pd(II)/SOX catalyst 
promotes C—H amination fragment coupling with complex N-triflyl protected amines. c, Cross-coupling of 












1.2 Results and Discussion 
1.2.1 Reaction Development 
We initiated our investigation by examining the reactivity of a prototypical aliphatic amine 
nucleophile that bears one strongly electron withdrawing group, N-triflyl phenethylamine, with 
allyl cyclohexane under previously reported allylic C—H amination conditions15,30(Table 1, entry 
1). Using the singly activated aliphatic amine nucleophile, we observed trace reactivity with the 
Pd(II)/bis-sulfoxide catalytic system in the presence of additives reported to activate the p-allyl Pd 
electrophile [Cr(salen)/BQ] and the nucleophile (DIPEA) towards functionalization. However, 
under the reported Pd(II)/SOX-catalyzed asymmetric allylic C—H oxidation conditions, using a 
simple racemic (±)-SOX ligand (L-1) we were delighted to observe that the reaction proceeds in 
30% yield with outstanding regio- and stereoselectivity to form the sterically preferred linear 
product (entry 2, >20:1 linear : branched, >20:1  E:Z). Evaluation of readily available quinone 
oxidants indicated alkyl substitution was beneficial: benzoquinone (BQ) diminished the reactivity 
(entry 3), whereas 2,5-dimethylbenzoquinone (2,5-DMBQ) boosted reactivity furnishing product 
in 52% isolated yield (entry 4).  The highly modular nature of the SOX ligand framework enables 
rapid evaluation of electronic and steric modifications.28 We found exchanging the dimethyl 
groups on the oxazoline for diphenyls lowered the yield to 21% (entry 5). Whereas electronic 
modifications on the aryl backbone para to the oxazoline did not significantly positively impact 
the yield (entry 6, 7), electron donating methoxy substituents para to the sulfoxide on both the 
ligand backbone and the aryl sulfoxide moiety resulted in substantial improvements in yield (entry 
8, 9). No synergy was observed by combining these electron donating modifications (entry 10, 11). 
A catalyst comprised of (±)-MeO-SOX ligand (L-5)/Pd(OAc)2 was therefore selected for further 
study. Lowering the (±)-MeO-SOX ligand (L-5)/Pd(OAc)2 catalyst loading to 5% maintained a 
prepartively useful yield (entry 12). Omission of (±)-MeO-SOX ligand (L-5) gave no detectable 
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product (entry 13). Significantly, the reaction can be run for 48 h (entry 14) and in many cases for 
24 h (entry 15; vide infra) without significant diminution in yield. The reaction temperature can 
also be increased to 55 °C and in some cases provides good yields and selectivities with shorter 
reaction times (24 hrs, entry 16).  
Table 1. Reaction Development 
 
1.2.2 Reaction Scope 
            Having established reaction conditions, we first explored the substrate scope with respect 
to the amine component (Table 2a). Biologically relevant aniline and benzyl amines3 could be 
introduced with good yields and excellent regio- and stereoselectivities (Table 2a, 2-4). More basic 
entry Ligand Quinone % YieldPd(II)
1a bis-sulfoxide BQPd(OAc)2 <5

















L-8 2,5 DMBQ 74Pd(OAc)2
12 L-5 (5%) 2,5 DMBQ 53Pd(OAc)2 (5%)




















9 63L-6 2,5 DMBQPd(OAc)2
2,5 DMBQ
15 L-5 2,5 DMBQ 54Pd(OAc)2

















16c L-5 2,5 DMBQ 65Pd(OAc)2 24
Isolated yields are average of two runs. a Conditions: 0.2 mmol (1.0 equiv.) olefin, 0.2 
mmol amine nucleophile, 10 mol% Pd(OAc)2/bis-sulfoxide, 2.0 equiv. BQ, 6% 










L-1:  R1 = H,      R2 = H,  
L-2:  R1 = H,      R2 = H,
L-3:  R1 = H,      R2 = CF3, 
L-4:  R1 = H,      R2 = OMe,
L-5:  R1 = OMe, R2 = H,
L-6:  R1 = H,      R2 = H,
L-7:  R1 = OMe, R2 = OMe,

























aliphatic amines including methylamine and butylamine are also well tolerated in the reaction (5, 
6). The ability of this reaction to tolerate functionality on the amine nucleophile is notable. Amines 
containing dense functionality all afforded linear aminated product in prepartively useful yields: 
ethylene diamine (7), aminoethanol (8), bromoethanamine (9) and trifluoroethanamine (10). 
Significantly, amino acid derived nucleophiles with a-stereocenters underwent efficient 
intermolecular allylic C—H amination with no epimerization (11-13).  
Table 2. Substrate Scope 
 
We next explored the scope with respect to the olefin component (Table 2b). Olefins with 
remote electrophilic functionality such esters, amides, and ketones and even a terminal epoxide 






2,5 DMBQ (1.1 equiv.)
toluene (1.0 M)




























































































a. Sulfonamide (N-triflyl protected amine) scope
b. Fragment coupling between diverse olefins and sulfonamides
(±)-MeO-SOX (L5)
H


























(-)-24, 62%,  >20:1 dr
(L)-phenyl alanine
(+)-25, 60%, >20:1 dr
(D)-phenyl alanine
(-)-26, 75% (67%a), >20:1 dr
(L)-phenyl alanine





22, R = H, 54%c
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conditions of this intermolecular allylic C—H amination reaction (Table 2b, 14-17). Di- and 
trisubstituted internal olefins can be accommodated with the allylic C—H amination that is 
completely chemoselective for terminal olefins (18, 19). A dibenz[b,f]azepine derived substrate 
(20) as well as sugar derivative (21) were tolerated in allylic C—H amination with good yields 
and selectivities. For electrophilic functionality that cannot be maintained under the reductive 
conditions required for N-triflyl deprotection, N-nosyl alkyl amine nucleophiles may be used with 
only a slight dimishment in yield and deprotected under mildly conditions (PhSH) (22). Methyl 
and silyl ether-containing stereocenters found in the homoallylic position of the olefin substrates 
did not undergo any epimerization upon allylic C—H amination (23-27). The ability to pre-install 
stereogenic centers in both the olefin and amine components and couple them via a C—N bond 
forming reaction that retains the stereochemistry of each component enables rapid generation of 
optically enriched allylic amine products as all possible diastereomers. For example, stereodefined 
homoallylically substituted a-olefins can be coupled to either (L)- or (D)-phenyl alanine 
derivatives to generate different diastereomers (24-27).  
1.2.3 Late-Stage Diversification of Natural Products 
           The significance of carbon-heteroatom (C—X) linkages in joining modular building blocks 
in a streamlined manner is a well recognized concept inspired by nature’s assembly of critical 
biopolymers (nucleic acids, proteins, polysaccharides).31 Late-stage oxidation is emerging as a 
powerful strategy for streamlining synthesis32-33 and/or rapidly diversify complex, bioactive 
molecules34-39. However, current C—H functionalization methods are generally limited to adding 
heteroatom functionality that must be further manipulated to achieve fragment coupling at the 
newly forged C—X bond. For example, in previous Pd(II)-catalyzed allylic C—H amination 
reactions, the N-tosyl carbamate must be sequentially deprotected to reveal the nitrogen 
functionality capable of being connected via alkylation to a larger fragment15,21,30.  Using this 
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allylic C—H amination method, allylated natural product derivatives can be coupled via C—N 
bonds with complex sulfonamides to generate both functional and structural diversity via late stage 
C—H amination (Figure 2).  
Figure 2. Late-stage diversification of natural products via C—H to C—N cross-coupling. 
 
A range of readily available, bioactive phenolic natural products were allylated and 
subsequently evaluated for allylic C—H amination under fragment coupling conditions (1.0 equiv. 



























78%  (>20:1 E:Z) c
(+)-35
gramine-tocopherol conjugate
71%  (>20:1 E:Z) c
(+)-33
α-methyl benzylamine-tocopherol conjugate 







 88%  (>20:1 E:Z) a
(-)-29
dextramethorphan derivative






a. Natural product derivatives coupling with N-triflyl and N-nosyl protected benzyl amine




















(+)-31a 77% yield (over 2 steps) (+)-31b 44% yield (over 3 steps)
(+)-36
leelamine-tocopherol conjugate























(+)-31, R = Tf,         75%  (>20:1 E:Z) c 
(+)-32, R = Ns c, d          
            R = H          52%  (>20:1 E:Z) e
a 5 mol % Pd(OAc)2    5 mol% (±)-MeO-SOX L-5;  b  in situ protonation with 1.0 equiv. CHCl2COOH, 10 mol % Pd(OAc)2 10 mol% (±)-MeO-SOX L-5; c 10 mol % 
Pd(OAc)2 10 mol% (±)-MeO-SOX L-5; d 66% (Crude NMR) ;e Yield over two steps. Step 1: using N-Nosyl benzyl amine (1.0 equiv.), 10 mol % Pd(OAc)2 10 mol% 




Tocopherol, a member of vitamin E antioxidant family containing a chiral chroman core structure, 
was coupled to N-triflyl benzylamine in good yield using only 5 mol% catalyst (28). Basic tertiary 
amine functionality, prevalent in many alkaloid natural products and pharmaceuticals, is well-
tolerated under the allylic C—H amination coupling conditions upon in situ protonation with a 
dichloroacetic additive (1.0 equiv.). 40-42 
           For example allylated dextromethorphan derivative was effectively coupled to benzylamine 
to afford the allylic amine compound in excellent yields and selectivities (92% yield; >20:1 E:Z) 
(29). In the absence of the acid additive, diminished yields of the coupled product were observed 
(30 %), possibly because of the basic amine’s capacity to bind strongly to and inactivate the 
electrophilic (±)-MeO-SOX (L-5)/Pd(OAc)2 catalyst. Allylated derivatives of the steroid 
hormones ethinyl estradiol and estrone could be coupled to N-triflyl benzylamine in excellent to 
good yields (Figure 2a, 30-32). It is notable that an unprotected tertiary alcohol, internal alkyne, 
and ketone were tolerated in this C—H to C—N cross-coupling. Whereas carbonyl functionality 
cannot be maintained under the reductive conditions required for N-triflyl deprotection, an 
analogous N-nosyl protected amine can be used and readily deprotected to afford the aminated 
estrone derivative 32. Alternatively, this method enables such electrophilic functionality to be 
present during amination and then directly elaborated prior to amine deprotection. For example, 
the C17 ketone of N-triflyl aminated estrone 31 can be directly diversified to a medicinally relevant 
homoallylic alcohol43 and vinyl pyridine (abiraterone) followed by chemoselective deprotection 
to afford N-benzyl cinnamylamine analogues 31a and 31b in 77% yield and 44% overall yield 
(Figure 2b). This C—N coupling method’s ability to tolerate electrophilic functionality amenable 
to direct derivatization prior to amine deprotection contrasts reductive amination methods that 
generally require protection/deprotection sequences of such electrophilic functionality and 
possibly of the amine prior to derivatizations. 
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Given the broad scope of allylated natural product scaffolds demonstrated to undergo 
successful allylic C—H/C—N cross-coupling above, we next evaluated the effectiveness of this 
reaction to couple d-tocopherol with a variety of more complex amines (Figure 2c). N-triflyl 
protected amino acid, chiral a-methyl benzyl amine, and gramine indole alkaloid were all coupled 
to allylated d-tocopherol to furnish amine-tocopherol hybrids in good yields with high regio- and 
stereoselectivities (Figure 2b, 33-35). Even dehydroabietylamine (leelamine), a complex 
diterpenic amine being evaluated for chemotherapeutic activity,44 could be effectively coupled to 
allylated d-tocopherol under fragment coupling conditions (36). It is significant to note that in all 
of these examples, only one equivalent of both the olefin and amine are used, underscoring the 
capacity for this allylic C—H amination reaction to serve as an effective C—N coupling method 
for complex building blocks. Additionally, in many cases the reactions were run for only 24 h (28-
31). 
1.2.4 Streamlined Synthesis 
A strength of this hydrocarbon amination method is the ability to cross-couple complex 
sulfonamides with complex olefin fragments while generating stereochemically defined E-olefin 
functionality. We examined the ability of these features to enable rapid generation of important 
allylic amine core structures as well as streamlined syntheses via the rapid build-up of molecular 
complexity (Figure 3).  
            Abamines, small molecule inhibitors of the plant hormone abscisic acid biosynthetic 
pathway,45 comprise a biologically important N-benzyl cinnamylamine core structure.46 
Conventional syntheses of abamines proceed from cinnamaldehydes that are generated from the 
corresponding cinnamic acids via a reduction/oxidation sequence.45 Our formal synthesis of 
abamines proceeds via allylic C-H amination of commercially available 1,2-dimethoxy-4-
allylbenzene with N-triflyl 4-fluoro-benzylamine (Figure 3a). It is significant to note that only 2.5 
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mol% (±)-MeO-SOX ligand (L-5)/Pd(OAc)2 catalyst was used to furnish aminated product in 86% 
yield as single E-isomer which could readily be deprotected in the presence of the olefin to afford 
allylic amine 37 (92%), a known intermediate to abamines.47 Sixteen novel, functionally diverse 
abamine derivatives, many more circuitous to access via a cinnamic acid route due to the presence 
of functionality prone to reduction or oxidation (e.g. 39, 40, 42, 47), could directly be accessed via 
this method. Functionalities prone to reduction may be maintained after amine deprotection using 
the N-nosyl amine nucleophile (43, 44).   
Figure 3. Streamlining the synthesis of medicinally important small molecules. 
 
Reboxetine, a clinically used antidepressant marketed as racemate Endronax, has been 
shown to be significantly more potent in many biological assays as its (S, S)-enantiomer.48 (S, S)- 












a. Synthesis of abamine core (N-benzyl cinnamyl amine)
1. Pd(OAc)2/(MeO)SOX
   (2.5 mol%); 







1.0 equiv 1.0 equiv 37





38.  R = CF3
39.  R = CO2Me
40.  R = CHO
41.  R = Br

















49. R = F 




43.  R = CO2Me









47. R = H   90%a,
48. R = Me 88%a,
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Tf
45. R = o-OTBS






























91% yield (2 steps)
     CuI, Me4Phen















Previous work : 7 steps, 43% yield (ref. 49)




 2. LAH(10 equiv), 
 98% yield, 96% ee
Unless otherwise indicated, all reactions were run with 10% Pd(OAc)2 and (±) MeO-SOX L-5 for 72 h. a24 h.  b5% Pd(OAc)2 and (±) MeO-SOX L-5 were 





morpholine ring and the other in an adjacent ethoxyphenol fragment. Previous asymmetric 
syntheses have installed stereochemistry via chiral epoxides,48,49 for example asymmetric 
epoxidation of cinnamyl alcohol followed by functional group manipulations to regioselectively 
install the terminal amine functionality.48 We recognized that the allylic amines generated via this 
C—H amination may serve as synthons for chiral amino diols (Figure 3b). Moreover, the 
remarkable ability of this reaction to tolerate electrophilic functionality on both coupling partners 
(e.g. 9, 14, 16, 17, Table 2; 40, Figure 3) suggested the N-triflyl protected amine could be brought 
in containing a bromoethyl fragment that could subsequently enable direct formation of the 
morpholine ring. Allylic C—H amination between commercial available allylbenzene and N-triflyl 
2-bromoethylamine nucleophile furnished E-allylic amine 56 in good yield and excellent 
stereoselectivity (86%, >20:1 E:Z) (Figure 3b). Significantly, N-triflyl protection of the amine 
enables it to be compatible with electrophilic functionalities, like alkyl bromide, that serve as 
points for further derivatization on the product prior to amine deprotection. Sharpless asymmetric 
dihydroxylation of allylic amine 56 furnished diol that upon exposure to sodium hydride (NaH) 
directly cyclized with the alkyl bromide to the key morpholine intermediate 57 in 91% yield (over 
2 steps). Copper-catalyzed etherification followed by lithium aluminum hydride (LAH) cleavage 
of the triflate furnished (S, S)-Reboxetine in 96% ee. Significantly, the five step sequence (six with 
N-triflyl protection) furnished the desired enantioenriched compound in 48% overall yield; 
comparing favorably with the highly optimized seven step industrial route that proceeds 43% 
overall yield.48 This route provides expedient routes for rapidly diversifying the core structure by 
altering the allylated aromatic and/or amine starting materials that may be useful during discovery 





1.2.5 Mechanistic Studies 
We hypothesized that the catalytic cycle for Pd(II)/SOX catalyzed allylic C—H amination 
proceeds via allylic C—H cleavage to afford a cationic Pd(SOX) π-allyl intermediate A that is 
highly activated towards functionalization (Figure 4a) followed by catalyst regeneration with 2,5-
DMBQ. Initial rate studies measured on parallel reactions gave a primary kinetic isotope effect 
(KIE) of 2.4 ± 0.1, consistent with a mechanism proceeding via C—H cleavage (Figure 4b). The 
higher intramolecular KIE 4.0 ± 0.1 suggests that C—H cleavage is not the solely rate-determining 
step. (Figure 4a)50 
Figure 4. Proposed mechanism and mechanistic studies. 
 
A key question is why the SOX ligand framework promotes C—H amination with less 
activated amines and the previous bis-sulfoxide ligand is ineffective. In order to investigate if more 
coordinating N-triflyl amine was inhibiting Pd(II)/bis-sulfoxide catalysis, we ran a standard allylic 
C––H amination30 with N-tosyl carbamate nucleophiles in the presence of 1 equiv. of a N-triflyl 
amine (Figure 4c). Despite the significant drop in yield (84% to 32%), reactivity was not entirely 
suppressed. Interestingly, no allylic C—H amination product from the N-triflyl amine was 
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observed, suggesting that functionalization- not C—H cleavage- is the problematic step for the 
standard Pd(II)/bis-sulfoxide catalysis with this nucleophile. In order to directly probe the 
functionalization step, we synthesize a π-allyl Pd acetate dimer51 in situ and observed 
complexation with (±)-MeO-SOX ligand by 1H NMR (Figure 4d).  Subsequently subjection of the 
complex A to mock catalytic conditions furnished aminated product 61 in yields and selectivities 
comparable those of the catalytic reactions (Figure 4d, catalytic reaction decene, 55% yield, >20:1 
L:B and E:Z). This experiment is in consistent with our hypothesis that SOX ligand is bound to π-
allyl Pd to furnish a cationic complex A activated towards functionalization. In contrast, using the 
bis-sulfoxide ligand in analogous experiments we observed no complexation or functionalization 
(Figure 4d).  This is consistent with previously reported mechanistic studies that show that while 
the bis-sulfoxide ligand is critical for C—H cleavage it is unable to promote functionalization.51 
Taken together, this data strongly supports that a unique feature of the SOX ligand platform is the 
ability to stabilize cationic p-allyl Pd intermediates that are activated towards functionalization. 
This is analogous to the role phosphine ligands play in Pd(0)-catalyzed allylic substitution 
reactions and suggest that the SOX ligand framework may provide an alternative, oxidatively 
stable ligand platform for C—H oxidation reactions to promote and control functionalizations.  
1.3 Conclusions 
            The ability of C—H functionalizations to serve as cross-coupling methods that 
simultantiously introduce new functionality while joining two complex fragments has been 
underexplored. We have developed a (±)-MeO-SOX ligand/Pd(OAc)2-catalyzed intermolecular 
allylic C—H amination that cross couples complex a-olefins (1 equiv.) with complex alkyl and 
aryl sulfonamides (1 equiv.) to furnish stereochemically defined linear E- allylic amines with 
excellent regio- and stereoselectivity. The emergence of such reactive and selective methods that 
operate using only one equivalent of both the hydrocarbon and functionalization reagent enable 
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C—H functionalization methods to emerge as powerful methods for fragment coupling. 
Mechanistic studies indicate that the SOX ligand is effective at promoting functionalizations with 
Pd p-allyl electrophiles, likely by stabilizing a cationic intermediate, and suggests this ligand 
platform may be generally useful in expanding the nucleophile scope of allylic C—H 
functionalizations.  
 
1.4 Experimental Section 
1.4.1 General Information 
         The following commercially obtained reagents were used as received: Pd(OAc)2 (Johnson 
Mattey Chemicals) was stored in a glove box, and weighted out in the air at room temperature 
prior to use. Trifluoromethanesulfonic anhydride (Oakwood Chemicals) was stored in 5 °C fridge 
under N2. 1,4-benzoquinone, 2,6-dimethylbenzoquinone and 2,5-dimethylbenzoquinone was 
purchased from Sigma-Aldrich and used as received. All allylic amination reactions were run 
under ambient air with no precautions taken to exclude moisture. All other reactions were run in 
flame- or oven-dried glassware under an atmosphere of N2 or Ar gas with dry solvents unless 
otherwise stated. All products were filtered through a glass wool plug prior to obtaining a final 
weight. Anhydrous solvents were purified by passage through a bed of activated alumina 
immediately prior to use (Glass Countour, Laguna Beach, California). Chloroform-d was stored 
over 3Å molecular sieves in a secondary container with drierite. Thin-layer chromatography (TLC) 
was conducted with E. Merck silica gel 60 F254 pre-coated plates (0.25 mm) and visualized with 
UV and Cerium-ammonium-molybdate and potassium permanganate stains. Flash 
chromatography was performed using American International ZEOprep 60 ECO silica gel (230-
400 mesh).  
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             1H-NMR spectra were recorded on a Varian Inova-500 (500 MHz), Varian Unity-500 (500 
MHz) or Carver-Bruker 500 (500 MHz) spectrometer and are reported in ppm using solvent as an 
internal standard (CDCl3 at 7.26 ppm). Data reported as: s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, sxt = sextet, hept = septet, m = multiplet, br = broad, app = apparent; coupling 
constant(s) in Hz; integration. Proton-decoupled 13C-NMR spectra were recorded on a Varian 
Unity-500 (125 MHz) or Carver-Bruker 500 (125MHz) spectrometer and are reported in ppm 
using solvent as an internal standard (CDCl3 at 77.16 ppm). Chiral gas chromatographic (GC) 
analysis was performed on an Agilent 6890N Series instrument equipped with FID detectors using 
a J&W Cyclosil-B column. Chiral high pressure liquid chromatography (HPLC) analysis was 
performed on an Agilent 1100 Series instrument equipped with a UV detector, using a 
CHIRALPAK AD-RH or OJ-H column. Optical rotations were measured using a 1 mL cell with 
a 50 mm path length on a Jasco P-1020 polarimeter. Optical rotations were obtained with a sodium 
lamp and are reported as follows: [α]λToC (c = g/100 mL solvent). High-resolution mass spectra 
were obtained at the University of Illinois Mass Spectrometry Laboratory. Electrospray ionization 
(ESI) spectra were performed on a Waters Q-Tof µLtima spectrometer, and electron ionization 
(EI) and field desorption (FD) spectra were performed on a Micromass 70-VSE spectrometer.  
 
Synthesis of (±)-SOX ligands 
The general procedure for phenyloxazoline synthesis (Scheme 1):  
General procedure A: 
Ligand intermediate S1, S3, S4, S5 and S6 were synthesized according to the method of 
Helmchen and coworkers52 using the following general procedure: 
To a 100 mL oven-dried round-bottom flask was added the benzoic acid (10 mmol, 1.0 equiv) 
and CH2Cl2 (20 mL, 0.5 M). The solution was cooled to 0 °C, oxalyl chloride (15 mmol, 1.5 equiv) 
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was then added, followed by slowly addition of DMF (1.0 mmol, 0.1 equiv). The reaction was 
slowly warmed to room temperature and stirred overnight.  The reaction was diluted with CH2Cl2 
(300 mL), the organic layer was washed by 5% NaHCO3 (200 mL x 2) and dried over anhydrous 
Na2SO4, filtered, and concentrated under reduced pressure. The crude 2-bromobenzoyl chloride 
was carried through to the next step without further purification. 




To a 100 mL oven-dried round-bottom flask was added commercial 2-amino-2-methyl-1-
propanol (10 mmol, 1.0 equiv, Sigma Aldrich), Et3N (20 mmol, 2.0 equiv) and 1,4 dioxane (14 
mL). The solution was cooled to 0 °C, and the 2-bromobenzoyl chloride from the previous step in 
12 ml of 1,4 dioxane was added slowly. The reaction was allowed to warm up to room temperature 
and stirred for another 1 hour. The reaction mixture was filtered through a silica plug with ethyl 
acetate and concentrated under reduced pressure. The crude amide was carried through to the next 
















































































Following general procedure B:  
                            
S2: R1 = R2 = H, R3 = Ph
S1: R1 = H,      R2 = H,      R3 = Me
S3: R1 = H,      R2 = CF3,  R3 = Me
S4: R1 = H,      R2 = OMe, R3 = Me
S5: R1 = OMe, R2 = H,      R3 = Me
S6: R1 = OMe, R2 = OMe, R3 = Me
Following general procedure A:
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An oven-dried 300 mL round-bottom flask equipped with condenser was added the crude amide 
and toluene (70 mL). After cooled to 0 °C, thionyl chloride (2.2 mL, 30 mmol, 3.0 equiv) was 
added dropwise and the reaction was heated to reflux for 3 hours. The solution and thionyl chloride 
was removed by repeated rotary evaporation with ethyl acetate (3 times). The crude product was 
carried through without further purification.  
To the same round-bottom flask was added NaOH (15 mmol, 1.5 equiv) and MeOH (80 mL), 
and the mixture was heated to reflux open to air for 1 hour. After cooling to room temperature, 
diethyl ether (200 mL) was added. The resulting solution was washed 3 times with brine. The 
organic layer was dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
The crude mixture was purified via flash column chromatography (0% => 10% acetone in hexanes) 
to afford the desired phenyloxazoline.   
 
General procedure B: 
    Ligand intermediate S2 was synthesized according to the method of Stoltz and coworkers53 
using the following general procedure: 
To a 100 mL oven-dried round-bottom flask was added the benzoic acid (10 mmol, 1.0 equiv) 
and CH2Cl2 (20 mL, 0.5 M). The solution was cooled to 0 °C, oxalyl chloride (15 mmol, 1.5 equiv) 
was then added, followed by slow addition of DMF (1.0 mmol, 0.1 equiv). The reaction was slowly 
warmed to room temperature and stirred overnight.  The reaction was diluted with CH2Cl2 (300 
mL), the organic layer was washed by 5% NaHCO3 (200 mL x 2) and dried over anhydrous NaSO4, 
filtered, and concentrated under reduced pressure. The crude 2-bromobenzoyl chloride was carried 
through to the next step without further purification.  
 To a 100 mL oven-dried round-bottom flask was added 2-amino-2,2-diphenylethanol54(10 
mmol, 1.0 equiv), Et3N (20 mmol, 2.0 equiv) and 1,4 dioxane (14 mL). The solution was cooled 
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to 0 °C, and the crude 2-bromobenzoyl chloride from previous step in 12 ml of 1,4 dioxane was 
added slowly. The reaction was allowed to warm up to room temperature and stirred for another 1 
hour. The reaction mixture was filtered through a silica plug with ethyl acetate and concentrated 
under reduced pressure. The crude amide was carried through next step without further 
purification.  
To a solution of amide in CH2Cl2 (30 mL) was added tosyl chloride (13 mmol, 1.3 equiv) and 
Et3N (50 mmol, 5 equiv). The reaction was refluxed at 55 °C for 22 hours. After H2O (10 mL) was 
added, the reaction was refluxed at 75 °C for another 2 hours. The reaction was cooled, and the 
layers were separated. The aqueous layer was extracted with CH2Cl2 (30 mL x 2). The combined 
organic layers were dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. The crude mixture was purified via flash column chromatography (0% => 10% acetone 




Phenyloxazoline S1 was synthesized following the general procedure A in 73% yield (1.857 g, 
7.340 mmol) as a colorless oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.64 (dd, J = 7.7, 1.8 Hz, 1H), 7.62 (dd, J = 8.0, 1.3 Hz, 
1H), 7.33 (ddd, J = 7.5, 7.5, 1.3 Hz), 7.27 (ddd, J = 7.7, 7.5, 1.8 Hz, 1H), 4.14 (s, 2H), 1.41 (s, 














Phenyloxazoline S2 was synthesized following the general procedure B in 53% yield (2.009 g, 
5.311 mmol) as a colorless oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.81 (dd, J = 7.7, 1.8 Hz, 1H), 7.69 (dd, J = 8.0, 1.3 Hz, 
1H), 7.52-7.49 (m, 4H), 7.41-7.36 (m, 5H), 7.34-7.28 (m, 3H), 5.03 (s, 2H). 13C NMR (125 MHz, 
CDCl3) 162.5, 145.9, 134.0, 131.9, 131.7, 129.8, 128.6, 127.3, 127.2, 126.8, 122.2, 80.2, 79.9. 
HRMS (ESI) m/z calculated for C21H17NOBr [M+H]+: 378.0494, found 378.0492. 
 
 
Phenyloxazoline S3 was synthesized following the general procedure A in 51% yield (1.652 g, 
5.129 mmol) as a colorless oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.91-7.87 (m, 1H), 7.78 (dd, J = 8.1, 1.0 Hz, 1H), 7.59 (ddd, 
J = 8.1, 1.7, 0.8 Hz, 1H), 4.16 (s, 2H), 1.42 (s, 6H). 13C NMR (126 MHz, Chloroform-d) δ 160.7, 
133.5 (q, J = 33.2 Hz), 131.8，130.8 (q, J = 3.8 Hz), 124.1 (q, J = 3.6 Hz), 122.9 (q, J = 273.1 
Hz)， 122.4， 79.8，68.6，28.4. 19F NMR (470 MHz, Chloroform-d) δ -63.09. HRMS (ESI) 




Phenyloxazoline S4 was synthesized following the general procedure A in 59% yield (1.673 g, 
5.887 mmol) as a white solid.  
1H NMR (500 MHz, Chloroform-d) δ 7.57 (dd, J = 8.6, 0.6 Hz, 1H), 7.10 (d, J = 2.5 Hz, 1H), 6.80 









CDCl3) δ 161.47, 161.27, 132.30, 122.54, 122.31, 118.90, 113.04, 79.12, 67.84, 55.58, 28.26. 




Phenyloxazoline S5 was synthesized following the general procedure A in 79% yield (2.251 g, 
7.920 mmol) as a white solid.  
1H NMR (500 MHz, Chloroform-d) δ 7.48 (d, J = 8.8 Hz, 1H), 7.16 (d, J = 3.1 Hz, 1H), 6.83 (dd, 
J = 8.8, 3.1 Hz, 1H), 4.14 (s, 2H), 3.81 (s, 3H), 1.41 (s, 6H). These data are in agreement with that 




Phenyloxazoline S6 was synthesized following the general procedure A in 62% yield (1.954 g, 
6.219 mmol) as a white solid.  
1H NMR (500 MHz, Chloroform-d) δ 7.12 (s, 1H), 6.99 (s, 1H), 4.04 (s, 2H), 3.82 (s, 3H), 3.82 
(s, 3H), 1.33 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 161.5, 150.8, 147.8, 121.8, 116.2, 113.4, 
112.7, 79.1, 67.8, 56.1, 56.1, 28.2. HRMS (ESI) m/z calculated for C13H17NO3Br [M+H]+: 
314.0392, found 314.0385. 
 
The general procedure for the synthesis of methyl sulfinates: 
 





















S7: R = Me, 
S8: R = OMe, 




Ligand intermediates (methyl sulfinates) S7, S8 and S9 was synthesize according to the method of 
Ruano and coworkers57 using the following general procedure. To a solution of the coresponding 
disulfide (10 mmol, 1.0 equiv) in MeOH (25 mL, 0.4 M) was slowly added NBS (15 mmol, 1.5 
equiv) at room temperature. The reaction mixture was stirred and monitored by TLC. Upon 
completion, the reaction was diluted with CH2Cl2 (25 mL), washed with sat. aq. NaHSO3 (10 mL) 
and sat. aq. NaHCO3 (4 x 10 mL). The organic layer was dried over anhydrous Na2SO4, filtered 
and the solvent was removed under reduced pressure. 
 
 
Methyl sulfinate S7 was synthesize according to the general procedure in 95% yield (3.236 g, 
19.01 mmol) as a colorless oil.   
1H NMR (500 MHz, Chloroform-d) δ 7.59 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 3.46 (s, 




Methyl sulfinate S8 was synthesized according to the general procedure in 91% yield (3.396 g, 
18.24 mmol) as a colorless oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.64 (d, J = 8.8, 2H), 7.03 (d, J = 8.8, 2H), 3.87 (s, 3H), 

















Methyl sulfinate S9 was synthesized according to the general procedure in 94% yield (4.215 g, 
18.80 mmol) as a colorless oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.90-7.72 (m, 4H), 3.52 (s, 3H). These data are in agreement 
with that previously reported in the literature. 59 
 
The general procedure for (±)-SOX ligand synthesis:  
 
Scheme 3. Synthesis of (±)-SOX ligand. 
 
To an oven-dried round-bottom flask was added a stir bar, phenyloxazoline (5.0 mmol, 1.0 equiv), 
THF (25 ml, 0.2 M), and tetramethylethylenediamine (TMEDA, 5.5 mmol, 1.1 equiv). The 
reaction flask was cooled to -78 °C and n-butyllithium (1.6 M in hexane, 5.5 mmol, 1.1 equiv) was 
added dropwise. The reaction was stirred 20 minutes at -78 °C. Subsequently, the methyl sulfinate 
(6.0 mmol, 1.2 equiv) was added as a solution in THF (12 ml, 0.5 M) dropwise. The reaction was 
stirred 1 hour at -78 °C, then 1 hour at 0 °C, then 1 hour at room temperature. The reaction was 
quenched with water. The mixture was diluted with diethyl ether, and the layers were separated. 
The aqueous layer was extracted with diethyl ether (20 mL x 3). The combined organic layers were 
dried over anhydrous MgSO4, filtered, and concentrated under reduced pressure. The crude residue 

































(±)-SOX-Ligand 1 (L1) was synthesized following the general procedure. 1.27 g of 
phenyloxazoline S1 (5.0 mmol, 1.0 equiv) was used, along with 1.02 g of sulfinate S7 (6.0 mmol, 
1.2 equiv). The crude residue was purified via flash column chromatography (0% => 20% acetone 
in hexanes) to afford 1.176 g (3.76 mmol) of pure product as a white solid (75% yield).   
1H NMR (500MHz, CDCl3) δ 8.37 (dd, J = 7.9, 1.1 Hz, 1H), 7.85 (dd, J = 7.7, 1.3 Hz, 1H), 7.72 
(ddd, J = 7.7, 7.7, 1.1 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.50 (ddd, J = 7.5, 7.5, 0.9 Hz, 1H), 7.16 
(d, J = 8.4 Hz, 2H), 4.25 (dd, J = 10.1, 8.8 Hz, 1H), 4.16 (t, J = 8.1, Hz, 1H), 4.03 (dd, J = 10.1, 
7.9 Hz, 1H), 2.32 (s, 3H), 0.97 (s, 9H). These data are in agreement with that previously reported 
in the literature. 28 
 
 
(±)-SOX-Ligand 2 (L2) was synthesized following the general procedure. Phenyloxazoline S2 
(1.89 g, 5.0 mmol, 1.0 equiv) and sulfinate S7 (1.02 g, 6.0 mmol, 1.2 equiv) were used. The crude 
residue was purified via flash column chromatography (0% => 20% acetone in hexanes) to afford 
1.597 g (3.64 mmol) of pure product as a white solid (73% yield).  
1H NMR (500 MHz, Chloroform-d) δ 8.46 (dd, J = 8.0, 1.3 Hz, 1H), 8.01 (dd, J = 7.7, 1.4 Hz, 
1H), 7.77 (ddd, J = 7.7, 7.7, 1.4 Hz, 1H), 7.55 (ddd, J = 7.5, 7.5, 1.3 Hz, 1H), 7.51-7.47 (m, 4H), 
7.38 (dd, J = 8.5, 7.0 Hz, 2H), 7.31-7.27 (m, 1H), 7.23-7.16 (m, 3H), 7.04 (dd, J = 8.0, 1.7 Hz, 
2H), 7.00 (d, J = 8.1 Hz, 2H), 4.95 (d, J = 8.6 Hz, 1H), 4.85 (d, J = 8.7 Hz, 1H), 2.29 (s, 3H). 13C 
NMR (125 MHz, CDCl3) δ 159.9, 146.7, 145.6, 145.4, 143.5, 140.7, 132.2, 130.3, 129.9, 129.5, 
128.6, 128.28, 127.3, 127.05 126.7, 126.7, 126.6, 125.4, 125.1, 81.0, 79.5, 21.4. HRMS (ESI) m/z 












(±)-SOX-Ligand 3 (L3) was synthesized according to the following modified procedure. To an 
oven-dried flask was added a stir bar, phenyloxazoline S3 (322.1mg, 1.0 mmol, 1.0 equiv), THF 
(5 ml, 0.2M), and TMEDA (168 µL, 1.1 mmol, 1.1 equiv). The reaction flask was cooled to -94 
°C and n-butyllithium (688 µL, 1.6 M in hexane, 1.1 mmol, 1.1 equiv) was added dropwise. The 
reaction was stirred 20 minutes at -94 °C and then the reation was warmed up to -78 °C, the methyl 
sulfinate S7 (1.02g, 1.2 mmol, 1.2 equiv) was added as a solution in THF (5 mL, 0.2M) dropwise. 
The reaction was stirred 1 hour at -78 °C, then 1 hour at 0 °C, then 1 hour at room temperature. 
The reaction was then quenched with water. The mixture was diluted with diethyl ether, and the 
layers were separated. The aqueous layer was extracted with diethyl ether (25 mL x 3). The 
combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated under 
reduced pressure. The crude residue was purified via flash column chromatography (0% => 20% 
acetone in hexanes) to afford 171.6 mg (0.450 mmol) of pure product as a white solid (45% yield).  
1H NMR (500 MHz, Chloroform-d) δ 8.68 (d, J = 1.8 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.74 (dd, 
J = 8.1, 1.8 Hz, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 4.03 (d, J= 8.1 Hz, 1H) 
4.00 (d J = 8.1 Hz, 1H), 2.31 (s, 3H), 1.32 (s, 3H), 1.26 (s, 3H). 13C NMR (126 MHz, Chloroform-
d) δ 158.2, 148.4, 142.9, 141.6, 133.6 (q, J = 33.4 Hz), 130.4, 129.6, 128.7, 127.1, 127.0 (q, J = 
3.7 Hz), 123.5 (q, J = 273.2 Hz), 122.3 (q, J = 3.8 Hz), 79.1, 69.0, 28.6, 28.1, 21.4. 19F NMR (470 












(±)-SOX-Ligand 4 (L4) was synthesized following the general procedure. Phenyloxazoline S4 
(1.42 g, 5.0 mmol, 1.0 equiv) and sulfinate S7 (1.02 g, 6.0 mmol, 1.2 equiv) were used. The crude 
residue was purified via flash column chromatography (0% => 30% acetone in hexanes) to afford 
1.371 g (3.99 mol) of pure product as a white solid (80% yield).  
1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 2.6 Hz, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.54 (d, J = 8.2 
Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 6.94 (ddd, J = 8.6, 2.7, 0.7 Hz, 1H), 3.91 (s, 2H), 3.90 (s, 3H), 
2.27 (s, 3H), 1.25 (s, 3H), 1.18 (s, 3H).13C NMR (125 MHz, CDCl3) δ 162.5, 159.0, 148.3, 143.5, 
141.0, 131.5, 129.4, 127.0, 117.7, 116.3, 109.3, 78.6, 77.4, 77.2, 76.9, 68.29, 55.8, 28.6, 28.1, 21.3. 
HRMS (ESI) m/z calculated for C19H22NO3S [M+H]+: 344.1320, found 344.1322. 
 
 
(±)-MeO-SOX-Ligand 5 (L5) was synthesized following the general procedure. Phenyloxazoline 
S5 (1.42 g, 5.0 mmol, 1.0 equiv) and methyl sulfinate S7 (1.02 g, 6.0 mmol, 1.2 equiv). The crude 
residue was purified via flash column chromatography (0% => 30% acetone in hexanes) to afford 
1.371 g (3.99 mmol) of pure product as a white solid (80% yield).  
1H NMR (500 MHz, Chloroform-d) δ 8.18 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.2 Hz, 2H), 7.34 (d, 
J = 2.8 Hz, 1H), 7.15 (dd, J = 8.9, 2.7 Hz, 1H), 7.12 (d, J = 8.3 Hz, 2H), 3.96 (d, J = 1.5 Hz, 2H), 
3.81 (s, 3H), 2.27 (s, 3H), 1.27 (s, 3H), 1.22 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 161.0, 159.1, 
144.0, 140.7, 137.3, 129.3, 127.0, 126.9, 126.5, 117.4, 114.6, 78.9, 68.5, 55.7, 28.5, 28.1, 21.3. 















(±)-SOX-Ligand 6 (L6) was synthesized following the general procedure. Phenyloxazoline S1 
(1.27 g, 5.0 mmol, 1.0 equiv) and methyl sulfinate S8 (1.12 g, 6.0 mmol, 1.2 equiv). The crude 
residue was purified via flash column chromatography (0% => 20% acetone in hexanes) to afford 
1.381 g (4.19 mmol) of pure product as a white solid (84% yield).  
1H NMR (500 MHz, Chloroform-d) δ 8.37 (dd, J = 8.0, 1.3 Hz, 1H), 7.86 (dd, J = 7.7, 1.4 Hz, 
1H), 7.70 (ddd, J = 8.0, 7.4, 1.4 Hz, 1H), 7.61-7.57 (m, 2H), 7.49 (td, J = 7.5, 1.3 Hz, 1H), 6.86-
6.82 (m, 2H), 3.98 (d, J = 1.9 Hz, 2H), 3.75 (s, 3H), 1.29 (s, 3H), 1.24 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 161.5, 159.3, 146.5, 138.1, 131.7, 130.2, 129.8, 129.0, 125.5, 124.9, 114.2, 78.9, 




(±)-SOX-Ligand 7 (L7) was synthesized following the general procedure. Phenyloxazoline S6 
(1.57 g, 5.0 mmol, 1.0 equiv) and methyl sulfinate S7 (1.02 g, 6.0 mmol, 1.2 equiv) were used. 
The crude residue was purified via flash column chromatography (0% => 30% acetone in hexanes) 
to afford 1.438 g (3.85 mmol) of pure product as a white solid (77% yield).  
1H NMR (500 MHz, Chloroform-d) δ 7.80 (s, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (s, 1H), 7.12 (d, 
J = 8.0 Hz, 2H), 3.98 (s, 3H), 3.95-3.91 (m, 2H), 3.89 (s, 3H), 2.27 (s, 3H), 1.24 (s, 3H), 1.19 (s, 
3H). 13C NMR (125 MHz, CDCl3) δ 159.0, 151.7, 149.9, 143.9, 140.8, 138.6, 129.4, 126.6, 118.1, 
112.0, 107.1, 78.8, 68.3, 56.4, 56.3, 28.5, 28.1, 21.3. HRMS (ESI) m/z calculated for C20H24NO4S 
















(±)-SOX-Ligand 8 (L8) was synthesized following the general procedure. Phenyloxazoline S5 
(1.42 g, 5.0 mmol, 1.0 equiv) and methyl sulfinate S8 (1.12 g, 6.0 mmol, 1.2 equiv). The crude 
residue was purified via flash column chromatography (0% => 30% acetone in hexanes) to afford 
1.350 g (3.75 mmol) of pure product as a white solid (75% yield).  
1H NMR (500 MHz, Chloroform-d) δ 8.21 (d, J = 8.8 Hz, 1H), 7.60-7.54 (m, 2H), 7.35 (d, J = 2.7 
Hz, 1H), 7.18 (dd, J = 8.8, 2.7 Hz, 1H), 6.84-6.81 (m, 2H), 3.96 (s, 2H), 3.83 (s, 3H), 3.74 (s, 3H), 
1.28 (s, 3H), 1.22 (s, 3H).  13C NMR (125 MHz, CDCl3) δ 161.3, 161.0, 159.1, 138.5, 137.3, 128.6, 
126.9, 126.9, 117.4, 114.8, 114.1, 78.9, 68.6, 55.7, 55.4, 28.6, 28.2. HRMS (ESI) m/z calculated 
for C19H22NO4S [M+H]+: 360.1270, found 360.1268. 
 
 
Preparation of N-Triflyl protected amine nucleophiles 
General procedure for N-triflyl protected amine nucleophiles: 
Procedure A (From amines): 
An oven dried round-bottom flask equipped with a stir bar was charged with amine (5.0 mmol, 
1.0 equiv), CH2Cl2 (10ml, 0.5M) and Et3N (767 µL, 5.5 mmol, 1.1 equiv). The flask was cooled 
to -78 °C, and trifluoromethanesulfonic anhydride (840 µL, 1.41 g, 5.0 mmol, 1.0 equiv) was 
added dropwise. The reaction was stirred vigorously at -78 °C for 30 min and allowed to 
gradually warm up to room temperature .The reaction was then quenched with 20 mL H2O. The 
reaction mixture was partitioned between H2O and CH2Cl2 and layers were separated. The 









over Na2SO4, filtered, and concentrated under reduced pressure. The reaction mixture was 
applied directly to a flash silica column for purification (acetone/hexanes). 
 
 
Procedure B (From amine hydrochlorides): 
An oven dried round-bottom flask equipped with a stir bar was charged with amine hydrochloride 
(5.0mmol, 1.0 equiv), CH2Cl2 (10ml, 0.5M) and Et3N (1.53 mL, 11mmol, 2.2 equiv). The flask 
was cooled to -78 °C, and Trifluoromethanesulfonic anhydride (840 µL, 1.41 g, 5.0mmol, 1.0 
equiv) was added dropwise. The reaction was stirred vigorously at -78 °C for 30 min and allowed 
to gradually warm up to r.t. .The reaction was then quenched with 20 mL H2O. The reaction 
mixture was partitioned between H2O and CH2Cl2 and layers were separated. The aqueous layer 
was extracted with CH2Cl2 (20ml x 3). The organic layers were combined, dried over Na2SO4, 
filtered, and concentrated under reduced pressure. The reaction mixture was applied directly to a 
flash silica column for purification (acetone/hexanes). 
NOTE: Most N-triflyl protected amines are bench stable for at least one year. (Some of them 
exhibited color change and suboptimal reactivity (10-15% drop in yield) after storing on bench 
for over 12 months, repurification by flash column usually restored reactivity in these cases. 
 
 
N-(2-Phenylethyl)trifluoromethanesulfonamide (S10). The reaction was performed according 
general procedure A with distilled 2-phenylethylamine (630 µL, 5.0 mmol). The reaction mixture 
was purified by flash column chromatography on silica (100 mL silica gel, 2.5% acetone/hexanes 
=> 10% acetone/hexanes) to give 1.192 g (4.71 mmol) pure N-triflyl protected amine (S10) as a 




1H NMR (500 MHz, CDCl3) δ 7.36 (m, 2H), 7.29 (m, 1H), 7.20 (dd, J = 7.9 Hz, 1.1 Hz, 1H), 4.67 
(br s, 1H), 3.58 (q, J = 6.3 Hz, 2H), 2.92 (t, J = 6.8 Hz, 2H). These data are in agreement with that 
previously reported in the literature.60 
 
 
1,1,1-trifluoro-N-phenylmethanesulfonamide (S11). The reaction was performed according to 
general procedure A with aniline (460 µL, 5.0 mmol). The reaction mixture was purified by flash 
column chromatography on silica (100 mL silica gel, 2.5% acetone/hexanes => 10% 
acetone/hexanes) to give 1.079 g (4.79 mmol) pure N-triflyl protected amine (S11) as a white solid 
in 96% yield.   
1H NMR (500 MHz, CDCl3) δ 7.40 (dd, J = 8.4Hz, 6.9 Hz, 2H), 7.33 (m, 1H), 7.27 (m, 2H), 6.68 
(br s, 1H). These data are in agreement with that previously reported in the literature.61  
 
  
N-benzyl-1,1,1-trifluoromethanesulfonamide (S12). The reaction was performed according to 
general procedure A with distilled benzylamine (516 µL, 5.0 mmol). The reaction mixture was 
purified by flash column chromatography on silica (100 mL silica gel, 2.5% acetone/hexanes => 
10% acetone/hexanes) to give 1.103 g (4.61 mmol) pure N-triflyl protected amine (S12) as a white 
solid in 92% yield.   
1H NMR (500 MHz, CDCl3) δ 7.44-7.30 (m, 5H), 4.94 (br s, 1H), 4.46 (d, J = 5.8 Hz, 2H). These 








1,1,1-trifluoro-N-(naphthalen-1-ylmethyl)methanesulfonamide (S13). The reaction was 
performed according to general procedure A with 1-naphthylmethylamine (733 µL, 786 mg, 5.0 
mmol). The reaction mixture was purified by flash column chromatography on silica (100ml silica 
gel, 5% acetone/hexanes => 10% acetone/hexanes) to give 1.298 g (4.49 mmol) pure N-triflyl 
protected amine (S13) as a white solid in 90% yield.   
1H NMR (500 MHz, Chloroform-d) δ 8.01 (dd, J = 8.4, 1.0 Hz, 1H), 7.94-7.90 (m, 1H), 7.89 (dt, 
J = 7.9, 1.1 Hz, 1H), 7.62 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.56 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.51-
7.45 (m, 2H), 4.98 (t, J = 5.3 Hz, 1H), 4.90 (d, J = 5.1 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 
134.1, 131.0, 130.3, 130.1, 129.3, 127.4, 127.4, 126.6, 125.5, 122.6, 119.9(q, J = 321.4 Hz), 46.5. 
19F NMR (470 MHz, Chloroform-d) δ -76.84. HRMS (ESI) m/z calculated for C12H10NO2SF3Na 
[M+Na] +: 312.0282, found 312.0293. 
 
 
1,1,1-trifluoro-N-methylmethanesulfonamide (S14). The reaction was performed according to 
general procedure B with methylamine hydrochloride (378 mg, 5.0 mmol). The reaction mixture 
was purified by flash column chromatography on silica (100 mL silica gel, 5% acetone/hexanes) 
=> give 698 mg (4.28 mmol) pure N-triflyl protected amine (S14) as a colorless oil in 86% yield.   
1H NMR (500 MHz, Chloroform-d) δ 4.99 (s, 1H), 2.98 (q, J = 1.2 Hz, 3H). 13C NMR (125 MHz, 
Chloroform-d) δ 119.9 (q, J = 321.2 Hz), 30.2. 19F NMR (470 MHz, Chloroform-d) δ -76.90. 
HRMS (EI) m/z calculated for C2H4NO2SF3 [M] +: 162.9915, found 162.9915. 
 
 
N-butyl-1,1,1-trifluoromethanesulfonamide (S15). The reaction was performed according to 





purified by flash column chromatography on silica (100 mL silica gel using 2.5% acetone/hexanes 
=> 5% acetone/hexanes as eluent) to give 864 mg (4.21 mmol) pure N-triflyl protected amine (S15) 
as a white solid in 84% yield.   
1H NMR (500 MHz, Chloroform-d) δ 5.11 (br s, 1H), 3.35-3.16 (m, 2H), 1.57 (tt, J = 7.8, 6.5 Hz, 
2H), 1.45-1.28 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H). These data are in agreement with that previously 
reported in the literature.63 
 
 
tert-Butyl (2-((trifluoromethyl)sulfonamido)ethyl)carbamate (S16). The reaction was 
performed according to general procedure A with N-boc-ethylenediamine (792 µL, 801 mg, 5.0 
mmol). The reaction mixture was purified by flash column chromatography on silica (100 mL 
silica gel, 5% acetone/hexanes => 10% acetone/hexanes) to give 1.388 g (4.75 mmol) pure N-
triflyl protected amine (S16) as a white solid in 95% yield.   
1H NMR (500 MHz, Chloroform-d) δ 6.80 (br s, 1H), 5.05 (br s, 1H), 3.36 (t, J = 5.6 Hz, 2H), 
3.31 (q, J = 5.8 Hz, 2H), 1.44 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 157.5, 120.0 (q, J = 321.3), 
80.9, 45.3, 40.6, 28.4. 19F NMR (470 MHz, Chloroform-d) δ -77.85. HRMS (EI) m/z calculated 
for C8H16N2O4SF3 [M+H]+: 293.0783, found 293.0786. 
 
 
1,1,1-trifluoro-N-(2-methoxyethyl)methanesulfonamide (S17). The reaction was performed 
according to general procedure A with 2-methoxyethylamine (435 µL, 376 mg, 5.0 mmol). The 
reaction mixture was purified by flash column chromatography on silica (100ml silica gel, 5% 
acetone/hexanes => 10% acetone/hexanes) to give 999 mg (4.82 mmol) pure N-triflyl protected 







1H NMR (500 MHz, Chloroform-d) δ 5.35 (br s, 1H), 3.53 (m, 2H), 3.48-3.43 (m, 2H), 3.39 (s, 
3H). 13C NMR (125 MHz, Chloroform-d) δ 119.8 (q, J = 321.0 Hz), 71.0, 59.1, 44.1. 19F NMR 
(470 MHz, Chloroform-d) δ -77.87.   HRMS (EI) m/z calculated for C4H8NO3SF3 [M+H]+: 
208.02553, found 208.02523. 
 
 
N-(2-bromoethyl)-1,1,1-trifluoromethanesulfonamide (S18). An oven dried 100 mL round-
bottom flask equipped with a stir was charged with 2-bromoethylamine hydrobromide (2.05 g, 
10.0 mmol, 1.0 equiv), CH2Cl2 (20 mL, 0.5 M).The flask was cooled to -78 °C, and anhydrous 
K2CO3 (1.38 g, 10.0 mmol, 2.0 equiv) was added in one batch followed by slowly addition of 
trifluoromethanesulfonic anhydride (1.68 mL, 2.82 g, 10.0 mmol, 1.0 equiv). The reaction was 
stirred vigorously at -78 °C for 30 min. After warmed up to 0 °C, the reaction was quenched with 
20 mL cold H2O. The reaction mixture was partitioned between H2O and CH2Cl2 and the layers 
were separated. The aqueous layer was then extracted with CH2Cl2 (20ml x 3). The organic layers 
were combined, dried over NaSO4, filtered, and concentrated under reduced pressure.). The 
reaction mixture was purified by flash column chromatography on silica (100 mL silica gel, 2.5% 
acetone/hexanes => 5% acetone/hexanes) to give 1.213 g (4.74 mmol) pure N-triflyl protected 
amine (S18) as a colorless oil in 47% yield.   
1H NMR (500 MHz, Chloroform-d) δ 5.52 (br s, 1H), 3.70 (q, J = 5.9 Hz, 2H), 3.51 (t, J = 5.8 Hz, 
2H). 13C NMR (125 MHz, Chloroform-d) δ 119.6 (q, J = 320.5 Hz), 45.7, 31.4. 19F NMR (470 
MHz, Chloroform-d) δ -77.90. HRMS (EI) m/z calculated for C3H6NO2BrSF3 [M+H]+: 255.92546, 








1,1,1-Trifluoro-N-(2,2,2-trifluoroethyl)methanesulfonamide (S19). An oven dried round-
bottom flask equipped with a stir bar was charged with 2,2,2-trifluoroethylamine hydrochloride 
(677.6 mg, 5.0 mmol, 1.0 equiv), CH2Cl2 (10 mL, 0.5M) and Et3N (1.53 mL, 11mmol, 2.2 equiv). 
The flask was cooled to -78 °C, and Trifluoromethanesulfonic anhydride (840 µL, 1.41 g, 5.0 
mmol, 1.0 equiv) was added dropwise. The reaction was stirred vigorously at -78 °C for 30 min 
and allowed to gradually warm up to r.t. The reaction mixture was concentrated under reduced 
pressure, the remaining mixture was dissolve in 20 mL 3 M NaOH, extracted with CH2Cl2 (20 mL 
x 3), the aqueous layer was neutralized by 3 M HCl, and extracted with 3 x 20 mL CH2Cl2. The 
combined organic layers were concentrated to afford 982 mg (4.25 mmol) pure N-triflyl protected 
amine (S19) as a colorless oil in 85% yield.   
1H NMR (500 MHz, Chloroform-d) δ 5.27 (br s, 1H), 3.91-3.84 (m, 2H). 13C NMR (125 MHz, 
Chloroform-d) δ 122.8 (q, J = 278.1 Hz), 122.0 (q, J = 320.1 Hz), 45.4 (q, J = 36.7 Hz). 19F NMR 
(470 MHz, Chloroform-d) δ -73.50, -77.64. HRMS (ESI) m/z calculated for C3H2NO2SF6 [M-H]+: 
229.9710, found 229.9705. 
 
 
Methyl ((trifluoromethyl)sulfonyl)-L-alaninate (S20). The reaction was performed according to 
general procedure B with L-alanine methyl ester hydrochloride (698 mg, 5.0 mmol). The reaction 
mixture was purified by flash column chromatography on silica (100 mL silica gel, 5% 
acetone/hexanes => 10% acetone/hexanes) to give 1.069 g (4.55 mmol) pure N-triflyl protected 
amine (S20) as a white solid in 91% yield.   
1H NMR (500 MHz, Chloroform-d) δ 5.53 (s, 1H), 4.32 (q, J = 7.2 Hz, 1H), 3.83 (s, 3H), 1.54 







(+)-Methyl ((trifluoromethyl)sulfonyl)-L-phenylalaninate (S21). The reaction was performed 
according to general procedure B with L-phenylalanine methyl ester hydrochloride (1.08 g, 5.0 
mmol). The reaction mixture was purified by flash column chromatography on silica (100 mL 
silica gel, 5% acetone/hexanes =>10% acetone/hexanes) to give 1.442 g (4.63 mmol) pure N-triflyl 
protected amine (S21) as a white solid in 93% yield.   
1H NMR (500 MHz, Chloroform-d) δ 7.39-7.28 (m, 3H), 7.16-7.10 (m, 2H), 5.33 (br s, 1H), 4.53 
(dt, J = 9.3, 5.5 Hz, 1H), 3.79 (s, 3H), 3.24-3.10 (m, 2H). 13C NMR (125 MHz, Chloroform-d) δ 
170.8, 134.3, 129.5, 128.8, 127.7, 119.5 (q, J = 320.7 Hz), 58.2, 53.0, 39.5. These data are in 
agreement with that previously reported in the literature.60 [α]23D = 28.4 (c = 1.01, CHCl3).  
 
 
(-)-Methyl ((trifluoromethyl)sulfonyl)-D-phenylalaninate (S22). The reaction was performed 
under general procedure B with D-phenylalanine methyl ester hydrochloride (1.08 g, 5.0 mmol). 
The reaction mixture was purified by flash column chromatography on silica (100ml silica gel, 5% 
acetone/hexanes => 10% acetone/hexanes) to give 1.424 g (4.57 mmol) pure N-triflyl protected 
amine (S22) as a white solid in 91% yield.   
1H NMR (500 MHz, Chloroform-d) δ 7.37-7.27 (m, 3H), 7.17-7.15 (m, 2H), 5.91 (br s, 1H), 4.51 
(t, J = 6.0 Hz, 1H), 3.76 (s, 3H), 3.14 (d, J = 6.0 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.7, 
134.2, 129.5, 128.9, 127.8, 119.5 (q, J = 320.8 Hz), 58.1, 53.1, 39.6. 19F NMR (470 MHz, 
Chloroform-d) δ -77.72. HRMS (ESI) m/z calculated for C11H13NO4F3S [M+H]+: 312.0517, found 











Methyl ((trifluoromethyl)sulfonyl)-L-isoleucinate (S23). The reaction was performed according 
to general procedure B with L-isoleucine methyl ester hydrochloride (909 mg, 5.0 mmol). The 
reaction mixture was purified by flash column chromatography on silica (100 mL silica gel, 5% 
acetone/hexanes => 10% acetone/hexanes) to give 1.221 g (4.40 mmol) pure N-triflyl protected 
amine (S23) as a colorless oil in 88% yield.   
1H NMR (500 MHz, Chloroform-d) δ 5.51 (br s, 1H), 4.13 (d, J = 4.7 Hz, 1H), 3.81 (s, 3H), 1.94 
(dqd, J = 9.3, 4.6, 2.4 Hz, 1H), 1.49-1.33 (m, 1H), 1.19 (dtd, J = 13.7, 7.3, 2.0 Hz, 1H), 0.99 (d, J 
= 6.8 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). These data are in agreement with that previously reported 
in the literature.64 
 
 
1,1,1-Trifluoro-N-(4-fluorobenzyl)methanesulfonamide (S24). The reaction was performed 
under general procedure B with 4-fluorobenzylamine (568 µL, 626 mg, 5.0 mmol). The reaction 
mixture was purified by flash column chromatography on silica (100 mL silica gel, 5% 
acetone/hexanes => 10% acetone/hexanes) to give 1.203 g (4.68 mmol) pure N-triflyl protected 
amine (S24) as a colorless oil in 93% yield.   
1H NMR (500 MHz, Chloroform-d) δ 7.31 (dd, J = 8.7, 5.2 Hz, 2H), 7.11-7.04 (m, 2H), 5.11 (s, 
1H), 4.42 (s, 2H). 13C NMR (125 MHz, Chloroform-d) δ 163.0 (d, J = 248.0 Hz), 131.1 (d, J = 
3.3 Hz), 129.9 (d, J = 8.4 Hz), 119.8 (q, J = 321.0 Hz), 116.2 (d, J = 21.8 Hz), 47.7.  19F NMR 
(470 MHz, Chloroform-d) δ -77.61, -113.30. HRMS (ESI) m/z calculated for C8H7NO2NaSF4 









N-(3,4-dimethoxybenzyl)-1,1,1-trifluoromethanesulfonamide (S25). The reaction was 
performed according to general procedure A with 3,4-Dimethoxyphenyl)methanamine (745 µL, 
836 mg, 5.0 mmol). The reaction mixture was purified by flash column chromatography on silica 
(100 mL silica gel, 5% acetone/hexanes => 20% acetone/hexanes) to give 1.373 g (4.59 mmol) 
pure N-triflyl protected amine (S25) as a white solid in 92% yield.   
1H NMR (500 MHz, Chloroform-d) δ 6.80 (dd, J = 8.2, 2.0 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.72 
(d, J = 2.0 Hz, 1H), 5.71 (br d, J = 5.2 Hz, 1H), 4.32 (d, J = 4.3 Hz, 2H), 3.80 (s, 3H), 3.77 (s, 3H). 
13C NMR (125 MHz, CDCl3) δ 149.1, 149.0, 128.0, 120.6, 119.9 (q, J = 321.2 Hz) 111.5, 111.1, 
56.0, 55.8, 48.1. 19F NMR (470 MHz, CDCl3) δ -77.22. HRMS (ESI) m/z calculated for 
C10H12NO4F3SNa [M+Na]+: 322.0337, found 322.0349. 
 
 
N-(4-(dimethylamino)benzyl)-1,1,1-trifluoromethanesulfonamide (S26). The reaction was 
performed according to general procedure A with 4-(aminomethyl)-N,N-dimethylaniline (745 µL, 
836 mg, 5.0 mmol). The reaction mixture was purified by flash column chromatography on silica 
(100 mL silica gel, 5% acetone/hexanes => 20% acetone/hexanes) to give 1.158 g (4.10 mmol) 
pure N-triflyl protected amine (S26) as a white solid in 82% yield. 
1H NMR (500 MHz, Chloroform-d) δ 7.15 (d, J = 8.8 Hz, 2H), 6.69 (d, J = 8.8 Hz, 2H), 5.13 (br 
s, 1H), 4.32 (s, 2H), 2.95 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 150.8, 129.3, 122.7, 119.9 (q, J 
= 321.3 Hz), 113.0, 48.3, 40.7. 19F NMR (470 MHz, CDCl3) δ -77.15. HRMS (ESI) m/z calculated 










(-)-(S)-1,1,1-trifluoro-N-(1-(4-nitrophenyl)ethyl)methanesulfonamide (-)-S27. The reaction 
was performed according to general procedure A with (S)-α-methyl-4-nitrobenzylamine 
hydrochloride (1.01 g, 5.0 mmol). The reaction mixture was purified by flash column 
chromatography on silica (100 mL silica gel, 5% acetone/hexanes => 20% acetone/hexanes) to 
give 1.425 g (4.78 mmol) pure N-triflyl protected amine (-)-S27 as a light yellow solid in 95% 
yield. 
1H NMR (500 MHz, Chloroform-d) δ 8.24 (d, J = 8.7 Hz, 2H), 7.51 (d, J = 8.7 Hz, 2H), 5.55 (d, 
J = 8.5 Hz, 1H), 4.90 (app p, J = 7.2 Hz, 1H), 1.66 (d, J = 7.0 Hz, 3H). 13C NMR (125 MHz, 
Chloroform-d) δ 148.7, 147.6, 127.0, 124.4, 119.5 (q, J = 320.8 Hz), 54.7, 23.4. 19F NMR (470 
MHz, Chloroform-d) δ -78.0. HRMS (ESI) m/z calculated for C9H8N2O4F3S [M-H]+: 297.0157, 
found 297.0151. [α]22D = -54.7 (c = 1.00, CHCl3). 
 
 
(+)-N-triflyl protected dihydroabietylamine (+)-S28.  (-)-(N-
nitroisoindolyl)dihydroabietylamine23 (1.15g, 2.5 mmol) was dissolved in hot ethanol (20 mL 
0.125 M), treated with hydrazine monohydrate (0.72 mL, 15 mmol) and heated at reflux for 3 
hours. Then, without cooling a white solid was filtered off and washed with fresh ethanol to give 
the crude dihydroabietylamine. Triflyl protection was performed directly on the crude 
dihydroabietylamine under general procedure A. The reaction mixture was purified by flash 






acetone/hexanes) to give 868 mg (2.08 mmol) pure N-triflyl protected amine (+)-S28 as a white 
solid in 83% yield over two steps. 
1H NMR (500 MHz, Chloroform-d) δ 7.27 (d, J = 8.6 Hz, 1H), 7.10 (dd, J = 8.2, 2.0 Hz, 1H), 7.00 
(d, J = 2.0 Hz, 1H), 5.32 (br s, 1H), 3.25 (d, J = 13.2 Hz, 1H), 3.17 (d, J = 13.2 Hz, 1H), 3.04-2.95 
(m, 2H), 2.93 (hept, J = 6.9 Hz, 1H), 2.44-2.38 (m, 1H), 1.89-1.75 (m, 4H), 1.61-1.43 (m, 3H), 
1.37 (dd, J = 13.2, 4.6 Hz, 1H), 1.33 (d, J = 7.0 Hz, 6H), 1.33 (s, 3H), 1.06 (s, 3H). 13C NMR (125 
MHz, CDCl3) δ 146.8, 145.9, 134.5, 127.0, 124.2, 124.0, 119.9 (q, J = 321.7 Hz), 55.1, 45.2, 38.2, 
37.5, 37.1, 35.7, 33.6, 29.9, 25.3, 24.1, 24.0, 18.9, 18.4, 18.1.19F NMR (470 MHz, Chloroform-d) 
δ -77.17. HRMS (ESI) m/z calculated for C21H30NO2F3SNa [M+Na]+: 440.1847, found 440.1846. 
[α]23D = +25.3 (c = 0.50, CHCl3). 
 
 
Methyl-(S)-2-((trifluoromethyl)sulfonamido)-3-(4-(((trifluoromethyl)sulfonyl) oxy) phenyl) 
propanoate (S29).  The reaction was performed according to reported procedure65 with L-tyrosine 
methyl ester hydrochloride (1.16 g, 5 mmol) affording 1.035 g (2.25 mmol) pure N-triflyl protected 
amine (S29) as a white solid in 45% yield. 
1H NMR (500 MHz, Chloroform-d) δ 7.33-7.18 (m, 4H), 5.39 (br s, 1H), 4.51 (t, J = 5.9 Hz, 1H), 
3.79 (d, J = 1.0 Hz, 3H), 3.25-3.12 (m, 2H). These data are in agreement with that previously 












1,1,1-trifluoro-N-((1-methyl-1H-indol-3-yl) methyl) methanesulfonamide (S30). The reaction 
was performed according to general procedure A with 3-(aminomethyl)-1-methylindole (730 mL, 
801 mg, 5.0 mmol). The reaction mixture was purified by flash column chromatography on silica 
(100 mL silica gel, 20% CH2Cl2/hexanes => 50% CH2Cl2/hexanes) to give 1.180 g (4.04 mmol) 
pure N-triflyl protected amine (S30) as a white solid in 81% yield. 
1H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J = 7.9 Hz, 1H), 7.39-7.29 (m, 2H), 7.22 (ddd, J = 
8.0, 6.7, 1.2 Hz, 1H), 7.07 (s, 1H), 5.03 (br s, 1H), 4.60 (s, 2H), 3.77 (s, 3H). 13C NMR (125 MHz, 
Chloroform-d) δ 137.2, 128.7, 126.5, 122.5, 120.0, 119.9 (q, J = 321.3 Hz), 118.5, 109.8, 108.3, 
40.0, 32.8. 19F NMR (470 MHz, Chloroform-d) δ -77.50. HRMS (ESI) m/z calculated for 




Preparation of Olefins 
 
 
N, N-diethylbut-3-enamide (S31). An oven-dried round-bottom flask was charged with a stir bar 
and vinyl acetic acid (426 µL, 5 mmol, 1.0 equiv). Oxalyl chloride (465 µL, 5.5 mmol, 1.1 equiv) 
was added dropwise to the reaction mixture at 0 °C and the reaction was warmed up to room 
temperature and stirred for 3 hours. The acid chloride was carried through to the next step without 
purification. To a solution of Et3N (730 µL, 5.25 mmol, 1.05 equiv) and Et2NH (517 µL, 5 mmol) 
in CH2Cl2 (25 mL, 0.2 M) at 0 °C was slowly added the acid chloride (1.0 equiv) and the reaction 
was allowed to warm to room temperature and stirred overnight. The reaction was quenched by 
addition of sat. aq. NH4Cl, extracted with CH2Cl2, dried over anhydrous Na2SO4 and concentrated 





mL silica gel, 10% ethyl acetate/hexanes => 20% ethyl acetate/hexanes) to give 593 mg (4.20 
mmol) product in 84% yield as a colorless oil. 
1H NMR (500 MHz, Chloroform-d) δ 5.98 (ddt, J = 16.9, 10.2, 6.5, 1H), 5.22-5.01 (m, 2H), 3.37 
(q, J = 7.1, 2H), 3.30 (q, J = 7.2, 2H), 3.11 (m, 2H), 1.17 (td, J = 7.2, 1.1 Hz, 3H), 1.11 (td, J = 
7.2, 1.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 170.1, 132.3, 117.4, 42.2, 40.2, 38.7, 14.5, 13.2. 
HRMS (ESI) m/z calculated for C8H16NO [M+H]+: 142.1232, found 142.1230. 
 
 
Dec-9-en-5-one (S32). An oven-dried round-bottom flask was charged with a stir bar, N-methoxy-
N-methylhex-5-enamide66 (786 mg, 5 mmol) and THF (20 mL, 0.25 M). The reaction mixture was 
cooled to -78 °C and n-BuLi (1.6 M in hexanes, 3.75 mL,  6.0 mmol, 1.2 equiv) was added 
dropwise. The reaction was stirred for 30 min and quenched with sat. aq. NH4Cl. Layers were 
separated, aqueous layer was extracted with Et2O, dried over anhydrous MgSO4 and concentrated 
under reduced pressure. The crude mixture was purified by flash column chromatography (100 
mL silica gel, 5% ethyl acetate/hexanes => 10% ethyl acetate/hexanes) to give 625 mg (4.05 mmol) 
product in 81% yield as a colorless oil. 
1H NMR (500 MHz, Chloroform-d) δ 5.76 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.05-4.94 (m, 2H), 
2.39 (q, J = 7.5 Hz, 4H), 2.10-2.02 (m, 2H), 1.67 (p, J = 7.3 Hz, 2H), 1.60-1.49 (m, 2H), 1.36-1.22 
(m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 211.4, 138.2, 115.3, 42.8, 42.0, 
33.3, 26.1, 23.0, 22.5, 14.0. HRMS (EI) m/z calculated for C10H17O [M-H]+: 153.12795, found 
153.12766. 










(±)-(E)-tert-butyldimethyl(nona-1,7-dien-4-yloxy)silane (S35).  
    An oven-dried round-bottom flask was charged with a stir bar, Weinreb amide ((4E)-N-
methoxy-N-methyl-4-hexenamide)67 (786 mg, 5 mmol, 1.0 equiv) and THF (20 mL, 0.25 M). The 
reaction mixture was cooled to -10 °C and allylmagnesium bromide (1.0 M in Et2O, 6.5 mL,  6.5 
mmol, 1.3 equiv) was added dropwise. The reaction was stirred for 30 min at -10 °C and poured 
onto a mixture of crushed ice (40 mL), sat. aq. NH4Cl (70 mL) and 1M HCl (15 mL). Layers were 
separated, aqueous layer was extracted with Et2O, dried over anhydrous MgSO4 and concentrated 
under reduced pressure. The crude mixture was purified by flash column chromatography (5% 
ethyl acetate/hexanes => 10% ethyl acetate/hexanes) to give 622 mg (4.05 mmol) product (S33) 
in 90% yield as a colorless oil. 
     An oven-dried round-bottom flask was charged with a stir bar, ketone (S33) (622mg, 4.05 
mmol, 1.0 equiv) and MeOH (8.0 mL, 0.5 M). The reaction was cooled to 0 °C and NaBH4 (613 
mg, 16.2 mmol, 4.0 equiv) was added in one portion. The reaction was allowed to warm up to 
room temperature and stirred overnight. The reaction was quenched with water. The resulting 
layers were separated and the aqueous layer was extracted by ethyl acetate (20 mL x 3).  The crude 
mixture was purified by flash column chromatography (10% ethyl acetate/hexanes => 20% ethyl 
acetate/hexanes) to give 495 mg (3.52 mmol) product (S34) in 87% yield as a colorless oil. 
     To an oven-dried round-bottom flask with a stir bar was added alcohol (S34) (495mg, 3.52 
mmol, 1.0 equiv), CH2Cl2 (18 mL, 0.2 M), TBSCl (583 mg, 5.87 mmol, 1.1 equiv) and imidazole 
(359mg, 5.28 mmol, 1.5 equiv). The reaction mixture was cooled to 0 °C and DMAP (43 mg, 0.1 
equiv) was added in one portion. The reaction was allowed to warm up to room temperature and 
stirred overnight. The reaction was quench with water. The resulting layers were separated and the 
aqueous layer was extracted by CH2Cl2 (20 mL x 3). Organic layers were combined, dried with 
anhydrous MgSO4 and concentrated under reduced pressure. The crude mixture was purified by 
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flash column chromatography (5% ethyl acetate/hexanes => 10% ethyl acetate/hexanes) to give 
769 mg (3.02 mmol) product (S35) in 86% yield as a colorless oil. 
1H NMR (500 MHz, Chloroform-d) δ 5.81 (ddt, J = 16.8, 10.4, 7.2 Hz, 1H), 5.42 (m, 2H), 5.08-
4.97 (m, 2H), 3.70 (p, J = 5.8 Hz, 1H), 2.21 (dddt, J = 6.8, 5.3, 4.0, 1.3 Hz, 2H), 2.11-1.92 (m, 
2H), 1.64 (dd, J = 3.5, 1.3 Hz, 3H), 1.54-1.42 (m, 2H), 0.89 (s, 9H), 0.05 (d, J = 0.9 Hz, 6H). 13C 
NMR (125 MHz, CDCl3) δ 135.5, 131.4, 124.9, 116.8, 71.7, 42.1, 36.9, 28.7, 26.1, 18.3, 18.1, -
4.2, -4.4. HRMS (EI) m/z calculated for C15H29OSi [M-H]+: 253.1988, found 253.1982. 
 
 
5-(pent-4-en-1-yl)-5H-dibenz[b,f]azepine (S36).  
To an oven-dried round-bottom flask with a stir bar was added 5H-dibenz[b,f]azepine (193 mg, 
1.0 mmol), 1,2-dichloroethane (5 mL, 0.2M), acetic acid (172 µL, 3.0 mmol, 3.0 equiv) and 4-
pentenal (197 µL, 2.0 mmol, 2.0 equiv). The reaction was stirred under room temperature for 30 
min. Then NaBH(OAc)3 (423 mg, 2.0 mmol, 2.0 equiv) was added, the reaction was stirred for 2 
hours. Upon completion, the reaction mixture was poured into a separatory funnel with sat. aq. 
NaHCO3. Layers were separated, and aqueous layers was extracted with ethyl acetate (10 mL x 
3). The crude mixture was purified by flash column chromatography (pure pentane) to give 238 
mg (0.91 mmol) product (S36) in 91% yield as a bright yellow oil. 
1H NMR (500 MHz, Chloroform-d) δ 7.25 (ddd, J = 8.1, 7.2, 1.7 Hz, 2H), 7.06 (dd, J = 7.6, 1.7 
Hz, 2H), 7.01 (dd, J = 8.2, 1.1 Hz, 2H), 6.98 (td, J = 7.4, 1.2 Hz, 2H), 6.73 (s, 2H), 5.76 (ddt, J = 
17.0, 10.2, 6.7 Hz, 1H), 5.03-4.83 (m, 2H), 3.72 (t, J = 6.9 Hz, 2H), 2.19-2.09 (m, 2H), 1.72-1.57 








2-(4-allylphenyl)-1,3,4-oxadiazole (S37).  
To an oven-dried round-bottom-flask equipped with a condenser was added a stir bar, LiCl (1.06 
g, 25 mmol, 5.0 equiv), THF (50 mL, 0.1 M), allyltributylstannane (1.7 mL, 5.5 mmol, 1.1 equiv), 
2-(4-bromophenyl)-1,3,4-oxadiazole (1.13g, 5.0 mmol, 1.0 equiv) and Pd(PPh3)4 (578 mg, 0.50 
mmol, 0.1 equiv). The reaction was heated to reflux and stirred overnight. Upon completion, the 
reaction was cooled to room temperature, transferred into a separatory funnel with ice cold 10% 
NH4OH solution (50 mL, diluted from 30% NH4OH solution) and shaken vigorously. Layers were 
separated, aqueous layer was extracted with ethyl acetate (30 mL x 3). Organic layers were 
combined and concentrated under reduced pressure. The crude mixture was purified by flash 
column chromatography (acetone/hexanes) to give 884 mg (4.75 mmol) product (S37) in 95% 
yield as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 8.45 (s, 1H), 8.01(d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 
2H), 6.05-5.85 (m, 1H), 5.17-5.05 (m, 2H), 3.46 (dd, J = 6.7, 1.6 Hz, 2H). 13C NMR (125 MHz, 
CDCl3) δ 164.6, 152.5, 144.4, 136.2, 129.3, 127.1, 121.3, 116.7, 40.0. HRMS (ESI) m/z calculated 








General Procedure to synthesis olefin substrates from phenolic compounds 
 
Scheme 5. General procedure for olefin substrate from phenolic compounds. 
 
 
    To an oven-dried round-bottom flask with a stir bar was added phenol starting material (5.0 
mmol, 1.0 equiv), CH2Cl2 (25 mL, 0.2 M), Et3N (1.39 mL ,10 mmol, 2.0 equiv). The reaction was 
cooled to 0 °C.  Trifluoromethanesulfonic anhydride (Tf2O, 1.0 mL, 6.0 mmol, 1.2 equiv) was 
added dropwise and the reaction was stirred at 0 °C for 30 min. After warming up to room 
temperature, the reaction was quenched with addition of cold water. The layers were separated, 
and the aqueous layer was extracted with CH2Cl2 (20 mL x 3). The organic layers were combined 
and concentrated under reduced pressure. The crude mixture was purified by flash column 
chromatography to the phenol triflate compound. 
     To an oven-dried round bottom flask equipped with condenser was added a stir bar, LiCl (4.0 
equiv), DMF (0.25 M), allyltributylstannane (1.1 equiv), phenol triflate (1.0 equiv) and Pd(PPh3)4 
(0.03 equiv). The reaction was heated to 100 °C and stirred for 12 hours. Upon completion, the 
reaction was cooled to room temperature, transferred into a separatory funnel with iced 10% 
NH4OH solution (1:1 to DMF) and shake vigorously. Layers were separated, aqueous layer was 
extracted with ethyl acetate (30 mL x 3). The organic layers were combined and concentrated 
under reduced pressure. The crude mixture was purified by flash column chromatography to give 










6-allyl-2H-chromen-2-one (S38) was synthesized according to the general procedure from 6-
hydroxycoumarin (811 mg, 5.0 mmol) in 60% yield (550.2 mg, 3.0 mmol) over two steps as a 
white solid.  
1H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J = 9.6 Hz, 1H), 7.35 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 
(d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 6.40 (d, J = 9.5 Hz, 1H), 5.95 (ddt, J = 16.9, 10.1, 
6.7 Hz, 1H), 5.20-4.98 (m, 2H), 3.43 (dt, J = 6.6, 1.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
161.1, 152.7, 143.5, 136.7, 136.5, 132.5, 127.5, 118.9, 117.0, 116.8, 116.8, 39.4. HRMS (ESI) 
m/z calculated for C12H11O2 [M+H]+: 187.0759, found 187.0764. 
 
 
(+)-Allylated-δ-Tocopherol derivative (S39) was synthesized according to the general procedure 
from (+)-δ-Tocopherol (2.01 g, 5.0 mmol) in 75% yield (1.602 g, 3.7 mmol) over two steps as a 
colorless oil.   
1H NMR (500 MHz, Chloroform-d) δ 6.80 (d, J = 2.2 Hz, 1H), 6.73 (d, J = 2.1 Hz, 1H), 5.97 (ddt, 
J = 16.8, 10.0, 6.8 Hz, 1H), 5.13-4.95 (m, 2H), 3.28 (d, J = 6.8 Hz, 2H), 2.80-2.61 (m, 2H), 2.16 
(s, 3H), 1.86-1.71 (m, 2H), 1.64-1.03 (m, 24H), 0.91-0.84 (m, 12H). 13C NMR (125 MHz, CDCl3) 
δ 150.5, 138.5, 130.2, 128.6, 126.8, 126.3, 120.4, 115.2, 75.96, 40.3, 39.7, 39.5, 37.6, 37.6, 37.4, 
33.0, 32.9, 31.4, 28.1, 25.0, 24.6, 24.4, 22.9, 22.8, 22.5, 21.1, 19.9, 19.8, 16.2. HRMS (ESI) m/z 










Scheme 6. Synthesis of olefin S41. 
 
(-)-Allylated ethinyl estradiol derivative (S41).  
     Allylated estrone (S40) was synthesized according to general procedure to form olefin 
substrates from phenolic compounds from estrone (1.35 g, 5.0 mmol, 1.0 equiv) in 73% yield (1.07 
g, 3.64 mmol) over 2 steps as a light yellow solid. 
     Following the procedure of Sierra and coworkers.68 t-BuLi (8.8 mL, 1.7 M in pentane, 5.0 
equiv) was carefully added dropwise to a solution of ethynyltrimethylsilane (2.22 mL, 15.0 mmol, 
5.0 equiv) in THF (60 mL) at -78 °C. After stirring at this temperature for 30 min the reaction was 
warmed up to 0 °C and then a solution of allylated estrone (883 mg, 3.0 mmol, 1.0 equiv) was 
added. The reaction was allowed to reach room temperature and stirred for 2 hours. Upon 
completion (monitored by TLC). The reaction mixture was cooled to 0 °C and quenched by sat. 
aq. NH4Cl. The layers were separated, and the aqueous layer was extracted with ethyl acetate (30 
mL x 3). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude mixture was purified by flash column 
chromatography (0 => 5% ethyl acetate/hexanes, 100 mL silica gel) to give allylated ethinyl 
estradiol derivative (S41) in 93% yield (1.104 g, 2.81 mmol) as a colorless gel.  
1H NMR (500 MHz, Chloroform-d) δ 7.26 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 8.1 Hz, 1H), 6.92 (s, 
1H), 5.96 (ddt, J = 16.8, 10.1, 6.8, 1H), 5.15-5.00 (m, 2H), 3.34 (d, J = 6.8 Hz, 2H), 2.86 (dd, J = 
7.7, 3.1 Hz, 2H), 2.40 (dq, J = 13.1, 4.0 Hz, 1H), 2.31 (ddd, J = 13.5, 9.6, 5.6 Hz, 1H), 2.27-2.19 
(m, 1H), 2.00 (ddd, J = 13.6, 11.9, 3.9 Hz, 1H), 1.94-1.75 (m, 4H), 1.74-1.66 (m, 2H), 1.55-1.34 















129.2, 126.0, 125.6, 115.7, 109.7, 90.1, 80.2, 49.8, 47.3, 44.2, 39.9, 39.4, 39.0, 33.0, 29.7, 27.4, 
26.4, 23.0, 12.9, 0.2. HRMS (EI) m/z calculated for C26H36OSi [M]+: 392.2536, found 392.2533. 
[α]22D = -9.0 (c = 0.51, CHCl3) 
 
(+)-Allylated dextromethorphan derivative (S42) was synthesized from 3-(OTf) 
dextromethorphan42 (1.95g, 5.0 mmol, 1.0 equiv) under the allylation condition from general 
procedure. The crude mixture was purified by flash column chromatography (5% =>20%, 100 mL 
Act II basic Al2O3) to give allylated olefin product (S42) in 88% yield (1.239 g, 4.40 mmol) as a 
colorless gel. 
1H NMR (500 MHz, Chloroform-d) δ 7.05 (s, 1H), 7.03 (d, J = 7.8 Hz, 1H), 6.93 (dd, J = 7.7, 1.8 
Hz, 1H), 5.97 (ddt, J = 16.8, 10.1, 6.7 Hz, 1H), 5.12-5.00 (m, 2H), 3.35 (d, J = 6.7 Hz, 2H), 3.00 
(d, J = 18.4 Hz, 1H), 2.81 (dd, J = 5.8, 3.1 Hz, 1H), 2.61 (dd, J = 18.4, 5.8 Hz, 1H), 2.46-2.37 (m, 
2H), 2.40 (s, 3H) 2.07 (td, J = 12.3, 3.3 Hz, 1H), 1.83 (dt, J = 12.8, 3.2 Hz, 1H), 1.74 (td, J = 12.6, 
4.8 Hz, 1H), 1.67-1.61 (m, 1H), 1.54-1.48 (m, 1H), 1.44-1.22 (m, 5H), 1.18-1.08 (m, 1H). 13C 
NMR (126 MHz, CDCl3) δ 140.5, 138.0, 137.8, 135.5, 127.8, 125.7, 125.6, 115.6, 58.1, 47.4, 45.7, 
42.9, 42.3, 40.3, 37.2, 36.7, 26.9, 26.8, 24.0, 22.3. HRMS (EI) m/z calculated for C20H28N 














Reaction development of Pd-Sulfoxide catalyzed allylic C—H Amination (Table 1) 
Entry 1 
Reaction proceeded according to reported procedure15 using Pd(OAc)2/bissulfoxide (10 mg, 0.02 
mmol, 0.1 equiv), Cr(salen)Cl (7.6 mg, 0.012 mmol, 0.06 equiv), 1,4 benzoquinone (43.2 mg, 0.4 
mmol, 2.0 equiv), allylcyclohexane (30.9 mg, 0.2 mmol, 1.0 equiv), N-(2-
Phenylethyl)trifluoromethanesulfonamide (50.6 mg, 0.2 mmol, 1.0 equiv) and 0.3 mL TBME 
(0.66 M). The mixture was concentrated under reduced pressure, the remaining mixture was 
diluted with 2 mL CDCl3 and crude 1H NMR was taken with internal standard (trifluorotoluene 
14.6 mg, 0.1 mmol, 0.5 equiv). Trace amount of product was observed by crude 1H NMR. The 
mixture was concentrated under reduced pressure and subjected to flash column chromatography 
(0% => 10% acetone in hexanes). No product was isolated by flash column chromatography. 
 
Reaction proceeded according to reported procedure30 using Pd(OAc)2/bissulfoxide (10 mg, 0.02 
mmol, 0.1 equiv), DIPEA (2.1 µL, 0.012 mmol, 0.06 equiv), BQ, (1,4 benzoquinone) (43.2 mg, 
0.4 mmol, 2.0 equiv), allylcyclohexane (30.9 mg, 0.2 mmol, 1.0 equiv), N-(2-
Phenylethyl)trifluoromethanesulfonamide (50.6 mg, 0.2 mmol, 1.0 equiv) and 0.3 mL TBME 
(0.66 M). Trace amount of product was observed by crude 1H NMR. No product was isolated by 
flash column chromatography. 
 
Entry 2  
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), ligand 1 (6.3 mg, 
0.02 mmol, 0.1 equiv), 2,6 DMBQ (2,6-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 
allylcyclohexane (30.9 mg, 0.2 mmol, 1.0 equiv) and N-(2-
Phenylethyl)trifluoromethanesulfonamide (50.6 mg, 0.2 mmol, 1.0 equiv). Toluene (0.2 mL, 1.0 
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M) was added and the vial was capped and heated to 45 °C for 72 hours. The vial was allowed to 
cool to room temperature and diluted with 1 mL acetone. The reaction mixture was filtered through 
a pipette silica plug into a 20mL vial with acetone. The mixture was concentrated under reduced 
pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H NMR with internal standard 
(trifluorotoluene 14.6 mg, 0.1 mmol, 0.5 equiv). The mixture was then concentrated under reduced 
pressure and subjected to flash column chromatography (0% => 10% acetone in hexanes) to 
provide allylic amine product 1 as a clear oil. Run 1(22.1 mg, 29.4% yield); Run 2 (22.9 mg, 30.5% 
yield); Average: 30% yield. 
 
Entry 3 
The same conditions used in Entry 3 were used except using BQ (benzoquinone) (23.8 mg, 0.22 




General procedure: The following procedure was used with no effort to exclude air or moisture. 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-SOX-Ligand 
1(L1) (6.3 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv), allylcyclohexane (30.9 mg, 0.2 mmol, 1.0 equiv) and N-(2-
Phenylethyl)trifluoromethanesulfonamide (50.6 mg, 0.2 mmol, 1.0 equiv). Toluene (0.2 mL, 1.0 
M) was added and the vial was capped and heated to 45 °C for 72 hours. The vial was allowed to 
cool to room temperature and diluted with 1 mL acetone. The reaction mixture was filtered through 
a pipette silica plug into a 20mL vial with acetone. The mixture was concentrated under reduced 
pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H NMR with internal standard 
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(trifluorotoluene 14.6 mg, 0.1 mmol, 0.5 equiv). The mixture was then concentrated under reduced 
pressure and subjected to flash column chromatography (0% => 20% CH2Cl2 in hexanes) to 
provide allylic amine 1 as a clear oil. Run 1 (38.8 mg, 51.7% yield); Run 2 (39.4 mg, 52.5% yield); 
Average: 52% yield. 
 
Entry 5 
The general procedure was followed using (±)-SOX-Ligand 2 (L2) (8.7 mg, 0.02 mmol, 0.1 equiv). 
Run 1 (15.7 mg, 20.9% yield); Run 2 (16.0 mg, 21.3% yield); Average: 21% yield. 
 
Entry 6 
The general procedure was followed using (±)-SOX-Ligand 3 (L3) (7.6 mg, 0.02 mmol, 0.1 equiv). 
Run 1 (23.8 mg, 31.7% yield); Run 2 (23.7 mg, 31.6% yield); Average: 32% yield. 
 
Entry 7 
The general procedure was followed using (±)-SOX-Ligand 4 (L4) (6.9 mg, 0.02 mmol, 0.1 equiv). 
Run 1 (41.3 mg, 54.9% yield); Run 2 (41.8 mg, 55.7% yield); Average: 55% yield. 
 
Entry 8 
The general procedure was followed using (±)-MeO-SOX Ligand (L5) (6.9 mg, 0.02 mmol, 0.1 
equiv). Run 1 (56.9 mg, 75.8% yield); Run 2 (56.1 mg, 74.7% yield); Run 3 (56.6 mg, 75.3% 







The general procedure was followed using (±)-SOX-Ligand 6 (L6) (6.6 mg, 0.02 mmol, 0.1 equiv). 
Run 1 (46.6 mg, 62.1% yield); Run 2 (47.2 mg, 62.9% yield); Average: 63% yield. 
 
Entry 10 
The general procedure was followed using (±)-SOX-Ligand 7 (L7) (7.4 mg, 0.02 mmol, 0.1 equiv). 
Run 1 (41.7 mg, 55.5% yield); Run 2 (41.2 mg, 54.8% yield); Average: 55% yield. 
 
Entry 11 
The general procedure was followed using (±)-SOX-Ligand 8 (L8) (7.2 mg, 0.02 mmol, 0.1 equiv). 
Run 1 (55.2 mg, 73.5% yield); Run 2 (55.4 mg, 73.7% yield); Average: 74% yield. 
 
Entry 12 
The reaction proceeded under general procedure using Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv) 
(±)-MeO-SOX Ligand (L5) (3.4 mg, 0.01 mmol, 0.05 equiv). Run 1(39.9 mg, 53.1% yield); Run 
2 (40.1 mg, 53.4% yield); Average: 53% yield. 
 
Entry 13 
The general procedure was followed without any ligand. No product was detected by crude 1H 
NMR. No product or allylcyclohexene (volatile under reduced pressure) could be isolated by flash 







The general procedure was followed and the reaction was stopped at 48 h. Run 1 (54.6 mg, 72.7% 
yield); Run 2 (55.1 mg, 73.4% yield); Average: 73% yield. 
 
Entry 15 
The general procedure was followed and the reaction was stopped at 24 h. Run 1 (40.7 mg, 54.2% 
yield); Run 2 (40.1 mg, 53.4% yield); Average: 54% yield. 
 
Entry 16 
The general procedure was followed. The reaction was run at 55 and was stopped at 24 h. Run 1 
(49.4 mg, 65.8% yield); Run 2 (48.8 mg, 65.0% yield); Average: 65% yield. 
                        
 
(E)-N-(3-cyclohexylallyl)-1,1,1-trifluoro-N-phenethylmethanesulfonamide (1).  
1H NMR (500 MHz, Chloroform-d) δ 7.35 (dd, J = 8.1, 6.7 Hz, 2H), 7.30-7.25 (m, 1H), 7.22-7.18 
(m, 2H), 5.69 (dd, J = 15.4, 6.8 Hz, 1H), 5.37 (dt, J = 15.4, 7.0, 1H), 3.92 (d, J = 7.0 Hz, 2H), 3.55 
(br s, 2H), 2.94 (t, J = 8.0 Hz, 2H), 2.09-2.00 (m, 1H), 1.77 (m, 4H), 1.72-1.67 (m, 1H), 1.37-1.26 
(m, 2H), 1.24-1.07 (m, 3H). 13C NMR (126 MHz, Chloroform-d) δ 144.0, 137.6, 128.9, 127.0, 
120.6 120.2 (q, J = 323.3 Hz). 51.2, 48.8, 40.5, 35.5, 32.7, 26.1, 26.0. (one carbon missing probably 
due to overlapping) 19F NMR (470 MHz, Chloroform-d) δ -76.42. HRMS (ESI) m/z calculated 







Reaction scope  
General procedure:  
The following procedure was used with no effort to exclude air or moisture. To a ½ dram vial was 
added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 
0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 
olefin (0.2 mmol, 1.0 equiv) and N-trifyl protected amine (0.2 mmol, 1.0 equiv). Toluene (0.2 mL, 
1.0 M) was added and the vial was capped and heated to 45 °C for 24-72 hours (monitored by 
TLC). The vial was allowed to cool to room temperature and diluted with 1 mL acetone. The 
reaction mixture was filtered through a pipette silica plug into a 20 mL vial with acetone. The 
mixture was concentrated under reduced pressure, diluted with 2 mL CDCl3 and analyzed by crude 
1H NMR with internal standard (trifluorotoluene 14.6 mg, 0.1 mmol, 0.5 equiv). The mixture was 
then concentrated under reduced pressure and subjected to flash column chromatography. 
 
 
(E)-N-(3-cyclohexylallyl)-1,1,1-trifluoro-N-phenylmethanesulfonamide (2). Pd(OAc)2 (4.4 
mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane (24.8 mg, 
0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S11) (45.0 mg, 0.2 mmol, 
1.0 equiv) were reacted according to the general procedure for 72 hours. Purification by flash 
column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product 
2 as a colorless oil. Run 1: (48.1 mg, 69.2% yield); Run 2: (49.1 mg, 70.6% yield); Run 3: (49.2 





1H NMR (500 MHz, Chloroform-d) δ 7.42-7.34 (m, 3H), 7.29-7.23 (m, 2H), 5.43-5.33 (m, 2H), 
4.27 (d, J = 5.2 Hz, 2H), 1.92-1.82 (m, 1H), 1.69-1.51 (m, 5H), 1.28-1.15 (m, 2H), 1.14-1.05 (m, 
1H), 0.98-0.87 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 144.2, 136.9, 129.8, 129.4, 129.2, 120.5 
(q, J = 323.7), 120.4, 56.1, 40.3, 32.5, 26.1, 25.9. 19F NMR (470 MHz, CDCl3) δ -76.67. HRMS 
(ESI) m/z calculated for C16H20NO2F3SNa [M+Na]+: 370.1065, found 370.1074. 
 
 
(E)-N-benzyl-N-(3-cyclohexylallyl)-1,1,1-trifluoromethanesulfonamide (3). Pd(OAc)2 (4.4 
mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane (24.8 mg, 
0.2 mmol, 1.0 equiv) and N-benzyl-1,1,1-trifluoromethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 
1.0 equiv) were reacted according to the general procedure for 72 hours. Purification by flash 
column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product 
3 as a colorless oil. Run 1: (58.9 mg, 81.5% yield); Run 2: (59.4 mg, 82.2% yield); Run 3: (59.6 
mg, 82.4% yield). Average: 82% yield ± 0.5%.    
1H NMR (500 MHz, Chloroform-d) δ 7.41-7.33 (m, 3H), 7.32-7.28 (m, 2H), 5.50 (dd, J = 15.4, 
6.8 Hz, 1H), 5.29 (dt, J = 14.8, 7.0 Hz, 1H), 4.49 (br s, 2H), 3.81 (br s, 2H), 2.05-1.92 (m, 1H), 
1.78-1.62 (m, 5H), 1.33-1.22 (m, 2H), 1.22-1.12 (m, 1H), 1.10-1.00 (m, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 144.6, 134.3, 129.0, 128.7, 128.5, 120.2 (q, J = 322.8 Hz), 119.7, 50.4, 49.6, 40.6, 
32.7, 26.2, 26.0. 19F NMR (470 MHz, Chloroform-d) δ -76.40. HRMS (EI) m/z calculated for 









(4). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl 
cyclohexane (24.8 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-(naphthalen-1-
ylmethyl)methanesulfonamide (S13) (57.9 mg, 0.2 mmol, 1.0 equiv) were reacted according to the 
general procedure for 72 hours. Purification by flash column chromatography (50 mL silica gel, 
0% => 30% CH2Cl2 in hexanes) provided pure product 4 as a colorless oil. Run 1: (57.9 mg, 70.4% 
yield); Run 2: (57.0 mg, 69.3% yield); Run 3: (58.5 mg, 71.1% yield). Average: 70% yield ± 
0.9%.    
1H NMR (500 MHz, Chloroform-d) δ 8.12 (dd, J = 8.4, 1.1 Hz, 1H), 7.91-7.88 (m, 1H), 7.86 (d, 
J = 7.4 Hz, 1H), 7.60-7.45 (m, 4H), 5.36-5.19 (m, 2H), 5.01 (br s, 2H), 3.83 (br s, 2H), 1.90-1.76 
(m, 1H), 1.70-1.59 (m, 3H), 1.57-1.50 (m, 2H), 1.29-1.15 (m, 2H), 1.14-1.03 (m, 1H), 0.94-0.82 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 144.0, 134.0, 131.6, 129.5, 129.4, 129.0, 127.3, 126.9, 
126.2, 125.3, 122.9, 120.4 (q, J = 323.8 Hz), 119.9, 50.2, 48.8, 40.4, 32.5, 26.1, 25.9. 19F NMR 
(470 MHz, Chloroform-d) δ -75.47. HRMS (ESI) m/z calculated for C21H24NO2F3SNa [M+Na]+: 
434.1378, found 434.1388. 
 
 
(E)-N-(3-cyclohexylallyl)-1,1,1-trifluoro-N-methylmethanesulfonamide (5). Pd(OAc)2 (4.4 
mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane (24.8 mg, 







1.0 equiv) were reacted according to the general procedure for 72 hours. Purification by flash 
column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product 
5 as a colorless oil. Run 1: (41.7 mg, 73.1% yield); Run 2: (41.4 mg, 72.6% yield); Run 3: (41.9 
mg, 73.6% yield). Average: 73% yield ± 0.5%.    
1H NMR (500 MHz, Chloroform-d) δ 5.68 (dd, J = 15.4, 6.7 Hz, 1H), 5.34 (dt, J = 15.3, 6.9Hz, 
1H), 3.87 (br s, 2H), 2.94 (s, 3H), 2.07-1.90 (m, 1H), 1.76-1.61 (m, 5H), 1.33-1.22 (m, 2H), 1.20-
1.12 (m, 1H), 1.12-1.02 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 144.0, 120.3 (q, J = 323.6 
Hz), 120.2, 53.2, 40.5, 34.3, 32.8, 26.2, 26.0. 19F NMR (470 MHz, Chloroform-d) δ -75.77. 
HRMS (EI) m/z calculated for C11H18NO2F3S [M]+: 285.1010, found 285.1012. 
 
 
(E)-N-butyl-N-(3-cyclohexylallyl)-1,1,1-trifluoromethanesulfonamide (6). Pd(OAc)2 (4.4 mg, 
0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ 
(2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane (24.8 mg, 0.2 mmol, 
1.0 equiv) and N-butyl-1,1,1-trifluoromethanesulfonamide (S15) (41.0 mg, 0.2 mmol, 1.0 equiv) 
were reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product 6 as a 
colorless oil. Run 1: (33.1 mg, 50.5% yield); Run 2: (33.6 mg, 51.3% yield); Run 3: (33.4 mg, 
51.0% yield). Average: 51% yield ± 0.4%.    
1H NMR (500 MHz, Chloroform-d) δ 5.66 (dd, J = 15.4, 6.7 Hz, 1H), 5.34 (dt, J = 15.4, 7.0, 1H), 
3.91 (d, J = 7.0 Hz, 2H), 3.30 (br s, 2H), 2.06-1.95 (m, 1H), 1.77-1.67 (m, 5H), 1.57 (p, J = 7.7 
Hz, 2H), 1.36-1.21 (m, 4H), 1.21-1.13 (m, 1H), 1.12-1.02 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C 










(7). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl 
cyclohexane (24.8 mg, 0.2 mmol, 1.0 equiv) and tert-butyl (2-
((trifluoromethyl)sulfonamido)ethyl)carbamate (S16) (58.4  mg, 0.2 mmol, 1.0 equiv) were 
reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (50 mL silica gel, 0% => 5% acetone in hexanes) and preparative TLC (10% ethyl 
acetate in hexanes) provided pure product 7 as a colorless oil. Run 1: (52.3 mg, 63.1% yield); Run 
2: (51.9mg, 62.6% yield); Run 3: (52.9 mg, 63.9% yield). Average: 63% yield ± 0.7%.   
1H NMR (500 MHz, Chloroform-d) δ 5.73 (dd, J = 15.5, 6.7 Hz, 1H), 5.38-5.28 (m, 1H), 4.74 (d, 
J = 6.4 Hz, 1H), 3.97 (d, J = 7.1 Hz, 2H), 3.41 (br s, 2H), 3.30 (br q, J = 6.2 Hz, 2H), 2.05-1.93 
(m, 1H), 1.77-1.61 (m, 5H), 1.44 (s, 9H), 1.31-1.21 (m, 2H), 1.19-1.12 (m, 1H), 1.12-1.02 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ 156.0, 144.7, 120.11 (q, J = 120.11), 120.1, 79.9, 51.0, 46.6, 40.5, 
38.4, 32.6, 28.4, 26.1, 26.0. 19F NMR (470 MHz, CDCl3) δ -76.28. HRMS (ESI) m/z calculated 
for C17H30N2O4F3S [M+H]+: 415.1878, found 415.1866. 
 
 
(E)-N-(3-cyclohexylallyl)-1,1,1-trifluoro-N-(2-methoxyethyl) methanesulfonamide (8). 









equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane 
(24.8 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-(2-methoxyethyl)methanesulfonamide (S17) 
(41.4 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. 
Purification by flash column chromatography (50 mL silica gel, 0% => 20% acetone in hexanes) 
provided pure product 8 as a colorless oil. Run 1: (40.9mg, 62.1% yield); Run 2: (41.6 mg, 63.1% 
yield); Run 3: (42.2 mg, 64.1% yield). Average: 63% yield ± 1.0%.   
 1H NMR (500 MHz, Chloroform-d) δ 5.68 (dd, J = 15.5, 6.6 Hz, 1H), 5.34 (dt, J = 15.3, 7.0, 1H), 
4.00 (d, J = 6.9 Hz, 2H), 3.54 (t, J = 5.7 Hz, 2H), 3.48 (br s, 2H), 3.34 (s, 3H), 2.04-1.95 (m, 1H), 
1.75-1.68 (m, 4H), 1.68-1.63 (m, 1H), 1.31-1.05 (m, 5H).  13C NMR (125 MHz, CDCl3) δ 144.0, 
121.4, 121.4 (q, J =321.3 Hz), 71.3, 59.0, 52.0, 46.4, 40.5, 32.7, 26.2, 26.0. 19F NMR (470 MHz, 





Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane 
(24.8 mg, 0.2 mmol, 1.0 equiv) and N-(2-bromoethyl)-1,1,1-trifluoromethanesulfonamide (S18).  
(51.2 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. 
Purification by flash column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) 
provided pure product 9 as a colorless oil. Run 1: (44.9 mg, 59.4% yield); Run 2: (45.7 mg, 60.5% 
yield); Run 3: (45.6 mg, 60.3% yield). Average: 60% yield ± 0.6%.   
1H NMR (500 MHz, Chloroform-d) δ 5.82-5.60 (m, 1H), 5.36 (dtd, J = 15.4, 7.1, 1.3 Hz, 1H), 






4H), 1.33-1.22 (m, 2H), 1.21-1.14 (m, 1H), 1.13-1.03 (m, 2H). 13C NMR (126 MHz, Chloroform-
d) δ 144.8, 120.3, 120.0 (q, J = 323.0 Hz), 52.2, 48.7, 40.5, 32.6, 27.9, 26.1, 26.0. 19F NMR (470 
MHz, Chloroform-d) δ -76.20. HRMS (ESI) m/z calculated for C12H19NO2F3SNa [M+Na]+: 




Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane 
(24.8 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-(2,2,2-trifluoroethyl)methanesulfonamide 
(S19) (46.2 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 24 hours. 
Purification by flash column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) 
provided pure product 10 as a colorless oil. Run 1: (63.2 mg, 89.5% yield); Run 2: (64.1 mg, 90.7% 
yield); Run 3: (63.5 mg, 89.8% yield). Average: 90% yield ± 0.6%.   
1H NMR (500 MHz, Chloroform-d) δ 5.77 (dd, J = 15.5, 6.8 Hz, 1H), 5.38-5.23 (m, 1H), 4.06 (d, 
J = 7.3 Hz, 2H), 3.89 (q, J = 8.4 Hz, 2H), 2.04 (dtt, J = 10.8, 6.9, 3.5 Hz, 1H), 1.79-1.63 (m, 5H), 
1.34-1.22 (m, 2H), 1.22-1.14 (m, 1H), 1.14-1.05 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 
146.9, 123.58 (q, J = 280.3 Hz), 119.83 (q, J = 322.2 Hz), 118.5, 52.0, 46.22 (q, J = 35.8 Hz), 40.6, 
32.6, 26.0, 25.9. 19F NMR (470 MHz, Chloroform-d) δ -69.96, -76.32. HRMS (EI) m/z calculated 











(-)-Methyl (E)-N-(3-cyclohexylallyl)-N-((trifluoromethyl)sulfonyl)-L-alaninate (11). 
Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane 
(24.8 mg, 0.2 mmol, 1.0 equiv) and methyl ((trifluoromethyl)sulfonyl)-L-alaninate (S20) (47.0 mg, 
0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. Purification 
by flash column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure 
product (-)-11 as a colorless oil. Run 1: (57.3 mg, 80.2% yield); Run 2: (57.0 mg, 79.7% yield); 
Run 3: (57.8 mg, 80.9% yield). Average: 80% yield ± 0.6%.    
1H NMR (500 MHz, Chloroform-d) δ 5.61 (dd, J = 15.5, 6.6, 1H), 5.41 (dt, J = 14.8, 6.8 Hz, 1H), 
4.56 (q, J = 7.3 Hz, 1H), 4.01 (d, J = 6.6 Hz, 2H), 3.76 (s, 3H), 1.99-1.90 (m, 1H), 1.77-1.61 (m, 
5H), 1.53 (d, J = 7.4 Hz, 3H), 1.31-1.21 (m, 2H), 1.20-1.12 (m, 1H), 1.10-0.99 (m, 2H). 13C NMR 
(125 MHz, CDCl3) δ 170.8, 142.6, 122.3, 119.9 (q, J = 323.0), 56.5, 52.7, 50.0, 41.4, 32.5, 26.2, 
26.0, 16.6. 19F NMR (470 MHz, CDCl3) δ -76.61. HRMS (ESI) m/z calculated for 
C14H22NO4F3SNa [M+Na]+: 380.1119, found 380.1120.  [α]23D = -1.84 (c = 0.51, CHCl3) 
 
 
(-)-methyl (E)-N-(3-cyclohexylallyl)-N-((trifluoromethyl)sulfonyl)-L-phenylalaninate (12). 
Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane 
(24.8 mg, 0.2 mmol, 1.0 equiv) and methyl ((trifluoromethyl)sulfonyl)-L-phenylalaninate (S21) 
(62.2 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. 







provided pure product (-)-12 as a colorless oil. Run 1: (60.0 mg, 69.2% yield); Run 2: (60.9 mg, 
70.2% yield); Run 3: (61.4 mg, 70.8% yield). Average: 70% yield ± 0.8%.    
1H NMR (500 MHz, Chloroform-d) δ 7.34-7.30 (m, 2H), 7.28-7.22 (m, 3H), 5.68 (dd, J = 15.5, 
6.5, 1H), 5.42 (dt, J = 15.4, 6.9, 1H), 4.71 (t, J = 7.4 Hz, 1H), 4.06 (dd, J = 7.0, 3.7 Hz, 2H), 3.71 
(s, 3H), 3.44 (dd, J = 14.1, 8.0 Hz, 1H), 3.04 (dd, J = 14.1, 6.8 Hz, 1H), 2.06-1.89 (m, 1H), 1.84-
1.58 (m, 5H), 1.34-1.22 (m, 2H), 1.22-1.14 (m, 1H), 1.14-1.02 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 169.9, 143.0, 136.3, 129.4, 128.9, 127.4, 122.2, 119.9 (q, J = 323.5 Hz) 62.3, 52.7, 50.3, 
40.5, 37.3, 32.6, 26.3, 26.1. 19F NMR (470 MHz, Chloroform-d) δ -75.98. HRMS (ESI) m/z 
calculated for C20H26NO4F3SNa [M+Na]+: 454.1432, found 454.1422.  [α]23D = -36.8 (c = 0.50, 
CHCl3) 
Complete stereoretention was proven by chiral HPLC analysis. The enantiomeric excess was 
determined to be >99% ee by chiral HPLC analysis (against mixture of (-)-12 (52%) and (+)-12 
(48%)) (CHIRALPAK AD-RH column, 0.25 mL/min, 80% EtOH in H2O, λ = 220nm (4nm). 
tR(major) = 20.177 min).  
 
 
(-)-methyl N-((E)-3-cyclohexylallyl)-N-((trifluoromethyl)sulfonyl)-L-alloisoleucinate (13). 
Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allyl cyclohexane 
(24.8 mg, 0.2 mmol, 1.0 equiv) and Methyl ((trifluoromethyl)sulfonyl)-L-isoleucinate (S23) (55.5 
mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. 







provided pure product (-)-13 as a colorless oil. Run 1: (60.0 mg, 75.1% yield); Run 2: (60.4 mg, 
75.6% yield); Run 3: (59.7 mg, 74.7% yield). Average: 75% yield ± 0.5%.    
1H NMR (500 MHz, Chloroform-d) δ 5.64 (dd, J = 15.5, 6.5 Hz, 1H), 5.52-5.43 (m, 1H), 4.24 (dd, 
J = 16.0, 8.4 Hz, 1H), 4.16-4.05 (m, 2H), 3.74 (s, 3H), 2.05-1.90 (m, 2H), 1.75-1.62 (m, 6H), 1.31-
0.98 (m, 6H), 0.93-0.86 (m, 6H).  13C NMR (125 MHz, CDCl3) δ 170.7, 141.8, 123.0, 119.9 (q, J 
=323.2 Hz), 65.7, 52.1, 49.3, 40.4, 34.4, 32.5, 26.2, 26.0, 25.2, 15.4, 10.7. 19F NMR (470 MHz, 
CDCl3) δ -75.45. HRMS (ESI) m/z calculated for C17H28NO4F3SNa [M+Na]+: 422.1589, found 




Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 6-Heptenoic acid 
methyl ester (28.4 mg, 0.2 mmol, 1.0 equiv) and N-(2-Phenylethyl)trifluoromethanesulfonamide 
(S10) (50.6 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. 
Purification by flash column chromatography (50 mL silica gel, 0% => 10% acetone in hexanes) 
and preparative TLC provided pure product 14 as a colorless oil. Run 1: (46.6 mg, 59.2% yield); 
Run 2: (47.4 mg, 60.3% yield); Run 3: (47.8 mg, 60.8% yield). Average: 60% yield ± 0.8%.    
1H NMR (500 MHz, Chloroform-d) δ 7.37-7.29 (m, 2H), 7.27-7.23 (m, 1H), 7.21-7.14 (m, 2H), 
5.72-5.62 (m, 1H), 5.41 (dt, J = 15.3, 6.9, 1H), 3.88 (d, J = 6.9 Hz, 2H), 3.67 (s, 3H), 3.52 (br s, 
2H), 2.91 (t, J = 7.9 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 2.18-2.08 (m, 2H), 1.74 (p, J = 7.5 Hz, 2H). 
13C NMR (126 MHz, Chloroform-d) δ 173.8, 137.5, 136.8, 128.9, 128.9, 127.0, 124.2, 120.1 (q, 
J = 323.2 Hz), 51.7, 50.8, 48.9, 35.5, 33.4, 31.6, 24.2. 19F NMR (470 MHz, Chloroform-d) δ -









(15). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), N, N-
diethylbut-3-enamide (S31). (28.2 mg, 0.2 mmol, 1.0 equiv) and N-(2-bromoethyl)-1,1,1-
trifluoromethanesulfonamide (S18). (51.2 mg, 0.2 mmol, 1.0 equiv) were reacted according to the 
general procedure for 72 hours. Purification by flash column chromatography (column 1: 50 mL 
silica gel, 0% => 10% acetone in hexanes) and preparative TLC provided pure product 15 as 
colorless oil. Run 1: (67.4 mg, 85.3% yield); Run 2: (66.7 mg, 84.4% yield); Run 3: (68.0 mg, 
86.0% yield). Average: 85% yield ± 0.8%.    
1H NMR (500 MHz, Chloroform-d) δ 6.74 (dt, J = 15.1, 6.3 Hz, 1H), 6.45 (d, J = 15.1,  1H), 4.22 
(d, J = 6.3 Hz, 2H), 3.72 (br s, 2H), 3.46 (t, J = 7.1 Hz, 2H), 3.42 (q, J = 7.2 Hz, 2H), 3.36 (q, J = 
7.2 Hz, 2H), 1.19 (t, J = 7.2 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, Chloroform-
d) δ 164.1, 136.4, 125.9, 119.8 (q, J = 322.9 Hz), 50.6, 49.6, 42.4, 42.1, 27.9, 15.0, 13.1. 19F NMR 
(470 MHz, Chloroform-d) δ -76.19. HRMS (ESI) m/z calculated for C11H19N2O3F3SBr [M+H]+: 
395.0252, found 395.0251. 
 
 
(E)-N-benzyl-1,1,1-trifluoro-N-(6-oxodec-2-en-1-yl)methanesulfonamide (16). Pd(OAc)2 (4.4 
mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), Dec-9-en-5-one (S32) (30.9 
mg, 0.2 mmol, 1.0 equiv) and1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 










flash column chromatography (50 mL silica gel, 0% => 5% acetone in hexanes) and preparative 
TLC (40% CH2Cl2 in hexanes) provided pure product 16 as a colorless oil. Run 1: (42.5 mg, 54.3% 
yield); Run 2: (43.1 mg, 55.0% yield); Run 3: (43.4 mg, 55.5% yield). Average: 55% yield ± 
0.6%.    
1H NMR (500 MHz, Methylene Chloride-d2) δ 7.39-7.30 (m, 3H), 7.30-7.26 (m, 2H), 5.59-5.45 
(m, 1H), 5.37-5.27 (m, 1H), 4.45 (br s, 2H), 3.78 (br s, 2H), 2.41 (t, J = 7.2 Hz, 2H), 2.35 (t, J = 
7.5 Hz, 2H), 2.27-2.19 (m, 2H), 1.49 (p, J = 7.5 Hz, 2H), 1.32-1.21 (m, 2H), 0.87 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 210.3, 137.7, 135.2, 129.6, 129.3, 129.1, 123.8, 122.2 
(q, J = 323.8 Hz), 51.4, 50.2, 43.2, 42.1, 26.9, 26.7, 23.1, 14.4. 19F NMR (470 MHz, Methylene 




(+)-tert-butyl-(S,E)-(2-((1,1,1-trifluoro-N-(3-(4-(oxiran-2-ylmethoxy) phenyl) allyl) methyl) 
sulfonamido) ethyl)carbamate (17). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv), (S)-2-((4-allylphenoxy)methyl)oxirane30 (30.9 mg, 0.2 mmol, 1.0 equiv) 
and1,1,1-trifluoro-N-phenylmethanesulfonamide (S16). (47.8 mg, 0.2 mmol, 1.0 equiv) were 
reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (column 1: 50 mL silica gel, 0% => 15% acetone in hexanes) provided pure 
product 17 as a white solid. Run 1: (86.9 mg, 90.4% yield); Run 2: (85.6 mg, 89.1% yield); Run 









1H NMR (500 MHz, Chloroform-d) δ 7.33 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.61 (d, 
J = 15.7 Hz, 1H), 5.97 (dt, J = 15.7, 7.2 Hz, 1H), 4.81-4.75 (m, 1H), 4.24 (dd, J = 11.0, 3.1 Hz, 
1H), 4.18 (d, J = 7.2 Hz, 2H), 3.95 (dd, J = 11.1, 5.8 Hz, 1H), 3.47 (br s, 2H), 3.38-3.30 (m, 3H), 
2.91 (t, J = 4.5 Hz, 1H), 2.76 (dd, J = 4.9, 2.6 Hz, 1H), 1.44 (s, 9H). 13C NMR (126 MHz, 
Chloroform-d) δ 158.9, 156.1, 136.0, 129.0, 128.2, 120.11 (q, J = 323.0 Hz), 119.8, 114.9, 80.0, 
68.9, 51.1, 50.2, 46.9, 44.8, 38.4, 28.5. 19F NMR (470 MHz, Chloroform-d) δ -76.29. HRMS 
(ESI) m/z calculated for C20H27N2O6F3SNa [M+Na]+: 503.1434, found 503.1441. [α]22D = +2.5 (c 




trifluoromethanesulfonamide (18). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv),  (±)-(E)-tert-butyldimethyl(nona-1,7-dien-4-yloxy)silane (S35) (50.9 mg, 0.2 
mmol, 1.0 equiv) and1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 
equiv) were reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (column 1: 50 mL silica gel, 0% => 5% acetone in hexanes) provided pure 
product (±)-18 as a colorless oil. Run 1: (58.7 mg, 59.7% yield); Run 2: (59.7 mg, 60.7% yield); 
Run 3: (59.4 mg, 60.4% yield). Average: 60% yield ± 0.5%.    
1H NMR (500 MHz, Chloroform-d) δ 7.42-7.33 (m, 3H), 7.32-7.29 (m, 2H), 5.64-5.50 (m, 2H), 
5.48-5.36 (m, 2H), 4.48 (br s, 2H), 4.14 (q, J = 5.7 Hz, 1H), 3.85 (br s, 2H), 2.07-1.97 (m, 2H), 
1.66 (d, J = 4.9, 3H), 1.61-1.42 (m, 2H), 0.92 (s, 9H), 0.07 (s, 3H), 0.04 (s, 3H). 13C NMR (126 
MHz, Chloroform-d) δ 141.1, 134.1, 130.8, 129.1,128.7, 128.6, 125.4, 121.5, 120.19 (q, J = 322.7 










phenethylmethanesulfonamide (19). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv), (R)-4,8-dimethylnona-1,7-diene69 (30.5 mg, 0.2 mmol, 1.0 equiv) and N-(2-
Phenylethyl)trifluoromethanesulfonamide (S10) (50.6 mg, 0.2 mmol, 1.0 equiv) were reacted 
according to the general procedure for 72 hours. Purification by flash column chromatography (50 
mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product 14 as colorless oil. Run 1: 
(54.4 mg, 67.4% yield); Run 2: (55.1 mg, 68.3% yield); Run 3: (55.7 mg, 69.0% yield). Average: 
68% yield ± 0.8%.    
1H NMR (500 MHz, Chloroform-d) δ 7.35-7.29 (m, 2H), 7.29-7.22 (m, 1H), 7.20-7.16 (m, 2H), 
5.59 (dd, J = 15.3, 7.8, 1H), 5.36 (dt, J = 14.6, 7.0, 1H), 5.12-5.05 (m, 1H), 3.96-3.85 (m, 2H), 
3.55 (br s, 2H), 2.92 (t, J = 8.0 Hz, 2H), 2.21 (hept, J = 7.0 Hz, 1H), 1.96 (q, J = 7.6 Hz, 2H), 1.69 
(s, 3H), 1.58 (s, 3H), 1.35 (q, J = 7.3 Hz, 2H), 1.02 (d, J = 6.7, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 144.0, 137.6, 131.9, 128.9, 128.9, 127.1, 124.2, 121.5, 120.1 (q, J = 323.3 Hz), 
51.0, 48.8, 36.8, 36.2, 35.4, 25.9, 25.9, 20.4, 17.8. 19F NMR (470 MHz, Chloroform-d) δ -76.47. 
HRMS (ESI) m/z calculated for C20H28NO2F3SNa [M+Na]+: 426.1691, found 426.1700. [α]23D = 
-16.9 (c = 0.50, CHCl3) 
Complete stereoretention was determined by chiral HPLC analysis. The enantiomeric excess was 
determined to be >99% ee (from pure chiral olefin starting material) by chiral HPLC analysis 









methylmethanesulfonamide (20). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv), 5-(pent-4-en-1-yl)-5H-dibenz[b,f]azepine (S36) (52.3 mg, 0.2 mmol, 1.0 equiv) 
and 1,1,1-trifluoro-N-methylmethanesulfonamide (S14) (32.6 mg, 0.2 mmol, 1.0 equiv) were 
reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product 20 as a 
yellow oil. Run 1: (50.3 mg, 59.5% yield); Run 2: (51.1 mg, 60.5% yield); Run 3: (51.3 mg, 60.7% 
yield). Average: 60% yield ± 0.6%.    
1H NMR (500 MHz, Methanol-d4) δ 7.23 (ddd, J = 8.2, 7.2, 1.7 Hz, 2H), 7.02 (m, 4H), 6.95 (ddd, 
J = 7.4, 7.4, 1.1 Hz, 2H), 6.66 (s, 2H), 5.74 (dt, J = 15.1, 6.9, 1H), 5.23 (dt, J = 15.1, 6.8, 1H), 
3.88-3.68 (m, 4H), 2.84 (s, 3H), 2.24 (q, J = 6.6, 2H). 13C NMR (126 MHz, Methanol-d4) δ 152.0, 
136.1, 135.4, 133.1, 130.2, 130.0, 125.4, 124.4, 121.6, 121.6 (q, J = 323.0 Hz), 53.6, 51.0, 34.9, 
31.2. 19F NMR (470 MHz, Methanol-d4) δ -77.66. HRMS (ESI) m/z calculated for 
















(21). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 1-allyl -
2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside70 (74.5 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-
N-(naphthalen-1-ylmethyl)methanesulfonamide (S13) (57.9 mg, 0.2 mmol, 1.0 equiv) were 
reacted according to thegeneral procedure for 72 hours. Purification by flash column 
chromatography (50 mL silica gel, 0% => 20% Acetone in hexanes) and preparative TLC (66% 
Et2O in hexanes) provided pure product (+)-21 as a white solid. Run 1: (91.4 mg, 69.3% yield); 
Run 2: (93.5 mg, 70.9% yield); Run 3: (92.7 mg, 70.3% yield). Average: 70% yield ± 0.8%.   
1H NMR (500 MHz, Chloroform-d) δ 8.17-8.14 (m, 1H), 7.90 (td, J = 7.7, 7.2, 1.8 Hz, 2H), 7.61 
(ddd, J = 8.5, 6.8, 1.4 Hz, 1H), 7.55 (ddd, J = 8.1, 6.8, 1.1 Hz, 1H), 7.52-7.48 (m, 2H), 5.68 (dt, J 
= 14.3, 6.4 Hz, 1H), 5.48 (dd, J = 15.8, 5.1 Hz, 1H), 5.40-4.60 (br s, 2H), 5.11 (dd, J = 10.1, 9.1 
Hz, 1H), 5.01-4.92 (m, 2H), 4.50 (s, 1H), 4.11 (dd, J = 12.3, 5.1 Hz, 1H), 4.03-3.98 (m, 1H), 3.94-
3.83 (m, 2H), 3.59 (s, 1H), 2.07 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.8, 170.2, 169.5, 169.5, 133.9, 131.6, 130.2, 130.0, 129.2, 128.8, 128.0, 127.9, 
127.3, 126.6, 125.2, 122.8, 120.3 (q, J = 323.6 Hz), 72.0, 70.5, 70.1, 69.6, 68.8, 62.3, 50.1, 49.3, 
20.8, 20.8, 20.7, 20.7. 19F NMR (470 MHz, Chloroform-d) δ -75.25. HRMS (ESI) m/z calculated 
for C29H32NO11F3SNa [M+Na]+: 682.1546, found 682.1552. [α]22D = +65.3 (c = 0.56, CHCl3) 
 
 
Methyl (E)-4-(3-(phenethylamino)prop-1-en-1-yl)benzoate (22). Pd(OAc)2 (6.7 mg, 0.03 
mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (10.2 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (45 mg, 0.33 mmol, 1.1 equiv), methyl 4-allylbenzoate (51.3 mg, 0.3 






were reacted according to the general procedure in dioxane (0.3 mL, 1.0 M) for 72 hours. 
Purification by flash column chromatography (100 mL silica gel, 0% => 15% acetone in hexanes 
provided a mixture of product 22 with 4-nitro-N-phenethylbenzenesulfonamide. 
      To a 20 mL vial was added a stir bar, mixture from last step, Cs2CO3 (325.8 mg, 1.0 mmol), 
DMF (1 mL) and PhSH (307.3 μL, 3.0 mmol). The reaction was heated to 45 °C for 2 hours. The 
vial was allowed to cool to room temperature, diluted with 10 mL Et2O and added 5% aq. NaHCO3. 
Layers were separated, aqueous layer was extracted with Et2O. Organic layers were combined, 
dried over anhydrous MgSO4 and concentrated under reduced pressure. The crude mixture was 
purified by flash silica plug (50 mL silica gel, 100 mL 2% MeOH/ CH2Cl2 then switch to 4% 
MeOH/CH2Cl2 to give pure product as a colorless oil. 
     Run 1: (48.9 mg, 55.2% yield); Run 2: (47.2 mg, 53.0% yield); Run 3: (48.5 mg, 54.7% yield). 
Average: 54% yield ± 1.2% over two steps.   
1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.34 – 
7.27 (m, 2H), 7.24 – 7.19 (m, 3H), 6.57 – 6.50 (m, 1H), 6.39 (dt, J = 15.9, 6.1 Hz, 1H), 3.90 (s, 
3H), 3.46 (dd, J = 6.2, 1.6 Hz, 2H), 2.96 (t, J = 7.3 Hz, 2H), 2.86 (t, J = 7.1 Hz, 2H), 1.91 (br s, 
1H). 13C NMR (126 MHz, Chloroform-d) δ 167.0, 141.7, 139.9, 131.1, 130.6, 130.0, 129.0, 128.9, 
128.7, 126.4, 126.3, 52.2, 51.7, 50.7, 36.4. HRMS (ESI) m/z calculated for C19H22NO2 [M+H]+: 




phenethylmethyl)sulfonamido)pent-3-enamide (23). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), 
(±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-








enamide15 (31.44 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-phenethylmethanesulfonamide 
(S10) (50.6 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 72 hours. 
Purification by flash column chromatography (column1: 50 mL silica gel, 0% => 20% Acetone in 
hexanes; column 2: 50 mL silica gel, 100% CH2Cl2 => 0.5% MeOH in CH2Cl2) provided pure 
product (+)-23 as a colorless oil. Run 1: (49.9 mg, 61.1% yield); Run 2: (50.8 mg, 62.2% yield); 
Run 3: (51.8 mg, 63.4% yield). Average: 62% yield ± 1.2%.   
When stopped at 24 h. Run 1: (41.0 mg, 50.2% yield); Run 2: (42.0 mg, 51.4% yield); Run 3: 
(42.5 mg, 52.0% yield). Average: 51% yield ± 0.9%.   
1H NMR (500 MHz, Chloroform-d) δ 7.33-7.29 (m, 2H), 7.26-7.22 (m, 1H), 7.17 (dd, J = 8.1, 1.3 
Hz, 2H), 5.85 (dd, J = 15.5, 8.0, 1H), 5.50 (dt, J = 15.3, 7.0, 1H), 3.91 (d, J = 7.0 Hz, 2H), 3.69 (s, 
3H), 3.67-3.61 (m, 1H), 3.53 (m, 2H), 3.18 (s, 3H), 2.90 (t, J = 8.0 Hz, 2H), 1.27 (d, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 174.8, 137.4, 137.4, 128.9, 128.9, 127.1, 124.4, 120.1 (q, J 
= 323.3 Hz), 61.7, 50.8, 49.2, 38.8, 35.5, 32.4, 17.7. 19F NMR (470 MHz, CDCl3) δ -76.40. HRMS 
(ESI) m/z calculated for C17H24N2O4F3S [M+H]+: 409.1409, found 409.1399. [α]23D = +5.4 (c = 
0.57, CHCl3) 
Complete stereoretention was proven by chiral GC and HPLC analysis. Olefin starting material 
was determined by chiral GC analysis to be 94% ee. The allylic amine product 22 was determined 
by chiral HPLC analysis to be 94% ee. (CHIRALPAK AD-RH column, 0.3 mL/min, 50% EtOH in 













(±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (S)-N-methoxy-N,2-dimethylpent-4-
enamide15 (31.44 mg, 0.2 mmol, 1.0 equiv) and (+)-methyl ((trifluoromethyl)sulfonyl)-L-
phenylalaninate (S21) (62.3 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general 
procedure for 72 hours. Purification by flash column chromatography (column1: 50 mL silica gel, 
0% => 20% Acetone in hexanes; column 2: 50 mL silica gel, 100% CH2Cl2 => 1% MeOH in 
CH2Cl2) provided pure product (-)-24 as a colorless oil. Run 1: (58.0 mg, 62.1% yield); Run 2: 
(57.6mg, 61.7% yield); Run 3: (58.7 mg, 62.9% yield). Average: 62% yield ± 0.6%.   
 
1H NMR (500 MHz, Chloroform-d) δ 7.33-7.28 (m, 2H), 7.26-7.21 (m, 3H), 5.86 (dd, J = 15.6, 
7.7 Hz, 1H), 5.59 (dt, J = 16.0, 6.8 Hz, 1H), 4.71 (t, J = 7.5 Hz, 1H), 4.08 (qd, J = 16.0, 6.8 Hz, 
2H), 3.69 (s, 3H), 3.69 (s, 3H), 3.63-3.57 (m, 1H), 3.42 (dd, J = 14.2, 8.0 Hz, 1H), 3.17 (s, 3H), 
3.03 (dd, J = 14.2, 7.0 Hz, 1H), 1.24 (d, J = 6.9 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 174.8, 
169.7, 136.1, 136.0, 129.3, 128.8, 127.4, 125.9, 119.8 (q, J = 323.4 Hz), 62.4, 61.7, 52.7, 49.7, 
38.6, 37.3, 32.5, 17.3. 19F NMR (470 MHz, CDCl3) δ -75.93. HRMS (ESI) m/z calculated for 




((trifluoromethyl)sulfonyl)-D-phenylalaninate (25). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), 
(±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (S)-N-methoxy-N,2-dimethylpent-4-









(S22) (62.3 mg, 0.2 mmol) were reacted according to the general procedure for 72 hours. 
Purification by flash column chromatography (column1: 50 mL silica gel, 0% => 20% Acetone in 
hexanes; column 2: 50 mL silica gel, 100% CH2Cl2 => 1% MeOH in CH2Cl2) provided pure 
product (+)-25 as a colorless oil. Run 1: (55.3 mg, 59.3% yield); Run 2: (56.4 mg, 60.4% yield); 
Run 3: (57.2 mg, 61.3% yield). Average: 60% yield ± 1.0%.    
1H NMR (500 MHz, Chloroform-d) δ 7.33-7.28 (m, 2H), 7.26-7.20 (m, 3H), 5.85 (dd, J = 15.5, 
7.8, 1H), 5.58 (dt, J = 15.3, 6.9, 1H), 4.72 (t, J = 7.5 Hz, 1H), 4.09 (t, J = 6.3 Hz, 2H), 3.71 (s, 3H), 
3.69 (s, 3H), 3.58 (q, J = 6.3, 5.4 Hz, 1H), 3.41 (dd, J = 14.2, 7.8 Hz, 1H), 3.17 (s, 3H), 3.03 (dd, 
J = 14.2, 7.2 Hz, 1H), 1.24 (d, J = 6.9 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 174.8, 169.8, 136.1, 
136.0, 129.3, 128.8, 127.4, 126.1, 119.8 (q, J = 323.7 Hz), 62.4, 61.7, 52.7, 49.7, 38.8, 37.1, 32.5, 
17.5. 19F NMR (470 MHz, CDCl3) δ -75.92. HRMS (ESI) m/z calculated for C19H26N2O6F3S 




yl)-N-((trifluoromethyl)sulfonyl)-L-phenylalaninate (26). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 
equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (R)-tert-butyl((1-((4-
methoxybenzyl)oxy)pent-4-en-2-yl)oxy)dimethylsilane15 (67.3 mg, 0.2 mmol, 1.0 equiv) and (+)-
methyl ((trifluoromethyl)sulfonyl)-L-phenylalaninate (S21) (62.3 mg, 0.2 mmol, 1.0 equiv) were 
reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (column 1: 50 mL silica gel, 0% => 20% Acetone in hexanes; column 2: 50 mL 







Run 1: (96.7 mg, 74.9% yield); Run 2: (97.9 mg, 75.8% yield); Run 3: (95.6 mg, 74.0 % yield). 
Average: 75% yield ± 0.9%.  
When stopped at 24 hour: Run 1: (86.3 mg, 66.8% yield); Run 2: (87.7 mg, 67.9% yield); Run 
3: (85.8 mg, 66.4 % yield). Average: 67% yield ± 0.8%.  
1H NMR (500 MHz, Chloroform-d) δ 7.33 (dd, J = 8.1, 6.5 Hz, 2H), 7.30-7.20 (m, 5H), 6.88 (d, 
J = 8.6 Hz, 2H), 5.90-5.77 (m, 2H), 4.72 (t, J = 7.5 Hz, 1H), 4.50 (br s, 2H), 4.38-4.32 (m, 1H), 
4.14 (d, J = 5.2 Hz, 2H), 3.82 (s, 3H), 3.70 (s, 3H), 3.47-3.34 (m, 3H), 3.04 (dd, J = 14.0, 6.7 Hz, 
1H), 0.93 (s, 9H), 0.09 (s, 3H), 0.07(s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.7, 159.3, 136.8, 
136.0, 130.4, 129.4, 129.3, 128.8, 127.3, 124.8, 119.7 (q, J = 323.8 Hz), 113.8, 74.3, 73.2, 71.2, 
62.1, 55.4, 52.7, 49.3, 37.4, 25.9, 18.3, -4.6, -4.7. 19F NMR (470 MHz, Chloroform-d) δ -75.93. 
HRMS (ESI) m/z calculated for C30H42NO7F3SSiNa [M+Na]+: 668.2301, found 668.2304. [α]23D 





yl)-N-((trifluoromethyl)sulfonyl)-D-phenylalaninate (27). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 
equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (R)-tert-butyl((1-((4-
methoxybenzyl)oxy)pent-4-en-2-yl)oxy)dimethylsilane15 (67.3 mg, 0.2 mmol, 1.0 equiv) and (-)-
methyl ((trifluoromethyl)sulfonyl)-D-phenylalaninate (S22) (62.3 mg, 0.2 mmol, 1.0 equiv) were 
reacted according to the general procedure for 72 hours. Purification by flash column 







silica gel, 100% CH2Cl2 => 2% MeOH in CH2Cl2) provided pure product (+)-27 as a colorless oil. 
Run 1: (101.3 mg, 78.4% yield); Run 2: (100.0 mg, 77.4% yield); Run 3: (101.5 mg, 78.6 % yield). 
Average: 78% yield ± 0.6%.    
1H NMR (500 MHz, Chloroform-d) δ 7.35 (dd, J = 8.0, 6.4 Hz, 2H), 7.32-7.24 (m, 5H), 6.88 (d, 
J = 8.6 Hz, 2H), 5.85 (s, 2H), 4.74 (t, J = 7.6 Hz, 1H), 4.55-4.46 (m, 2H), 4.41-4.35 (m, 1H), 4.27-
4.19 (m, 1H), 4.13 (s, 1H), 3.84 (s, 3H), 3.71 (s, 3H), 3.48-3.37 (m, 3H), 3.09 (dd, J = 13.9, 6.6 
Hz, 1H), 0.95 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.7, 159.3, 
136.4, 135.9, 130.4, 129.3, 129.3, 128.8, 127.3, 125.3, 119.7 (q, J = 324.0 Hz),113.8, 74.4, 73.2, 
71.4, 62.6, 55.4, 52.7, 49.4, 37.7, 25.9, 18.4, -4.6, -4.7. 19F NMR (470 MHz, Chloroform-d) δ -
75.90. HRMS (ESI) m/z calculated for C30H42NO7F3SSiNa [M+Na]+: 668.2301, found 668.2284. 
[α]23D = +31.3 (c = 1.06, CHCl3) 
 
 
Natural product derivatizations 
General procedure:  
No effort to exclude air or moisture is required. To a ½ dram vial was added a stir bar, Pd(OAc)2 
(4.4 mg, 0.02 mmol, 0.1 equiv), ligand (0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), olefin (0.2 mmol, 1.0 equiv) and N-triflyl 
protected amine (0.2 mmol, 1.0 equiv). Toluene (0.2 mL, 1.0M) was added and the vial was capped 
and heated to 45 °C for 24-72 hours (monitored by TLC). The vial was allowed to cool to room 
temperature and diluted with acetone. The reaction mixture was filtered through a ½ inch pipette 
silica plug into a 20mL vial with acetone. The mixture was concentrated under reduced pressure, 
diluted with 2 mL CDCl3 and an internal standard (trifluorotoluene 14.6 mg, 0.1 mmol, 0.5 equiv) 
75 
 
for crude 1HNMR analysis, the mixture was concentrated under reduced pressure and subjected to 
flash column chromatography for purification. 
 
 
δ-Tocopherol derivative (+)-28. The reaction was performed according to the general procedure 
using Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX ligand (L-5) (3.4 mg, 0.01 mmol, 
0.05 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (+)-allylated-
δ-Tocopherol derivative (S39) (85.3 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-
phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol,1.0 equiv) for 24 hours. The reaction 
mixture was purified by flash column chromatography (50 mL silica gel, 0% => 20% acetone in 
hexanes) to provide pure desired product (+)-28 as a colorless oil. Run 1: (116.8 mg, 88.0% yield); 
Run 2: (118.4 mg, 89.2% yield); Run 3: (117.0 mg, 88.1% yield). Average: 88% yield ± 0.7%.   
(MW = 663.9) 
1H NMR (500 MHz, Chloroform-d) δ 7.46-7.33 (m, 5H), 7.00 (d, J = 2.2 Hz, 1H), 6.92 (d, J = 2.2 
Hz, 1H), 6.32 (d, J = 15.6 Hz, 1H), 5.87 (dt, J = 15.7, 7.2 Hz, 1H), 4.56 (br s, 2H), 4.01 (br s, 2H), 
2.81-2.74 (m, 2H), 2.20 (s, 3H), 1.86 (dt, J = 13.8, 6.7 Hz, 1H), 1.79 (dt, J = 13.3, 6.5 Hz, 1H), 
1.65-1.04 (m, 24H). 0.93-0.82 (m, 12H). 13C NMR (125 MHz, CDCl3) δ 152.95, 136.86, 134.37, 
129.06, 128.73, 128.56, 126.81, 126.75, 126.53, 125.70, 120.73, 120.25 (q, 322.7 Hz), 118.04, 
76.67, 50.52, 49.86, 40.29, 39.52, 37.59, 37.57, 37.43, 32.95, 32.83, 31.28, 28.13, 24.96, 24.60, 
24.41, 22.87, 22.78, 22.42, 21.12, 19.91, 19.81, 16.23. 19F NMR (470 MHz, CDCl3) δ -76.37. 
HRMS (ESI) m/z calculated for C38H57NO3F3S [M+H]+: 664.4011, found 664.3995. [α]23D = 









Dextramethorphan derivative (+)-29. To a ½ dram vial equipped with a stir bar, (+)-allylated 
dextromethorphan derivative (S42) (56.3 mg, 0.2 mmol, 1.0 equiv) and toluene (0.2 mL, 1.0 M) 
were added, followed by dichloroacetic acid (16.5 μL, 0.2 mmol, 1.0 equiv). The mixture was 
stirred at 45 °C for 20 min. Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-
5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5-dimethylbenzoquinone (2,5 DMBQ) (30 mg, 0.22 mmol, 
1.1 equiv) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol,1.0 equiv) 
was added and the vial was capped and heated to 45 °C for 24 hours (monitored by TLC). The vial 
was allowed to cool to room temperature and diluted with ethyl acetate (1 mL). The reaction 
mixture was washed with sat. aq. K2CO3, layers are separated and the aqueous layer was extracted 
ethyl acetate (20 mL x 3). The mixture was concentrated under reduced pressure, diluted with 2 
mL CDCl3 and an internal standard (trifluorotoluene 14.6 mg, 0.1 mmol, 0.5 equiv) was added for 
crude 1H NMR analysis. The mixture was then concentrated under reduced pressure and subjected 
to flash column chromatography (50ml silica gel, 0% => 10% MeOH in CH2Cl2) to provide desired 
product (+)-29 as a colorless oil.  Run 1: (95.7 mg, 92.3% yield); Run 2: (94.9 mg, 91.5% yield); 
Run 3: (94.8 mg, 91.4% yield). Average: 92% yield ± 0.5%.  Without dichloroacetic acid 
following general procedure, 31.4 mg, 30% yield.  
1H NMR (500 MHz, Chloroform-d) δ 7.42-7.32 (m, 5H), 7.17-7.13 (m, 2H), 7.10 (d, J = 7.8 Hz, 
1H), 6.38 (d, J = 15.7 Hz, 1H), 5.94 (dt, J = 15.7, 7.1 Hz, 1H), 4.55 (br s, 2H), 4.02 (br s, 2H), 3.05 
(d, J = 18.9 Hz, 1H), 3.00 (s, 1H), 2.79 (dd, J = 18.9, 5.8 Hz, 1H), 2.68-2.60 (m, 1H), 2.51 (s, 3H), 
2.41 (d, J = 13.9 Hz, 1H), 2.18 (t, J = 12.7 Hz, 1H), 2.02 (d, J = 10.5 Hz, 1H), 1.91 (td, J = 13.0, 
4.7 Hz, 1H), 1.66 (d, J = 12.5 Hz, 1H), 1.57 (d, J = 13.4 Hz, 1H), 1.48-1.35 (m, 4H), 1.29-1.20 (m, 







129.03, 128.68, 128.62, 128.36, 124.26, 123.73, 120.89, 120.17 (q, 322.8 Hz,), 58.46, 51.10, 49.90, 
47.34, 44.24, 42.37, 41.15, 36.84, 36.11, 26.57, 26.34, 24.50, 22.07. 19F NMR (470 MHz, CDCl3) 
δ -76.25. HRMS (ESI) m/z calculated for C28H34N2O2F3S [M+H]+: 519.2293, found 519.2301. 
[α]23D = +19.6  (c = 0.50, CHCl3) 
 
Ethinyl estradiol derivative (-)-30. The reaction was performed according to the general 
procedure using Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 
0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (-
)-Allylated ethinyl estradiol derivative (S41) (78.5 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-
N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv) for 24 hours. The reaction 
mixture was purified by flash column chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in 
hexanes) to provide pure desired product (-)-30 as a colorless oil. Run 1: (113.8 mg, 90.3% yield); 
Run 2: (113.2 mg, 89.9% yield); Run 3: (114.4 mg, 90.8% yield). Average: 90% yield ± 0.5%.    
1H NMR (500 MHz, Chloroform-d) δ 7.39 (m, 3H), 7.35-7.32 (m, 2H), 7.31 (d, J = 8.2 Hz, 1H), 
7.14 (d, J = 8.0 Hz, 1H), 7.06 (s, 1H), 6.37 (d, J = 15.7 Hz, 1H), 5.99 (dt, J = 15.1, 7.2 Hz, 1H), 
4.54 (br s, 2H), 4.01 (br s, 2H), 2.88 (dd, J = 8.8, 4.1 Hz, 2H), 2.45-2.37 (m, 1H), 2.32 (ddd, J = 
13.6, 9.5, 5.6 Hz, 1H), 2.30-2.21 (m, 1H), 2.01 (ddd, J = 13.6, 11.9, 3.8 Hz, 1H), 1.91 (td, J = 12.8, 
3.8 Hz, 2H), 1.86-1.77 (m, 2H), 1.77-1.65 (ddt, J = 18.9, 11.0, 5.4 Hz, 2H), 1.57-1.35 (m, 4H), 
0.88 (s, 3H), 0.19 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 141.10, 137.28, 136.50, 134.24, 133.12, 
129.10, 128.74, 128.65, 127.39, 125.98, 124.06, 120.79, 120.24 (q, 321.0 Hz), 109.54, 90.33, 
80.22, 50.82, 49.85, 49.74, 47.33, 44.38, 39.32, 39.09, 33.02, 29.68, 27.32, 26.39, 23.01, 12.91, 
0.20. 19F NMR (470 MHz, CDCl3) δ -76.33. HRMS (ESI) m/z calculated for C34H41NO2SiF3S 









Estrone derivative (+)-31. The reaction was performed according to the general procedure using 
Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allylated estrone 
(S40) (58.9 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) 
(47.8 mg, 0.2 mmol, 1.0 equiv) for 24 hours. The reaction mixture was purified by flash column 
chromatography (50 mL silica gel, 0% => 10% acetone in hexanes) to provide pure desired product 
(+)-31 as a white solid. Run 1: (79.9 mg, 75.2% yield); Run 2: (80.5 mg, 75.7% yield); Run 3: 
(79.1 mg, 74.3% yield). Average: 75% yield ± 0.7%.    
1H NMR (500 MHz, Chloroform-d) δ 7.44-7.36 (m, 3H), 7.34 (d, J = 6.7 Hz, 2H), 7.29 (d, J = 8.1 
Hz, 1H), 7.15 (d, J = 8.1 Hz, 1H), 7.08 (s, 1H), 6.38 (d, J = 15.7 Hz, 1H), 6.00 (dt, J = 15.9, 7.0 
Hz, 1H), 4.54 (br s, 2H), 4.01 (br s, 2H), 2.94 (dd, J = 9.3, 4.2 Hz, 2H), 2.52 (dd, J = 18.9, 8.7 Hz, 
1H), 2.47-2.41 (m, 1H), 2.37-2.28 (m, 1H), 2.16 (dt, J = 18.2, 8.8 Hz, 1H), 2.11-2.03 (m, 2H), 
2.01-1.97 (m, 1H), 1.71-1.41 (m, 6H), 0.93 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 220.81, 140.51, 
137.01, 136.30, 134.17, 133.31, 129.07, 128.69, 128.63, 127.35, 125.88, 124.16, 120.97, 120.19 
(q, 322.8 Hz), 50.81, 50.58, 49.68, 48.06, 44.57, 38.20, 35.95, 31.68, 29.46, 26.52, 25.81, 21.70, 
13.94. (470 MHz, CDCl3) δ -73.31. HRMS (ESI) m/z calculated for C29H33NO3F3S [M+H]+: 












Estrone derivative (+)-31a.  
       To an oven-dried 25 mL round-bottom flask equipped with a stir bar, (+)-44 (531.6 mg, 1.0 
mmol, 1.0 equiv) and THF (10 mL, 0.1 M) were added. The reaction flask was cooled to -78 °C 
and allylmagnesium chloride (0.6 mL, 2.0 M, 1.2 equiv) was added dropwise. The reaction was 
allowed to stir at -78 °C for 1 h and then quenched with sat. aq. NH4Cl. Layers were separated and 
the aqueous layer was extracted with diethyl ether (20 ml x 3). The organic layers were combined 
and dried over MgSO4, filtered, concentrated under vacuum and subjected to a flash column 
chromatography (100 mL silica gel, 0% => 10% Acetone in hexanes) to provide pure product as 
a colorless oil. Run 1: (485.4 mg, 84.6% yield); Run 2: (492.2 mg, 85.8% yield). Average: 85% 
yield. 
        An oven-dried 25 ml round-bottom flask was charged with a stir bar, product from last step 
(286.9 mg, 0.5 mmol, 1.0 equiv) and toluene (10 ml, 0.05 M). The reaction was cooled to 0 °C and 
Red-Al (3.5 M in toluene) (sodium bis(2-methoxyethoxy)aluminumhydride) (5.0 mmol, 1.42 mL) 
was added dropwise and the reaction was allowed to warm up to room temperature and stirred at 
room temperature for 16 hours. Upon completion,  the reaction was cooled to 0 °C and 5% NH4Cl 
was added. Layers were separated and the aqueous layer was further extracted with CH2Cl2 (30 ml 
x 3). The organic layers were combined and dried over Na2SO4, filtered, concentrated under 
vacuum and subjected to a flash column chromatography (100 mL silica gel, 0% => 5% MeOH in 
CH2Cl2) to provide pure product as a colorless gel. Run 1: (201.9 mg, 91.4% yield); Run 2: (199.6 
mg, 90.4 % yield) Average: 91% yield. 
1H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.31 (m, 4H), 7.28 – 7.23 (m, 2H), 7.17 (d, J = 8.1, 







10.2, 7.1 Hz, 1H), 5.25 – 5.11 (m, 2H), 3.84 (s, 2H), 3.43 (d, J = 6.4, 2H), 2.87-2.80 (m, 2H), 2.41 
– 2.32 (m, 2H), 2.24-2.18 (m, 2H), 2.05 – 1.96 (m, 1H), 1.95-1.88 (m, 1H), 1.79 – 1.32 (m, 11H), 
0.93 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 140.2, 139.8, 136.9, 135.0, 134.5, 131.5, 128.5, 
128.3, 127.5, 127.1, 127.0, 125.6, 123.6, 119.2, 82.5, 53.2, 51.3, 49.7, 46.5, 44.3, 41.9, 39.4, 34.9, 
31.9, 29.6, 27.5, 26.2, 23.5, 14.4. HRMS (ESI) m/z calculated for C31H40NO [M+H]+: 442.3110, 
found 442.3113. [α]22D = +85.3 (c = 0.53, CHCl3) 
 
Estrone derivative (+)-31b.  
      To a flame-dried 250 mL round bottom flask equipped with a stir bar was added (+)-44 (1.595 
g, 3.0 mmol, 1.0 equiv) and THF (20 mL). The reaction mixture was cooled down to -78 °C. with 
stirring. LHMDS (551 mg, 3.3 mmol, 1.1 equiv) was dissolved in THF (20 mL), and was slowly 
added into the reaction mixture. The reaction was stirred for 1 h. PhN(SO2CF3)2 (1.18 g, 3.3 mmol, 
1.1 equiv) was then dissolved in THF (3 mL) and was added dropwise into the reaction mixture 
via syringe. The reaction was stirred for an additional 20 min and then allowed to warm up to room 
temperature and stirred for an additional hour. Water (5 mL) was then added to quench the reaction 
and THF was removed in vacuo. Diethyl ether (20 mL) was added to extract the product, and the 
organic layer was washed with sat. aq. NH4Cl (10 mL) and brine (10 mL). The organic layer was 
then separated, dried over MgSO4 and concentrated in vacuo. Purification by flash 
chromatography on silica eluting with 2 => 5% EtOAc/hexanes yielded the product as a white 
solid. Run 1: (1.585 g, 79.6% yield); Run 2: (1.609 mg, 80.8% yield). Average: 80% yield. with 







     The product (2.655 g, 2.0 mmol, 1.0 equiv) was dissolved in DMSO (60 mL) at 60 °C and 
cannulated into a flame-dried 500 mL Schlenk flask charged with LiCl (1.02 g, 24 mmol, 6.0 
equiv), Pd(PPh3)4 (462.2 mg, 0.4 mmol, 0.10 equiv), CuCl (1.98 g, 20 mmol, 5.0 equiv), DMSO 
(100 mL) and a magnetic stir bar. 3-(tributylstannyl)pyridine (2.6 mL, 4 mmol, 2.0 equiv) was 
then added via syringe. The mixture was degassed through freeze-pump-thaw (-78 °C→0 °C) three 
times, and was stirred for 1 h at room temperature. The reaction flask was then placed into 60 °C 
oil bath and stirred vigorously for 20 h. The reaction was then quenched with the mixed solution 
of concentrated NH4OH (5 mL) and brine (100 mL), extracted with diethyl ether (4 x 50 mL). The 
organic layers were then combined, dried over MgSO4 and concentrated in vacuo. Purification by 
flash chromatography on silica eluting with 2 => 10% Methanol in hexanes yielded product as a 
colorless gel. Run 1: (1.036 g, 87.4% yield); Run 2: (1.020 g, 86.1% yield). Average: 87% yield.  
     An oven-dried 25 ml round-bottom flask was charged with a stir bar, product from last step 
(296.1 mg, 0.5 mmol, 1.0 equiv) and toluene (10 ml, 0.05 M). The reaction was cooled to 0 °C and 
Red-Al (3.5 M in toluene) (sodium bis(2-methoxyethoxy)aluminumhydride) (5.0 mmol, 1.42 mL) 
was added dropwise and the reaction was allowed to warm up to room temperature and stirred at 
room temperature for 16 hours. Upon completion,  the reaction was cooled to 0 °C and 5% NH4Cl 
was added. Layers were separated and the aqueous layer was further extracted with CH2Cl2 (30 ml 
x 3). The organic layers were combined and dried over Na2SO4, filtered, concentrated under 
vacuum and subjected to a flash column chromatography (100 mL silica gel, 0% => 10% MeOH 
in CH2Cl2) to provide pure product as a colorless gel. Run 1: (147.7 mg, 64.1% yield); Run 2: 
(142.8 mg, 62.0% yield). Average: 63% yield.  
1H NMR (500 MHz, Chloroform-d) δ 8.65 (dd, J = 2.3, 0.9 Hz, 1H), 8.48 (dd, J = 4.8, 1.6 Hz, 1H), 
7.68 (dt, J = 7.9, 1.9 Hz, 1H), 7.35 – 7.32 (m, 4H), 7.29 – 7.22 (m, 3H), 7.18 (dd, J = 8.1, 1.9 Hz, 
1H), 7.12 (d, J = 1.8 Hz, 1H), 6.53 – 6.47 (m, 1H), 6.28 (dt, J = 15.8, 6.3 Hz, 1H), 6.03 (dd, J = 
82 
 
3.3, 1.8 Hz, 1H), 3.84 (s, 2H), 3.44 (d, J = 6.32H), 3.00 – 2.83 (m, 2H), 2.45 – 2.31 (m, 3H), 2.22 
– 2.11 (m, 2H), 1.99 (m , 1H), 1.83 (m, 2H), 1.74 – 1.63 (m, 3H), 1.57 – 1.44 (m, 1H), 1.05 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 152.0, 148.1, 148.1, 140.4, 139.9, 136.9, 134.7, 133.8, 133.1, 
131.5, 129.2, 128.6, 128.4, 127.8, 127.1, 127.1, 125.4, 123.7, 123.2, 57.0, 53.4, 51.4, 47.9, 44.7, 
37.3, 35.5, 31.7, 29.6, 27.8, 26.5, 16.8. HRMS (ESI) m/z calculated for C33H37N2 [M+H]+: 
461.2957, found 461.2948. [α]22D = +23.8 (c = 0.82, CHCl3) 
 
 
Estrone derivative (+)-32.   
     Pd(OAc)2 (6.7 mg, 0.03 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (10.2 mg, 0.03 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (45 mg, 0.33 mmol, 1.1 equiv), allylated 
estrone (S40) (88.4 mg, 0.3 mmol, 1.0 equiv) and 4-nitro-N-phenethylbenzenesulfonamide (91.8 
mg, 0.3 mmol, 1.0 equiv) were reacted according to the general procedure in dioxane (0.3 mL, 1.0 
M) for 72 hours. The mixture was concentrated under reduced pressure, diluted with 2 mL CDCl3 
and analyzed by crude 1H NMR with internal standard (trifluorotoluene 44.1 mg, 0.1 0.302 mmol, 
1.01 equiv): about 66% NMR yield. Purification by flash column chromatography (100 mL silica 
gel, 0% => 15% Acetone in hexanes provided a mixture of product 32 with 4-nitro-N-
phenethylbenzenesulfonamide.  
      To a 20 mL vial was added a stir bar, mixture from last step, Cs2CO3 (325.8 mg, 1.0 mmol), 
DMF (1 mL) and PhSH (307.3 μL, 3.0 mmol). The reaction was heated to 45 °C for 2 hours. The 
vial was allowed to cool to room temperature, diluted with 10 mL Et2O and added 5% aq. NaHCO3. 
Layers were separated, aqueous layer was extracted with Et2O. Organic layers were combined, 







purified by flash silica plug (50 mL silica gel, 100 mL 2% MeOH/ CH2Cl2 then switch to 4% 
MeOH/CH2Cl2 to give pure product as a colorless oil. 
Run 1: (60.5 mg, 50.5% yield); Run 2: (63.7 mg, 53.1% yield); Run 3: (64.0 mg, 53.4% yield). 
Average: 52% yield ± 1.9% over two steps.   
1H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.31 (m, 4H), 7.30 – 7.21 (m, 2H), 7.18 (dd, J = 8.1, 
1.9 Hz, 1H), 7.11 (d, J = 1.8 Hz, 1H), 6.50 (d, J = 15.8 Hz, 1H), 6.28 (dt, J = 15.8, 6.4 Hz, 1H), 
3.87 (s, 2H), 4.00-3.70 (br s, 1H), 3.45 (d, J = 6.4 Hz, 2H), 2.90 (dd, J = 9.1, 4.2 Hz, 2H), 2.54 – 
2.45 (m, 1H), 2.45 – 2.36 (m, 1H), 2.28 (td, J = 10.8, 4.3 Hz, 1H), 2.14-1.92 (m, 3H), 1.67 – 1.37 
(m, 6H), 0.91 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 221.2, 139.7, 138.8, 137.0, 134.8, 
132.9, 128.9, 127.8, 127.4, 126.3, 126.0, 124.2, 55.9, 50.9, 50.9, 48.4, 44.8, 38.5, 36.2, 32.0, 29.8, 
26.9, 26.1, 22.0, 14.2. HRMS (ESI) m/z calculated for C28H34NO [M+H]+: 400.2640, found 
400.2629. [α]22D = +84.9 (c = 1.0, CHCl3) 
 
 
α-Methyl benzylamine-tocopherol conjugate (+)-33. The reaction was performed according to 
the general procedure using Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-
5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 
1.1 equiv), (+)-Allylated-δ-Tocopherol derivative (S39) (85.3 mg, 0.2 mmol, 1.0 equiv) and (-)-
(S)-1,1,1-trifluoro-N-(1-(4-nitrophenyl)ethyl)methanesulfonamide (S27) (59.6 mg, 0.2 mmol, 1.0 
equiv) for 72 hours. The reaction mixture purified by flash column chromatography (column 1: 50 
mL silica gel, 0% => 5% acetone in hexanes; column 2: 50 mL silica gel, 10% => 50% CH2Cl2 in 
hexanes) to provide pure desired product (+)-33 as a yellow oil. Run 1: (112.4 mg, 77.7% yield); 








With 5% Pd(OAc)2 and (±)-MeO-SOX ligand (L-5): Run 1: (92.0 mg, 63.6% yield); Run 2: 
(93.1 mg, 64.4% yield); Average: 64% yield 
1H NMR (500 MHz, Chloroform-d) δ 8.20 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 8.3 Hz, 2H), 6.73 (s, 
1H), 6.61 (s, 1H), 6.08 (d, J = 15.7 Hz, 1H), 5.54 (s, 1H), 5.41-5.32 (m, 1H), 4.09-3.85 (m, 2H), 
2.75-2.58 (m, 2H), 2.11 (s, 3H), 1.81 (d, J = 7.1, 3H), 1.79-1.70 (m, 2H), 1.62-1.02 (m, 24H), 0.92-
0.81 (m, 12H). 13C NMR (125 MHz, CDCl3) δ 152.84, 147.74, 146.07, 134.72, 128.97, 126.73, 
126.43, 126.31, 125.41, 123.88, 120.65, 120.52, 120.07(q, 321.3 Hz), 76.65, 56.68, 48.68, 40.35, 
39.51, 37.58 37.55, 37.41, 32.93, 32.82, 31.20, 28.12, 24.94, 24.59, 24.32, 22.86, 22.77, 22.30, 
21.10, 19.89, 19.79, 16.15. (one peak missing probably due to overlapping). 19F NMR (470 MHz, 
CDCl3) δ -76.17. HRMS (ESI) m/z calculated for C39H57N2O5F3S [M+H]+: 722.3940, found 
722.3926. [α]23D = +37.8 (c = 0.5, CHCl3) 
Complete stereoretention for this cross-coupling was determined by chiral HPLC analysis. 
(Product from reaction using (-)-(S)-1,1,1-trifluoro-N-(1-(4-
nitrophenyl)ethyl)methanesulfonamide (S27) versus product from reaction using known mixture 
of 62% (-)-(S)-1,1,1-trifluoro-N-(1-(4-nitrophenyl)ethyl)methanesulfonamide (S27) and 38% (+)-
(R)-1,1,1-trifluoro-N-(1-(4-nitrophenyl)ethyl)methanesulfonamide). Chiralpak AD-RH column, 
0.5 mL/min, 10% EtOH in H2O, λ = 254nm (4nm). tR(major) = 22.401 min. 
 
 
Gramine-tocopherol conjugate (+)-34.  The reaction was performed according to the general 
procedure using Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 
0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 








N-((1-methyl-1H-indol-3-yl) methyl) methanesulfonamide (S30) (58.2 mg, 0.2 mmol, 1.0 equiv) 
for 24 hours. The reaction mixture was purified by flash column chromatography (50 mL silica 
gel, 10% => 30% CH2Cl2 in hexanes) to provide pure desired product (+)-34 as a colorless oil. 
Run 1: (100.8 mg, 70.3 % yield); Run 2: (101.6 mg, 70.9% yield); Run 3: (102.2 mg, 71.3% yield). 
Average: 71% yield ± 0.5%.   
1H NMR (500 MHz, Chloroform-d) δ 7.76 (dd, J = 8.0, 1.0 Hz, 1H), 7.35 (d, J = 8.2 Hz, 1H), 7.30 
(ddd, J = 8.2, 6.8, 1.1 Hz, 1H), 7.20 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.11 (s, 1H), 6.97 (br s, 1H), 
6.89 (br s, 1H), 6.33 (d, J = 15.7 Hz, 1H), 5.89 (dt, J = 15.7, 7.0 Hz, 1H), 4.76 (br s, 2H), 4.02 (br 
s, 2H), 3.80 (s, 3H), 2.84-2.71 (m, 2H), 2.20 (s, 3H), 1.86 (dt, J = 13.8Hz, 6.9 Hz, 1H), 1.79 (dt, J 
= 13.3Hz, 6.5 Hz, 1H), 1.64-1.01 (m, 24H), 0.98-0.81 (m, 12H). 13C NMR (125 MHz, CDCl3) δ 
152.80, 137.15, 135.95, 129.72, 127.44, 126.76, 126.73, 126.68, 125.56, 122.33, 120.71, 120.29 
(q, 322.8 Hz), 120.00, 119.23, 118.92, 109.62, 107.53, 76.63, 49.36, 42.45, 40.29, 39.52, 37.58, 
37.58, 37.42, 33.05, 32.94, 32.84, 31.29, 28.13, 24.96, 24.60, 24.41, 22.88, 22.78, 22.44, 21.13, 
19.91, 19.81, 16.26. 19F NMR (470 MHz, CDCl3) δ -76.40. HRMS (ESI) m/z calculated for 
C41H60N2O3F3S [M+H]+: 717.4277, found 717.4265. [α]22D = +7.3 (c = 0.51, CHCl3) 
 
 
Tyrosine-tocopherol conjugate (-)-35. The reaction was performed according to the general 
procedure using Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 
0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 
(+)-Allylated-δ-Tocopherol derivative (S39) (85.3 mg, 0.2 mmol, 1.0 equiv) and methyl-(S)-2-










(91.9 mg, 0.2 mmol, 1.0 equiv) for 72 hours. The reaction mixture was purified by flash column 
chromatography (column 1: 50 mL silica gel, 0% => 5% acetone in hexanes; column 2: 50 mL 
silica gel, 10% => 50% CH2Cl2 in hexanes) to provide pure desired product (-)-35 as a colorless 
oil. Run 1: (136.7 mg, 77.3% yield); Run 2: (135.4 mg, 76.6% yield); Run 3: (139.8 mg, 79.1% 
yield). Average: 78% yield ± 1.3%.  
1H NMR (500 MHz, Chloroform-d) δ 7.30 (d, J = 8.7 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.98 (br 
s, 1H), 6.89 (br s, 1H), 6.43 (d, J = 15.8 Hz, 1H), 5.88 (dt, J = 15.8, 7.1 Hz, 1H), 4.71 (br s, 1H), 
4.20 (br s, 2H), 3.69 (s, 3H), 3.50 (dd, J = 14.3, 8.0 Hz, 1H), 3.09 (dd, J = 14.2, 7.0 Hz, 1H), 2.79-
2.68 (m, 2H), 2.16 (s, 3H), 1.83 (m, 1H), 1.76 (m, 1H), 1.62-0.99 (m, 24H), 0.88-0.82 (m, 12H). 
13C NMR (125 MHz, CDCl3) δ 169.42, 153.10, 148.80, 136.88, 135.83, 131.41, 126.86, 126.82, 
126.54, 125.77, 121.60, 120.85, 119.92, 119.91(q, J = 323.1Hz), 118.95 (q, 320.8 Hz), 76.75, 
61.98, 52.96, 50.74, 40.51, 39.57, 37.65, 37.63, 37.60, 37.48, 36.61, 32.97, 32.87, 31.37, 28.14, 
24.95, 24.61, 24.37, 22.83, 22.75, 22.46, 21.15, 19.89, 19.79, 16.14. 19F NMR (470 MHz, CDCl3) 
δ -73.30, -75.91. HRMS (ESI) m/z calculated for C42H60NO8F6S2 [M+H]+: 884.3665, found 
884.3657. [α]22D = -15.6 (c = 0.50, CHCl3) 
 
 
Leelamine-tocopherol conjugate (+)-36.  The reaction was performed according to the general 
procedure using Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 
0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 
(+)-Allylated-δ-Tocopherol derivative (S39) (85.3 mg, 0.2 mmol, 1.0 equiv) and (+)-N-triflyl 








mixture purified by flash column chromatography (50 mL silica gel, 0% => 10% acetone in 
hexanes) to provide pure desired product (+)-36 as a colorless oil. Run 1: (100.2 mg, 59.5% yield); 
Run 2: (98.9 mg, 58.7% yield); Run 3: (100.8 mg, 59.8% yield). Average: 59% yield ± 0.6%.   
(MW = 842.2) 
1H NMR (500 MHz, Chloroform-d) δ 7.17 (d, J = 8.2 Hz, 1H), 7.01 (s, 2H), 6.92 (dd, J = 9.2, 2.1 
Hz, 2H), 6.46 (d, J = 15.7 Hz, 1H), 5.93 (dt, J = 15.1, 7.1 Hz, 1H), 4.33 (br s, 1H), 4.17 (br s, 1H), 
3.46 (d, J = 14.9 Hz, 1H), 3.24-3.16 (m, 1H), 2.97-2.88 (m, 2H), 2.84 (p, J = 6.9 Hz, 1H), 2.80-
2.73 (m, 2H), 2.35-2.29 (m, 1H), 2.19 (s, 3H), 1.91-1.66 (m, 6H), 1.64-1.03 (m, 40H), 0.93-0.83 
(m, 12H). 13C NMR (125 MHz, CDCl3) δ 152.95, 147.23, 145.86, 136.85, 134.44, 126.99, 126.82, 
126.72, 126.49, 125.71, 124.03, 123.98, 120.73, 120.54 (q, J = 325.3 Hz) 118.51, 76.66, 57.69, 
53.61, 46.31, 40.28, 39.52, 39.34, 38.14, 37.79, 37.58, 37.55, 37.42, 33.60, 32.94, 32.83, 31.24, 
29.88, 28.13, 25.78, 24.96, 24.59, 24.41, 24.15, 24.11, 22.88, 22.79, 22.40, 21.12, 19.91, 19.80, 
19.42, 18.65, 16.25. (48 peaks in total, one peak missing probably due to overlapping). 19F NMR 
(470 MHz, CDCl3) δ -74.31 HRMS (ESI) m/z calculated for C51H79NO3F3S [M+H]+: 842.5733, 











































sulfonamide (S43). To a 1 dram vial equipped with a stir bar was added Pd(OAc)2 (5.6 mg, 0.025 
mmol, 0.025 equiv), (±)-MeO-SOX ligand (L-5) (8.6 mg, 0.025 mmol, 0.025 equiv), 2,5 DMBQ 
(2,5-dimethylbenzoquinone) (150 mg, 1.1 mmol, 1.1 equiv), methyl eugenol (178.2 mg, 1.0 mmol, 
1.0 equiv) and 1,1,1-trifluoro-N-(4-fluorobenzyl)methanesulfonamide (S24) (257.2 mg, 1.0 mmol, 
1.0 equiv). Toluene (1.0 mL, 1.0 M) was added and the vial was capped and heated at 45 °C for 
48 hours (monitored by TLC). The vial was allowed to cool to room temperature and diluted with 
acetone (1 mL). The reaction mixture was plug filtered a ½ inch pipette silica plug and 
concentrated under reduced pressure. The crude mixture was diluted with 10 mL CDCl3 and an 
internal standard (trifluorotoluene 73 mg, 0.5 mmol, 0.5 equiv) was added for crude 1H NMR. The 
mixture was concentrated under reduced pressure and subjected to flash column chromatography 
(column 1: 100 mL silica gel 10% => 30% acetone in hexanes; column 2: 100 ml silica gel, 10% 
=> 100% CH2Cl2 in hexanes) to provide pure desired product S43 as white solid. Run 1: (371.6 
mg, 85.7% yield); Run 2: (374.1mg, 86.3 % yield Average: 86% yield.  
1H NMR (500 MHz, Chloroform-d) δ 7.32 (dd, J = 8.4, 5.2 Hz, 2H), 7.07 (t, J = 8.4 Hz, 2H), 6.87 
(dd, J = 8.3, 1.8 Hz, 1H), 6.85-6.81 (m, 2H), 6.34 (d, J = 15.7 Hz, 1H), 5.84 (dt, J = 15.0, 7.1 Hz, 
1H), 4.52 (br s, 2H), 4.01 (br s, 2H), 3.90 (s, 3H), 3.89 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
162.8 (d, J = 247.6 Hz), 149.7, 149.2, 136.1, 130.5 (d, J = 8.3 Hz), 130.2 (d, J = 3.1 Hz), 128.6, 
120.2 (q, J = 322.8 Hz (124.0, 121.4, 118.9, 116.3)), 120.1, 119.5, 116.0 (d, J = 21.6 Hz), 111.2, 
108.9, 56.0, 55.9, 50.3, 50.0. 19F NMR (470 MHz, CDCl3) δ -76.26, -113.55. HRMS (ESI) m/z 









(E)-3-(3,4-dimethoxyphenyl)-N-(4-fluorobenzyl)prop-2-en-1-amine (37). An oven-dried 25 ml 
flask was charged with a stir bar, S43 (216.7 mg, 0.5 mmol, 1.0 equiv) and toluene (10 ml, 0.05 
M). The reaction was cooled to 0 °C and Red-Al (3.5 M in toluene) (sodium bis(2-
methoxyethoxy)aluminumhydride) (5.0 mmol, 1.42 mL) was added dropwise and the reaction was 
allowed to warm up to room temperature and stirred at room temperature for 16 hours. Upon 
completion,  the reaction was cooled to 0 °C and 5% NH4Cl was added. Layers were separated and 
the aqueous layer was further extracted with CH2Cl2 (30 ml x 3). The organic layers were combined 
and dried over Na2SO4, filtered, concentrated under vacuum and subjected to a flash column 
chromatography (100 mL silica gel, 0% => 10% MeOH in CH2Cl2) to provide pure product (37). 
Run 1: (138.9 mg, 92.2% yield); Run 2: (139.5 mg, 92.6 % yield Average: 92% yield.  
1H NMR (500 MHz, Chloroform-d) δ 7.31 (dd, J = 8.4, 5.6 Hz, 2H), 7.01 (t, J = 8.7 Hz, 2H), 6.93 
(d, J = 1.9 Hz, 1H), 6.89 (dd, J = 8.2, 2.0 Hz, 1H), 6.80 (d, J = 8.2 Hz, 1H), 6.47 (d, J = 15.8 Hz, 
1H), 6.17 (dt, J = 15.6, 6.4 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.80 (s, 2H), 3.41 (d, J = 6.4 Hz, 




(38). Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX ligand (L-5) (3.4 mg, 0.01 mmol, 
0.05 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 1-allyl-4-
(trifluoromethyl)benzene (37.2 mg, 0.2 mmol) and 1,1,1-trifluoro-N-phenylmethanesulfonamide 
(S12) (47.8 mg, 0.2 mmol) were reacted according to the general procedure for 24 hours. 











provided pure product 38 as a colorless oil. Run 1: (67.9 mg, 80.1% yield); Run 2: (68.0 mg, 80.3% 
yield); Run 3: (67.6 mg, 79.8% yield). Average: 80% yield ± 0.3%.    
1H NMR (500 MHz, Chloroform-d) δ 7.59 (d, J = 8.1 Hz, 2H), 7.43-7.37 (m, 5H), 7.37-7.34 (m, 
2H), 6.44 (d, J = 15.8 Hz, 1H), 6.10 (dt, J = 15.8, 7.0 Hz, 1H), 4.57 (br s, 2H), 4.07 (br s, 2H). 13C 
NMR (126 MHz, Chloroform-d) δ 139.2, 134.6, 134.1, 130.33 (q, J = 32.4 Hz), 129.2, 128.8, 
128.7, 126.9, 125.9 (d, J = 260.2 Hz), 125.8 (q, J = 3.8 Hz), 124.9, 120.2 (q, J = 322.7 Hz), 51.6, 
49.7. 19F NMR (470 MHz, Chloroform-d) δ -63.02, -76.20. HRMS (ESI) m/z calculated for 




(39). Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX ligand (L-5) (3.4 mg, 0.01 mmol, 
0.05 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), Methyl 4-
allylbenzoate (35.2 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-phenylmethanesulfonamide 
(S12) (47.8 mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 24 hours. 
Purification by flash column chromatography (column 1: 50 mL silica gel, 2.5% => 15% acetone 
in hexanes, column 2: 50 mL silica gel, 10% => 50% CH2Cl2 in hexanes) provided pure product 
39 as a colorless oil. Run 1: (78.0 mg, 94.3% yield); Run 2: (78.6 mg, 95.1% yield); Run 3: (79.1 
mg, 95.7% yield). Average: 95% yield ± 0.7%.    
1H NMR (500 MHz, Chloroform-d) δ 8.00 (d, J = 8.1 Hz, 2H), 7.43-7.31 (m, 7H), 6.43 (d, J = 
15.8 Hz, 1H), 6.11 (dt, J = 15.8, 7.0 Hz, 1H), 4.56 (br s, 2H), 4.06 (br s, 2H), 3.93 (s, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 166.9, 140.2, 135.2, 134.2, 130.3, 130.1, 129.3, 128.9, 128.9, 
126.7, 124.8, 120.33 (q, J = 322.9 Hz), 52.4, 51.6, 49.9. 19F NMR (470 MHz, Chloroform-d) δ -








(E)-N-benzyl-1,1,1-trifluoro-N-(3-(4-formylphenyl)allyl)methanesulfonamide (40). Pd(OAc)2 
(2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX ligand (L-5) (3.4 mg, 0.01 mmol, 0.05 equiv), 
2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 4-allylbenzaldehyde (29.2 
mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 
mmol, 1.0 equiv) were reacted according to the general procedure for 24 hours. Purification by 
flash column chromatography (column 1: 50 mL silica gel, 2.5% => 15% acetone in hexanes, 
column 2: 50 mL silica gel, 10% => 50% CH2Cl2 in hexanes) provided pure product 40 as a 
colorless oil. Run 1: (62.0 mg, 80.9% yield); Run 2: (60.9 mg, 79.4% yield); Run 3: (61.5 mg, 
80.2% yield). Average: 80% yield ± 0.8%.    
1H NMR (500 MHz, Chloroform-d) δ 10.00 (s, 1H), 7.87-7.82 (m, 2H), 7.48-7.32 (m, 7H), 6.44 
(d, J = 15.8 Hz, 1H), 6.15 (dt, J = 15.8, 7.0, 1H), 4.56 (br s, 2H), 4.07 (br s, 2H). 13C NMR (126 
MHz, Chloroform-d) δ 191.8, 141.7, 136.2, 134.9, 134.2, 130.4, 129.3, 129.0, 128.9, 127.4, 125.9, 
120.3 (q, J = 322.7 Hz), 51.8, 49.9. 19F NMR (470 MHz, Chloroform-d) δ -76.16. HRMS (ESI) 
m/z calculated for C18H17NO3F3S [M+H]+: 383.0881, found 384.0880. 
 
 
(E)-N-benzyl-N-(3-(4-bromophenyl)allyl)-1,1,1-trifluoromethanesulfonamide (41). Pd(OAc)2 
(4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 1-allyl-4-bromobenzene 
(39.4 mg, 0.2 mmol) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol) 









chromatography (50 mL silica gel, 2.5% => 15% acetone in hexanes) provided pure product 41 as 
a colorless oil. Run 1: (78.2 mg, 90.0% yield); Run 2: (79.0 mg, 91.0% yield); Run 3: (61.5 mg, 
79.0% yield). Average: 90% yield ± 0.6%.    
1H NMR (500 MHz, Chloroform-d) δ 7.46 (d, J = 8.4 Hz, 2H), 7.43-7.35 (m, 3H), 7.35-7.31 (m, 
2H), 7.17 (d, J = 8.4 Hz, 2H), 6.34 (d, J = 15.8 Hz, 1H), 6.00 (dt, J = 15.8, 7.0 Hz, 1H), 4.55 (br 
s, 2H), 4.02 (br s, 2H). 13C NMR (126 MHz, Chloroform-d) δ 135.0, 134.7, 134.1, 132.0, 129.1, 
128.8, 128.7, 128.2, 122.8, 122.5, 120.2 (q, J = 322.8 Hz), 51.3, 49.8. 19F NMR (470 MHz, 





(42). Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX ligand (L-5) (3.4 mg, 0.01 mmol, 
0.05 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), (4-
allylphenyl)methanol (29.6 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-
phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv) were reacted according to the 
general procedure for 24 hours. Purification by flash column chromatography (column 1: 50 mL 
silica gel, 2.5% => 15% acetone in hexanes, column 2: 50 mL silica gel, 10% => 50% CH2Cl2 in 
hexanes) provided pure product 42 as a white solid. Run 1: (68.1 mg, 88.3% yield); Run 2: (67.5 
mg, 87.6% yield); Run 3: (69.6 mg, 90.3% yield). Average: 89% yield ± 1.4%.    
1H NMR (500 MHz, Chloroform-d) δ 7.44-7.30 (m, 9H), 6.41 (d, J = 15.8 Hz, 1H), 6.02 (dt, J = 
15.7, 7.1 Hz, 1H), 4.70 (s, 2H), 4.56 (br s, 2H), 4.03 (br s, 2H), 1.77 (s, 1H). 13C NMR (126 MHz, 






= 322.7 Hz), 65.0, 51.1, 49.8. 19F NMR (470 MHz, Chloroform-d) δ -76.26. HRMS (EI) m/z 
calculated for C18H18NO3F3S  [M]+: 385.0960, found 385.0959. 
 
 
Methyl (E)-4-(3-(benzylamino)prop-1-en-1-yl)benzoate (43). Pd(OAc)2 (6.7 mg, 0.03 mmol, 
0.1 equiv), (±)-MeO-SOX ligand (L-5) (10.2 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (45 mg, 0.33 mmol, 1.1 equiv), Methyl 4-allylbenzoate (51.3 mg, 0.3 
mmol, 1.0 equiv) and 4-nitro-N-phenethylbenzenesulfonamide (91.8 mg, 0.3 mmol, 1.0 equiv) 
were reacted according to the general procedure in dioxane (0.3 mL, 1.0 M) for 72 hours. The 
mixture was concentrated under reduced pressure, diluted with 2 mL CDCl3 and analyzed by crude 
1H NMR with internal standard (trifluorotoluene 24.3 mg, 0.166 mmol, 0.555 equiv): about 71% 
NMR yield. Purification by flash column chromatography (100 mL silica gel, 0% => 15% acetone 
in hexanes provided a mixture of product 43 with 4-nitro-N-phenethylbenzenesulfonamide. 
      To a 20 mL vial was added a stir bar, mixture from last step, Cs2CO3 (325.8 mg, 1.0 mmol), 
DMF (1 mL) and PhSH (307.3μL, 3.0 mmol). The reaction was heated to 45 °C for 2 hours. The 
vial was allowed to cool to room temperature, diluted with 10 mL Et2O and added 5% aq. NaHCO3. 
Layers were separated, aqueous layer was extracted with Et2O. Organic layers were combined, 
dried over anhydrous MgSO4 and concentrated under reduced pressure. The crude mixture was 
purified by flash silica plug (50 mL silica gel, 100 mL 2% MeOH/ CH2Cl2 then switch to 4% 
MeOH/CH2Cl2 to give pure product. 
Run 1: (56.3 mg, 66.7% yield); Run 2: (57.5 mg, 68.1% yield); Run 3: (54.6 mg, 64.7% yield). 
Average: 67% yield ± 1.7% over two steps.   
1H NMR (500 MHz, Chloroform-d) δ 7.98 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.37 – 






(s, 3H), 3.86 (s, 2H), 3.47 (d, J = 6.1 Hz, 2H), 2.19 – 1.98 (br s, 1H). 13C NMR (126 MHz, 
Chloroform-d) δ 167.0, 141.7, 139.9, 131.2, 130.7, 130.0, 129.0, 128.6, 128.4, 127.3, 126.3, 53.4, 
52.2, 51.1. HRMS (EI) m/z calculated for C18H20NO2 [M+H]+: 282.1494, found 282.1493. 
 
 
tert-Butyl (E)-benzyl(3-(4-formylphenyl)allyl)carbamate (44). Pd(OAc)2 (6.7 mg, 0.03 mmol, 
0.1 equiv), (±)-MeO-SOX ligand (L-5) (10.2 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (45 mg, 0.33 mmol, 1.1 equiv), 4-allylbenzaldehyde (43.8 mg, 0.23 mmol, 
1.0 equiv) and 4-nitro-N-phenethylbenzenesulfonamide (91.8 mg, 0.3 mmol, 1.0 equiv) were 
reacted according to the general procedure in dioxane (0.3 mL, 1.0 M) for 72 hours. The mixture 
was concentrated under reduced pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H 
NMR with internal standard (trifluorotoluene 21.8 mg, 0.149 mmol, 0.498 equiv): about 63% 
NMR yield. Purification by flash column chromatography (100 mL silica gel, 0% => 15% Acetone 
in hexanes provided a mixture of product 44 with 4-nitro-N-phenethylbenzenesulfonamide. 
      To a 20 mL vial was added a stir bar, mixture from last step, Cs2CO3 (325.8 mg, 1.0 mmol), 
DMF (1 mL) and PhSH (307.3 μL, 3.0 mmol). The reaction was heated to 45 °C for 2 hours. The 
vial was allowed to cool to room temperature, diluted with 10 mL Et2O and added 5% aq. NaHCO3. 
Layers were separated, aqueous layer was extracted with Et2O. Organic layers were combined, 
dried over anhydrous MgSO4 and concentrated under reduced pressure. The crude mixture was 
purified by flash silica plug (50 mL silica gel, 100 mL 2% MeOH/ CH2Cl2 then switch to 4% 
MeOH/CH2Cl2 to collect pure amine product (not stable under room temperature, was carried 
through the next step ).  
     To a 20 mL vial was added a stir bar, amine product from last step, di-tert-butyldicarbonate 






was stirred at room temperature for 2 hours and concentrated under reduced pressure. The crude 
mixture was purified by flash column chromatography (100 mL silica gel, 0% acetone/ hexanes 
=> 10% acetone/hexanes) to give pure product as a colorless oil.  
     Run 1: (58.1 mg, 55.1% yield); Run 2: (57.1 mg, 54.1% yield); Run 3: (58.9 mg, 55.9% yield). 
Average: 55% yield ± 2.5% over three steps.   
1H NMR (500 MHz, Chloroform-d) δ 9.98 (s, 1H), 7.82 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 7.9 Hz, 
2H), 7.36 – 7.31 (m, 2H), 7.30 – 7.22 (m, 3H), 6.45 (d, J = 15.9 Hz, 1H), 6.28 (s, 1H), 4.48 (s, 2H), 
4.00 (s, 2H), 1.50 (s, 8H). 13C NMR (126 MHz, Chloroform-d) δ 191.6, 155.8, 143.0, 138.3, 135.7, 
130.9, 130.2, 129.7, 128.7, 127.8, 127.5, 127.0, 80.3, 50.2, 48.5, 28.6. HRMS (EI) m/z calculated 




trifluoromethanesulfonamide (45). Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX 
ligand (L-5) (3.4 mg, 0.01 mmol, 0.05 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 
0.22 mmol, 1.1 equiv), (2-allylphenoxy)(tert-butyl)dimethylsilane (49.7 mg, 0.2 mmol, 1.0 equiv) 
and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv) were 
reacted according to the general procedure for 24 hours. Purification by flash column 
chromatography (column 1: 50 mL silica gel, 10% => 30% CH2Cl2 in hexanes) provided pure 
product 45 as a colorless oil. Run 1: (79.0 mg, 81.3% yield); Run 2: (78.7 mg, 81.0% yield); Run 
3: (79.3 mg, 81.7% yield). Average: 81% yield ± 0.4%. 
1H NMR (500 MHz, Chloroform-d) δ 7.48-7.32 (m, 6H), 7.24-7.17 (m, 1H), 6.97 (td, J = 7.5, 1.3 
Hz, 1H), 6.90-6.79 (m, 2H), 6.04 (ddd, J = 15.9, 7.9, 6.4 Hz, 1H), 4.57 (br s, 2H), 4.07 (br s, 2H), 






128.7, 128.6, 127.0, 126.7, 121.6, 121.4, 120.2 (q, J = 322.9 Hz), 119.7, 50.7, 50.0, 25.9, 18.5, 4.0. 
19F NMR (470 MHz, Chloroform-d) δ -76.33. HRMS (EI) m/z calculated for C23H31NO3F3SSi 




(46). Pd(OAc)2 (2.2 mg, 0.01 mmol, 0.05 equiv), (±)-MeO-SOX ligand (L-5) (3.4 mg, 0.01 mmol, 
0.05 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 1-allyl-3-
(trifluoromethyl)benzene (37.2 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-
phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv) were reacted according to the 
general procedure for 24 hours. Purification by flash column chromatography (column 1: 50 mL 
silica gel, 10% => 30% CH2Cl2 in hexanes) provided pure product 46 as a colorless oil. Run 1: 
(71.4 mg, 84.3% yield); Run 2: (72.5 mg, 85.7% yield); Run 3: (72.2 mg, 85.3% yield). Average: 
85% yield ± 0.7%.   
1H NMR (500 MHz, Chloroform-d) δ 7.54 (d, J = 6.9 Hz, 1H), 7.52-7.45 (m, 3H), 7.43-7.33 (m, 
5H), 6.43 (d, J = 15.8 Hz, 1H), 6.06 (dt, J = 15.7, 7.0 Hz, 1H), 4.56 (br s, 2H), 4.07 (br s, 2H). 13C 
NMR (126 MHz, Chloroform-d) δ 136.6, 134.5, 134.2, 131.3 (q, J = 32.3 Hz), 129.8, 129.3, 129.2, 
128.8, 128.8, 125.1 (q, J = 3.8 Hz), 124.2, 124.1 (q, J = 272.3 Hz), 123.5 (q, J = 3.8 Hz), 120.2 (q, 
J = 322.7 Hz), 51.7, 49.8. 19F NMR (470 MHz, Chloroform-d) δ -63.20, -76.18. HRMS (ESI) m/z 













(47). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), eugenol (32.8 
mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 
mmol) were reacted according to the general procedure for 24 hours. Purification by flash column 
chromatography (column 1: 50 mL silica gel, 2.5% => 10% acetone in hexanes; column 2: 50 mL 
silica gel, 10% => 30% CH2Cl2 in hexanes) provided pure product 47 as a yellow oil. Run 1: (72.4 
mg, 90.2% yield); Run 2: (71.7 mg, 89.3% yield); Run 3: (72.8 mg, 90.7% yield). Average: 90% 
yield ± 0.7%.    
1H NMR (500 MHz, Chloroform-d) δ 7.44-7.31 (m, 5H), 6.89 (d, J = 8.0 Hz, 1H), 6.86-6.81 (m, 
2H), 6.33 (d, J = 15.7 Hz, 1H), 5.85 (dt, J = 15.7, 7.2 Hz, 1H), 5.74 (s, 1H), 4.56 (br s, 2H), 4.02 
(br s, 2H), 3.92 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 146.8, 146.3, 136.3, 134.3, 129.1, 
128.7, 128.6, 128.3, 120.8, 120.2 (q, J = 322.8 Hz), 119.3, 116.4, 114.6, 56.0, 51.0, 50.0. 19F NMR 
(470 MHz, Chloroform-d) δ -76.25. HRMS (ESI) m/z calculated for C18H19NO4F3S [M+H]+: 




Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 4-allyl-1,2-
dimethoxybenzene (35.6 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-
phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv) were reacted according to the 
general procedure for 24 hours. Purification by flash column chromatography (column 1: 50 mL 







hexanes) provided pure product 48 as a colorless oil. Run 1: (71.9 mg, 86.5% yield); Run 2: (74.9 
mg, 90.1% yield); Run 3: (73.9 mg, 89.0% yield). Average: 88% yield ± 1.8%.  
1H NMR (500 MHz, Chloroform-d) δ 7.44-7.32 (m, 5H), 6.88 (dd, J = 8.2, 2.0 Hz, 1H), 6.83 (d, 
J = 8.4 Hz, 2H), 6.34 (d, J = 15.7 Hz, 1H), 5.86 (dt, J = 15.7, 7.1 Hz, 1H), 4.56 (br s, 2H), 4.03 (br 
s, 2H), 3.91 (s, 3H), 3.90 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 149.6, 149.2, 136.1, 
134.3, 129.0, 128.8, 128.7, 128.6, 120.2 (q, J = 322.8 Hz), 120.1, 119.7, 111.2, 108.9, 56.0, 56.0, 
51.0, 50.0. 19F NMR (470 MHz, Chloroform-d) δ -76.25. HRMS (EI) m/z calculated for 
C19H20NO4F3S [M]+: 415.10651, found 415.10649. 
 
 
N-cinnamyl-1,1,1-trifluoro-N-(4-fluorobenzyl)methanesulfonamide (49). Pd(OAc)2 (4.4 mg, 
0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ 
(2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allylbenzene (23.6 mg, 0.2 mmol, 1.0 
equiv) and 1,1,1-trifluoro-N-(4-fluorobenzyl)methanesulfonamide (S24) (51.4 mg, 0.2 mmol, 1.0 
equiv) were reacted according to the general procedure for 24 hours. Purification by flash column 
chromatography (50 mL silica gel, 10% => 20% CH2Cl2 in hexanes) provided pure product 49 as 
a colorless oil. Run 1: (66.1 mg, 88.5% yield); Run 2: (66.8 mg, 89.4% yield); Run 3: (66.6 mg, 
89.2% yield). Average: 89% yield ± 0.5%.    
1H NMR (500 MHz, Chloroform-d) δ 7.40-7.29 (m, 7H), 7.09 (t, J = 8.6 Hz, 2H), 6.43 (d, J = 15.8 
Hz, 1H), 6.03 (dt, J = 15.8, 7.1 Hz, 1H), 4.51 (br s, 2H), 4.03 (br s, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 162.9 (d, J = 247.7 Hz), 136.5, 135.6, 130.6 (d, J = 8.3 Hz), 130.0 (d, J = 3.2 Hz), 
128.9, 128.7, 126.7, 121.7, 120.2 (q, J = 322.6 Hz), 116.1 (d, J = 21.6 Hz), 50.3, 49.8. 19F NMR 
(470 MHz, Chloroform-d) δ -76.30, -113.45. HRMS (EI) m/z calculated for C17H15NO2F4SNa 








Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 
equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allylbenzene (23.6 
mg, 0.2 mmol, 1.0 equiv) and N-(4-(dimethylamino)benzyl)-1,1,1-trifluoromethanesulfonamide 
(S26) (56.5 mg, 0.2 mmol, 1.0 equiv) were reacted according to general procedure for 24 hours. 
Purification by flash column chromatography (50 mL silica gel, 2% => 4% Ethyl acetate in 
hexanes) provided pure product 50 as a white solid. Run 1: (68.0 mg, 85.3% yield); Run 2: (68.7 
mg, 86.2% yield); Run 3: (67.5 mg, 84.7% yield). Average: 85% yield ± 0.8%.    
1H NMR (500 MHz, Chloroform-d) δ 7.34 (app d, J = 4.3 Hz, 4H), 7.32-7.27 (m, 1H), 7.20 (d, J 
= 8.2 Hz, 2H), 6.73 (app s, 2H), 6.43 (d, J = 15.8, 1H), 6.02 (dt, J = 15.8, 7.0 Hz, 1H), 4.44 (br s, 
2H), 4.00 (br s, 2H), 2.97 (s, 6H). 13C NMR (126 MHz, Chloroform-d) δ 150.7, 136.0, 135.9, 
130.1, 128.8, 128.4, 126.7, 122.3, 121.1, 120.3 (q, J = 322.8 Hz), 112.6, 50.8, 49.1, 40.6. 19F NMR 
(470 MHz, Chloroform-d) δ -76.42. HRMS (ESI) m/z calculated for C19H22N2O2F3S [M+H]+: 
399.1354, found 399.1349. 
 
 
N-cinnamyl-N-(3,4-dimethoxybenzyl)-1,1,1-trifluoromethanesulfonamide (51). Pd(OAc)2 
(4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), allylbenzene (23.6 mg, 0.2 
mmol, 1.0 equiv) and N-(3,4-dimethoxybenzyl)-1,1,1-trifluoromethanesulfonamide (S25) (59.9 
mg, 0.2 mmol, 1.0 equiv) were reacted according to the general procedure for 24 hours. 










provided pure product 51 as a colorless oil. Run 1: (71.6 mg, 86.2% yield); Run 2: (72.6 mg, 87.4% 
yield); Run 3: (73.3 mg, 88.2% yield). Average: 87% yield ± 1.0%.    
1H NMR (500 MHz, Chloroform-d) δ 7.38-7.27 (m, 5H), 6.87 (app s, 1H), 6.85 (app s, 2H), 6.43 
(d, J = 15.7, 1H), 6.04 (dt, J = 15.7, 7.1 Hz, 1H), 4.48 (br s, 2H), 4.10-3.93 (m, 2H), 3.89 (s, 3H), 
3.86 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 149.5, 149.3, 136.2, 135.7, 128.9, 128.6, 
126.7, 126.4, 121.9, 121.5, 120.2 (q, J = 322.7 Hz), 111.5, 111.1, 56.0, 56.0, 50.9, 49.5. 19F NMR 
(470 MHz, Chloroform-d) δ -76.30. HRMS (ESI) m/z calculated for C19H21NO4F3S [M+H]+: 
416.1143, found 416.1130. 
 
 
(E)-N-benzyl-1,1,1-trifluoro-N-(3-phenylbut-2-en-1-yl)methanesulfonamide (52). Pd(OAc)2 
(4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 
DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), but-3-en-2-ylbenzene71 (26.4 
mg, 0.2 mmol) and 1,1,1-trifluoro-N-phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol) were 
reacted according to the general procedure for 72 hours. Purification by flash column 
chromatography (column1: 50 mL silica gel, 2.5% => 5% acetone in hexanes; column2: 50 mL 
silica gel, 10% => 20% CH2Cl2 in hexanes) provided product 52 as a colorless oil (E:Z = 15:1). 
E:Z selectivity was measured by 1H NMR: triplet of doublet at 5.65 ppm (E isomer) and triplet at 
5.46 (Z isomer).  Run 1: (51.9 mg, 70.2% yield, 15:1 E:Z, 66.2% yield for E); Run 2: (51.2 mg, 
69.3% yield, 15:1 E:Z, 64.8% yield for E isomer); Run 3: (51.7 mg, 70.0% yield, 15:1 E:Z, 65.4% 
yield for E iosmer). Average: 65% yield ± 0.7%.   Further purification column chromatography 
was applied to afford pure E isomer (>20:1 E:Z).  





1H NMR (500 MHz, Chloroform-d) δ 7.43-7.27 (m, 10H), 5.65 (td, J = 7.1, 1.6 Hz, 1H), 4.57(br 
s, 2H), 4.10 (br s, 2H), 1.82 (d, J = 1.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 142.5, 141.2, 
134.4, 129.1, 128.7, 128.6, 128.5, 127.9, 125.9, 120.4, 120.3 (q, J = 322.8 Hz), 51.5, 45.9, 16.2. 
19F NMR (470 MHz, Chloroform-d) δ -76.22. HRMS (ESI) m/z calculated for C18H18NO2F3SNa 
[M+Na]+: 392.0908, found 392.0910.  
E/Z configuration assignment is based on 13C NMR analogy to similar compounds (the chemical 
shifts of the methyl group attached to olefin, geranyl acetate (E, 16.4 ppm) and neryl acetate(Z, 
23.5 ppm)) from previous literature72,73. In addition to 13C NMR, in NOESY-1D, no NOE to the 
olefin proton was observed when irradiating the methyl group; larger NOE observed between 
olefin proton and the aryl proton and the neighboring methylene, but not to the methyl group (tiny 




(53). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX ligand (L-5) (6.9 mg, 0.02 mmol, 
0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), 2-(4-
allylphenyl)-1,3,4-oxadiazole(S37) (37.2 mg, 0.2 mmol, 1.0 equiv) and 1,1,1-trifluoro-N-
phenylmethanesulfonamide (S12) (47.8 mg, 0.2 mmol,1.0 equiv) were reacted according to the 
general procedure for 72 hours. Purification by flash column chromatography (column1: 50 mL 
silica gel, 2.5% => 15% acetone in hexanes) provided pure product 53 as white solid. Run 1: (53.7 
mg, 63.4% yield); Run 2: (54.8 mg, 64.7% yield); Run 3: (54.6 mg, 64.5% yield). Average: 64% 







1H NMR (500 MHz, Chloroform-d) δ 8.48 (s, 1H), 8.04 (d, J = 8.3 Hz, 2H), 7.45-7.33 (m, 7H), 
6.43 (d, J = 15.8 Hz, 1H), 6.12 (dt, J = 15.8, 7.0 Hz, 1H), 4.56 (br s, 2H), 4.07 (br s, 2H). 13C NMR 
(126 MHz, CDCl3) δ 164.5, 152.8, 139.3, 134.7, 134.1, 129.1, 128.8, 128.7, 127.6, 127.3, 124.8, 
123.2, 120.2(q, J = 322.8 Hz), 51.6, 49.8. 19F NMR (470 MHz, Chloroform-d) δ -76.17. HRMS 




ylmethyl)methanesulfonamide (54). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv), 5-allylbenzo[b]thiophene (34.9 mg, 0.2 mmol, 1.0 equiv) and and 1,1,1-
trifluoro-N-(naphthalen-1-ylmethyl)methanesulfonamide (S13) (57.9 mg, 0.2 mmol, 1.0 equiv) 
were reacted according to the general procedure for 24 hours. Purification by flash column 
chromatography (50 mL silica gel, 0% => 30% CH2Cl2 in hexanes) provided pure product (54) as 
a colorless oil. Run 1: (81.1 mg, 87.9% yield); Run 2: (83.0 mg, 89.9% yield); Run 3: (82.5 mg, 
89.4% yield). Average: 89% yield ± 1.0%.    
1H NMR (500 MHz, Chloroform-d) δ 8.17 (d, J = 8.5 Hz, 1H), 7.90 (t, J = 9.2 Hz, 2H), 7.80 (d, J 
= 8.4 Hz, 1H), 7.62-7.50 (m, 5H), 7.47 (d, J = 5.4 Hz, 1H), 7.31 (dd, J = 5.5, 0.8 Hz, 1H), 7.19 
(dd, J = 8.4, 1.7 Hz, 1H), 6.29 (d, J = 15.7 Hz, 1H), 6.00 (dt, J = 15.7, 7.0 Hz, 1H), 5.11 (br s, 2H), 
4.09 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 140.0, 139.7, 136.2, 134.0, 132.1, 131.6, 129.7, 
129.2, 129.1, 127.5, 127.3, 127.1, 126.3, 125.3, 124.0, 123.0, 122.7, 122.5, 122.1, 121.4, 120.4 (q, 
J = 323.6 Hz), 50.2, 49.3. 19F NMR (470 MHz, CDCl3) δ -75.4. HRMS (ESI) m/z calculated for 








yl)allyl)methanesulfonamide (55). Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (L-5) (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 
mmol, 1.1 equiv), 6-allyl-2H-chromen-2-one (S38) (37.2 mg, 0.2 mmol,1.0 equiv) and (S)-1,1,1-
trifluoro-N-(1-(4-nitrophenyl)ethyl)methanesulfonamide (S27) (59.6 mg, 0.2 mmol, 1.0 equiv) 
were reacted according to the general procedure for 24 hours. Purification by flash column 
chromatography (column1: 50 mL silica gel, 2.5% => 30% acetone in hexanes provided pure 
product (+)-55 as a yellow oil. Run 1: (85.8 mg, 88.9% yield); Run 2: (87.3 mg, 90.5% yield); Run 
3: (88.2 mg, 91.4% yield). Average: 88% yield ± 1.3%.   
1H NMR (500 MHz, Chloroform-d) δ 8.19 (d, J = 8.0 Hz, 2H), 7.70-7.53 (m, 3H), 7.34-7.11 (m, 
3H), 6.41 (d, J = 9.4 Hz, 1H), 6.23 (d, J = 15.7 Hz, 1H), 5.78 (br s, 1H), 5.39 (q, J = 7.1 Hz, 1H), 
4.08-3.93 (m, 2H), 1.82 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 160.4, 153.8, 
147.9, 145.7, 143.1, 132.5, 132.2, 129.5, 129.0, 125.6, 125.2, 123.9, 119.9 (q, J = 322.9 Hz), 119.0, 
117.3, 56.9, 47.7, 17.1. 19F NMR (470 MHz, Chloroform-d) δ -76.13. HRMS (ESI) m/z calculated 

























N-(2-bromoethyl)-N-cinnamyl-1,1,1-trifluoromethanesulfonamide (56). To a 25 mL round 
bottom flask equipped with a stir bar was added Pd(OAc)2 (67 mg, 0.3 mmol, 0.1 equiv), (±)-MeO-
SOX ligand (L-5) (102.9 mg, 0.3 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (450 
mg, 33 mmol, 1.1 equiv), allylbenzene (354.5 mg, 3.0 mmol, 1.0 equiv) and N-(2-bromoethyl)-
1,1,1-trifluoromethanesulfonamide (S18) (768.1 mg, 3.0 mmol, 1.0 equiv). Toluene (3.0 mL, 1.0 
M) was added and the flask was capped and heated at 45 °C for 72 hours (monitored by TLC). The 
vial was allowed to cool to room temperature and diluted with acetone (10 mL). The reaction 
mixture was filtered through a ½ pipette silica plug into a 100 mL vial using acetone (30 mL), 
concentrated under reduced pressure and subjected to flash column chromatography (200 mL silica 
gel, 10% => 30% CH2Cl2 in hexanes) to provide pure desired product 56 as a colorless oil. Run 1: 
(962.1 mg, 86.2% yield); Run 2: (970.5 mg, 86.9 % yield; Run 3: (951.1 mg, 85.2% yield) 
Average: 86% yield ± 0.9%. The reaction has also been run under smaller scale (0.3 mmol) 
using Pd(OAc)2 (6.7 mg, 0.03 mmol, 0.1 equiv), ligand 5 (10.3 mg, 0.03 mmol, 0.1 equiv), 2,5-
dimethylbenzoquinone (2,5 DMBQ) (45.0 mg, 3.3 mmol, 1.1 equiv), allylbenzene (35.5 mg, 0.3 


















30% CuI, 60% Me4Phen



























mmol, 1.0 equiv). Toluene (0.3 mL, 1.0 M), the reaction gave comparable result: 100.6 mg, 90% 
yield. 
1H NMR (500 MHz, Chloroform-d) δ 7.42-7.39 (m, 2H), 7.39-7.35 (m, 2H), 7.34-7.30 (m, 1H), 
6.66 (d, J = 15.8 Hz, 1H), 6.13 (dt, J = 15.6, 7.0 Hz, 1H), 4.23 (m, 2H), 3.75 (br s, 2H), 3.50 (t, J 
= 7.3 Hz, 2H). 13C NMR (125 MHz, CDCl3) δ 136.5, 135.4, 128.9, 128.8, 126.8, 121.9, 120.0 (q, 
J = 323.0 Hz), 52.1, 49.0, 28.0. 19F NMR (470 MHz, CDCl3) δ -76.16. HRMS (ESI) m/z 




trifluoromethanesulfonamide (S44). To a 50 mL round bottom flask equipped with a stir bar was 
added 52 (744.4 mg, 2 mmol, 1 equiv), t-BuOH (10 mL) and H2O (10 mL). The reaction was 
cooled to 0 °C. AD-mix-α (2.8g), additional (DHQ)2PHAL (75 mg, 0.096 mmol, 0.048 equiv) and 
K2OsO4.H2O (10.2 mg, 0.028 mmol, 0.014 equiv) were added. The reaction was stirred at 0 °C 
until all solid was fully dissolved and two clear phases were produced. MeSO2NH2 (190 mg, 2.0 
mmol, 1.0 equiv) was added and the reaction was slowly warmed up to room temperature and 
stirred under room temperature for 24 hours (monitored by TLC). Upon completion, the reaction 
was cooled to 0 °C and Na2SO3 (3 g) was added.  The reaction mixture was allowed to warm up to 
room temperature over 30 mins. The reaction was diluted with ethyl acetate (30 mL) and the layers 
were separated. The aqueous layer was extracted with ethyl acetate (20 mL x 3). Combined organic 
layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The 
mixture was filtered through a short silica plug (ethyl acetate/hexane), concentrated under reduced 









(S)-phenyl((S)-4-((trifluoromethyl)sulfonyl)morpholin-2-yl)methanol (57). To an oven-dried 
25 mL round bottom flask under N2, S44 (carried through from last step) was added as a solution 
in DMF (14 mL 0.13M). The reaction was cooled to 0 °C, then NaH (120 mg, 5 mmol, 2.5 equiv) 
was added in one portion. The reaction was stirred for 1 hour at 0 °C and slowly quenched with 
H2O (20 ml) at 0 °C. Ethyl acetate (20 mL) was added, and the layers were separated. The aqueous 
layer was extracted with ethyl acetate (20 mL x 3). And the combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude mixture was 
purified via flash column chromatography (100 mL silica gel, 30% ethyl acetate in hexanes) to 
afford the desired product 57 as a white solid. Run 1: (588.8 mg, 90.5% yield); Run 2: (595.9 mg, 
91.6 % yield) Average: 91% yield over two steps. 
1H NMR (500 MHz, Chloroform-d) δ 7.45-7.26 (m, 5H), 4.55 (d, J = 6.7 Hz, 1H), 4.07 (dd, J = 
11.7, 3.3 Hz, 1H), 3.70 (br d, J = 15.2 Hz, 1H), 3.68-3.62 (m, 2H), 3.45 (br d, J = 12.8 Hz, 1H), 
3.22 (br t, J = 11.9 Hz, 1H), 3.01 (br t, J = 11.7 Hz, 1H), 2.85 (br s, 1H). 13C NMR (125 MHz, 
CDCl3) δ 138.5, 129.0, 126.8, 120.1 (q, J = 323.6 Hz )79.2, 74.7, 66.4, 47.4, 45.9. (one peak 
missing probably due to overlapping). HRMS (ESI) m/z calculated for C12H14NO4F3SNa 
[M+Na]+: 348.0493, found 348.0494. 
 
 
(S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine (S45). To an oven-dried sealed tube 










mg, 0.30 mmol, 0.3 equiv), 4-methyl-1,10-phenanthroline (141.8 mg, 0.60 mmol, 0.6 equiv), 
Cs2CO3 (651.6 mg, 2.0 mmol, 2.0 equiv), 1-ethoxy-2-iodo-benzene (372.1 mg, 1.5 mmol, 1.5 
equiv) and toluene (0.5 mL, 2.0 M), the tube was sealed and heated to 100 °C for 96 hours. The 
reaction was cooled to room temperature, diluted with ethyl ether (5 mL), and filtered through a 
silica plug. The mixture was concentrated under reduced pressure and purified via flash column 
chromatography (100 mL silica gel, 0% => 15% ethyl acetate in hexanes) to afford the desired 
product S44 as a colorless oil. Run 1: (278.3 mg, 62.5% yield; 101.2 mg recover alcohol 57, 
31.1%); Run 2: (284.2 mg, 63.8 % yield; 100.6 mg recover alcohol 57, 30.9%); Average: 63% 
yield. 
1H NMR (500 MHz, Chloroform-d) δ 7.45-7.40 (m, 2H), 7.39-7.30 (m, 3H), 6.94-6.84 (m, 2H), 
6.79-6.69 (m, 2H), 5.19 (d, J = 4.4 Hz, 1H), 4.11-4.03 (m, 3H), 3.95 (ddd, J = 10.6, 4.4, 2.6 Hz, 
1H), 3.86 (d, J = 12.9 Hz, 1H), 3.70 (dd, J = 12.9, 1.5 Hz, 1H), 3.64 (td, J = 11.8, 2.8 Hz, 1H), 
3.32-3.18 (m, 2H), 1.47 (t, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 150.3, 147.2, 136.9, 
128.5, 128.4, 127.5, 123.2, 120.8, 120.1(q, J = 323.4), 119.3, 113.8, 81.9, 78.1, 66.7, 64.5, 47.6, 
46.1, 15.0. 19F NMR (470 MHz, CDCl3) δ -75.43. HRMS (ESI) m/z calculated for 
C20H22NO5F3SNa [M+Na]+: 468.1068, found 468.1060. 
 
 
(S, S)-Reboxetine. To an oven-dried 50 mL round bottom flask equipped with a stir bar and 
condenser under N2 was added S45 (222.8 mg, 0.50 mmol, 0.5 equiv), dioxane (20 ml, 0.025 M) 
and LAH (190 mg, 5.0 mmol, 10 equiv). The reaction was heated up to 100 °C for 1 hour, then 







were added dropwise, followed by anhydrous MgSO4. The mixture was filtered through a celite 
plug, concentrated under reduced pressure and purified via flash column chromatography (100 mL 
silica gel, 0% => 7% MeOH in CH2Cl2) to afford the (S, S)-Reboxetine as a colorless oil. Run 1: 
(152.9 mg, 97.6% yield); Run 2: (154.5 mg, 98.5% yield). Average: 98% yield.  
1H NMR (500 MHz, Methanol-d4) δ 7.40-7.36 (m, 2H), 7.28 (t, J = 7.4 Hz, 2H), 7.25-7.21 (m, 
1H), 6.86 (dd, J = 7.9, 1.6 Hz, 1H), 6.82-6.76 (m, 2H), 6.67 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H), 5.16 
(d, J = 6.0 Hz, 1H), 4.09-3.96 (m, 2H), 3.94-3.86 (m, 2H), 3.60 (ddd, J = 11.9, 7.9, 6.1 Hz, 1H), 
2.74 (dd, J = 6.3, 2.0 Hz, 2H), 2.67-2.54 (m, 2H), 1.39 (t, J = 6.9 Hz, 3H). 13C NMR (125 MHz, 
CD3OD) δ 150.9, 149.0, 139.0, 129.2, 129.1, 128.5, 123.2, 122.0, 118.6, 115.5, 83.7, 79.8, 68.2, 
65.7, 47.6, 45.9, 15.4. [α]25D = +15.73o (c = 1.03, CHCl3); HRMS (ESI) m/z calculated for 
C19H24NO3 [M+H]+: 314.1756, found 314.1755. These data are in agreement with that previously 
reported in the literature7\4. The enantiomeric excess was determined to be 96% by chiral HPLC 
analysis (Chiralpak IB3 column, 1.0 mL/min, 10% Isopropanol in hexanes (0.2% Et2NH), λ = 
215nm (4nm). tR(minor) = 9.868 min, tR(major) = 11.308 min. 
 
 
Preparation of (±)-MeO-SOX SOX ligand (L5)/Pd(OAc)2 
To a 1-dram vial was added Pd(OAc)2 (22.5 mg, 0.1 mmol, 1.0 equiv) and (±)-MeO-SOX ligand 
(L5) (34.3 mg, 0.1 mmol, 1.0 equiv) and 1.0 mL toluene (0.1 M), the mixture was stirred at 45 °C 
for 30 min. Upon completion, the complex was separated from the reaction mixture by filtration 
as a light green powder (51.8 mg, 93% yield). 
1H NMR (500 MHz, Chloroform-d) δ 8.08 – 8.04 (m, 3H), 7.37 (d, J = 2.6 Hz, 1H), 7.34 (dd, J = 
8.8, 2.6 Hz, 1H), 7.31 – 7.30 (m, 1H), 7.30 – 7.29 (m, 1H), 4.22 (d, J = 8.5 Hz, 1H), 3.96 (s, 3H), 
3.85 (d, J = 8.5 Hz, 1H), 2.41 (s, 3H), 1.99 (s, 3H), 1.96 (s, 3H), 1.47 (s, 3H), 1.38 (s, 3H).  
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13C NMR (126 MHz, CDCl3) δ 178.3, 177.7, 163.4, 161.1, 145.2, 139.3, 130.1, 128.8, 128.4, 
127.2, 124.6, 118.6, 117.6, 81.9, 71.4, 56.4, 27.0, 26.8, 23.6, 22.3, 21.8. HRMS (FAB) m/z 
calculated for C21H24NO5SPd [M-OAc]+: 508.04101, found 508.04103. 
 
The complex was not bench-stable and has to be stored in the glove box (stable for at least a 
month). Reactions using the complex gave comparable yields to reactions using (±)-MeO-SOX 





Single Crystal structure X-ray analysis of (±)-MeO-SOX ligand (L5)/Pd(OAc)2 
 




A suitable crystal was mounted with Paratone-N oil (Exxon) on a 0.3 mm cryo-loop (Hampton 
Research) and transferred to the goniometer of a Bruker D8 Venture/Photon 100 diffractometer. 
Data was collected at 100 K utilizing a cold stream of N2(g). Microfocus sealed tube Mo Ka 
radiation (l = 0.71073 Å) was used. The structure was phased by intrinsic methods with SHELXT 
(v2014/4)75 and refined by full-matrix least-squares refinement on F2 using SHELXL (v2014/7).76 
The intensities were corrected for Lorentz and polarization effects by integration using SADABS 
(v2014/5).77 All non-hydrogen atoms were refined anisotropically. Methyl H atom positions, R-
CH3, were optimized by rotation about R-C bonds with idealized C-H, R--H and H--H distances. 
Remaining H atoms were included as riding idealized contributors. Methyl H atom U's were 
assigned as 1.5 times Ueq of the carrier atom; remaining H atom U's were assigned as 1.2 times 
carrier Ueq. Details of the crystal data and a summary of the intensity data for (±)-MeO-SOX 















Table 3.  Crystal Data and Structure Refinement for dd16dsa ((±)-MeO-SOX Ligand (L5)/Pd(OAc)2) 
Identification code  dd16dsa (((±)-MeO-SOX ligand (L5)/Pd(OAc)2) 
Empirical formula  C23 H27 N O7 Pd S 
Formula weight  567.91 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  I41/a 
Unit cell dimensions a = 27.5166(8) Å a= 90°. 
 b = 27.5166(8) Å b= 90°. 
 c = 12.2492(4) Å g = 90°. 
Volume 9274.6(6) Å3 
Z 16 
Density (calculated) 1.627 Mg/m3 
Absorption coefficient 0.935 mm-1 
F(000) 4640 
Crystal size 0.359 x 0.173 x 0.129 mm 
Theta range for data collection 2.346 to 28.287° 
Index ranges -36<=h<=36, -36<=k<=36, -16<=l<=15 
Reflections collected 63453 
Independent reflections 5757 [R(int) = 0.0375] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Integration 
Max. and min. transmission 0.9481 and 0.8474 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5757 / 6 / 307 
Goodness-of-fit on F2 1.115 
Final R indices [I>2sigma(I)] R1 = 0.0249, wR2 = 0.0597 
R indices (all data) R1 = 0.0301, wR2 = 0.0620 
Extinction coefficient n/a 







Determination of Kinetic Isotope Effect: 
 
 
1-decene-d2 (58-d2). To a flamed-dried 25 mL flask under N2 was added a stir bar, Nonanal (1.42g, 
10 mmol, 1.0 equiv), 4-dimethylaminopyridine (122.2mg, 1 mmol, 0.1 equiv), D2O (2.5 mL, 4.0 
M), and was heated to 100 °C for 2 h. The reaction was cooled to room temperature and diluted 
with CH2Cl2 (25 mL). The layers were separated and the organic layer was washed with 1N HCl 
(10 mL x 2) and brine, dried over anhydrous MgSO4, filtered through a short silica gel plug and 
concentrated under reduced pressure at 0 °C. The yellow oil was then re-subject to the same 
reaction condition again to achieve Nonanal-d2 with >95% D incorporation (1.07 g, 7.42 mmol). 
The Nonanal-d2 was carried through next step without further purification. To a flamed–dried 100 
mL flask under N2 was added Nonanal-d2 (750 mg, 5.2 mmol, 1.0 equiv), 
methyltriphenylphosphonium bromide (3.25 g, 8.8 mmol, 1.7 equiv) and diethyl ether (20 mL). 
The reaction was cooled to 0 °C and added KOt-Bu (953 mg, 7.8 mmol, 1.5 equiv). The reaction 
was allowed to warm up to room temperature and stirred for additional 3 h. Upon completion, the 
reaction was quenched with sat. aq. NH4Cl. Layers were separated and the aqueous layer was 
extracted with diethyl ether (25 mL x 3). The combined organic layers were washed with brine, 
dried over anhydrous MgSO4, filtered and carefully concentrated under reduced pressure at  0 °C. 
The resulting mixture was purified purified via flash column chromatography (100 mL silica gel, 
pentane) to afford the 1-decene-d2 (58- d2) in 89% yield as a colorless oil (696.3mg, 4.89 mmol) 







1-decene-d1 (59).  To a flamed-dried 50 mL flask under N2 was added a stir bar, LAD (lithium 
aluminum deuteride, 252 mg, 6.0 mmol, 1.0 equiv) and THF (6.0 mL). The reaction was cooled to 
0 °C and octanal (937μL, 6.0 mmol) in THF (12 mL) was added dropwise. The reaction was 
allowed to warm up to room temperature and stirred for additional 1 h, then cooled to 0 °C. 
Sequentially, 0.25 mL of H2O, 0.35 mL of 15% NaOH solution and 0.75 mL of H2O were added 
dropwise, followed by anhydrous MgSO4. The mixture was filtered, concentrated under reduced 
pressure and purified via flash column chromatography (100 mL silica gel, 0% => 5% acetone in 
hexanes) to afford the alcohol (762.1 mg, 5.5 mmol, 92% yield) as a colorless oil.  
      To a flamed-dried 50 mL flask under N2 was added a stir bar, PPh3 (1.57 g, 6.0 mmol, 1.2 
equiv.), Et2O (15 mL), imidazole (546 mg, 8.0 mmol, 1.5 equiv.) and iodine (2.0 g, 7.8 mmol, 1.3 
equiv.). A solution of alcohol from last step (693 mg, 5.0 mmol, 1.0 equiv) in Et2O (10 mL) was 
added to the resulting mixture. The reaction was stirred at room temperature overnight. The 
mixture was filtered, concentrated under reduced pressure and purified via flash silica plug to gave 
pure alkyl iodide as colorless oil (988.7 mg, 4.1 mmol, 82% yield).  
      To a flamed-dried 50 mL flask under N2 was added a stir bar, CuI (1.142 g, 6.0 mmol, 1.5 
equiv.), alkyl iodide (964.6, 4.0 mmol, 1.0 equiv) in THF (8 mL). The reaction was cooled to 0 °C 
and vinyl megnesium bromide (1.0 M, 5.2 mL, 1.3 equiv) was added dropwise and the reaction 
was allow to warm to room temperature for 2 hours. The reaction was quenched by addition of sat. 
aq. NH4Cl, extracted with Et2O, dried over anhydrous MgSO4 and concentrated under reduced 
pressure (low temperature). The crude mixture was purified by flash column chromatography (100 
mL silica gel, 100% pentane) to give 156.8 mg (1.1 mmol) 59 in 27.5% yield as a colorless oil 
with 98% D incorporation (Determined by 1H NMR). 






(E)-N-benzyl-N-(dec-2-en-1-yl)-1,1,1-trifluoromethanesulfonamide (61).  
1H NMR (500 MHz, Chloroform-d) δ δ 7.41 – 7.29 (m, 5H), 5.62 – 5.52 (m, 1H), 5.39 – 5.30 (m, 
1H), 4.50 (br s, 2H), 3.82 (br s, 2H), 2.04 (app q, J = 7.0 Hz, 2H), 1.39 – 1.23 (m, 10H), 0.90 (t, J 
= 6.9 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 138.8, 134.2, 128.9, 128.5, 128.4, 122.1, 
120.1 (q, J = 322.8 Hz), 50.4, 49.3, 32.2, 31.8, 29.1, 28.9, 22.7, 14.1. (one peak missing probably 
due to overlapping) 19F NMR (470 MHz, Chloroform-d) δ -76.04. HRMS (EI) m/z calculated for 
C18H26NO2F3Na [M+Na]+: 400.1525, found 400.1534. 
 
Intermolecular Kinetic isotope effect via initial rates: 
 




General procedure for initial rate analysis: 
In order to obtain accurate initial rate data, all reactions were run at 0.5M concentration. To a ½ 
dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX L5 (6.9 
mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 
equiv), N-benzyl-1,1,1-trifluoromethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv) and 
1,4-di-tert-butylbenzene (15.2 mg, 0.8 mmol, 0.4 equiv) as internal standard. Toluene (0.4 mL, 0.4 
M) was added and the vial was capped and heated to 45 °C then 1-decene or 1-decene-d2 (0.2 
mmol, 1.0 equiv) was added by injection through the screw-cap. Aliquots (15μL) were taken at 

















2,5 DMBQ (1.1 equiv.)




(0.6 mL) for HPLC analysis (Elipse XDB C-8, 75% MeCN / 25% H2O, 1 mL/min). The yield was 
determined by integration of the product peak (22.8 min) relative to the 1,4-di-tert-butylbenzene 
internal standard peak (9.8 min) and corrected by a standard curve. Yields are reported as the 
average of three runs with error bars denoting standard deviation. Error for kinetic isotopes was 
calculated via propagation of the standard error of the mean for each set of rates. 
kH/kD = 0.0231 / 0.0095 = 2.4 ± 0.1 
 
Figure 6. Initial rates with 55 and 55-d2. 
 
 
Intramolecular Kinetic isotope effect: 
Scheme 10.  Intramolecular kinetic isotope effect. 
 
 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
L5 (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (30 mg, 0.22 mmol, 
1-decene-d2 (55-d2)
y = 0.0095x - 0.0232
R² = 0.99936
1-decene (55)


























1.1 equiv), N-benzyl-1,1,1-trifluoromethanesulfonamide (S12) (47.8 mg, 0.2 mmol, 1.0 equiv), 1-
decene-d1 (28.3 mg, 0.2 mmol, 1.0 equiv) and Toluene (0.4 mL, 0.4 M) was added. The vial was 
capped and heated to 45 °C for 72 hours. The vial was allowed to cool to room temperature and 
diluted with 1 mL acetone. The reaction mixture was filtered through a pipette silica plug into a 
20mL vial with acetone. The mixture was concentrated under reduced pressure, diluted with 2 mL 
CDCl3 and analyzed by crude 1H NMR with internal standard (trifluorotoluene 14.6 mg, 0.1 mmol, 
0.5 equiv). The mixture was then concentrated under reduced pressure and subjected to flash 
column chromatography (0% => 20% CH2Cl2 in hexanes) to provide allylic amine mixture as a 
colorless oil. The column-purified product mixture was analyzed by 1H NMR (500 MHz 
instrument). The KIE was reported as the area of the protonated peak over that of the deuterated 
peak. The experiment was run in triplicate and each was analyzed by 1H NMR. An average value 
was calculated with error reported as a standard deviation. 
kH/kD = 4.0 ± 0.1 (4.0, 4.0, 3.9) 
 
Effect of N-triflyl amine on standard Pd(II)/bis-sulfoxide C—H amination 
 




a. Control experiment (without S10): 
Following the reported procedure.30 To a ½ dram vial was added a stir bar, 1,2-
Bis(phenylsulfinyl)ethane palladium(II) acetate (10.0 mg, 0.02 mmol, 0.10 equiv), benzoquinone 
Cy
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(43.3 mg, 0.4 mmol, 2.0 equiv) and methyl tosylcarbamate (91.7 mg, 0.4mmol, 2.0 equiv). 
Allylcyclohexane (30.9 mg, 0.2 mmol, 1.0 equiv) and t-butyl methyl ether (0.30 mL) and N,N-
diisopropylethylamine (2.09 µL, 0.012 mmol, 0.06 equiv) was sequentially added. The vial was 
fitted with a Teflon cap, and heated to 45 °C for 72 h. The reaction was allowed to cool to room 
temperature, and thoroughly rinsed into a 125 mL separatory funnel with diethyl ether (30 mL). 
The organic phase was washed with 5% aq. K2CO3 (6 x 10 mL), and the aqueous rinses back-
extracted with ether (2 x 30 mL). The combined organic extracts were dried over MgSO4, filtered 
through a 1:1 mixture of Celite/silica gel, and concentrated under reduced pressure. The crude 
product was purified by flash chromatograph on silica gel (100 mL silica gel, 2.5% => 10% 
EtOAc/hexanes) to afford a colorless oil.  
 
Run 1 (58.8 mg, 0.167 mmol, 83.6% yield); run 2 (59.9 mg, 0.169 mmol, 85.2% yield); run 3 (57.5 
mg, 0.164 mmol, 81.7% yield). Average yield: 84% (>20:1 linear : branched >20 : 1 E : Z). 
Spectroscopic data for the amination product matched that which was reported previously.22 
 
b. Inhibition experiment (with 1.0 equiv. S10): 
Following the same reported procedure.30 To a ½ dram vial was added a stir bar, 1,2-
Bis(phenylsulfinyl)ethane palladium(II) acetate (10.0 mg, 0.02 mmol, 0.10 equiv), benzoquinone 
(43.3 mg, 0.4 mmol, 2.0 equiv) and methyl tosylcarbamate (91.7 mg, 0.4mmol, 2.0 equiv). 
Allylcyclohexane (30.9 mg, 0.2 mmol, 1.0 equiv) and t-butyl methyl ether (0.30 mL) and N,N-
diisopropylethylamine (2.09 µL, 0.012 mmol, 0.06 equiv) was sequentially added.  The reaction 
was stirred at room temperature for 10 min and N-(2-Phenylethyl)trifluoromethanesulfonamide 
(S10) (50.6 mg, 0.2 mmol, 1.0 equiv) was added. The vial was heated to 45 °C for 72 h. Upon 
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completion, the same work-up and purification procedure from controlled experiments was 
followed. 
 
Run 1 (21.7 mg, 0.0617 mmol, 30.8% yield); run 2 (23.3 mg, 0.0663 mmol, 33.1% yield); run 3 
(23.1 mg, 0.0657 mmol, 33.0% yield). Average yield: 32% (>20:1 linear : branched >20 : 1 E : Z). 
No N-triflyl amine product 1 was detected. Spectroscopic data for the amination product matched 
that which was reported previously.30 
 
Stoichiometric Pd π–allyl study to evaluate functionalization 
Scheme 12. Stoichiometric Pd π–allyl study to evaluate functionalization. 
 
 
a. “Mock catalytic” condition with SOX Ligand 
To a 1-dram vial under N2 was added a stirred bar, π-allyl Pd chloride dimer15 (28.2mg, 0.05 mmol, 
1.0 equiv), AgOAc (16.7 mg, 0.1 mmol, 2.0 equiv, 1.0 equiv to Pd)) and CDCl3 (0.4 mL). The vial 
was capped, wrapped with aluminum foil and stirred at 45 °C for 10 min., (±)-MeO-SOX L5 (34.3 
mg, 0.1 mmol, 2.0 equiv (1.0 equiv to Pd)) was added, the reaction was stirred at 45 °C for another 
10 min. Reaction was filtered by a pipette filled with glass wool into a NMR tube with additional 
0.3 mL CDCl3. 1H NMR was taken under both room temperature and -20 °C, complesation 
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>20:1 E/Z , L/B
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dram vial and N-benzyl-1,1,1-trifluoromethanesulfonamide (S12) (239 mg, 1.0 mmol, 20 equiv 
(10 equiv to Pd) was added, the reaction was stirred at 45 °C for 2 hours. The vial was allowed to 
cool to room temperature and diluted with 1 mL acetone. The reaction mixture was filtered through 
a pipette silica plug into a 20 mL vial with acetone. The mixture was concentrated under reduced 
pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H NMR with internal standard 
(trifluorotoluene 14.6 mg, 0.1 mmol, 1.0 equiv). The mixture was then concentrated under reduced 
pressure and subjected to flash column chromatography (50 mL silica gel. 10%=>15% 
CH2Cl2/hexanes) to afford pure product 61 as a colorless oil.   
Run 1 (24.7 mg, 65.4% yield); run 2 (25.3 mg, 67.1% yield). Average yield: 66% (>20:1 linear : 
branched >20 : 1 E : Z). 
 
b. “Mock catalytic” condition with bis-sulfoxide Ligand 
Follow same procedure, but switching (±)-MeO-SOX L5 to bis-sulfoxide ligand (27.8 mg, 0.1 
mmol, 2.0 equiv (1.0 equiv to Pd)). No complexation between Pd metal and bis-sulfoxide was 
observed and no aminated product 61 was detected by TLC or Crude 1H NMR. No product could 
be isolated by flash column chromatography. 
Additional control experiments were conducted without any ligand. The reactions provided no 
aminated product 61. 
Additional control experiments were conducted with 2,5 DMBQ instead of SOX or bisulfoxide 







c. Catalytic condition with SOX ligand.  
Following the general procedure for Table 2 in 0.2 mmol scale in CDCl3. Run 1 (44.1 mg, 0.117 
mmol, 58.4% yield); run 2 (44.8 mg, 0.119 mmol, 59.3% yield); run 3 (45.6 mg, 0.121 mmol, 
60.5% yield). Average yield: 59% ± 1.1%.    (>20:1 linear: branched >20 : 1 E : Z). 
 
Exploratory studies on internal olefins 
General procedure (same as Table 1): The following procedure was used with no effort to 
exclude air or moisture. To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 
equiv), (±)-SOX-Ligand 5 (L5) (6.3 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-
dimethylbenzoquinone) (30 mg, 0.22 mmol, 1.1 equiv), olefin (0.2 mmol, 1.0 equiv) and N-(2-
Phenylethyl)trifluoromethanesulfonamide (50.6 mg, 0.2 mmol, 1.0 equiv). Toluene (0.2 mL, 1.0 
M) was added and the vial was capped and heated to 45 °C for 72 hours. The vial was allowed to 
cool to room temperature and diluted with 1 mL acetone. The reaction mixture was filtered through 
a pipette silica plug into a 20mL vial with acetone. The mixture was concentrated under reduced 
pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H NMR with internal standard 
(trifluorotoluene 14.6 mg, 0.1 mmol, 0.5 equiv).  
 
 
Following the general procedure using (E)-prop-1-ene-1,3-diyldibenzene (38.9 mg 0.2 mmol, 1.0 
equiv). Curde H1 NMR showed 60% remaining olefin starting material (volatility / side reactions), 
98% remaining unreacted N-(2-Phenylethyl)trifluoromethanesulfonamide, no aminated product 





Following the general procedure using trans-β-methylstyrene (23.6 mg 0.2 mmol, 1.0 equiv). 
Curde H1 NMR showed 36% remaining olefin starting material (volatility / side reactions), 98% 
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CHAPTER 2: SYNTHESIS OF ANTI-1,3-AMINO ALCOHOLS VIA 
PALLADIUM(II)/SOX CATALYSIS WITH THE CAPACITY FOR 
STEREODIVERGENCEb 
2.1 Introduction 
1,3 amino alcohols are important motifs exist in a wide range of biologically active small 
molecule natural products and pharmaceuticals. Highly selective direct C––H amination methods 
(Figure 7) have been developed, including metallonitrene systems1 and Pd(II)/bis-sulfoxide 
catalyzed allylic C––H amination2, for synthesizing syn-1,3 amino alcohols with reduced 
oxidation-state manipulations and synthetic overhead. However, none has been developed for 
generated anti-1,3 amino alcohols. Classic ways to synthesize anti-1,3 amino alcohols typically 
involve diastereoselective reduction of pre-oxidized compounds such as β-hydroxy imines3 or β-
amino ketones4. Advances have been made in transition metal catalyzed processes to generate anti-
1,3 amino alcohols through C-N cyclization of N-tosyl carbamates into allylic oxygenates5 and 
allene6. However, use of pre-oxidized, highly reactive starting material inevitably requires 
unproductive synthetic steps to install and maintain those functionalities. 
Our group has previously reported a highly selective Pd(II)/bis-sulfoxide catalyzed 
intramolecular allylic C—H amination using N-nosyl carbamates affords syn-1,3 amino alcohols 
in high yields (avg. 60%, >20:1 dr) and diastereoselectivities (avg. 5.4:1 dr).2a This system 
proceeds via a weakly/reversibly coordinating bis-sulfoxide ligand that requires p acidic 
benzoquinone oxidant to promote intramolecular functionalization of nitrogen nucleophile into a 
neutral Pd π-allyl. We questioned if the newly developed Pd(II)/sulfoxide-oxazoline(SOX) 
catalysis8,9, where the functionalization step has been shown to proceed via a ligand ligated 





cationic SOX Pd π-allyl intermediate9 with a stronger coordinating SOX ligand, may give an 
alternative stereooutcome.  
Figure 7. C––H amination methods for syn-1,3-amino alcohols. 
 
2.2 Results and Discussion 
2.2.1 Reaction Development 
We decided to switch to a less acidic but more readily accessible N-tosyl carbamate from 
previous used, synthetic challenging N-Nosyl carbamate. Under reported Pd(II)/bis-sulfoxide 
catalysis2a (Table 4, entry 1), the reaction showed low reactivity favoring kinetic syn-oxazinanone. 
Switching to (±)-MeO-SOX ligand (L-5), a ligand developed to promote intermolecular allylic 
C—H aminations with less acidic sulfonamide nucleophiles (vide supra, Chapter 1),9 we only 
observed trace yield of aminated product under otherwise identical reaction conditions (entry 2). 
Similar to the intermolecular system  (vide supra, Chapter 1), use of substituted quinone oxidant 
2,5 dimethyl benzoquinone (2,5 DMBQ) boosted the yield to 88%. Significantly, the reaction 
proceeded with high level of diastereoselectivity in 7.8:1 dr favoring the elusive thermodynamic 
anti- oxazinanone (entry 3). Investigation into the reaction conditions revealed lowering the 
















































































amount of 2,5 DMBQ oxidant (2.0 => 1.2 equiv) further increase the reaction yield and 
diastereoselectivity (entry 4).  
Table 4. Reaction Development 
 
Evaluation of electronically varied racemic SOX ligand showed that simple (±)-SOX 
ligand (L-1) without backbone substitution gave lower dr favoring anti-diastereomer (4:1, entry 
5), whereas SOX ligand bearing an electron-withdrawing CF3 group ((±)-CF3-SOX, L-8) favored 
the kinetic syn-diastereomer (1:4, entry 6). Using ((±)-CF3-SOX ligand, evaluation of different 
quinone oxidants revealed that less sterically hindered BQ was beneficial to the yield and 
diastereoselectivity for syn-selective condition (76%, 7:1 dr, entry 7). Decreasing the equivalents 
of the BQ oxidant (2 => 1.6 equiv) increased the yield further to 87% with no detrimental effect 
to the diastereoselectivity (entry 8). Further lowering BQ equivalents was not beneficial (entry 9). 
















Entry Ligand Quinone  Yield % (isolated)b
1c Ph-BQ (2.0 eq.) 29 (syn)
(±)-MeO-SOX Ph-BQ (2.0 eq.)2 -





4 (±)-MeO-SOX 2,5 DMBQ (1.2 eq.) 78 (anti) 91 (7.8:1; 8.4:1c)
5
6
2,5 DMBQ (2.0 eq.) 61 (anti)
(±)-CF3-SOX 2,5 DMBQ (2.0 eq.)
(±)-SOX 86 (3.6:1)
69 (1:4.3) 51 (syn)
7 (±)-CF3-SOX BQ (2.0 eq.) 60 (syn)76 (1:6.8)
8 (±)-CF3-SOX BQ (1.6 eq.) 71 (syn)87 (1:6.7; 1:7.0c)
9 (±)-CF3-SOX BQ (1.2 eq.) 57 (syn)72 (1:6.7)
10d 2,5 DMBQ (1.2 eq.) 72 (anti)88 (6.4:1)
















a Yield and dr determined by crude 1H NMR. b Isolated yield of pure diastereomer with >20:1 dr. 
c Determined by HPLC. d 10% Ph2P(O)OH was added; 6h e Commercial Pd(OAc)2 bis-sulfoxide 




12e 2,5 DMBQ (1.2 eq.) 46 (syn)60 (1:5.5)





phosphinic acid)8a in comparable overall yield and slightly lower diastereoselectivities (entry 10, 
11). This ability to increase reactivity is further demonstrated to achieve synthetic useful yield with 
challenging substrates (vide infra, Table 5 and Table 7). As controlled experiment, re-evaluation 
of Pd(II)/bis-sulfoxide catalysis under otherwise identical anti- and syn- reaction conditions used 
for the SOX ligands showed an improvement in yields but the same level of diastereoselectivity 
favoring the kinetic syn-1,3-oxazinanone (entry 12, 13). This underscores the significant ligand 
influence of SOX ligand in stereodivergence.   
 
2.2.2 Reaction Scope 
Table 5. Substrate Scope for anti-1,3 Amino Alcohols (Part 1: Aromatic) 
 
A broad range of functionalized N-tosyl carbamate substrates were evaluated under the 




(±)-63, R = H,
(±)-64, R = OMe,
(±)-65, R = Me,
(±)-66, R = Br,
(±)-67, R = Cl,
(±)-68, R = CF3
(±)-69, R = CO2Me,
81%;    (91%,  8.9:1 dr)
70%;   (80%,  5.7:1 dr)  
69%;   (92%,  8.9:1 dr)  
72%;   (81%,  9.8:1 dr)  
69%;   (80%,  9.9:1 dr)
54%;   (58%, >20:1 dr)  









O Pd(OAc)2 (10 mol%)
(±)-SOX ligand (10 mol%)
2,5 DMBQ (1.2 equiv)
DCE (0.66M)




























anti isolated yielda 
















(±)-74, 58%;  
(67%, 9.5:1 dr)
(±)-72, 54%;  
(65%, 7.5:1 dr)
aIsolated yield of anti diastereomer (>20:1 dr) over 3 runs. b Yield and dr determined by crude 
1HNMR. c 10% Ph2P(O)OH added to increase reactivity. d 8.6:1 dr by HPLC
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observed formation of anti-1,3 amino alcohol precursors with synthetically useful yield and 
diastereoselectivity. Arylated 1, 3-amino alcohol motifs, widely existing in biologically active 
small molecule natural products and pharmaceuticals such as CERT antagonist HPA-1210, 
sedacryptine11 and nikkomucin Z12, afforded preparative yields and diastereoselectivities 
irrespective of their electronic substitution (Table 5, 63-70). Substrates bearing different 
substituted naphthalene undergo allylic C—H amination in high yield and diastereoselectivity (71, 
72). Medicinally important heteroaromatic moieties including indole, benzothiophene, benzofuran 
dibenzothiazine, and phenyl sulfonyl morpholine are all well tolerated in our allylic C––H 
amination and afford desired products with preparative yields and diastereoselectivities (73-77). 
Table 6. Substrate Scope for anti-1,3 Amino Alcohols (Part 2: Aliphatic) 
 
Aliphatic 1,3 amino alcohols are also widely represented motifs among biologically active 






(±)-78, 66%;  
(79%, 5.2:1 dr)










R = TBS, (±)-84
73%;  (86%, 8.1:1 dr)
R = H, (±)-85









(+)-89, 69%;  
(76%, 13:1 dr)




O Pd(OAc)2 (10 mol%)
(±)-SOX ligand (10 mol%)
2,5 DMBQ (1.2 equiv)
DCE (0.66M)




















(±)-80, 74%;  
(82%, >20:1 dr)
aIsolated yield of anti diastereomer (>20:1 dr) over 3 runs. b Yield and dr determined by crude 









(±)-82, 52%;  
(76%, 5.3:1 dr)










aliphatic substrates derived from readily available aldehydes, in all cases observed formation of 
anti-1,3-amino alcohol precursors in preparative yields and diastereoselectivities (Table 6). We 
demonstrated that diastereoselectivity is not strongly impacted by the steric bulkiness of the alkyl 
substituent adjacent to the carbamate, ranging in size from the small methyl group (Table 6, 78) to 
larger cyclic aliphatic motifs such as cyclopropanes (79, 80), cyclopentane (81) and adamantane 
(82). Common nitrogen containing heterocycles such as Boc-protected piperidine are well-
tolerated (83). This reaction can also tolerate remote primary alcohols, both silyl protected and 
unprotected, undergo allylic C—H amination with no observed alcohol oxidation (84, 85), 
showing chemoselectivity not common for Pd(II) oxidation systems.16 Different from metallo-
nitrene based C—H amination systems1, our Pd(II)/sulfoxide-catalyzed allylic C—H amination 
shows complete chemoselectivity for allylic C—H bonds over benzylic, propargylic and ethereal 
C—H bonds (86-88). The orthogonality of this oxidative method to existing β-hydroxy imines3 or 
β-amino ketones4 reduction and rhodium-hydride catalyzed cyclization6 is highlighted by the 
tolerance of reduction-sensitive proximal alkyne and ketone functionalities (87, 89). In addition, 
substrates with acidic proximal stereocenter, undergo no epimerization under our allylic C––H 
amination condition (89).  
We also evaluated several of the aromatic and aliphatic N-tosyl carbamate substrates for 
their ability to form kinetic syn- oxazinanone products under Pd(OAc)2/(±)-CF3-SOX/BQ 
conditon. We were delighted to find that by simply altering the catalyst and oxidant, we were able 
to obtain the syn- oxazinanone products as major in preparative yields and diastereoselectivities 
(Table 7). It is worth mentioning that while the previous Pd(II)/bis-sulfoxide catalyzed allylic C—
H amination method also affords syn-1,3 amino alcohols in useful yields, the more acidic synthetic 
challenging N-nosyl carbamates are required (Table 4, entry 1).2 In comparison, N-tosyl 
carbamates are synthesized one step from commercial tosyl isocyanate and homo-allylic alcohol. 
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Moreover, using the Pd(II)/SOX catalysis reported herein, we can afford either anti- or syn-1,3 
amino alcohols stereodivergently. 
Table 7. Substrate Scope for syn-1,3 Amino Alcohols  
 
             
2.2.3 Stereodivergent Streamlined Synthesis 
       Advantages of stereodivergent nature of this reaction are showcased in the synthesis of 
diastereomerically pure anti- and syn- 1,3-aminoalcohol intermediates for Vitamin D3 analogue 






(±)-CF3-SOX ligand (10 mol%)
BQ (1.6 equiv)
DCE (0.66M)


































































R = TBS, (±)-101,
56%, (73%, 7.4:1 dr)
R = H, (±)-102,























aIsolated yield of anti diastereomer (>20:1 dr) over 3 runs. b Yield and dr determined by crude 
1HNMR. c 10% Ph2P(O)OH added to increase reactivity.
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amino alcohol fragments towards modified A-ring moieties were evaluated in the discovery of 
Vitamin D3 analogue17 for treating metabolic diseases (Figure 8).  The report synthetic sequence 
started from a highly oxygenated chiral precursor (L)-malic acid and proceeded via a lengthy 
sequence of functional group manipulations to install functionalities including a terminal 
carbamate (Figure 8). The allylic C—N bond was formed from a pre-functionalized allylic 
carbamat via a poorly diastereoselective intramolecular rearrangement to generate the syn- and 
anti- amino alcohols as a 2:1 mixture in ca. 18 steps ca. 14.5% yield for the anti-isomer and 7.3% 
for the syn-isomer (Figure 8).17   
Figure 8. Previous synthesis of anti- and syn- 1,3 amino alcohols towards vitamin D3 with 
modified A ring. 
 
 
Our  allylic C—H amination route starts from commercial (-)-epichlorohydrin, the 
hydrocarbon core of the chiral homoallylic carbamate (-)-107 could be readily assembled in just 
4 steps (Figure 9). In contrast to C–O to C–N functional group manipulations, we installed the 
nitrogen into hydrocarbon scaffold to afford preparative yields of the desired anti-(-)-108a or syn-
(-)-108b configuration by using either Pd(II)/(±)-MeO-SOX or Pd(II)/(±)-CF3-SOX catalysis. 



























NHBocOTBS 1. TBAF OH NHBoc OH NHBoc+
anti : syn = 2 : 1 14.5% 7.3%




followed by desilylation afford the desired anti- and syn-1,3 amino alcohol motifs (+)-109a, (-)-
109b in 9 steps (half chemical steps) and significantly higher 21.9% and 18.3% overall yields.  
Figure 9. Allylic C––H amination route to anti- and syn- 1,3 amino alcohols. 
 
2.2.4 Stereodivergent Synthesis of Diamino Alcohol Motifs 
We have demonstrated that our stereodivergent allylic C—H amination has shown 
predictable and controllable diastereomeric outcome (anti or syn), even in the presence of proximal 
stereogenic centers on the substrate (Table 6, entry 88, 89 and Table 7, 105, 106). In those chiral 
substrates, the absolute stereochemistry of the aminated site is controlled by the Pd(II)/SOX 
catalytic system in combination with the carbamate stereocenter. We figured this distinctive feature 
allows quick access to all possible stereoisomers of chiral diamino alcohol cores that are found in 





C−H to C−N route: 
9 steps, 21.9% yield
C−O to C−N route: 
















6. Mg powder, 















ref. 17 ref. 17
(-)-epichlorohydrin
C−H to C−N route: 
9 steps, 18.3% yield
C−O to C−N route:  
18 steps, 7.3% yield
(+)-109a (-)-109b
(-)-107
a Isolated yield (>20:1 dr);  b Yield and dr determined by crude H1 NMR.
70% a
(78%, 19:1 dr) b
61% a







6. Mg powder, 






Our route started from alkylating of the Weinreb amide derivatives of Boc protected (L)- 
and (D)-phenylalanine (Figure 10) to furnish homoallylic amino ketones (+)-110 and (-)-ent-110. 
Using either LiAl(Ot-Bu)3H or Alpine hydride, homoallylic ketones were reduced into anti- amino 
alcohols (-)-111  and  (+)-ent-111 or syn- amino alcohols (-)-112 and (+)-ent-112.18 Facile 
installation of the N-tosyl carbamate was followed by stereodivergent allylic C—H amination 
using either Pd(II)/(±)-MeO-SOX to form or Pd(II)/(±)-CF3-SOX catalysis. All eight 
diastereomers of chiral diamino alcohols precursors were furnished in preparative yields of the 
major diastereomer (54- 73%, 113-116a, 113-116b). Our allylic C––H amination approach is not 
only highly competitive with previous routes that involve pre-oxidized intermediates (α-amino-g-
lactone,19 enaminone,13 epoxides,20 etc…) and also provides a more streamlined route to all eight 
possible stereoisomers. 


































































     Pd(OAc)2
4. TsNCO
5. (±)-CF3-SOX
     Pd(OAc)2
4. TsNCO
5. (±)-MeO-SOX
     Pd(OAc)2
4. TsNCO
5. (±)-MeO-SOX
     Pd(OAc)2
(-)-113a
71%a (89%, 9.1:1 dr)b
(-)-113b
54% (68%, 6.5:1 dr)
(+)-114a
60% (85%, 3.3:1 dr)
(+)-114b
73% (86%, 13:1 dr)
(+)-115a
70% (84%, 9.3:1 dr)
(+)-115b
58% (72%, 7.4:1 dr)
(-)-116a
54% (79%, 3.5:1 dr)
(-)-116b
71% (82%, 14:1 dr)
4. TsNCO
5. (±)-CF3-SOX
     Pd(OAc)2
4. TsNCO
5. (±)-CF3-SOX
     Pd(OAc)2
4. TsNCO
5. (±)-MeO-SOX
     Pd(OAc)2











a Isolated yield of major diastereomer. b Yield and dr determined by curde 1H NMR.
4. TsNCO
5. (±)-MeO-SOX












2.2.5 Proposed Mechanism and Mechanistic Studies 
       Analogue to other Pd(II)/SOX-catalyzed allylic C—H functionalization, we believe this 
reaction proceeds via ligand assisted heterolytic allylic C—H cleavage to afford a cationic Pd(SOX) 
π-allyl intermediate9 which is under rapid p-s-p isomerization8a (Figure 11a). The later suggests 
that the C—H cleavage cannot be the stereo determining step. Thus, we decided to focus on the 
functionalization step and questioned if the diastereoselectivity is determined by a kinetic 
preference during carbamate functionalization (C-N bond formation) step to form syn-
oxazinanone or a thermodynamic preference to form the more stable anti-isomer.  
Figure 11. Proposed mechanism and reaction profiles. 
 
a. Proposed mechanism:
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R1 = aryl or alkyl
137 
 
         We evaluated  the diastereometric excess (de) of Pd(OAc)2/(±)-MeO-SOX/2,5-DMBQ 
system over time and observed that the diastereoselectivity of the reaction shifts from favoring the 
syn-isomer to anti-isomer (Figure 11b). In contrast, the diastereoselecivity of Pd(OAc)2/(±)-CF3-
SOX/BQ shows no change, consistently favoring the syn-isomer (Figure 11b). This strongly 
indicates that under both catalytic systems, the syn-oxazinanone is the kinetic product5,6,21 and anti-
selective condition (Pd(OAc)2/(±)-MeO-SOX/2,5-DMBQ) promotes isomerization of kinetic syn-
oxazinanone to the thermodynamically favored anti-oxazinanone5,6,21.  
Figure 12. Pd(0)/SOX isomerization. 
 
 
We wanted to probe the role of electron rich (±)-MeO-SOX ligand and sterically bulky 2,5-
DMBQ oxidant in the Pd(0) isomerization process. To test how the SOX ligands effect a Pd(0)-
mediated isomerization, we exposed pure syn-oxazinanone (±)-62b to Pd2(dba)3 in the presence of 
either (±)-MeO-SOX or (±)-CF3-SOX and measured the relative initial rates of anti-oxazinanone 
(±)-62a formation (Figure 12): Pd2(dba)3/(±)-MeO-SOX is nearly four times as fast as 


















Figure 13. Cross-over experiments. 
 
We next decided to investigate the isomerization process. We ran the allylic C—H 
amination reaction under standard Pd(OAc)2/(±)-MeO-SOX/2,5-DMBQ conditions in the 
presence of 10% syn-oxazinanone (±)-62b (Figure 13). Remarkably, syn-oxazinanones 62b is 
competitive with 2,5 DMBQ in reacting with Pd(0) even at very low concentrations (0.1 eq. 62b 
compared with 1.1 eq. 2,5 DMBQ), and isomerization of 62b is comparable to standard catalytic 
conditions (Table 4, entry 4, Figure 13, entry 1). This suggests that the Pd(0) species generated in 
the reaction is long-lived under these conditions due to sluggish reactivity with the sterically 
hindered quinone (2,5 DMBQ). Supporting this hypothesis, with the Pd(OAc)2/(±)-MeO-SOX 
catalyst, the reaction favors formation of syn-103 and syn-62b does not undergo isomerization 
(Figure 13, entry 2) when less sterically hindered BQ oxidant is used. In addition, in Pd(OAc)2/(±)-
CF3-SOX catalysis, 2,5 DMBQ erodes the syn:anti ratio under the reaction conditions in both 
product formation and in isomerization of syn-oxazinanone (±)-62b, but does not turn it over to 
favor the anti-product (entry 3,4).  Collectively, cross-over experiments suggest that an electron 
rich SOX ligand ((±)-MeO-SOX) that can promote Pd(0) opening of the syn-oxazinanone in 
combination of a sterically hindered quinone oxidant (2,5 DMBQ) that is sluggish in Pd(0) re-























    (±)-62b   syn-103 + anti-86
syn : anti (62b :62a)dsyn : anti (103 : 86)dSOX / quinone
62b + 62a(0.1 equiv.)
  1   : 8.3
>20 :  1
>20 :  1 
 3.5 :  1
MeO-SOX / 2,5 DMBQ
MeO-SOX / BQ
CF3-SOX / BQ
CF3-SOX / 2,5 DMBQ
 1   : 8.7
6.5 :  1 (low conversion)
7.2 :  1










In conclusion, we herein report the first general C––H amination method for 
stereodivergent synthesis of both anti- and syn- 1,3 amino alcohols via Pd(II)/SOX catalysis. The 
diastereoselectivity is tunable based on the combination of SOX ligand and quinone oxidant used. 
Mechanistic studies indicate that the reaction proceeds a Pd(II)/SOX catalysis promotes C—H 
amination to generate kinetic syn-oxazinanone and Pd(0)/SOX-promotes isomerization of the 
heterocycle to the thermodynamic anti-isomer. The capacity of SOX ligand for supporting both 
Pd(II) and Pd(0) prcesses is unveiled and will be the topic of future studies in our group.  
 
2.4 Experimental Section 
2.4.1 General Information 
The following commercially obtained reagents were used as received: Pd(OAc)2 (Johnson 
Mattey Chemicals) was stored in a glove box, and weighted out in the air at room temperature 
prior to use. 1,4-benzoquinone (bright yellow solid. If not, sublimation is required to achieve 
optimal yield), phenylbenzoquinone and 2,5-dimethylbenzoquinone was purchased from Sigma-
Aldrich and used as received. Diphenyl phosphinic acid was purchased from Sigma-Aldrich and 
used as received. All amination reactions were run under ambient air with no precautions taken to 
exclude moisture. All other reactions were run in flame- or oven-dried glassware under an 
atmosphere of N2 or Ar gas with dry solvents unless otherwise stated. All products were filtered 
through a glass wool plug prior to obtaining a final weight. Anhydrous solvents were purified by 
passage through a bed of activated alumina immediately prior to use (Glass Countour, Laguna 
Beach, California). Chloroform-d was stored over 3Å molecular sieves in a secondary container 
with drierite. Thin-layer chromatography (TLC) was conducted with E. Merck silica gel 60 F254 
pre-coated plates (0.25 mm) and visualized with UV and Cerium-ammonium-molybdate and 
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potassium permanganate stains. Flash chromatography was performed using American 
International ZEOprep 60 ECO silica gel (230-400 mesh).  
1H-NMR spectra were recorded on a Varian Inova-500 (500 MHz), Varian Unity-500 (500 
MHz) or Carver-Bruker 500 (500 MHz) spectrometer and are reported in ppm using solvent as an 
internal standard (CDCl3 at 7.26 ppm). Data reported as: s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, sxt = sextet, hept = septet, m = multiplet, br = broad, app = apparent; coupling 
constant(s) in Hz; integration. Proton-decoupled 13C-NMR spectra were recorded on a Varian 
Unity-500 (125 MHz) or Carver-Bruker 500 (125MHz) spectrometer and are reported in ppm 
using solvent as an internal standard (CDCl3 at 77.16 ppm). Chiral gas chromatographic (GC) 
analysis was performed on an Agilent 6890N Series instrument equipped with FID detectors using 
a J&W Cyclosil-B column. Chiral high pressure liquid chromatography (HPLC) analysis was 
performed on an Agilent 1100 Series instrument equipped with a UV detector, using a 
CHIRALPAK AD-RH or OJ-H column. Optical rotations were measured using a 1 mL cell with 
a 50 mm path length on a Jasco P-1020 polarimeter. Optical rotations were obtained with a sodium 
lamp and are reported as follows: [α]λToC (c = g/100 mL solvent). High-resolution mass spectra 
were obtained at the University of Illinois Mass Spectrometry Laboratory. Electrospray ionization 
(ESI) spectra were performed on a Waters Q-Tof µLtima spectrometer, and electron ionization 
(EI) and field desorption (FD) spectra were performed on a Micromass 70-VSE spectrometer.  
 
Synthesis of (±)-SOX Ligands 
 
Ligand intermediate, (±)-MeO-SOX (L-5), (±)-SOX (L-1), (±)-CF3-SOX (L-8) were synthesized 





(±)-CF3-Ligand. 1H NMR (500 MHz, Chloroform-d) δ 8.54 (d, J = 8.3 Hz, 1H), 8.14 (d, J = 1.9 
Hz, 1H), 7.96 (dd, J = 8.4, 1.9 Hz, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 4.04 (q, 
J = 8.1 Hz, 2H), 2.33 (s, 3H), 1.34 (s, 3H), 1.28 (s, 3H). 13C NMR (126 MHz, Chloroform-d) δ 
158.25, 151.17, 143.01, 141.62, 132.55 (q, J = 33.3 Hz), 129.69, 128.30 (q, J = 3.7 Hz), 127.12, 
126.90 (q, J = 3.7 Hz), 126.38, 125.90, 123.46 (q, J = 272.7 Hz).79.22, 69.13, 28.70, 28.23, 21.51. 
. 19F NMR (470 MHz, Chloroform-d) δ -62.85. HRMS (ESI) m/z calculated for C19H19NO2SF3 
[M+H]+: 382.1089, found 382.1091. 
 
Synthesis of bis-Homoallylic N-Tosyl Carbamate Substrates 
General Procedure for the synthesis of bis-homoallylic alcohols: 
A flame dried 100 mL round bottom flask under argon was charged with a stir bar, aldehyde (10 
mmol), and THF (20 mL). The flask was cooled to 0 °C and 3-butenylmagnesium bromide (1.0 
M, 12 mL, 12 mmol, 1.2 equiv.) was added dropwise. The reaction was stirred for 30 min and 
warmed up to room temperature then quenched with sat. aq. NH4Cl. The mixture was transferred 
into a separatory funnel and the layers were separated. The aqueous layer was extracted with Et2O 
(30 mL x 2). The combined organic layer was dried over MgSO4, filtered, and concentrated in 












General Procedure for the synthesis of bis-homoallylic N-tosyl carbamates: 
A flame dried 100 mL round bottom flask under argon was charged with a stir bar, homoallylic 
alcohol (10 mmol), and THF (10 mL). The flask was cooled to 0 °C and p-toluenesulfonyl 
isocyanate (1.84 mL, 12 mmol) was added dropwise. The reaction was stirred for 30 min and then 
quenched with sat. aq. NH4Cl. The mixture was diluted with ethyl acetate (50 mL) and washed 
once with brine (50 mL). The organic layer was dried over MgSO4, filtered, and concentrated in 
vacuo. Purification by flash silica plug (acetone/hexanes or ethyl acetate hexanes) provided pure 
bis-homoallylic N-tosyl carbamates.  
 
2-methylhept-6-en-3-yl tosylcarbamate (S46) was synthesized from 2-methylhept-6-en-3-ol 
(1.28g, 10 mmol) following the general procedure in 79% yield (2.57 g, 7.91 mmol) as a white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.4 Hz, 2H), 7.68 (br. s, 1H), 7.33 (d, J = 
8.4 Hz, 2H), 5.64 (ddt, J = 16.9, 10.4, 6.6 Hz, 1H), 4.91 – 4.84 (m, 2H), 4.63 (dt, J = 7.1, 5.4 Hz, 
1H), 2.43 (s, 3H), 1.88 – 1.73 (m, 3H), 1.56 – 1.46 (m, 2H), 0.82 (d, J = 7.0 Hz, 3H), 0.80 (d, J = 
7.2 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 150.7, 145.1, 137.6, 136.0, 129.7, 128.4, 
115.1, 82.2, 31.6, 30.2, 29.6, 21.8, 18.3, 17.5. HRMS (ESI) m/z calculated for C16H23NO4S [M-





1-phenylpent-4-en-1-yl tosylcarbamate (S47) was synthesized from 1-phenylpent-4-en-1-ol 
(1.62g, 10 mmol) following the general procedure in 71% yield (3.54 g, 7.06 mmol) as a white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.4 Hz, 2H), 7.69 (br s, 1H), 7.31 (d, J = 
8.1 Hz, 2H), 7.31-7.26 (m, 3H), 7.19-7.13 (m, 2H), 5.70 (ddt, J = 16.7, 10.5, 6.3 Hz, 1H), 5.63-
5.59 (m, 1H), 5.00-4.86 (m, 2H), 2.44 (s, 3H), 2.04-1.87 (m, 3H), 1.86-1.76 (m, 1H). 13C NMR 
(126 MHz, Chloroform-d) δ 149.9, 145.1, 139.1, 137.0, 135.8, 129.7, 128.6, 128.5, 128.4, 126.5, 
115.6, 79.1, 35.3, 29.5, 21.8. HRMS (ESI) m/z calculated for C19H21NO4S [M+Na]+: 382.1089, 
found 382.1102.  
 
1-(4-methoxyphenyl)pent-4-en-1-yl tosylcarbamate (S48) was synthesized from 1-(4-
methoxyphenyl)pent-4-en-1-ol (1.92g, 10 mmol) following the general procedure in 78% yield 
(3.04 g, 7.80 mmol) as a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 8.4 Hz, 
2H), 7.60 (br s, 1H), 7.31 (d, J = 7.8 Hz, 2H), 7.10 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 
5.70 (ddt, J = 16.8, 10.4, 6.4 Hz, 1H), 5.56 (t, J = 6.9 Hz, 1H), 4.96 – 4.89 (m, 2H), 3.78 (s, 3H), 
2.44 (s, 3H), 1.99-1.93 (m, 1H), 1.92-1.86 (m, 2H), 1.82 – 1.74 (m, 1H). 13C NMR (126 MHz, 
Chloroform-d) δ 159.7, 149.9, 145.1, 137.1, 135.8, 131.1, 129.7, 128.4, 128.1, 115.6, 114.0, 78.9, 





(±)-1-(p-tolyl)pent-4-en-1-yl tosylcarbamate (S49). was synthesized from 1-(p-tolyl)pent-4-en-
1-ol (1.76g, 10 mmol) following the general procedure in 71% yield (2.63 g, 7.05 mmol) as a white 
solid. Product obtained as a yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8,4 Hz, 
2H), 7.86 (br s, 1H), 7.31 (d, J = 8.1 Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 
5.71 (ddt, J = 16.6, 10.4, 6.2 Hz, 1H), 5.58 (t, J = 6.6 Hz, 1H), 5.01-4.82 (m, 2H), 2.44 (s, 3H), 
2.32 (s, 3H), 2.06-1.88 (m, 3H), 1.83-1.73 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 150.0, 
145.0, 138.2, 137.1, 136.1, 135.8, 129.7, 129.3, 128.4, 126.5, 115.5, 79.0, 35.2, 29.5, 21.8, 21.3. 
HRMS (ESI) m/z calculated for C20H23NO4S [M+Na]+: 396.1245, found 396.1237.  
 
1-(4-bromophenyl)pent-4-en-1-yl tosylcarbamate (S50). was synthesized from 1-(4-
bromophenyl)pent-4-en-1-ol (2.41 g, 10 mmol) following the general procedure in 89% yield (3.90 
g, 8.92 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 8.3 Hz, 2H), 
7.44 (br s, 1H),  7.41 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 5.69 
(ddt, J = 16.5, 10.4, 6.3 Hz, 1H), 5.57 – 5.51 (m, 1H), 4.97-4.88 (m, 2H), 2.45 (s, 3H), 1.96-1.87 
(m, 3H), 1.81-1.73 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 149.7, 145.3, 138.2, 136.8, 
135.7, 131.9, 129.8, 128.4, 128.2, 122.5, 115.9, 78.3, 35.1, 29.4, 21.9 HRMS (ESI) m/z calculated 





1-(4-chlorophenyl)pent-4-en-1-yl tosylcarbamate (S51). was synthesized from 1-(4-
chlorophenyl)pent-4-en-1-ol (1.97g, 10 mmol) following the general procedure in 52% yield (2.05 
g, 5.21 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.32 (br s, 1H), 7.88 (d, J = 
8.4 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 2H), 5.68 (ddt, 
J = 16.5, 10.3, 6.2 Hz, 1H), 5.59 – 5.53 (m, 1H), 5.00 – 4.85 (m, 2H), 2.44 (s, 3H), 1.97 – 1.81 (m, 
3H), 1.82 – 1.69 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 150.1, 145.2, 137.7, 136.8, 135.6, 
134.1, 129.7, 128.7, 128.3, 127.8, 115.7, 78.1, 35.1, 29.3, 21.8. HRMS (ESI) m/z calculated for 
C19H20ClNO4S [M+Na]+: 416.0699, 416.0704.  
 
 
1-(4-(trifluoromethyl)phenyl)pent-4-en-1-yl tosylcarbamate (S52). was synthesized from 1-(4-
(trifluoromethyl)phenyl)pent-4-en-1-ol (2.30 g, 10 mmol) following the general procedure in 66% 
yield (2.82 g, 6.60 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.28 (br s, 1H), 
7.90 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.0 Hz, 
2H), 5.67 - 5.62 (m, 2H), 4.98 – 4.88 (m, 2H), 2.44 (s, 3H), 2.00-1.85 (m, 3H), 1.86-1.71 (m, 1H). 
13C NMR (126 MHz, Chloroform-d) δ  150.0, 145.3, 143.3, 143.3, 136.7, 134.4 (q, J = 32.5Hz), 
129.8, 128.4, 126.6, 125.6 (q, J = 3.7 Hz), 124.0 (q, J = 272.2 Hz), 115.9, 78.0, 35.3, 27.3, 21.7. 
19F NMR (470 MHz, Chloroform-d) δ -62.65. HRMS (ESI) m/z calculated for C20H20NO4F3S [M-





Methyl-4-(1-((tosylcarbamoyl)oxy)pent-4-en-1-yl)benzoate (S53) was synthesized from 
Methyl-4-(1-hydroxypent-4-en-1-yl)benzoate (1.1 g, 5.00 mmol) following the general procedure 
in 55% yield (1.15g, 2.75 mmol) as a colorless oil.  
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.35, 2H), 7.89 (d, J = 8.35, 2H), 7.45 (br s, 
1H), 7.33 (d, J = 8.0, 2H), 7.20 (d, J = 8.2, 2H), 5.76-5.66 (m, 1H), 5.66-5.61 (m, 1H), 4.99 – 4.88 
(m, 2H), 3.91 (s, 3H), 2.45 (s, 3H), 1.98 – 1.88 (m, 3H), 1.85 – 1.75 (m, 1H). 13C NMR (126 MHz, 
Chloroform-d) δ 166.7, 149.7, 145.4, 144.2, 136.7, 135.7, 130.2, 130.0, 129.8, 128.5, 126.3, 115.9, 




1-(2-bromophenyl)pent-4-en-1-ol (S54a) was synthesized from commercially available 2-
bromo-benzaldehyde (2.00 g, 10.80 mmol) following a modified general procedure (3.0 equiv. 3-
butenylmagnesium bromide and quenched at 0 °C) in 53% yield (1.39g, 5.76 mmol) as a colorless 
oil. 1H NMR (500 MHz, Chloroform-d) δ 7.56 (dd, J = 7.8, 1.6 Hz, 1H), 7.51 (dd, J = 8.0, 1.2 Hz, 
1H), 7.34 (td, J = 7.6, 1.2 Hz, 1H), 7.13 (td, J = 7.7, 1.7 Hz, 1H), 5.89 (ddt, J = 17.0, 10.2, 6.7 Hz, 
1H), 5.13 – 5.04 (m, 2H), 5.01 (ddt, J = 10.2, 2.2, 1.3 Hz, 1H), 2.34 – 2.17 (m, 2H), 1.99 (d, J = 








143.7, 138.2, 132.8, 128.9, 127.8, 127.4, 122.1, 115.2, 72.6, 36.8, 30.2. HRMS (ESI) m/z 
calculated for C11H13OBr [M+H]+: 240.0149, found 240.0140. 
 
 
1-(2-bromophenyl)pent-4-en-1-yl tosylcarbamate (S54) was synthesized from 1-(2-
bromophenyl)pent-4-en-1-ol (1.39 g, 5.76 mmol) following the general procedure in 80% yield 
(2.01 g, 4.59 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.92 (d, J = 8.3 Hz, 
2H), 7.49 (d, J = 8.0, 1H), 7.34 (d, J = 8.3 Hz, 2H), 7.26-7.21 (m, J = 7.5, 1.4 Hz, 1H), 7.17 – 7.10 
(m, 2H), 5.98 (dd, J = 8.5, 4.5, 1H), 5.72 (ddt, J = 17.2, 10.8, 6.5, 1H), 4.97 – 4.89 (m, 2H), 2.45 
(s, , 3H), 2.01 – 1.94 (m, 2H), 1.91 – 1.76 (m, 2H). (NH proton not shown) 13C NMR (126 MHz, 
Chloroform-d) δ 149.4, 145.3, 139.1, 136.9, 135.8, 133.0, 129.8, 129.6, 128.5, 127.9, 127.0, 121.9, 




1-(naphthalen-2-yl)pent-4-en-1-yl tosylcarbamate (S55) was synthesized from 1-(naphthalen-
2-yl)pent-4-en-1-ol (2.12g, 10 mmol) following the general procedure in 77% yield (3.17g, 7.73 
mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 8.4 Hz, 2H), 7.82 – 7.77 






(d, J = 8.2 Hz, 2H), 5.83 – 5.78 (m, 1H), 5.78 – 5.70 (m, 1H), 4.98 – 4.91 (m, 2H), 2.39 (s, 3H), 
2.10 – 2.00 (m, 1H), 1.99 – 1.94 (m, 2H), 1.94 – 1.86 (m, 1H). (NH proton not observed) 13C NMR 
(126 MHz, Chloroform-d) δ 150.2, 145.1, 137.0, 136.5, 135.8, 133.3, 133.1, 129.7, 128.6, 128.4, 
128.2, 127.8, 126.4, 126.4, 125.9, 123.9, 115.6, 79.2, 35.2, 29.5, 21.7. HRMS (ESI) m/z calculated 
for C23H23NO4S [M+Na]+: 432.1245, found 432.1229.  
 
 
1-(4-fluoronaphthalen-1-yl)pent-4-en-1-ol (S56a) was synthesized from 4-fluoro-1-
naphthaldehyde (2.1 g, 12.0 mmol) following a modified general procedure (3.0 equiv. 3-
butenylmagnesium bromide and quenched at 0 °C) in 74% yield (2.08 g, 9.03mmol) as a colorless 
oil. S11a was characterized to simplify the interpretation of spectra of S11. 1H NMR (500 MHz, 
Chloroform-d) δ 8.17 – 8.12 (m, 1H), 8.12 – 8.08 (m, 1H), 7.59 – 7.52 (m, 3H), 7.12 (dd, J = 10.2, 
8.0 Hz, 1H), 5.89 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H), 5.42 (dd, J = 7.6, 5.2 Hz, 1H), 5.13 – 4.98 (m, 
2H), 2.31 – 2.20 (m, 2H), 2.07 (br s, 1H), 2.04 – 1.96 (m, 2H). 13C NMR (126 MHz, Chloroform-
d) δ 158.4 (d, J = 251.5 Hz),  138.2, 136.2 (d, J = 4.4 Hz), 131.8 (d, J = 4.3 Hz), 127.0, 126.0 (d, 
J = 2.1 Hz), 124.1 (d, J = 16.2 Hz), 123.3 (d, J = 2.8 Hz), 123.0 (d, J = 8.6 Hz), 121.4 (d, J = 6.0 
Hz), 115.4, 108.9 (d, J = 19.8 Hz), 70.6, 37.5, 30.5.. HRMS (ESI) m/z calculated for 







1-(4-fluoronaphthalen-1-yl)pent-4-en-1-yl tosylcarbamate (S56) was synthesized from 1-(4-
fluoronaphthalen-1-yl)pent-4-en-1-ol (2.0 g, 8.68 mmol) following the general procedure in 78% 
yield (2.92g, 6.83mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 8.17 – 8.13 (m, 
1H), 7.99-7.93 (m, 1H), 7.89 (d, J = 8.2 Hz, 2H), 7.60 – 7.51 (m, 2H), 7.40 (br s, 1H), 7.33-7.27 
(m, 3H), 7.07 (dd, J = 10.0, 8.0 Hz, 1H), 6.35 (dd, J = 8.0, 4.5 Hz, 1H), 5.75 (ddt, J = 16.3, 10.0, 
6.0 Hz, 1H), 5.02 – 4.93 (m, 2H), 2.45 (s, 3H), 2.14 - 1.98 (m, 4H). 13C NMR (126 MHz, 
Chloroform-d) δ 158.9 (d, J = 253.1 Hz) 149.8, 145.3, 136.9, 135.7, 131.6 (d, J = 4.6 Hz), 131.1 
(d, J = 4.4 Hz), 129.8, 128.4, 127.6, 126.3, 124.1 (d, J = 9.0 Hz), 124.0 (d, J = 16.0 Hz),, 123.0 (d, 
J = 2.6 Hz), 121.5 (d, J = 6.0 Hz), 115.9, 108.9 (d, J = 20.2 Hz), 76.0, 35.1, 29.8, 21.8. 19F NMR 
(471 MHz, Chloroform-d) δ -122.2 (dd, J = 10.6, 5.4 Hz). HRMS (ESI) m/z calculated for 
C23H22NO4SF[M+Na]+: 450.1151, found 450.116 
 
 
1-(1-tosyl-1H-indol-5-yl)pent-4-en-1-yl tosylcarbamate (S57). was synthesized from 1-(1-tosyl-
1H-indol-5-yl)pent-4-en-1-ol (3.55 g, 10 mmol) following the general procedure in 51% yield 
(2.66 g, 5.09 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 8.5 Hz, 
1H), 7.86 (d, J = 8.3 Hz, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 3.6 Hz, 1H), 7.32 (d, J = 1.6 







= 3.7, 1H), 5.72 – 5.66 (m, 1H), 5.66 – 5.61 (m, 1H), 4.94 – 4.86 (m, 2H), 2.41 (s, 3H), 2.33 (s, 
3H), 1.99 – 1.92 (m, 1H), 1.88 (app q, J = 6.9 Hz, 2H), 1.83 – 1.70 (m, 1H). (NH proton is 
underneath 7.86 doublet) 13C NMR (126 MHz, Chloroform-d) δ 150.0, 145.3, 145.1, 137.0, 135.6, 
135.2, 134.5, 134.3, 130.8, 130.1, 129.7, 128.4, 127.0, 126.9, 123.0, 119.6, 115.6, 113.6, 109.0, 
79.1, 35.4, 29.5, 21.8, 21.7. HRMS (ESI) m/z calculated for C28H28N2O3S2 [M+Na]+: 575.1287, 
found 575.1312.  
 
 
1-(benzo[b]thiophen-5-yl)pent-4-en-1-yl tosylcarbamate (S58). was synthesized from 1-
(benzo[b]thiophen-5-yl)pent-4-en-1-ol (654.9 mg, 3 mmol) following the general procedure in 
67% yield (834.7 mg, 2.01 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, 
J = 8.4 Hz, 2H), 7.78 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.45 (d, J = 5.4 Hz, 1H), 7.29 
– 7.24 (m, 3H), 7.14 (dd, J = 8.4, 1.7 Hz, 1H), 5.79 – 5.66 (m, 2H), 4.99 – 4.91 (m, 2H), 2.41 (s, 
3H), 2.08 – 1.99 (m, 1H), 1.98 – 1.92 (m, 2H), 1.91 – 1.82 (m, 1H). (NH proton is a very broad 
peak around 8.0-7.5 ppm) 13C NMR (126 MHz, Chloroform-d) δ 149.9, 145.0, 139.7, 139.6, 
136.9, 135.7, 135.3, 129.6, 128.3, 127.2, 123.8, 122.7, 122.6, 121.7, 115.5, 79.2, 35.3, 29.5, 21.7 





1-(benzofuran-5-yl)pent-4-en-1-yl tosylcarbamate (S59). was synthesized from 1-(benzofuran-
2-yl)pent-4-en-1-ol (2.71 g, 13.4 mmol) following the general procedure in 62% yield (3.31 g, 
8.30 mmol) as a yellow solid. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 8.4 Hz, 2H), 7.52 
(d, J = 7.6 Hz. 1H), ), 7.52 (d, J = 8.2 Hz. 1H), 7.40 (br s, 1H), 7.30 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 
7.25 – 7.20 (m, 3H), 6.63 (s, 1H), 5.83 (t, J = 7.1 Hz, 1H), 5.73 (ddt, J = 17.8, 9.4, 6.5 Hz, 1H), 
4.99-4.92 (m, 2H), 2.37 (s, 3H), 2.14 – 2.06 (m, 2H), 2.05 – 1.95 (m, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 154.9, 153.2, 149.8, 145.2, 136.6, 135.4, 129.7, 128.5, 127.6, 125.0, 123.1, 121.5, 
116.0, 111.5, 106.1, 71.8, 31.4, 29.3, 21.8. HRMS (ESI) m/z calculated for C21H21NO5S [M-H]+: 
398.1062, found 398.1059. 
 
 
1-(4-(morpholinosulfonyl)phenyl)pent-4-en-1-ol (S60a) was synthesized from 4-
(morpholinosulfonyl)benzaldehyde (1.54 g, 6.03 mmol)  following a modified general procedure 
(3.0 equiv. 3-butenylmagnesium bromide and quenched at 0 °C) in 48% yield (0.829g, 2.66 mmol) 
as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.73 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.2 
Hz, 2H), 5.84 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H), 5.11 – 5.00 (m, 2H), 4.86 – 4.77 (m, 1H), 3.74 (t, 
J = 4.8 Hz, 4H), 3.00 (t, J = 4.6 Hz, 4H), 2.23 – 2.11 (m, 2H), 2.05 (br d, J = 3.6 Hz, 1H), 1.94 – 
1.76 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 150.3, 137.8, 134.2, 128.2, 126.6, 115.7, 










1-(4-(morpholinosulfonyl)phenyl)pent-4-en-1-yl tosylcarbamate (S60) was synthesized from 
1-(4-(morpholinosulfonyl)phenyl)pent-4-en-1-ol (830 mg, 2.66 mmol) following the general 
procedure. The crude residue was purified via flash column chromatography (10% => 30% acetone 
in hexanes) to afford pure product as a white solid in 66% yield (888mg, 1.74 mmol). 1H NMR 
(500 MHz, Chloroform-d) δ 7.90 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.1, 5.8 
Hz, 2H), 7.53 (br s, 1H), 7.35 (d, J = 8.3, 2H), 5.71 – 5.62 (m, 2H), 4.99 – 4.88 (m, 2H), 3.75 (t, J 
= 4.7 Hz, 4H), 3.01 (t, J = 4.5 Hz, 4H), 2.45 (s, 3H), 1.97 – 1.86 (m, 3H), 1.84 – 1.73 (m, 1H). 13C 
NMR (126 MHz, Chloroform-d) δ 149.7, 145.4, 144.8, 136.5, 135.7, 135.3, 129.84, 128.4, 128.3, 
127.0, 116.1, 77.7, 66.2, 46.0, 35.4, 29.3, 21.8. HRMS (ESI) m/z calculated for C19H20NO4SBr 
[M+Na]+: 460.0194, found 460.0204. 
 
 
1-(10H-phenothiazin-10-yl)hex-5-en-2-ol (S61a) was synthesized from 2-(10H-phenothiazin-
10-yl)acetaldehyde (386 mg, 1.59 mmol) following a modified general procedure (3.0 equiv. 3-
butenylmagnesium bromide and quenched at 0 °C) in 35% yield (167 mg, 0.56 mmol) as a light 
yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.24 – 7.13 (m, 4H), 7.02 – 6.89 (m, 4H), 5.85 












– 2.24 (m, 1H), 2.23 – 2.17 (m, 1H), 1.75 – 1.60 (m, 2H). 2.00-1.20 (br s, 1H). 13C NMR (126 
MHz, Chloroform-d) δ 145.5, 138.4, 127.9, 127.5, 126.9, 123.3, 116.3, 115.1, 66.9, 54.0, 33.6, 
30.0. HRMS (ESI) m/z calculated for C18H20NOS [M+H]+: 298.1266, found 298.1261. 
 
 
1-(10H-phenothiazin-10-yl)hex-5-en-2-yl tosylcarbamate (S61) was synthesized from 1-(10H-
phenothiazin-10-yl)hex-5-en-2-ol (167 mg, 0.56 mmol) following the general procedure in 38% 
(105 mg, 0.21 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 8.3, 2H), 
7.33 – 7.29 (m, 3H) (NH proton underneath), 7.14 (ddd, J = 8.5, 7.5, 1.5 Hz, 2H), 7.09 (dd, J = 
7.7, 1.5 Hz, 2H), 6.92 (ddd, J = 7.5, 7.5, 1.2 Hz, 2H), 6.87 (dd, J = 8.2, 1.2 Hz, 2H), 5.62 (ddt, J = 
17.4, 9.7, 6.5 Hz, 1H), 5.13 (dtd, J = 7.9, 6.5, 3.9 Hz, 1H), 4.89-4.81 (m, 2H), 4.01 (dd, J = 13.7, 
6.2 Hz, 1H), 3.87 (dd, J = 13.8, 6.8 Hz, 1H), 2.46 (s, 3H), 1.99 – 1.92 (m, 2H), 1.83 (dddd, J = 
14.0, 8.7, 6.7, 4.0 Hz, 1H), 1.66 (dtd, J = 14.4, 8.1, 6.6 Hz, 1H). 13C NMR (126 MHz, Chloroform-
d) δ 150.1, 145.2, 145.1, 137.8, 135.7, 129.7, 128.4, 127.8, 127.5, 126.4, 123.1, 116.0, 115.4, 73.8, 




Hex-5-en-2-yl tosylcarbamate (S62) was synthesized from hex-5-en-2-ol (1.4 g, 14.0 mmol) 










MHz, Chloroform-d) δ 7.91 (d, J = 8.3 Hz, 2H), 7.39 (br s, 1H), 7.34 (d, J = 8.0 Hz, 2H), 5.70 
(dddd, J = 18.4, 10.5, 7.2, 6.0 Hz, 1H), 4.97- 4.90 (m, 2H), 4.85 – 4.75 (m, 1H), 2.45 (s, 3H), 1.96 
(tdd, J = 7.9, 6.5, 1.4 Hz, 2H), 1.69 – 1.60 (m, 1H), 1.53 (dtd, J = 13.7, 7.8, 5.5 Hz, 1H), 1.18 (d, 
J = 6.3 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 150.1, 145.1, 137.4, 135.8, 129.7, 128.5, 
115.3, 74.5, 34.9, 29.4, 21.8, 19.9. HRMS (ESI) m/z calculated for C14H19NO4S [M+Na]+: 
320.0932, found 320.0929. 
 
 
1-cyclopropylpent-4-en-1-yl tosylcarbamate (S63) was synthesized from 1-cyclopropylpent-4-
en-1-ol (1.00 g, 7.92 mmol) following the general procedure in 76% yield (1.958 g, 6.05 mmol) 
as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.0 
Hz, 2H), 5.68 (ddt, J = 18.0, 9.1, 6.5 Hz, 1H), 4.96 – 4.86 (m, 2H), 4.12 (ddd, J = 8.8, 7.0, 5.6 Hz, 
1H), 2.44 (s, 3H), 2.01 – 1.87 (m, 2H), 1.76 – 1.64 (m, 2H), 0.94 - 0.84 (m, 1H), 0.56 – 0.49 (m, 
1H), 0.42 – 0.29 (m, 2H), 0.22-0.16 (m, 1H). (NH proton not observed) 13C NMR (126 MHz, 
Chloroform-d) δ 150.7, 144.9, 137.5, 135.91, 129.6, 128.4, 115.1, 82.3, 33.7, 29.4, 21.7, 15.0, 3.3, 
3.2. HRMS (ESI) m/z calculated for C16H21NO4S [M+Na]+: 346.1100, found 346.1089. 
 
 
1-(1-phenylcyclopropyl)pent-4-en-1-ol (S64a) was synthesized from 1-phenylcyclopropane-1-
carbaldehyde (598 mg, 4.09 mmol) following a modified general procedure (3.0 equiv. 3-




colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.35 (m, 2H), 7.33 – 7.27 (m, 2H), 7.27 
– 7.22 (m, 1H), 5.78 (ddt, J = 17.0, 10.2, 6.7, 1H), 5.05 – 4.90 (m, 2H), 3.11 (ddd, J = 9.2, 5.2, 3.4 
Hz, 1H), 2.25 – 2.04 (m, 2H), 1.69 – 1.54 (m, 1H), 1.47 (d, J = 5.4 Hz, 1H), 1.39 – 1.26 (m, 1H), 
0.91 – 0.83 (m, 2H), 0.83 – 0.70 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 141.4, 138.6, 
131.2, 128.2, 126.9, 114.9, 78.4, 34.4, 31.6, 30.6, 11.4, 10.3. HRMS (ESI) m/z calculated for 
C14H18O [M+Na]+: 225.1264, found 225.1255.  
 
 
1-(1-phenylcyclopropyl)pent-4-en-1-yl tosylcarbamate (S64) was synthesized from 1-(1-
phenylcyclopropyl)pent-4-en-1-ol (462 mg, 2.28 mmol) following the general procedure in 55% 
yield as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.83 (d, J = 8.3 2H), 7.32 (s, 1H), 
7.31 – 7.27 (m, 7H), 5.54 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H), 4.85 – 4.75 (m, 2H), 4.34 (ddd, J = 9.6, 
4.0, 1.5 Hz, 1H), 2.42 (s, 3H), 1.80 (m, 1H), 1.75-1.65 (m, 1H), 1.61 – 1.53 (m, 1H), 1.39-1.30 (m, 
1H), 1.00 – 0.94 (m, 1H), 0.94 – 0.88 (m, 1H), 0.78-0.72 (m, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 150.5, 145.1, 140.4, 137.3, 135.7, 131.4, 129.7, 128.5, 128.1, 127.3, 115.3, 83.9, 
32.1, 29.9, 29.4, 21.80, 12.0, 11.2. HRMS (ESI) m/z calculated for C22H25NO4S [M+Na]+: 










1-cyclopentylpent-4-en-1-yl tosylcarbamate (S65) was synthesized from 1-cyclopentylpent-4-
en 1-ol (300 mg, 1.94 mmol) following the general procedure in 80% yield (548 mg, 1.55 mmol) 
as a light yellow oil. 1H NMR (500 MHz, Chloroform-d) δ 7.93 – 7.86 (d, J = 8.1 Hz, 2H), 7.33 
(d, J = 8.1 Hz, 2H) (NH proton underneath), 5.65 (ddt, J = 17.0, 10.4, 6.6 Hz, 1H), 4.92 – 4.85 (m, 
2H), 4.75 – 4.67 (m, 1H), 2.44 (s, 3H), 1.94 (m, 1H), 1.89 – 1.80 (m, 2H), 1.65 – 1.37 (m, 8H), 
1.20 – 1.04 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 150.5, 145.1, 137.6, 135.9, 129.7, 
128.5, 115.1, 81.2, 43.9, 32.6, 29.5, 28.9, 28.4, 25.5, 25.3, 21.8. HRMS (ESI) m/z calculated for 
C18H25NO4S [M+Na]+: 374.1418, found 374.1402 
 
 
1-((3R,5R,7R)-adamantan-1-yl)pent-4-en-1-yl tosylcarbamate (S66) was synthesized from 1-
((3r,5r,7r)-adamantan-1-yl)pent-4-en-1-ol (426 mg, 1.93 mmol) following the general procedure 
in 42% yield (343 mg, 0.82 mmol) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.90(d, 
J = 8.4 Hz, 2H), 7.37 (s, 1H), 7.33 (d, J = 8.0 Hz, 2H), 5.59 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 4.89 
– 4.78 (m, 2H), 4.44 (dd, J = 11.0, 2.0 Hz, 1H), 2.43 (br s, 3H), 1.95 – 1.90 (m, 3H), 1.70 – 1.63 
(m, 5H), 1.59 – 1.51 (m, 4H), 1.44 – 1.38 (m, 7H). 13C NMR (126 MHz, Chloroform-d) δ 150.7, 
145.1, 137.7, 136.0, 129.7, 128.4, 115.1, 85.2, 37.9, 37.0, 36.6, 30.2, 28.2, 27.3, 21.8. HRMS 











tert-Butyl 4-(1-((tosylcarbamoyl)oxy)pent-4-en-1-yl)piperidine-1-carboxylate (S67) was 
synthesized from tert-butyl 4-(1-hydroxypent-4-en-1-yl)piperidine-1-carboxylate (2.69 g, 10 
mmol) following the general procedure in 79% yield (3.69 mg, 0.79 mmol) as a white solid.  
1H NMR (500 MHz, Chloroform-d) δ 8.01 (s, 1H), 7.88 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 
2H), 5.62 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H), 4.95 – 4.82 (m, 2H), 4.65 (dt, J = 8.0, 5.5 Hz, 1H), 4.07 
(m, 2H), 2.58-2.54 (m, 2H), 2.44 (s, 3H), 1.83 (td, J = 8.2, 4.0 Hz, 2H), 1.62 – 1.50 (m, 2H), 1.44 
(s, 9H), 1.48-1.38 (m, 2H), 1.15-1.05 (m, 2H).13C NMR (126 MHz, CDCl3) δ 154.8, 150.5, 145.1, 
137.3, 136.2, 129.7, 128.4, 115.4, 80.3, 79.7, 43.8, 40.0, 30.3, 29.4, 28.6, 27.9, 21.7. HRMS (ESI) 
m/z calculated for C23H35N2O6S [M+H]+: 467.2216, found 467.2213. 
 
 
9-((tert-butyldimethylsilyl)oxy)non-1-en-5-yl tosylcarbamate (S68). was synthesized from 9-
((tert-butyldimethylsilyl)oxy)non-1-en-5-ol (2.73g, 10 mmol) following the general procedure in 
83% yield (3.91 g, 8.32 mmol) as a colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J 
= 8.3 Hz, 2H), 7.61 (br. s, 1H), 7.33 (d, J = 7.9 Hz, 2H), 5.73 – 5.61 (m, 1H), 4.94 – 4.87 (m, 2H), 
4.76 (p, J = 6.3 Hz, 1H), 3.53 (t, J = 6.5 Hz, 2H), 2.44 (s, 3H), 1.95 – 1.84 (m, 2H), 1.61 – 1.53 
(m, 2H), 1.54 – 1.45 (m, 2H), 1.46 – 1.38 (m, 2H), 1.24 – 1.16 (m, 2H), 0.88 (s, 9H), 0.02 (s, 6H). 
13C NMR (126 MHz, Chloroform-d) δ 150.4, 145.1, 137.5, 135.8, 129.7, 128.4, 115.2, 77.8, 62.9, 
33.7, 33.0, 32.6, 29.3, 26.1, 21.8, 21.4, 18.5, -5.2, -5.2. HRMS (ESI) m/z calculated for 









9-hydroxynon-1-en-5-yl tosylcarbamate (S69). To a 100 mL over-dride roud-bottom flask was 
added S68 (1.41g, 3.0 mmol), THF 25 mL and tetrabutylammonium fluoride solution TBAF (1M 
in THF, 9 mL, 9 mmol, 3 equiv.). The reaction was stirred at room temperature overnight. The 
reaction mixture was concentrated and purified via flash column chromatography (0% => 30% 
ethyl acetate in hexanes) to afford the desired S68 in 91% yield (968 mg, 2.72 mmol) as a white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 
5.72 – 5.60 (m, 1H), 4.93 – 4.89 (m, 1H), 4.89 – 4.84 (m, 1H), 4.81 – 4.72 (m, 1H), 3.57 (t, J = 
6.4 Hz, 2H), 2.43 (s, 3H), 1.92 – 1.82 (m, 2H), 1.63 – 1.39 (m, 6H), 1.31 – 1.18 (m, 2H). 13C NMR 
(126 MHz, Chloroform-d) δ 150.8, 145.0, 137.4, 135.9, 129.6, 128.4, 115.2, 77.5, 62.5, 33.6, 33.0, 
32.3, 29.4, 21.8, 21.2. HRMS (ESI) m/z calculated for C17H25NO5S [M+H]+: 356.1532, found 
356.1544.  
 
1-phenylhept-6-en-3-yl tosylcarbamate (S70) was synthesized from 1-phenylhept-6-en-3-ol 
(1.90g, 10 mmol) following the general procedure in 82% yield (3.17 g, 8.17 mmol) as a white 
solid. 1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.4 Hz, 2H), 7.69 (br s, 1H), 7.36 (d, J = 
8.1 Hz, 2H), 7.27 (dd, J = 8.3 Hz, 6.8 Hz, 2H), 7.23-7.16 (m, 1H), 7.08 (d, J = 7.0, 2H), 5.77-5.64 
(m, 1H), 4.96-4.90 (m, 2H), 4.85 (tt, J = 7.2, 5.2 Hz, 1H), 2.53-2.47 (m, 2H), 2.44 (s, 3H), 1.99-










13C NMR (126 MHz, Chloroform-d) δ 150.4, 145.2, 141.2, 137.3, 135.9, 129.7, 128.6, 128.5, 
128.3, 126.1, 115.3, 77.4, 35.7, 33.2, 31.4, 29.3, 21.8. HRMS (ESI) m/z calculated for 
C21H25NO4S [M+H]+: 388.1583, found 388.1582.  
 
 
9-(triisopropylsilyl)non-1-en-8-yn-5-yl tosylcarbamate (S71). was synthesized from 9-
(triisopropylsilyl)non-1-en-8-yn-5-ol (2.95 g, 10 mmol) following the general procedure in 62% 
yield (3.05 g, 6.20 mmol) as a white solid.1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.4 
Hz, 2H), 7.42 (br s, 1H), 7.34 (d, J = 8.1 Hz, 2H), 5.67 (ddt, J = 18.1, 9.6, 6.5 Hz, 1H), 4.95 – 4.88 
(m, 2H), 4.85 (p, J = 6.2 Hz, 1H), 2.44 (s, 3H), 2.17-2.07 (m, 2H), 1.96 – 1.87 (m, 2H), 1.79 – 1.71 
(m, 2H), 1.67 – 1.56 (m, 2H), 1.08 – 0.96 (m, 21H). 13C NMR (126 MHz, Chloroform-d) δ 150.1, 
145.2, 137.2, 135.7, 129.7, 128.4, 115.4, 107.2, 81.2, 76.9, 33.2, 32.9, 29.3, 21.8, 18.7, 16.0, 11.3. 




yl)carbamate (S72) was synthesized following the procedure developed for chiral diamino 
alcohols (vide infra) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 8.1 Hz, 
2H), 7.77 (s, 1H), 7.33 (d, J = 8.1 Hz, 2H), 5.62 (ddt, J = 17.8, 9.2, 6.5 Hz, 1H), 4.88 (br s, 1H), 











– 1.77 (m, 2H), 1.72 (dddd, J = 13.9, 9.9, 5.9, 3.5 Hz, 1H), 1.58-1.52 (m, 1H), 1.43 (s, 9H), 0.84 
(s, 9H), -0.02 (s, 3H), -0.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 155.6, 149.9, 145.1, 137.5, 
135.9, 129.7, 128.5, 115.1, 79.9, 76.1, 61.7, 53.3, 30.2, 29.1, 28.5, 25.9, 21.8, 18.3, -5.5, -5.6. 
HRMS (ESI) m/z calculated for C26H45N2O7SSi [M+H]+: 557.2717, found 557.2715. Optical 
rotation: [α]23D = 6.5 (c = 1.05, CHCl3). 
 





(S73a) was synthesized following Scheuer’s procedure22 using pent-4-enal in 77% yield (4.88g, 
15.4 mmol). 
 
(2R,3S)-3-hydroxy-N-methoxy-N,2-dimethylhept-6-enamide (S73b). To an 100 mL oven-dried 
round bottom flask equipped with a stir bar was added N,O-Dimethylhydroxylamine 
hydrochloride (2.34g, 24 mmol) and THF. The reaction was cooled to 0 °C and AlMe3 (2.0M in 
toluene, 12 mL, 24 mmol) was added dropwise. The reaction was allow to warm up to room 
temperature for 1 hour and cooled back to 0 °C. S73a in 5 mL THF was added dropwise, then the 
reaction was warmed to room temperature and stirred for 2 hours. After completion, the reaction 
was cooled to 0 °C and 20 mL 1M HCl was added dropwise followed by 20 mL Et2O. The mixture 





































were separated. The aqueous layer was extracted with Et2O (30 mL x 2). The combined organic 
layers were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
crude mixture was purified via silica plug (30% ethyl acetate in hexanes) to afford the desired 
S73b in quantitative yield. 
 
(4R,5S)-5-hydroxy-4-methylnon-8-en-3-one (S73c). To an 100 mL oven-dried round bottom 
flask was added S73b (8 mmol) and 20 mL THF. The reaction was cooled to 0 °C and 
ethylmagnesium bromide (1.0 M in THF, 16 mL, 16 mmol) was added dropwise. The reaction was 
allowed to warm up to room temperature and stirred for 30 min. The reaction was cooled back to 
0 °C and quenched with sat. aq. NH4Cl. The mixture transferred into a separatory funnel and the 
layers were separated. The aqueous layer was extracted with Et2O (30 mL x 2). The combined 
organic layers were dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. The crude mixture was purified via flash column chromatography (ethyl acetate in 
hexanes) to afford the desired S73c in 80% yield (1.08g, 6.36 mmol) as a colorless oil. 
 
(-)-(5S, 6R)-6-methyl-7-oxonon-1-en-5-yl tosylcarbamate (S73) was synthesized from (4R,5S)-
5-hydroxy-4-methylnon-8-en-3-one (S73c) (341 mg, 2.00 mmol) following the general procedure 
in 99% yield (813 mg, 2.21 mmol) as a colorless gel. 
1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 8.4 Hz, 2H), 7.51 (s, 1H), 7.34 (d, J = 8.2 Hz, 
2H), 5.62 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.03 (ddd, J = 8.9, 5.7, 4.2 Hz, 1H), 4.93 – 4.84 (m, 
2H), 2.73 (qd, J = 7.0, 5.6 Hz, 1H), 2.44 (s, 3H)2.48 – 2.32 (m, 2H), 1.92 – 1.77 (m, 2H), 1.62 – 
1.47 (m, 2H), 0.99 (d, J = 7.0 Hz, 3H), 0.94 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, Chloroform-
d) δ 211.6, 150.1, 145.2, 137.0, 135.7, 129.8, 128.4, 115.6, 77.6, 49.2, 35.5, 31.1, 29.7, 21.8, 11.9, 
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7.7. HRMS (ESI) m/z calculated for C18H25NO5S [M-H]+: 366.1375, found 366.1375. Optical 




Entry 1.  
Reaction proceeded according to reported procedure2a using Pd(OAc)2/bis-sulfoxide catalyst (10 
mg, 0.02 mmol, 0.1 equiv), 2-methylhept-6-en-3-yl tosylcarbamate (S46) (65.1 mg, 0.2 mmol, 1.0 
equiv), phenyl benzoquinone (PhBQ)  (73.7mg, 0.4 mmol, 2.0 equiv) and dichloroethane (0.3 mL, 
0.67 M). After 24 hours, the reaction concentrated under reduced pressure, the remaining mixture 
was diluted with 2 mL CDCl3 and crude 1H NMR was taken with internal standard (Nitrobenzene, 
12.3 mg, 0.1 mmol, 0.5 equiv). 40% crude NMR yield (4.7:1 syn:anti). The mixture was 
concentrated under reduced pressure and subjected to flash column chromatography (0% => 20% 
ethyl acetate in hexanes) to provide 62b as a white solid.  
Run 1: Crude: 39% yield, 4.7:1 dr (syn:anti). Isolated 62b (>20:1 dr): 19.1mg, 0.059 mmol, 29.5% 
yield;  
Run 2: Crude: 40% yield, 4.6:1 dr (syn:anti). Isolated 62b (>20:1 dr): 18.8 mg, 0.058 mmol 29.1% 
yield;  
Average: Crude 40% yield, 4.7:1 dr (syn:anti). Isolated 62b: 29% yield (>20:1 dr). 
 
Entry 2. 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (6.9 mg, 0.02 mmol, 0.1 equiv), phenyl benzoquinone benzoquinone (PhBQ) (73.7 mg, 0.4 
mmol, 2.0 equiv), 2-methylhept-6-en-3-yl tosylcarbamate (S46) (65.1 mg, 0.2 mmol, 1.0 equiv), 
and dichloroethane (0.3 mL, 0.67 M). The vial was capped and heated to 45 °C for 24 hours. The 
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vial was allowed to cool to room temperature and diluted with 1 mL acetone. The reaction mixture 
was filtered through a pipette silica plug into a 20 mL vial with acetone. The mixture was 
concentrated under reduced pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H NMR 
with internal standard (nitrobenzene, 12.3 mg, 0.1 mmol, 0.5 equiv). The mixture was then 
concentrated under reduced pressure and dissolved in 30 mL diethyl ether and washed sequentially 
with 1M aq. NaOH (10 mL) and sat. aq. NaHSO3 (10 mL) (repeat this sequence for 3 times).  The 
organic layer was dried over MgSO4, concentrated under reduced pressure and subjected to flash 
column chromatography (0% => 20% ethyl acetate in hexanes). Trace amount of product was 
observed by crude 1H NMR. No product was isolated by flash column chromatography. 
 
Entry 3.  
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 dimethylbenzoquinone (2,5 DMBQ) (54.5 mg, 0.4 
mmol, 2.0 equiv), 2-methylhept-6-en-3-yl tosylcarbamate (S46) (65.1 mg, 0.2 mmol, 1.0 equiv), 
and dichloroethane (0.3 mL, 0.67 M). The vial was capped and heated to 45 °C for 24 hours. The 
vial was allowed to cool to room temperature and diluted with 1 mL acetone. The reaction mixture 
was filtered through a pipette silica plug into a 20 mL vial with acetone. The mixture was 
concentrated under reduced pressure, diluted with 2 mL CDCl3 and analyzed by crude 1H NMR 
with internal standard (nitrobenzene, 12.3 mg, 0.1 mmol, 0.5 equiv). The mixture was then 
concentrated under reduced pressure and dissolved in 30 mL diethyl ether and washed sequentially 
with 1M aq. NaOH (10 mL) and sat. aq. NaHSO3 (10 mL) (repeat this sequence for 3 times).  The 
organic layer was dried over MgSO4, concentrated under reduced pressure and subjected to flash 
column chromatography (0% => 20% ethyl acetate in hexanes) to provide 62a as a white solid.  
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Run 1: Crude: 87% yield, 7.1:1 dr (anti:syn). Isolated 62a (>20:1 dr): 46.3 mg, 0.143 mmol, 71.6 
% yield;  
Run 2: Crude: 89% yield, 7.4:1 dr (anti:syn). Isolated 62a (>20:1 dr): 46.8 mg, 0.145 mmol 72.4 
% yield;  
Average: Crude 88% yield, 7.3:1 dr (anti:syn). Isolated 62a: 72% yield (>20:1 dr). 
 
Entry 4.  
Following the same procedure of Entry 3 using 1.2 equiv of 2,5 dimethylbenzoquinone (2,5 
DMBQ) (32.7 mg, 0.24 mmol, 1.2 equiv).  
Run 1: Crude: 89% yield, 7.9:1 dr (anti:syn). Isolated 62a (>20:1 dr): 49.9 mg, 0.154 mmol, 77.1 
% yield;  
Run 2: Crude: 92% yield, 7.7:1 dr (anti:syn). Isolated 62a (>20:1 dr): 51.3 mg, 0.159 mmol 79.3 
% yield;  
Average: Crude 91% yield, 7.8:1 dr (anti:syn). Isolated 62a: 78% yield (>20:1 dr). 
 
Entry 5.  
Following the same procedure of Entry 3 using (±)-SOX ligand (6.3 mg, 0.02 mmol, 0.1 equiv).  
Run 1: Crude: 87% yield, 3.4:1 dr (anti:syn). Isolated 62a (>20:1 dr): 40.0 mg, 0.124 mmol, 61.8 
% yield;  
Run 2: Crude: 84% yield, 3.7:1 dr (anti:syn). Isolated 62a (>20:1 dr): 38.4 mg, 0.119 mmol 59.4 
% yield;  





Entry 6.  
Following the same procedure of Entry 3 using (±)-CF3-SOX ligand (7.6 mg, 0.02 mmol, 0.1 
equiv).  
Run 1: Crude: 69% yield, 1:4.3 dr (anti:syn). Isolated 62b (>20:1 dr): 33.0 mg, 0.102 mmol, 51.0 
% yield;  
Run 2: Crude: 69% yield, 1:4.2 dr (anti:syn). Isolated 62b (>20:1 dr): 33.3 mg, 0.103 mmol 51.5 
% yield;  
Average: Crude 69% yield, 1:4.3 dr (anti:syn). Isolated 62b: 51% yield (>20:1 dr). 
 
Entry 7.  
Following the same procedure of Entry 3 using (±)-CF3-SOX ligand (7.6 mg, 0.02 mmol, 0.1 
equiv) and 1,4 benzoquinone (BQ) (43.2 mg, 0.4 mmol, 2.0 equiv). 
Run 1: Crude: 77% yield, 1:6.8 dr (anti:syn). Isolated 62b (>20:1 dr): 39.8 mg, 0.123 mmol, 61.6 
% yield;  
Run 2: Crude: 75% yield, 1:6.8 dr (anti:syn). Isolated 62b (>20:1 dr): 38.2 mg, 0.118 mmol 59.1 
% yield;  
Average: Crude 76% yield, 1:4.3 dr (anti:syn). Isolated 62b: 60% yield (>20:1 dr). 
 
Entry 8.  
Following the same procedure of Entry 3 using (±)-CF3-SOX ligand (7.6 mg, 0.02 mmol, 0.1 
equiv) and 1,4 benzoquinone (BQ) (34.6 mg, 0.32 mmol, 1.6 equiv). 
Run 1: Crude: 85% yield, 1:6.8 dr (anti:syn). Isolated 62b (>20:1 dr): 45.2 mg, 0.140 mmol, 69.9 
% yield;  
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Run 2: Crude: 89% yield, 1:6.6 dr (anti:syn). Isolated 62b (>20:1 dr): 46.3 mg, 0.143 mmol 71.6 
% yield;  
Average: Crude 87% yield, 1:6.7 dr (anti:syn). Isolated 62b: 71% yield (>20:1 dr). 
 
Entry 9.  
Following the same procedure of Entry 3 using (±)-CF3-SOX ligand (7.6 mg, 0.02 mmol, 0.1 
equiv) and 1,4 benzoquinone (BQ) (34.6 mg, 0.24 mmol, 1.2 equiv). 
Run 1: Crude: 73% yield, 1:6.6 dr (anti:syn). Isolated 62b (>20:1 dr): 37.4 mg, 0.116 mmol, 57.8 
% yield;  
Run 2: Crude: 71% yield, 1:6.7 dr (anti:syn). Isolated 62b (>20:1 dr): 36.7 mg, 0.113 mmol 56.7 
% yield;  
Average: Crude 72% yield, 1:6.7 dr (anti:syn). Isolated 62b: 57% yield (>20:1 dr). 
 
Entry 10.  
Following the same procedure of Entry 4 with addition of Diphenyl phosphinic acid (Ph2P(O)OH, 
4.4 mg, 0.02 mmol, 0.1 equiv) for 6 hours.  
Run 1: Crude: 89% yield, 6.5:1 dr (anti:syn). Isolated 62a (>20:1 dr): 47.4 mg, 0.147 mmol, 73.3 
% yield;  
Run 2: Crude: 87% yield, 6.3:1 dr (anti:syn). Isolated 62a (>20:1 dr): 45.4 mg, 0.140 mmol 70.2 
% yield;  






Entry 11.  
Following the same procedure of Entry 8 with addition of Diphenyl phosphinic acid (Ph2P(O)OH, 
4.4 mg, 0.02 mmol, 0.1 equiv) for 6 hours.  
Run 1: Crude: 92% yield, 1:4.0 dr (anti:syn). Isolated 62b (>20:1 dr): 45.6 mg, 0.141 mmol, 70.5 
% yield;  
Run 2: Crude: 93% yield, 1:3.9 dr (anti:syn). Isolated 62b (>20:1 dr): 44.0 mg, 0.136 mmol 68.0 
% yield;  
Average: Crude 92% yield, 1:4.0 dr (anti:syn). Isolated 62b: 69% yield (>20:1 dr). 
 
Entry 12.  
Following the same procedure of Entry 3 using Pd(OAc)2/bis-sulfoxide catalyst (10 mg, 0.02 
mmol, 0.1 equiv). 
Run 1: Crude: 61% yield, 1:5.4 dr (anti:syn). Isolated 62b (>20:1 dr): 29.3 mg, 0.091 mmol, 45.3 
% yield;  
Run 2: Crude: 59% yield, 1:5.6 dr (anti:syn). Isolated 62b (>20:1 dr): 29.7 mg, 0.092 mmol 45.9 
% yield;  
Average: Crude 60% yield, 1:6.7 dr (anti:syn). Isolated 62b: 46% yield (>20:1 dr). 
 
Entry 13.  
Following the same procedure of Entry 3 using Pd(OAc)2/bis-sulfoxide catalyst (10 mg, 0.02 
mmol, 0.1 equiv) and 1,4 benzoquinone (BQ) (34.6 mg, 0.32 mmol, 1.6 equiv). 
Run 1: Crude: 55% yield, 1:4.3 dr (anti:syn). Isolated 62b (>20:1 dr): 24.7 mg, 0.076 mmol, 38.2 
% yield;  
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Run 2: Crude: 51% yield, 1:4.9 dr (anti:syn). Isolated 62b (>20:1 dr): 24.0 mg, 0.074 mmol 37.1 
% yield;  
Average: Crude 53% yield, 1:4.6 dr (anti:syn). Isolated 62b: 38% yield (>20:1 dr). 
 
(±)-(4S,6S)-6-isopropyl-3-tosyl-4-vinyl-1,3-oxazinan-2-one (62a).  
1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.88 (ddd, 
J = 17.1, 10.5, 5.0 Hz, 1H), 5.40 (dd, J = 10.5, 1.5 Hz, 1H), 5.34 (dd, J = 17.1, 1.7 Hz, 1H), 5.21 
(dt, J = 3.9, 2.5 Hz, 1H), 4.11 (ddd, J = 11.8, 6.2, 3.2 Hz, 1H), 2.41 (s, 3H), 2.12-1.86 (m, 2H), 
1.81 (dq, J = 13.4, 6.7 Hz, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, Chloroform-d) δ 148.6, 144.9, 135.6, 129.4, 129.2, 118.6, 80.3, 56.0, 32.1, 29.9, 21.7, 17.7, 
17.5. HRMS (ESI) m/z calculated for C16H21NO4S [M+H]+: 324.1270, found 324.1273. Spectra 
match literature reports.2a,23  






Details of the crystal data and a summary of the intensity data for (±)-62a are listed in Table 8. 
CCDC: 1899082 
 
Table 8.  Crystal Data and Structure Refinement for (±)-62a 
 
Identification code  dd25esa_sq 
Empirical formula  C16 H21 N O4 S 
Formula weight  323.40 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.9677(3) Å a= 106.578(2)°. 
 b = 11.8753(6) Å b= 100.198(2)°. 
 c = 15.0703(7) Å g = 104.470(2)°. 
Volume 955.00(8) Å3 
Z 2 
Density (calculated) 1.125 Mg/m3 
Absorption coefficient 0.184 mm-1 
F(000) 344 
Crystal size 0.247 x 0.152 x 0.072 mm3 
Theta range for data collection 2.760 to 27.191°. 
Index ranges -7<=h<=7, -15<=k<=15, -19<=l<=19 
Reflections collected 30439 
Independent reflections 4237 [R(int) = 0.0437] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Integration 
Max. and min. transmission 1.0000 and 0.9417 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4237 / 0 / 202 
Goodness-of-fit on F2 1.068 
Final R indices [I>2sigma(I)] R1 = 0.0388, wR2 = 0.0963 
R indices (all data) R1 = 0.0469, wR2 = 0.1008 
Extinction coefficient n/a 






 (±)-(4R, 6S)-6-isopropyl-3-tosyl-4-vinyl-1,3-oxazinan-2-one (62b).  
1H NMR (500 MHz, Chloroform-d) δ 7.98 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.55 (ddd, 
J = 16.9, 10.0, 8.1 Hz, 1H), 5.37 (d, J = 17.0 Hz, 1H), 5.23 (d, J = 10.0 Hz, 1H), 4.89 (dt, J = 9.9, 
8.1 Hz, 1H), 4.00 (ddd, J = 11.4, 6.0, 2.0 Hz, 1H), 2.42 (s, 3H), 2.29 (ddd, J = 14.2, 8.0, 2.1 Hz, 
1H), 1.94 – 1.81 (m, 1H), 1.67 (ddd, J = 14.1, 11.3, 9.9 Hz, 1H), 0.98 (d, J = 6.8 Hz, 3H), 0.95 (d, 
J = 6.8 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 150.6, 144.8, 137.1, 136.2, 129.7, 129.2, 
118.6, 81.0, 59.0, 33.2, 31.4, 21.7, 11.7 HRMS (ESI) m/z calculated for C16H21NO4S [M+H]+: 
324.1270, found 324.1280. Spectra match literature reports.2a,23 
 
Reaction Scope (Anti) 
General procedure for anti-1,3 oxazinanone: 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 dimethylbenzoquinone (2,5 DMBQ) (32.7 mg,  
0.24mmol, 1.2 equiv), N-tosyl carbamate (0.2 mmol, 1.0 equiv), and dichloroethane (0.3 mL, 0.67 
M). The vial was capped and heated to 45 °C for 24 hours. The vial was allowed to cool to room 
temperature and diluted with 1 mL acetone. The reaction mixture was filtered through a pipette 
silica plug into a 20 mL vial with acetone. The mixture was concentrated under reduced pressure, 
diluted with 2 mL CDCl3 and analyzed by crude 1H NMR with internal standard (nitrobenzene, 
12.3 mg, 0.1 mmol, 0.5 equiv). The mixture was then concentrated under reduced pressure and 
dissolved in 30 mL diethyl ether and washed sequentially with 1M aq. NaOH (10 mL) and sat. aq. 





MgSO4, concentrated under reduced pressure and subjected to flash column chromatography 
(ethyl acetate in hexanes) to provide anti-1,3-oxazinanone product.  
 
 
(±)-(4S,6S)-6-phenyl-3-tosyl-4-vinyl-1,3-oxazinan-2-one (63). Racemic carbamate S47 (71.8 
mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 20% ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude: 89%, 9.1:1 dr; isolated: 59.7 mg, 0.167 mmol, 83.5%, >20:1 dr);  
Run 2 (crude: 92%, 8.9:1 dr; isolated: 56.0 mg, 0.157 mmol, 78.3%, >20:1 dr);  
Run 3 (crude: 91%, 8.8:1 dr; isolated: 57.5 mg, 0.161 mmol, 80.4%, >20:1 dr). 
Average yield: 81%, >20:1 dr (anti:syn). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.5 Hz, 2H), 7.42-7.27 (m, 7H), 6.02 (ddd, J = 
17.1, 10.5, 4.8 Hz, 1H), 5.51 (dd, J = 10.6, 1.5 Hz, 1H), 5.46 (dd, J = 17.1, 1.7 Hz, 1H), 5.39 (t, J 
= 7.6 Hz, 1H), 5.31 – 5.26 (m, 1H), 2.44 (s, 3H), 2.30-2.21 (m, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 148.4, 145.3, 137.7, 135.5, 135.5, 129.6, 129.4, 129.0, 128.9, 125.9, 119.1, 77.0, 
56.4, 35.3, 21.8. HRMS (ESI) m/z calculated for C19H19NO4S [M+H]+: 358.1113, found 








(±)-(4S,6S)-6-(4-methoxyphenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (64). Racemic carbamate 
S48 (83.4 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 30% ethyl acetate/hexanes) afforded the anti-diastereomer as a colorless 
oil. 
Run 1 (crude: 80%, 5.9:1 dr; isolated: 55.3 mg, 0.143 mmol, 71.4%, >20:1 dr);  
Run 2 (crude: 80%, 5.5:1 dr; isolated: 54.0 mg, 0.139 mmol, 69.7%, >20:1 dr);  
Run 3 (crude: 80%, 5.6:1 dr; isolated: 53.6 mg, 0.138 mmol, 69.2%, >20:1 dr).  
Average yield: 70%, >20:1 dr (anti:syn). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.94 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.20 (d, 
J = 8.7 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.00 (ddd, J = 17.1, 10.5, 4.8 Hz, 1H), 5.49 (dd, J = 10.6, 
1.5 Hz, 1H), 5.45 (dd, J = 17.1, 1.6 Hz, 1H), 5.33 (dd, J = 11.7, 3.4 Hz, 1H), 5.30 – 5.25 (m, 1H), 
3.79 (s, 3H), 2.44 (s, 3H), 2.32 – 2.17 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 160.1, 
148.5, 145.2, 135.6, 129.7, 129.6, 129.4, 127.5, 119.0, 114.2, 76.9, 56.4, 55.4, 35.0, 21.8 (one 
signal missing due to overlapping). HRMS (ESI) m/z calculated for C20H21NO5S [M+H]+: 












(±)-(4S,6S)-6-(p-tolyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (65). Racemic carbamate S49 (74.7 
mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 25% ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude: 93%, 9.1:1 dr; isolated: 51.0 mg, 0.137 mmol, 68.6%, >20:1 dr);   
Run 2 (crude: 90%, 9.0:1 dr; isolated: 50.5 mg, 0.136 mmol, 68.0%, >20:1 dr);  
Run 3 (crude: 92%, 8.7:1 dr; isolated: 53.2 mg, 0.143 mmol, 71.6%, >20:1 dr).  
Average yield: 69%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.6, 2H), 7.19 – 7.14 
(m, 4H), 6.01 (ddd, J = 17.1, 10.5, 4.9 Hz, 1H), 5.51 (dd, J = 10.6, 1.5 Hz, 1H), 5.46 (dd, J = 17.1, 
1.6 Hz, 1H), 5.35 (dd, J = 10.8, 4.3 Hz, 1H), 5.28 (tdt, J = 4.8, 3.2, 1.6 Hz, 1H), 2.44 (s, 3H), 2.34 
(s, 3H), 2.29 – 2.19 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 148.5, 145.2, 139.0, 135.7, 
135.6, 134.8, 129.6, 129.5, 129.4, 125.9, 119.1, 77.0, 56.4, 35.3, 21.9, 21.3. HRMS (ESI) m/z 
calculated for C20H21NO4S [M+Na]+: 394.1089, found 394.1079. Spectra match literature report.23 
 
 
(±)-(4S,6S)-6-(4-bromophenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (66). Racemic carbamate 
S45 (87.7 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 20% ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid.  






Run 2 (crude: 79%, 9.6:1 dr; isolated: 65.4 mg, 0.150 mmol, 74.9%, >20:1 dr);  
Run 3 (crude: 81%, 10.3:1 dr; isolated: 59.9 mg, 0.137 mmol, 68.6%, >20:1 dr).  
Average yield: 72%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.94 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.33 (d, 
J = 7.7 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 6.01 (ddd, J = 17.0, 10.5, 4.8 Hz, 1H), 5.52 (dd, J = 10.6, 
1.5 Hz, 1H), 5.46 (dd, J = 17.1, 1.7 Hz, 1H), 5.35 (dd, J = 11.0, 4.1 Hz, 1H), 5.29 (m, 1H), 2.45 
(s, 3H), 2.27-2.14 (m, 2H). 13C NMR (126 MHz, Chloroform-d) δ 148.2, 145.4, 136.8, 135.4, 
135.4, 132.1, 129.7, 129.4, 127.6, 120.0, 119.3, 76.3, 56.3, 35.3, 21.9. HRMS (ESI) m/z calculated 
for C19H18BrNO4S [M+H]+: 436.0218, found 436.0210. Spectra match literature report.23 
 
 
(±)-(4S,6S)-6-(4-chlorophenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (67). Racemic carbamate 
S51 (78.8 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 25% ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude: 81%, 10.2:1 dr; isolated: 53.9 mg, 0.138 mmol, 68.7%, >20:1 dr);  
Run 2 (crude: 81%, 9.8:1 dr; isolated: 54.5 mg, 0.139 mmol, 69.5%, >20:1 dr);  
Run 3 (crude: 78%, 9.7:1 dr; isolated: 53.3 mg, 0.136 mmol, 68.0%, >20:1 dr).  







1H NMR (500 MHz, Chloroform-d) δ 7.94 (d, J = 7.8 Hz, 2H), 7.35 – 7.30 (m, 4H), 7.22 (d, J = 
8.3 Hz, 2H), 6.01 (ddd, J = 17.1, 10.6, 4.7 Hz, 1H), 5.52 (d, J = 10.6 Hz, 1H), 5.46 (d, J = 17.2 
Hz, 1H), 5.36 (dd, J = 10.8, 4.3 Hz, 1H), 5.31 – 5.26 (m, 1H), 2.44 (s, 3H), 2.27 – 2.15 (m, 2H). 
13C NMR (126 MHz, Chloroform-d) δ 148.3, 145.4, 136.2, 135.3, 134.9, 129.6, 129.4, 129.1, 
127.3, 119.3, 76.2, 56.3, 35.2, 21.9. (one peak missing due to overlap). HRMS (ESI) m/z 
calculated for C19H18ClNO4S [M+Na]+: 414.0543, found 414.0530. 
 
 
(±)-(4S,6S)-3-tosyl-6-(4-(trifluoromethyl)phenyl)-4-vinyl-1,3-oxazinan-2-one (68). Racemic 
carbamate S52 (85.5 mg, 0.2 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (10 => 20% ethyl acetate/hexanes) afforded the anti- diastereomer as a 
white solid.  
Run 1 (crude: 57%, >20:1 dr; isolated: 46.7 mg, 0.110 mmol, 54.8%, >20:1 dr);  
Run 2 (crude: 56%, >20:1 dr; isolated: 43.7 mg, 0.103 mmol, 51.4%, >20:1 dr);  
Run 3 (crude: 60%, >20:1 dr; isolated: 46.4 mg, 0.109 mmol, 54.5%, >20:1 dr).  
Average yield: 54%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.42 (d, 
J = 8.0 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 6.03 (ddd, J = 17.2, 10.6, 4.8 Hz, 1H), 5.54 (dd, J = 10.5, 
1.5 Hz, 1H), 5.51 – 5.39 (m, 2H), 5.34 – 5.28 (m, 1H), 2.45 (s, 3H), 2.33 – 2.14 (m, 2H). 13C NMR 






126.1, 125.9 (q, J = 3.8 Hz), 123.9 (q, J = 272.4 Hz), 119.5, 76.1, 56.2, 35.4, 21.9. 19F NMR (470 
MHz, Chloroform-d) δ -63.1. HRMS (ESI) m/z calculated for C20H18F3NO4S [M+H]+: 426.0987, 
found 426.0995. Spectra match literature report.23 
 
 
(±)-Methyl 4-((4S,6S)-2-oxo-3-tosyl-4-vinyl-1,3-oxazinan-6-yl)benzoate (69). Racemic 
carbamate S53 (83.5 mg, 0.2 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (5 => 30% ethyl acetate/hexanes) afforded the anti- diastereomer as a 
white solid.  
Run 1 (crude: 60%, >20:1 dr; isolated: 46.4 mg, 0.112 mmol, 55.8%, >20:1 dr),  
Run 2 (crude: 57%, >20:1 dr; isolated: 45.8 mg, 0.110 mmol, 55.1%, >20:1 dr), 
Run 3 (crude: 62%, >20:1 dr; isolated: 48.4 mg, 0.116 mmol, 58.2%, >20:1 dr),  
Average yield: 56%, >20:1 dr (anti:syn). 
 
1H NMR (500 MHz, Chloroform-d) δ 8.02 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 8.4 Hz, 2H), 7.36 (d, 
J = 8.2 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 6.02 (ddd, J = 17.1, 10.6, 4.8 Hz, 1H), 5.53 (dd, J = 10.5, 
1.5 Hz, 1H), 5.49 – 5.41 (m, 2H), 5.33-5.27 (m, 1H), 3.91 (s, 3H), 2.44 (s, 3H), 2.33 – 2.12 (m, 
2H). 13C NMR (126 MHz, Chloroform-d) δ 166.6, 148.2, 145.4, 142.6, 135.4, 135.3, 130.7, 130.2, 
129.6, 129.4, 125.7, 119.3, 76.3, 56.3, 52.4, 35.3, 21.9. HRMS (ESI) m/z calculated for 








(±)-(4S,6S)-6-(2-bromophenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (70). Racemic carbamate 
S54 (87.6 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (5 => 50% ethyl acetate/hexanes) afforded the anti- diastereomer as a white solid.  
Run 1 (crude: 79%, 20:1 dr; isolated: 64.8 mg, 0.149 mmol, 74.3%, >20:1 dr);  
Run 2 (crude: 80%, 20:1 dr; isolated: 65.3 mg, 0.150 mmol, 74.8%, >20:1 dr);  
Run 3 (crude: 80%, 20:1 dr; isolated: 66.9 mg, 0.153 mmol, 76.7%, >20:1 dr).  
Average yield: 75%, >20:1 dr (anti:syn).  
1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 8.1, 1.2 Hz, 1H), 7.46 
(dd, J = 7.8, 1.7 Hz, 1H), 7.34 (m, 3H), 7.19 (td, J = 7.7, 1.7 Hz, 1H), 6.07 (ddd, J = 16.9, 10.5, 
4.7 Hz, 1H), 5.74 (dd, J = 12.0, 2.7 Hz, 1H), 5.56 – 5.46 (m, 2H), 5.31 – 5.26 (m, 1H), 2.51 (dt, J 
= 14.4, 2.5 Hz, 1H), 2.45 (s, 3H), 1.98 (ddd, J = 14.2, 12.0, 5.1 Hz, 1H). 13C NMR (126 MHz, 
Chloroform-d) δ 148.5, 145.7, 137.2, 135.5, 135.04, 133.0, 130.2, 129.7, 129.4, 128.3, 127.4, 
120.7, 119.2, 76.3, 56.5, 33.9, 21.9. HRMS (ESI) m/z calculated for C19H19NO4SBr [M+H]+: 
436.0218, found 436.0232. 
 
 
(±)-(4S,6S)-6-(naphthalen-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (71). Racemic carbamate 








chromatography (10 => 25% ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude: 72%, 12:1 dr; isolated: 54.1 mg, 0.133 mmol, 66.4%, >20:1 dr);  
Run 2 (crude: 71%, 13:1 dr; isolated: 53.8 mg, 0.132 mmol, 66.0%, >20:1 dr); 
Run 3 (crude: 69%, 13:1 dr; isolated: 52.9 mg, 0.130 mmol, 65.0%, >20:1 dr).  
Average yield: 66%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.4 Hz, 2H), 7.87–7.73 (m, 4H), 7.55–7.44 (m, 
2H), 7.38 – 7.30 (m, 3H), 6.07 (ddd, J = 17.1, 10.6, 4.8 Hz, 1H), 5.59 – 5.53 (m, 2H), 5.51 (dd, J 
= 17.1, 1.6 Hz, 1H), 5.35–5.30 (m, 1H), 2.45 (s, 3H), 2.37–2.28 (m, 2H). 13C NMR (126 MHz, 
Chloroform-d) δ 148.5, 145.3, 135.6, 135.1, 133.5, 133.2, 129.7, 129.4, 128.9, 128.2, 127.9, 126.8, 
125.2, 123.2, 119.2, 77.1, 56.4, 35.4, 21.9. (two peaks missing due to overlapping). HRMS (ESI) 
m/z calculated for C23H21NO4S [M+H]+: 408.1270, found 408.1280.  
 
 
(±)-(4R,6S)-6-(4-fluoronaphthalen-1-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (72). Racemic 
carbamate S56 (85.5 mg, 0.2 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (0 => 25% ethyl acetate/hexanes) afforded the anti- diastereomer as a 
white solid.  
Run 1 (crude: 65%, 7.7:1 dr; isolated: 46.2 mg, 0.109 mmol, 54.3%, >20:1 dr); 







Run 3 (crude: 63%, 7.6:1 dr; isolated: 45.4 mg, 0.107 mmol, 53.3%, >20:1 dr).  
Average yield: 54%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.19 – 8.15 (m, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.71 (dt, J = 
7.0, 2.0 Hz, 1H), 7.61 – 7.55 (m, 2H), 7.53 (dd, J = 8.2, 5.2 Hz, 1H), 7.35 (d, J = 8.1 Hz, 2H), 7.13 
(dd, J = 10.0, 8.1 Hz, 1H), 6.23 – 6.10 (m, 2H), 5.70 – 5.53 (m, 2H), 5.37-5.33 (m, 1H), 2.49 – 
2.43 (m, 1H), 2.46 (s, 3H), 2.31 (ddd, J = 14.4, 12.0, 5.1 Hz, 1H). 13C NMR (126 MHz, 
Chloroform-d) δ 159.18 (d, J = 254.1 Hz), 148.6, 145.4, 135.7, 135.2, 131.12 (d, J = 4.5 Hz), 
129.7, 129.5, 128.99 (d, J = 4.4 Hz), 127.9, 126.42 (d, J = 1.9 Hz), 124.02 (d, J = 16.3 Hz), 123.83 
(d, J = 9.1 Hz), 121.90 (d, J = 3.3 Hz), 121.85 (d, J = 6.3 Hz ), 119.4, 109.11 (d, J = 20.3 Hz), 




(±)-(4S,6S)-3-tosyl-6-(1-tosyl-1H-indol-5-yl)-4-vinyl-1,3-oxazinan-2-one (73). Racemic 
carbamate 57 (110.3 mg, 0.2 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (5 => 25% acetone/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude: 73%, 10:1 dr; isolated:71.5 mg, 0.130 mmol, 64.9%, >20:1 dr);  
Run 2 (crude: 75%, 10:1 dr; isolated:72.3 mg, 0.131 mmol, 65.7%, >20:1 dr);  
Run 3 (crude: 75%, 10:1 dr; isolated:72.9 mg, 0.132 mmol, 66.2%, >20:1 dr).  








1H NMR (500 MHz, Chloroform-d) δ 7.94 (app. d, J = 8.4 Hz, 3H), 7.72 (d, J = 8.5 Hz, 2H), 7.56 
(d, J = 3.7 Hz, 1H), 7.46 (d, J = 1.7 Hz, 1H), 7.31 (d, J = 8.1 Hz, 2H), 7.23-7.13 (m, 3H), 6.59 (d, 
J = 3.8, 1H), 6.01 (ddd, J = 17.1, 10.6, 4.8 Hz, 1H), 5.50 (dd, J = 10.6, 1.5 Hz, 1H), 5.48-5.39 (m, 
2H), 5.31 – 5.25 (m, 1H), 2.43 (s, 3H), 2.32 (s, 3H), 2.29-2.21 (m, 2H).  13C NMR (126 MHz, 
Chloroform-d) δ 148.4, 145.3, 145.3, 135.5, 135.5, 135.1, 134.9, 132.8, 131.0, 130.1, 129.6, 129.4, 
127.4, 126.9, 122.5, 119.2, 119.1, 113.9, 109.0, 77.2, 56.4, 35.4, 21.8, 21.7. HRMS (ESI) m/z 
calculated for C28H26N2O6S2 [M+H]+: 551.1311, found 551.1317.  
 
 
(±)-(4S,6S)-6-(benzo[b]thiophen-5-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (74). Racemic 
carbamate S58 (83.1 mg, 0.2 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (10 => 25% ethyl acetate/hexanes) afforded the anti- diastereomer as a 
white solid.  
Run 1 (crude: 67%, 9.6:1 dr; isolated: 45.2 mg, 0.109 mmol, 54.6%, >20:1 dr);  
Run 2 (crude: 68%, 9.2:1 dr; isolated: 48.0 mg, 0.116 mmol, 58.0%, >20:1 dr);  
Run 3 (crude: 67%, 9.7:1 dr; isolated: 49.1 mg, 0.119 mmol, 59.4%, >20:1 dr). 
Average yield: 58%, >20:1 dr (anti:syn). 
 
 1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.3 Hz, 1H), 7.77 (d, 
J = 1.7 Hz, 1H), 7.48 (d, J = 5.4 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 7.30 (dd, J = 5.5, 0.8 Hz, 1H), 






5.29 (m, 1H), 2.45 (s, 3H), 2.34 – 2.26 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 148.5, 145.3, 
140.2, 139.8, 135.5, 135.5, 134.0, 129.6, 129.4, 127.8, 123.9, 123.0, 121.9, 121.1, 119.2, 77.4, 




(±)-(4S,6S)-6-(benzofuran-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (75). Racemic carbamate 
S59 (79.9 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10-25% gradient ethyl acetate/hexanes) afforded the anti- diastereomer as a 
white solid.  
Run 1 (crude: 71%, 3.9:1 dr; isolated: 43.5 mg, 0.109 mmol, 54.7%, >20:1 dr);  
Run 1 (crude: 68%, 4.3:1 dr; isolated: 43.0 mg, 0.108 mmol, 54.1%, >20:1 dr);  
Run 1 (crude: 73%, 4.1:1 dr; isolated: 44.8 mg, 0.112 mmol, 56.4%, >20:1 dr).  
Average yield: 55%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 7.8 Hz, 2H), 7.44 (d, 
J = 8.3 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.26 – 7.20 (m, 1H), 6.76 (s, 1H), 6.00 (ddd, J = 17.1, 10.6, 
4.6 Hz, 1H), 5.57 – 5.50 (m, 2H), 5.47 (dd, J = 17.1, 1.7 Hz, 1H), 5.40 – 5.35 (m, 1H), 2.62 (ddd, 
J = 14.3, 12.3, 5.2 Hz, 1H), 2.44 (s, 3H), 2.40 – 2.34 (m, 1H). 13C NMR (126 MHz, Chloroform-
d) δ 155.1, 151.9, 147.7, 145.4, 135.3, 135.0, 129.6, 129.4, 127.4, 125.4, 123.3, 121.7, 119.4, 
111.6, 106.0, 71.0, 56.0, 31.4, 21.9.HRMS (ESI) m/z calculated for C21H19NO5S [M+H]+: 








Racemic carbamate 60 (98.0 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (5 => 20% ethyl acetate/hexanes) afforded the anti- 
diastereomer as a white solid.  
Run 1 (crude: 65%, 12:1 dr, isolated: 55.3 mg, 0.112 mmol, 56.1%, >20:1 dr),  
Run 2 (crude: 62%, 12:1 dr, isolated: 56.7 mg, 0.115 mmol, 57.6%, >20:1 dr),  
Run 3 (crude: 63%, 12:1 dr, isolated: 55.7 mg, 0.113 mmol, 56.5%, >20:1 dr),  
Average yield: 57%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.90-7.86 (m, 2H), 7.33–7.29 (m, 2H), 7.20-7.14 (m, 4H), 
7.00-6.92 (m, 2H), 6.92-6.87 (m, 2H), 5.73 (ddt, J = 16.9, 11.0, 4.2 Hz, 1H), 5.25-5.20 (m, 3H),  
4.76-4.70 (m, 1H), 4.36-4.32 (m, 1H), 3.99-3.95 (m, 1H), 2.43 (s, 3H), 2.40-2.36 (m, 1H), 1.95 – 
1.84 (m, 1H). 3C NMR (126 MHz, Chloroform-d) δ 148.1, 145.2, 144.8, 135.5, 135.2, 129.5, 
129.4, 128.0, 127.7, 126.5, 123.6, 118.6, 116.1, 72.6, 56.2, 50.8, 31.2, 21.8. HRMS (ESI) m/z 
















Racemic carbamate S61 (101.7 mg, 0.2 mmol) was reacted according to the general procedure 
with addition of Ph2P(O)OH (4.4 mg, 0.02 mmol, 0.1 equiv). Purification by flash chromatography 
(20 => 65% ethyl acetate/hexanes) afforded the anti- diastereomer as a white solid.  
Run 1 (crude: 60%, 15:1 dr; isolated: 54.3 mg, 0.107 mmol, 53.6%, >20:1 dr); 
Run 2 (crude: 63%, 15:1 dr; isolated: 56.7 mg, 0.112 mmol, 56.0%, >20:1 dr);  
Run 3 (crude: 58%, 14:1 dr; isolated: 54.9 mg, 0.108 mmol, 54.2%, >20:1 dr), 
Average yield: 55%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 8.5 Hz, 2H), 7.49 (d, 
J = 8.4 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 6.03 (ddd, J = 17.1, 10.6, 4.7 Hz, 1H), 5.54 (app dd, J = 
10.5, 1.5 Hz, 1H), 5.50 – 5.43 (m, 2H), 5.33 (td, J = 4.9, 2.3 Hz, 1H), 3.75 – 3.69 (m, 4H), 3.00 – 
2.95 (m, 4H), 2.45 (s, 3H), 2.31 (ddd, J = 14.3, 2.8, 2.8 Hz, 1H), 2.21 (ddd, J = 14.3, 12.1, 5.1 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 147.9, 145.5, 143.1, 135.8, 135.3, 135.2, 129.7, 129.5, 128.5, 
126.5, 119.5, 75.9, 66.2, 56.2, 46.1, 35.2, 21.9. HRMS (ESI) m/z calculated for C23H27N2O7S2 




Racemic carbamate S62 (59.4 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (10 => 25% ethyl acetate/hexanes) afforded the anti-
diastereomer as a white solid.  





Run 2 (crude: 78%, 5.2:1 dr; isolated: 39.9 mg, 0.135 mmol, 67.5%, >20:1 dr);  
Run 3 (crude: 80%, 5.2:1 dr; isolated: 37.9 mg, 0.128 mmol, 64.2%, >20:1 dr).  
Average yield: 66%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 5.89 (ddd, 
J = 16.9, 10.5, 4.9 Hz, 1H), 5.44 – 5.33 (m, 2H), 5.20-5.16 (m, 1H), 4.53 (app dq, J = 12.5, 6.3, 
1H), 2.42 (s, 3H), 2.05 – 1.88 (m, 2H), 1.33 (d, J = 6.3 Hz, 3H). 13C NMR (126 MHz, Chloroform-
d) δ 148.5, 145.1, 135.8, 135.7, 129.5, 129.3, 118.6, 72.3, 56.3, 34.5, 21.8, 20.9. HRMS (ESI) m/z 




Racemic carbamate S63 (64.7 mg, 0.20 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (10 => 30% ethyl acetate/hexanes) afforded the anti-
diastereomer as a yellow oil.  
Run 1 (crude: 93%, 6.2:1 dr; isolated: 48.0 mg, 0.149 mmol, 74.6%, >20:1 dr);  
Run 2 (crude: 91%, 6.4:1 dr; isolated: 50.2 mg, 0.156 mmol, 78.1%, >20:1 dr);  
Run 3 (crude: 94%, 6.0:1 dr; isolated: 52.4 mg, 0.163 mmol, 81.5%, >20:1 dr).  
Average yield: 78%, >20:1 d.r. (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.84 (ddd, 





5.17 (m, 1H), 3.64 (ddd, J = 10.9, 8.5, 3.8 Hz, 1H), 2.42 (s, 3H), 2.17-2.04 (m, 2H), 0.98 (qt, J = 
8.2, 4.8, 1H), 0.62 (tdd, J = 8.2, 5.8, 4.7 Hz, 1H), 0.56 (tdd, J = 8.7, 5.7, 4.6 Hz, 1H), 0.46-0.40 
(m, 1H), 0.24-0.15 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 148.5, 145.1, 135.7, 135.6, 
129.5, 129.3, 118.7, 80.6, 56.1, 33.1, 21.8, 14.9, 3.7, 2.1. HRMS (ESI) m/z calculated for 




Racemic carbamate S64 (79.9 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (5 => 20% ethyl acetate/hexanes) afforded the anti- 
diastereomer as a white solid.  
Run 1 (crude: 84%, >20:1 dr; isolated: 58.1 mg, 0.141 mmol, 73%, >20:1 dr);  
Run 2 (crude: 80%, >20:1 dr; isolated: 56.9 mg, 0.139 mmol, 72%, >20:1 dr); 
Run 3 (crude: 83%, >20:1 dr; isolated: 60.2 mg, 0.148 mmol, 76%, >20:1 dr). 
Average yield: 74%, >20:1 dr (anti:syn).   
 
1H NMR (500 MHz, Chloroform-d) δ 7.83 (dd, J = 8.4, 1.5 Hz, 2H), 7.33 – 7.29 (m, 2H), 7.29 – 
7.20 (m, 5H), 5.83 (dddd, J = 17.0, 10.5, 5.0, 1.2 Hz, 1H), 5.36 (dt, J = 10.6, 1.4 Hz, 1H), 5.28 (dt, 
J = 17.1, 1.5 Hz, 1H), 5.11-5.06 (m, 1H), 3.89 (ddd, J = 12.2, 2.9, 1.3 Hz, 1H), 2.41 (s, 3H), 2.00 
(dt, J = 14.3, 2.7 Hz, 1H), 1.79 (dddd, J = 14.2, 12.2, 5.3, 1.3 Hz, 1H), 1.01 – 0.95 (m, 1H), 0.94 





135.5, 131.2, 129.5, 129.2, 128.4, 127.5, 118.6, 81.8, 55.8, 31.2, 28.6, 21.8, 11.6, 9.9. HRMS 




Racemic carbamate S65 (70.3 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (5 => 15% ethyl acetate/hexanes) afforded the anti- 
diastereomer as a white solid.  
Run 1 (crude: 82%, 8.1:1 dr; isolated: 48.0 mg, 0.137 mmol, 68.7%, >20:1 dr);  
Run 2 (crude: 79%, 8.3:1 dr; isolated: 48.2 mg, 0.138 mmol, 69.0%, >20:1 dr); 
Run 3 (crude: 80%, 7.9:1 dr; isolated: 45.3 mg, 0.130 mmol, 64.8%, >20:1 dr).  
Average yield: 68%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.88 (ddd, 
J = 17.1, 10.5, 5.0 Hz, 1H), 5.44 – 5.31 (m, 2H), 5.22 – 5.15 (m, 1H), 4.17 (ddd, J = 11.0, 7.6, 2.9 
Hz, 1H), 2.42 (s, 3H), 2.05 – 1.92 (m, 3H), 1.86 – 1.76 (m, 1H), 1.71– 1.45 (m, 5H), 1.39 – 1.30 
(m, 1H), 1.23 – 1.12 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 148.7, 145.0, 135.8, 135.7, 
129.5, 129.2, 118.6, 79.5, 56.2, 44.3, 32.2, 28.6, 28.4, 25.5, 25.4, 21.8. HRMS (ESI) m/z 









Racemic carbamate S66 (83.5 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (5 => 20% ethyl acetate/hexanes) afforded the anti- 
diastereomer as a white solid.  
Run 1 (crude: 74%, 5.4:1 dr; isolated: 45.0 mg, 0.108 mmol, 54.1%, >20:1 dr);  
Run 2 (crude: 77%, 5.2:1 dr; isolated: 42.0 mg, 0.101 mmol, 50.5%, >20:1 dr); 
Run 3 (crude: 76%, 5.2:1 dr; isolated: 43.4 mg, 0.104 mmol, 52.2%, >20:1 dr).  
Average yield: 52%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.91 – 
5.82 (m, 1H), 5.43 – 5.30 (m, 2H), 5.24 – 5.17 (m, 1H), 3.88 (dd, J = 11.7, 3.5 Hz, 1H), 2.42 (s, 
3H), 2.04 – 1.91 (m, 5H), 1.74 – 1.66 (m, 3H), 1.64 – 1.56 (m, 6H), 1.50 – 1.42 (m, 3H). 13C NMR 
(126 MHz, Chloroform-d) δ 149.0, 145.0, 135.7, 129.5, 129.3, 118.7, 83.3, 55.9, 37.5, 37.0, 35.6, 
28.1, 26.7, 21.8. (one peak missing due to overlapping) HRMS (ESI) m/z calculated for 












(83). Racemic carbamate S67 (93.3 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (5 => 35% ethyl acetate/hexanes) afforded the anti- 
diastereomer as a white solid.  
Run 1 (crude: 74%, 6.0:1 dr, isolated: 50.5 mg, 0.109 mmol, 54.3%, >20:1 dr);  
Run 2 (crude: 74%, 5.7:1 dr, isolated: 52.1 mg, 0.112 mmol, 56.1%, >20:1 dr);  
Run 3 (crude: 76%, 5.8:1 dr, isolated: 51.8 mg, 0.111 mmol, 55.7%, >20:1 dr).  
Average yield: 55%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.86 (ddd, 
J = 17.1, 10.5, 4.9 Hz, 1H), 5.43 – 5.31 (m, 2H), 5.22 (td, J = 4.8, 2.4 Hz, 1H), 4.19 – 4.00 (m, 
3H), 2.63-2.59 (m, 2H), 2.42(s, 3H), 2.01 (dt, J = 14.0, 2.9 Hz, 1H), 1.93 (ddd, J = 14.0, 11.9, 5.1 
Hz, 1H), 1.84 (d, J = 12.8 Hz, 1H), 1.65 (dtd, J = 13.5, 7.5, 3.3 Hz, 1H), 1.53 (dt, J = 12.8, 3.1 Hz, 
1H), 1.43 (s, 9H), 1.22-1.16 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 154.7, 148.4, 145.2, 135.5, 
135.4, 129.5, 129.3, 118.9, 79.7, 78.9, 55.9, 43.3, 40.5, 30.2, 28.5, 27.1, 21.8. HRMS (ESI) m/z 





Racemic carbamate S68 (93.9 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (10 => 25% ethyl acetate/hexanes) afforded the anti- 






Run 1 (crude: 89%, 7.9:1 dr; isolated: 69.9 mg, 0.144 mmol, 74.7%, >20:1 dr);  
Run 2 (crude: 84%, 8.3:1 dr; isolated: 66.6 mg, 0.142 mmol, 71.2%, >20:1 dr); 
Run 3 (crude: 86%, 8.0:1 dr; isolated: 69.1 mg, 0.145 mmol, 73.9%, >20:1 dr).  
Average yield: 73%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.88 (ddd, 
J = 17.1, 10.5, 4.9 Hz, 1H), 5.40 (dd, J = 10.6, 1.5 Hz, 1H), 5.36 (dd, J = 17.1, 1.6 Hz, 1H), 5.21 
– 5.16 (m, 1H), 4.36 (dddd, J = 12.2, 7.8, 5.0, 2.9 Hz, 1H), 3.56 (t, J = 6.1 Hz, 2H), 2.41 (s, 3H), 
2.01 (dt, J = 14.2, 2.7 Hz, 1H), 1.91 (ddd, J = 14.1, 11.8, 5.2 Hz, 1H), 1.72 – 1.62 (m, 1H), 1.59 – 
1.51 (m, 1H), 1.51 – 1.42 (m, 3H), 1.42 – 1.31 (m, 1H), 0.86 (s, 9H), 0.01 (s, 6H). 13C NMR (126 
MHz, Chloroform-d) δ 148.6, 145.1, 135.7, 135.6, 129.5, 129.3, 118.7, 75.8, 62.8, 56.2, 34.8, 32.8, 
32.4, 26.1, 21.8, 21.1, 18.4, -5.2. HRMS (ESI) m/z calculated for C23H38NO5SSi [M+H]+: 
468.2240, found 468.2234. 
 
 
(±)-(4S,6R)-6-(4-hydroxybutyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (85). Racemic carbamate 
S69 (71.1 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (20 => 60%  ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid (Solvent was very difficult to remove. Ethyl acetate is integrated out when reporting yield.).  
Run 1 (crude: 85%, 8.5:1 dr; isolated: 49.9 mg, 0.141 mmol, 70.6%, >20:1 dr);  
Run 2 (crude: 89%, 8.3:1 dr; isolated: 53.5 mg, 0.151 mmol, 75.7%, >20:1 dr);  
Run 3 (crude: 88%, 8.9:1 dr; isolated: 49.8 mg, 0.141 mmol, 70.4%, >20:1 dr).  






1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 7.8 Hz, 2H), 5.88 
(ddd, J = 17.1, 10.5, 4.9 Hz, 1H), 5.41 (dd, J = 10.5, 1.5 Hz, 1H), 5.36 (dd, J = 17.1, 1.6 Hz, 1H), 
5.23 – 5.15 (m, 1H), 4.38 (dddd, J = 11.9, 7.8, 4.6, 3.0 Hz, 1H), 3.62 (t, J = 6.0 Hz, 2H), 2.42 (s, 
3H), 2.04 – 1.99 (m, 1H), 1.94 (ddd, J = 14.2, 11.7, 5.2 Hz, 1H), 1.74 – 1.64 (m, 1H), 1.64 – 1.47 
(m, 4H), 1.46 – 1.36 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 148.6, 145.1, 135.7, 135.7, 
129.6, 129.3,  118.8, 75.8, 62.6, 56.2, 34.8, 32.9, 32.3, 21.8, 21.1. HRMS (ESI) m/z calculated 
for C17H24NO5S [M+H]+: 354.1375, found 354.1384. 
 
 
(±)-(4S,6R)-6-phenethyl-3-tosyl-4-vinyl-1,3-oxazinan-2-one (86). Racemic carbamate S70 
(77.5 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 30% ethyl acetate/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude: 84%, 7.5:1 dr; isolated: 54.8 mg, 0.142 mmol, 71.1%, >20:1 dr);  
Run 2 (crude: 87%, 7.2:1 dr; isolated: 54.7 mg, 0.142 mmol, 70.9%, >20:1 dr);  
Run 3 (crude: 88%, 7.2:1 dr; isolated: 53.1 mg, 0.138 mmol, 68.9%, >20:1 dr).  
Average yield: 70%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.93 (d, J = 8.4 Hz, 2H),  7.32 (d, J = 8.2 Hz, 2H), 7.30-
7.25 (m, 2H), 7.23-7.17 (m, 1H), 7.15 (d, J = 7.2 Hz, 2H), 5.87 (ddd, J = 17.1, 10.5, 5.0 Hz, 1H), 
5.41-5.34 (m, 2H), 5.23 - 5.18 (m, 1H), 4.43 -4.38 (m, 1H), 2.81 (ddd, J = 13.9, 9.8, 5.5 Hz 1H), 
2.68 (ddd, J = 13.8, 9.5, 6.7 Hz, 1H), 2.44 (s, 3H), 2.06-1.92 (m, 3H), 1.89 – 1.78 (m, 1H). 13C 






126.3, 118.7, 75.0, 56.2, 36.8, 32.9, 31.0, 21.8. HRMS (ESI) m/z calculated for C21H24NO4S 




Racemic carbamate S71 (98.4 mg, 0.20 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (10 => 20% ethyl acetate/hexanes) afforded the anti- 
diastereomer as a white solid.  
Run 1 (crude: 89%, 8.0:1 dr; isolated :76.2 mg, 0.156 mmol, 78%, >20:1 dr);  
Run 2 (crude: 93%, 8.0:1 dr; isolated: 71.0 mg, 0.145 mmol, 73%, >20:1 dr);  
Run 3 (crude: 90%, 7.8:1 dr; isolated: 72.3 mg, 0.148 mmol, 74%, >20:1 dr).  
Average yield: 75%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.3 Hz, 2H), 5.87 (ddd, 
J = 17.1, 10.5, 4.8 Hz, 1H), 5.42 – 5.33 (m, 2H), 5.24 – 5.18 (m, 1H), 4.68 – 4.57 (m, 1H), 2.49 – 
2.43 (m, 1H), 2.43 (s, 3H), 2.36 (dt, J = 17.2, 6.1 Hz, 1H), 2.08 (dt, J = 14.1, 2.7 Hz, 1H), 1.96 
(ddd, J = 14.1, 12.0, 5.1 Hz, 1H), 1.88 (ddt, J = 14.3, 8.3, 6.0 Hz, 1H), 1.71 (dddd, J = 13.5, 8.7, 
6.1, 4.4 Hz, 1H), 1.07 – 0.94 (m, 21H). 13C NMR (126 MHz, Chloroform-d) δ 148.4, 145.2, 135.5, 
135.4, 129.6, 129.3, 118.9, 106.6, 81.9, 74.4, 56.2, 34.2, 32.8, 21.8, 18.8, 15.7, 11.3. HRMS (ESI) 









oxazinan-6-yl)ethyl)carbamate (88). Racemic carbamate S72 (111.4 mg, 0.20 mmol) was 
reacted according to the general procedure. Purification by flash chromatography (10 => 30% ethyl 
acetate/hexanes) afforded the anti- diastereomer as a white solid.  
Run 1 (crude: 92%, 7.2:1 dr; isolated :90.9 mg, 0.164 mmol, 81.9%, >20:1 dr);  
Run 2 (crude: 91%, 7.4:1 dr; isolated: 85.7 mg, 0.154 mmol, 77.2%, >20:1 dr);  
Run 3 (crude: 90%, 7.2:1 dr; isolated: 89.1 mg, 0.161 mmol, 80.3%, >20:1 dr).  
Average yield: 80%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 7.9 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 5.89 (ddd, 
J = 17.1, 10.6, 4.3 Hz, 1H), 5.47 – 5.35 (m, 2H), 5.25-5.21 (m, 1H), 4.94 (d, J = 9.1 Hz, 1H), 4.38 
(app q, J = 8.1 Hz, 1H), 3.97 – 3.92 (m, 1H), 3.64-3.62 (m, 1H), 3.58 (dd, J = 10.3, 3.3 Hz, 1H), 
2.43 (s, 3H), 2.15 – 2.04 (m, 2H), 1.44 (s, 9H), 0.85 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 155.6, 148.0, 145.2, 135.6, 135.6, 129.4, 129.3, 118.6, 80.3, 73.9, 61.0, 56.4, 
54.1, 30.0, 28.5, 25.9, 21.8, 18.3, -5.4, -5.4. HRMS (ESI) m/z C26H43N2O7SSi [M+H]+: 555.2560, 













(+)-(4S,6S)-6-((R)-3-oxopentan-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (89). Racemic 
carbamate S73 (73.1 mg, 0.20 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (5 => 25% acetone/hexanes) afforded the anti- diastereomer as a white 
solid.  
Run 1 (crude:74%, 13:1 dr; isolated: 49.0 mg, 0.134 mmol, 67.0%, >20:1 dr);  
Run 2 (crude:76%, 12:1 dr; isolated: 48.5 mg, 0.133 mmol, 66.4%, >20:1 dr); 
Run 3 (crude:77%, 13:1 dr; isolated: 53.1 mg, 0.145 mmol, 72.7%, >20:1 dr).  
Average yield: 69%, >20:1 dr (anti:syn). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.88 (ddd, 
J = 17.1, 10.5, 4.9 Hz, 1H), 5.42 (dd, J = 10.6, 1.5 Hz, 1H), 5.34 (dd, J = 17.1, 1.6 Hz, 1H), 5.18 
(app tt, J = 5.0, 2.1 Hz, 1H), 4.53 (ddd, J = 12.0, 7.6, 2.8 Hz, 1H), 2.76 (app p, J = 7.2 Hz, 1H), 
2.55 (dq, J = 18.1, 7.2 Hz, 1H), 2.46 – 2.35 (m, 1H), 2.42 (s, 3H), 2.08 (dt, J = 14.0, 2.6 Hz, 1H), 
1.90 (ddd, J = 14.0, 12.0, 5.2 Hz, 1H), 1.19 (d, J = 7.1 Hz, 3H), 1.00 (t, J = 7.2 Hz, 3H).13C NMR 
(126 MHz, CDCl3) δ 211.9, 148.3, 145.2, 135.4, 135.2, 129.5, 129.3, 118.9, 76.7, 56.0, 49.8, 36.0, 
30.5, 21.8, 13.3, 7.6. HRMS (ESI) m/z calculated for C18H23NO5S [M+Na]+: 366.1375, found 
366.1375. Optical rotation: [α]23D = +6.8 (c = 1.02, CHCl3). 
Complete stereoretention of acidic methyl containing stereocenter  (α to ketone) was proven by 1H 
NMR analysis. If the stereocenter (α to ketone) in 89 was isomerized under our reaction condition, 
we would see 89c (inverse stereochemistry at the methyl containing stereocenter α to ketone) in 










(±)-(4S,6S)-6-((S)-3-oxopentan-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (89c) was synthesized 
following reported procedure of anti-Aldol reaction24 using using pent-4-enal, tert-butyl ester 
hydrolysis25, ketone synthesis through Weinreb amide26 (also see synthesis of S73), N-tosyl 
carbamate synthesis following the general procedure (vide infra) and general procedure of anti- 
oxazinanone (vide infra) to afford 89c as a white solid. 
 
1H NMR (500 MHz, Chloroform-d) δ 7.89 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 5.88 (ddd, 
J = 17.1, 10.5, 5.1, 1H), 5.41 (dd, J = 10.5, 1.5 Hz, 1H), 5.32 (dd, J = 17.0, 1.6 Hz, 1H), 5.26 – 
5.19 (m, 1H), 4.63 (ddd, J = 12.2, 7.7, 2.7 Hz, 1H), 2.82 (app p, J = 7.3, 1H), 2.54 – 2.46 (m, 2H), 






















1) c-Hex2BOTf, Et3N, 







































NMR (126 MHz, CDCl3) δ 211.7, 147.9, 145.2, 135.4, 135.1, 129.6, 129.3, 119.1, 77.0, 55.9, 49.4, 
36.4, 30.2, 21.8, 12.3, 7.4. HRMS (ESI) m/z calculated for C18H23NO5S [M+Na]+: 366.1375, 
found 366.1373.  
 




















Details of the crystal data and a summary of the intensity data for (±)-89c are listed in Table 9. 
CCDC: 1899081 
 
Table 9.  Crystal Data and Structure Refinement for (±)-89c 
Identification code  dm07tsa 
Empirical formula  C20.15 H27.88 Cl1.42 N O5 S 
Formula weight  446.67 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.9675(3) Å a= 80.064(2)°. 
 b = 11.0636(5) Å b= 89.981(2)°. 
 c = 16.9266(8) Å g = 75.078(2)°. 
Volume 1062.50(9) Å3 
Z 2 
Density (calculated) 1.396 Mg/m3 
Absorption coefficient 0.363 mm-1 
F(000) 472 
Crystal size 0.257 x 0.180 x 0.075 mm3 
Theta range for data collection 1.936 to 27.184°. 
Index ranges -7<=h<=7, -14<=k<=14, -21<=l<=21 
Reflections collected 32605 
Independent reflections 4701 [R(int) = 0.0430] 
Completeness to theta = 25.242° 99.7 %  
Absorption correction Integration 
Max. and min. transmission 0.9966 and 0.8700 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4701 / 124 / 305 
Goodness-of-fit on F2 1.057 
Final R indices [I>2sigma(I)] R1 = 0.0644, wR2 = 0.1853 
R indices (all data) R1 = 0.0715, wR2 = 0.1951 
Extinction coefficient n/a 






Reaction Scope (Syn) 
General procedure for syn-1,3 oxazinanone: 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO-SOX 
ligand (6.9 mg, 0.02 mmol, 0.1 equiv), 1,4 benzoquinone (BQ) (34.6 mg,  0.32mmol, 1.6 equiv), 
N-tosyl carbamate (0.2 mmol, 1.0 equiv), and dichloroethane (0.3 mL, 0.67 M). The vial was 
capped and heated to 45 °C for 24 hours. The vial was allowed to cool to room temperature and 
diluted with 1 mL acetone. The reaction mixture was filtered through a pipette silica plug into a 
20 mL vial with acetone. The mixture was concentrated under reduced pressure, diluted with 2 mL 
CDCl3 and analyzed by crude 1H NMR with internal standard (nitrobenzene, 12.3 mg, 0.1 mmol, 
0.5 equiv). The mixture was then concentrated under reduced pressure and dissolved in 30 mL 
diethyl ether and washed sequentially with 1M aq. NaOH (10 mL) and sat. aq. NaHSO3 (10 mL) 
(repeat this wash sequence for 3 times).  The organic layer was dried over MgSO4, concentrated 
under reduced pressure and subjected to flash column chromatography (ethyl acetate in hexanes) 




(±)-(4R,6S)-6-(4-methoxyphenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (90). Racemic carbamate 
S48 (77.9 mg, 0.2 mmol) was reacted according to the general procedure addition of Ph2P(O)OH 
(4.4 mg, 0.02 mmol, 0.1 equiv). Purification by flash chromatography (10 => 30% ethyl 
acetate/hexanes) afforded the anti-diastereomer as a yellow oil.  






Run 2 (crude: 68%, 6.3:1 dr; isolated: 42.7 mg, 0.110 mmol, 55.1%, >20:1 dr);  
Run 3 (crude: 66%, 6.2:1 dr; isolated: 41.2 mg, 0.106 mmol, 53.2%, >20:1 dr).  
Average yield: 54%, >20:1 dr (syn:anti). 
 
1H NMR (500 MHz, Chloroform-d) δ 8.01 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.24 (d, J 
= 8.8 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.59 (ddd, J = 16.9, 10.1, 8.1 Hz, 1H), 5.40 (d, J = 17.0 
Hz, 1H), 5.29 – 5.20 (m, 2H), 5.05 (dt, J = 9.7, 8.0 Hz, 1H), 3.80 (s, 3H), 2.52 (ddd, J = 14.4, 8.0, 
2.3 Hz, 1H), 2.44 (s, 3H), 2.07 (ddd, J = 14.3, 11.3, 9.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
160.2, 150.3, 145.1, 136.8, 136.0, 129.8, 129.3, 128.9, 127.7, 119.0, 114.3, 77.5, 59.1, 55.5, 38.2, 
21.8. HRMS (ESI) m/z calculated for C20H21NO5S [M+H]+: 388.1219, found 388.1217. Spectra 
match literature report.23 
 
 
(±)-(4R,6S)-6-(4-bromophenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (91). Racemic carbamate 
S50 (87.7 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 20% ethyl acetate/hexanes) afforded the syn- diastereomer as a white 
solid.  
Run 1 (crude: 82%, 6.7:1 dr; isolated: 54.0 mg, 0.124 mmol, 61.9%, >20:1 dr);  
Run 2 (crude: 83%, 6.8:1 dr; isolated: 54.5 mg, 0.125 mmol, 62.5%, >20:1 dr);  
Run 3 (crude: 86%, 6.1:1 dr; isolated: 56.6 mg, 0.130 mmol, 64.9%, >20:1 dr).  







1H NMR (500 MHz, Chloroform-d) δ 8.01 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.31 (d, 
J = 8.1 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 5.57 (ddd, J = 17.0, 10.1, 8.1 Hz, 1H), 5.40 (d, J = 17.0 
Hz, 1H), 5.27-5.23 (m, 2H), 5.07 (dt, J = 9.6, 8.0 Hz, 1H), 2.55 (ddd, J = 14.5, 7.9, 2.5 Hz, 1H), 
2.44 (s, 3H), 2.02 (ddd, J = 14.5, 11.1, 9.6 Hz, 1H).13C NMR (126 MHz, CDCl3) δ 149.9, 145.2, 
136.5, 136.0, 135.8, 132.1, 129.9, 129.3, 127.7, 123.1, 119.3, 58.9, 38.2, 29.9, 21.8. HRMS (ESI) 
m/z calculated for C19H18BrNO4S [M+H]+: 436.0218, found 436.0208. Spectra match literature 
report.23 
 
(±)-Methyl 4-((4R,6S)-2-oxo-3-tosyl-4-vinyl-1,3-oxazinan-6-yl)benzoate (92). Racemic 
carbamate S53 (83.5 mg, 0.2 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (5 => 25% ethyl acetate/hexanes) afforded the syn- diastereomer as a 
white solid.  
Run 1 (crude: 70%, 5.9:1 dr; isolated: 44.1 mg, 0.106 mmol, 53.1%, >20:1 dr);  
Run 2 (crude: 71%, 5.6:1 dr; isolated: 43.9 mg, 0.106 mmol, 52.8%, >20:1 dr);  
Run 3 (crude: 67%, 6.1:1 dr; isolated: 42.5 mg, 0.102 mmol, 51.1%, >20:1 dr).  
Average yield: 52%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.05 (d, J = 8.5 Hz, 2H), 8.01 (d, J = 8.5 Hz, 2H), 7.41 (d, 
J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 5.56 (dddd, J = 16.8, 9.8, 8.0, 1.1 Hz, 1H), 5.43 – 5.33 
(m, 2H), 5.25 (d, J = 10.1 Hz, 1H), 5.13 – 5.07 (m, 1H), 3.92 (s, 3H), 2.60 (dddd, J = 14.4, 7.8, 






166.6, 149.8, 145.2, 141.8, 136.5, 135.8, 130.8, 130.2, 129.9, 129.4, 125.9, 119.3, 77.0, 58.9, 52.4, 
38.2, 21.8. HRMS (ESI) m/z calculated for C21H23NO6S [M+H]+: 416.1168, found 416.1172. 
 
 
(±)-(4S,6S)-6-(2-bromophenyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (93). Racemic carbamate 
S54 (87.6 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (5 => 20% ethyl acetate/hexanes) afforded the syn- diastereomer as a white 
solid.  
Run 1 (crude: 71%, 9.0:1 dr; isolated: 52.5 mg, 0.120 mmol, 60.2%, >20:1 dr);  
Run 2 (crude: 69%, 9.2:1 dr; isolated: 50.7 mg, 0.116 mmol, 58.1%, >20:1 dr);  
Run 3 (crude: 72%, 8.9:1 dr; isolated: 55.0 mg, 0.126 mmol, 63.0%, >20:1 dr). 
Average yield: 60%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.03 (d, J = 8.3 Hz, 2H), 7.55 (dd, J = 8.0, 1.2 Hz, 1H), 7.49 
(dd, J = 7.9, 1.6 Hz, 1H), 7.37 – 7.30 (m, 3H), 7.20 (td, J = 7.7, 1.7 Hz, 1H), 5.63 – 5.55 (m, 2H), 
5.43 (d, J = 17.2 Hz, 1H), 5.27 (d, J = 10.1 Hz, 1H), 5.10 (dt, J = 9.7, 7.9 Hz, 1H), 2.72 (ddd, J = 
14.5, 7.8, 2.3 Hz, 1H), 2.44 (s, 3H), 1.84 (ddd, J = 14.4, 10.9, 9.9 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 150.1, 145.2, 136.5, 136.4, 135.9, 133.0, 130.2, 129.9, 129.3, 128.2, 127.4, 121.1, 119.3, 









(±)-(4R,6S)-6-(naphthalen-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (94). Racemic carbamate 
S55 (81.9 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 25% ethyl acetate/hexanes) afforded the syn- diastereomer as a white 
solid.  
Run 1 (crude: 74%, 6.2:1 dr; isolated: 46.7 mg, 0.114 mmol, 57.2%, >20:1 dr);  
Run 2 (crude: 72%, 5.9:1 dr; isolated: 45.8 mg, 0.112 mmol, 56.1%, >20:1 dr);  
Run 3 (crude: 71%, 6.5:1 dr; isolated: 45.2 mg, 0.111 mmol, 55.3%, >20:1 dr).  
Average yield: 56%, >20:1 dr (syn:anti). 
 
1H NMR (500 MHz, Chloroform-d) δ 8.04 (d, J = 8.4 Hz, 2H), 7.89 – 7.79 (m, 4H), 7.51 (dt, J = 
6.2, 3.4 Hz, 2H), 7.40 (dd, J = 8.5, 1.8 Hz, 1H), 7.33 (d, J = 8.1 Hz, 2H), 5.61 (ddd, J = 17.0, 10.1, 
8.1 Hz, 1H), 5.46 (dd, J = 11.0, 2.4 Hz, 1H), 5.42 (d, J = 17.0 Hz, 1H), 5.25 (d, J = 10.1 Hz, 1H), 
5.12 (dt, J = 9.6, 8.0 Hz, 1H), 2.65 (ddd, J = 14.4, 7.9, 2.5 Hz, 1H), 2.44 (s, 3H), 2.21 – 2.12 (m, 
1H). 13C NMR (126 MHz, CDCl3) δ 150.2, 145.1, 136.7, 135.9, 134.2, 133.5, 133.1, 129.8, 129.3, 
128.9, 128.3, 127.9, 126.8, 126.8, 125.4, 123.3, 119.2, 77.7, 59.1, 38.3, 21.8. HRMS (ESI) m/z 











(±)-(4R,6S)-3-tosyl-6-(1-tosyl-1H-indol-5-yl)-4-vinyl-1,3-oxazinan-2-one (95). Racemic 
carbamate S57 (110.3 mg, 0.2 mmol) was reacted according to the general procedure for syn-1,3 
amino alcohol. Purification by flash chromatography (5 => 25% acetone/hexanes) afforded the 
syn- diastereomer as a white solid.  
Run 1 (crude: 65%, 4.4:1 dr; isolated:55.6 mg, 0.101 mmol, 50.5%, >20:1 dr);  
Run 2 (crude: 67%, 4.3:1 dr; isolated:57.5 mg, 0.104 mmol, 52.2%, >20:1 dr);  
Run 3 (crude: 64%, 4.6:1 dr; isolated:56.5 mg, 0.103 mmol, 51.3%, >20:1 dr).  
Average yield: 51%, >20:1 dr (syn:anti). Major syn-diasteromer:  
 
1H NMR (500 MHz, Chloroform-d) δ 8.01 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.7 Hz, 1H), 7.73 (d, 
J = 8.5 Hz, 2H), 7.58 (d, J = 3.7 Hz, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.31 (d, J = 8.1 Hz, 2H), 7.24 
(dd, J = 8.7, 1.8 Hz, 1H), 7.21 (d, J = 8.1 Hz, 2H), 6.63 (d, J = 3.7 Hz, 1H), 5.57 (ddd, J = 16.9, 
10.0, 8.1 Hz, 1H), 5.40 (d, J = 17.0 Hz, 1H), 5.33 (dd, J = 11.3, 2.2 Hz, 1H), 5.24 (d, J = 10.0 Hz, 
1H), 5.06 (app dt, J = 9.8, 8.0 Hz, 1H), 2.54 (ddd, J = 14.4, 7.9, 2.2 Hz, 1H), 2.43 (s, 3H), 2.33 (s, 
3H), 2.08 (ddd, J = 14.4, 11.3, 9.9 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 150.2, 145.3, 
145.1, 136.6, 135.9, 135.0, 135.0, 131.9, 130.1, 130.0, 129.8, 129.3, 127.4, 126.9, 122.7, 119.3, 
119.2, 113.9, 109.1, 77.7, 59.1, 38.4, 21.8, 21.7. HRMS (ESI) m/z calculated for C28H26N2O6S2 
[M+H]+: 551.1311, found 551.1299. 
 
 
(±)-(4R,6S)-6-(benzo[b]thiophen-5-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (96). Racemic 






by flash chromatography (10 => 25% ethyl acetate/hexanes) afforded the syn- diastereomer as a 
white solid.  
Run 1 (crude: 89%, 4.3:1 dr; isolated: 51.4 mg, 0.124 mmol, 62.2%, >20:1 dr);  
Run 2 (crude: 86%, 4.0:1 dr; isolated: 54.1 mg, 0.131 mmol, 65.4%, >20:1 dr);  
Run 3 (crude: 88%, 4.1:1 dr; isolated: 51.1 mg, 0.124 mmol, 61.8%, >20:1 dr). 
Average yield: 63%, >20:1 dr (syn:anti). 
 
1H NMR (500 MHz, Chloroform-d) δ 8.03 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.4, 0.8 Hz, 1H), 7.80 
(d, J = 1.8 Hz, 1H), 7.49 (d, J = 5.5 Hz, 1H), 7.34 – 7.30 (m, 3H), 7.28 (dd, J = 8.4, 1.7 Hz, 1H), 
5.60 (ddd, J = 17.0, 10.1, 8.1 Hz, 1H), 5.44 – 5.39 (m, 2H), 5.25 (dd, J = 10.1, 0.8 Hz, 1H), 5.10 
(dt, J = 9.9, 8.0 Hz, 1H), 2.61 (ddd, J = 14.5, 7.9, 2.4 Hz, 1H), 2.44 (s, 3H), 2.14 (ddd, J = 14.4, 
11.1, 9.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 150.2, 145.1, 140.3, 139.8, 136.7, 136.0, 133.1, 
129.8, 129.3, 127.8, 124.0, 123.1, 122.0, 121.3, 119.1, 77.8, 59.1, 38.6, 21.8. HRMS (ESI) m/z 
calculated for C21H20NO4S2 [M+H]+: 414.0834, found 414.0842. 
 
 
(±)-(4R,6S)-6-(benzofuran-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (97). Racemic carbamate 
S59 (110.3 mg, 0.2 mmol) was reacted according to the general procedure for syn-1,3 amino 
alcohol. Purification by flash chromatography (5 => 25% acetone/hexanes) afforded the syn- 
diastereomer as a white solid.  
Run 1 (crude: 85%, 2.5:1 dr; isolated:40.1 mg, 0.101 mmol, 50.4%, >20:1 dr);  






Run 3 (crude: 87%, 2.5:1 dr; isolated:41.2 mg, 0.104 mmol, 51.8%, >20:1 dr).  
Average yield: 52%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.00 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.45 (dd, 
J = 8.3, 1.0 Hz, 1H), 7.34 – 7.29 (m, 3H), 7.25 – 7.22 (m, 1H), 6.77 (s, 1H), 5.60 (ddd, J = 17.0, 
10.1, 7.8 Hz, 1H), 5.49 (dd, J = 9.3, 3.3 Hz 1H), 5.39 (app d, J = 16.9 Hz, 1H), 5.21 (app d, J = 
10.1 Hz, 1H), 5.14 (app q, J = 7.9 Hz, 1H), 2.71 (ddd, J = 14.5, 7.8, 3.3 Hz, 1H), 2.52 – 2.45 (m, 
1H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 155.1, 151.6, 149.2, 145.3, 136.2, 135.7, 129.8, 
129.4, 127.6, 125.3, 123.4, 121.7, 119.2, 111.6, 105.9, 71.8, 58.3, 33.8, 21.8. HRMS (ESI) m/z 
calculated for C21H20NO5S [M+H]+: 398.1062, found 398.1051. 
 
 
(±)-(4S,6S)-6-methyl-3-tosyl-4-vinyl-1,3-oxazinan-2-one (98). Racemic carbamate S62 (59.5 
mg, 0.20 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 25%  ethyl acetate/hexanes) afforded the syn-diastereomer as a white solid.  
Run 1 (crude: 86%, 8.1:1 dr; isolated: 42.0 mg, 0.142 mmol, 71.1%, >20:1 dr);  
Run 2 (crude: 91%, 8.1:1 dr; isolated: 47.0 mg, 0.159 mmol, 79.6%, >20:1 dr);  
Run 3 (crude: 92%, 7.8:1 dr; isolated: 48.2 mg, 0.163 mmol, 81.6%, >20:1 dr).  
Average yield: 77%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.59 (ddd, 
J = 17.3, 10.1, 7.9 Hz, 1H), 5.36 (d, J = 17.0 Hz, 1H), 5.24 (d, J = 10.1 Hz, 1H), 4.94 (app q., J = 





1H), 1.71 (ddd, J = 14.3, 10.7, 9.6 Hz, 1H), 1.35 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, 
Chloroform-d) δ 150.32, 144.95, 137.00, 136.05, 129.71, 129.24, 118.70, 73.05, 58.76, 37.59, 
21.78, 20.18. HRMS (ESI) m/z calculated for C14H18NO4S [M+H]+: 296.0951, found 296.0957. 
 
 
(±)-(4R,6S)-6-(1-phenylcyclopropyl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (99).  
Racemic carbamate S64 (79.9 mg, 0.2 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (5 => 15% ethyl acetate/hexanes) afforded the syn- 
diastereomer as a white solid.  
Run 1 (crude: 90%, 7.8:1 dr; isolated: 57.0 mg, 0.143 mmol, 71.7%, >20:1 dr);  
Run 2 (crude: 90%, 7.6:1 dr; isolated: 56.8 mg, 0.143 mmol, 71.4%, >20:1 dr);  
Run 3 (crude: 86%, 8.1:1 dr; isolated: 53.7 mg, 0.135 mmol, 67.5%, >20:1 dr). 
Average yield: 70%, >20:1 dr (syn:anti). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.31 – 
7.26 (m, 5H), 5.42 – 5.29 (m, 2H), 5.17 (dd, J = 9.3, 1.5 Hz, 1H), 4.82 (dt, J = 10.4, 7.8 Hz, 1H), 
3.84 (dd, J = 11.6, 1.9 Hz, 1H), 2.42 (s, 3H), 2.31 (ddd, J = 14.4, 8.0, 1.9 Hz, 1H), 1.50 (ddd, J = 
14.3, 11.5, 10.4 Hz, 1H), 1.09 – 1.00 (m, 1H), 0.99 – 0.90 (m, 3H). 13C NMR (126 MHz, CDCl3) 
δ 150.3, 144.9, 139.3, 136.8, 136.1, 131.3, 129.8, 129.2, 128.4, 127.6, 118.9, 82.1, 59.1, 34.5, 28.0, 









(100). Racemic carbamate S67 (92.9 mg, 0.2 mmol) was reacted according to the general 
procedure. Purification by flash chromatography (5 => 35% ethyl acetate/hexanes) afforded the 
syn- diastereomer as a white solid.  
Run 1 (crude: 71%, 5.5:1 dr, isolated: 53.2 mg, 0.109 mmol, 57.2%, >20:1 dr); 
Run 2 (crude: 71%, 5.0:1 dr, isolated: 52.4 mg, 0.112 mmol, 56.4%, >20:1 dr);  
Run 3 (crude: 73%, 5.3:1 dr, isolated: 54.2 mg, 0.111 mmol, 58.3%, >20:1 dr).  
Average yield: 53%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 5.55 (ddd, 
J = 16.8, 10.0, 8.1 Hz, 1H), 5.37 (app d, J = 16.9, 1H), 5.24 (app d, J = 10.0, 1H), 4.90 (dt, J = 9.4, 
8.0 Hz, 1H), 4.24 – 4.09 (m, 2H), 4.06-4.02 (m, 1H), 2.68 – 2.58 (m, 2H), 2.43 (s, 3H), 2.32 (dd, 
J = 13.8, 7.7 Hz, 1H), 1.85 (d, J = 13.1 Hz, 1H), 1.74 – 1.66 (m, 2H), 1.59-1.52 (m, 1H), 1.45 (s, 
9H), 1.32 – 1.17 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 154.8, 150.4, 145.0, 136.9, 136.1, 129.8, 
129.3, 118.9, 79.8, 79.5, 58.8, 43.7, 39.7, 33.4, 28.6, 27.2, 21.8. HRMS (ESI) m/z calculated for 












(101). Racemic carbamate S68 (93.9 mg, 0.20 mmol) was reacted according to the general 
procedure. Purification by flash chromatography (10 => 25% ethyl acetate/hexanes) afforded the 
syn- diastereomer as a white solid.  
Run 1 (crude: 72%, 7.3:1 dr; isolated: 54.1 mg, 0.115 mmol, 55.7%, >20:1 dr);  
Run 2 (crude: 74%, 7.4:1 dr; isolated: 53.4 mg, 0.113 mmol, 56.9%, >20:1 dr);  
Run 3 (crude: 73%, 7.4:1 dr; isolated: 50.9 mg, 0.108 mmol, 54.2%, >20:1 dr).  
Average yield: 56%, >20:1 dr (syn:anti). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.56 (ddd, 
J = 17.0, 10.1, 8.1 Hz, 1H), 5.37 (app d, J = 16.9 Hz, 1H), 5.23 (app d, J = 10.0 Hz, 1H), 4.92 (dt, 
J = 9.7, 8.1 Hz, 1H), 4.24 (dddd, J = 10.9, 7.5, 5.1, 2.2 Hz, 1H), 3.59 (t, J = 6.0 Hz, 2H), 2.42 (s, 
3H), 2.32 (ddd, J = 14.3, 8.0, 2.3 Hz, 1H), 1.76 – 1.63 (m, 3H), 1.63 – 1.54 (m, 1H), 1.50 (ddt, J 
= 12.8, 9.5, 5.2 Hz, 2H), 1.44 – 1.35 (m, 1H), 0.88 (s, 9H), 0.03 (s, 6H).13C NMR (126 MHz, 
CDCl3) δ 150.4, 144.9, 137.0, 136.0, 129.7, 129.2, 118.8, 76.6, 62.8, 58.9, 35.9, 33.9, 32.4, 26.1, 





Racemic carbamate S69 (71.1 mg, 0.20 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (30 => 60% ethyl acetate/hexanes) afforded the syn- 






Run 1 (crude: 84%, 6.6:1 dr; isolated: 42.7 mg, 0.120 mmol, 60.1%, >20:1 dr);  
Run 2 (crude: 81%, 6.9:1 dr; isolated: 45.6 mg, 0.128 mmol, 64.2%, >20:1 dr);  
Run 3 (crude: 83%, 6.2:1 dr; isolated: 48.6 mg, 0.137 mmol, 68.4%, >20:1 dr).  
Average yield: 64%, 6.6:1 (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.57 (ddd, 
J = 16.8, 10.1, 8.0 Hz, 1H), 5.36 (app d, J = 17.0 Hz, 1H), 5.23 (app d, J = 10.1 Hz, 1H), 4.96 – 
4.89 (m, 1H), 4.25 (dddd, J = 10.7, 7.3, 4.8, 2.5 Hz, 1H), 3.64 (t, J = 6.1 Hz, 2H), 2.42 (s, 3H), 
2.33 (ddd, J = 14.2, 8.1, 2.3 Hz, 1H), 1.77 – 1.65 (m, 2H), 1.63 – 1.50 (m, 4H), 1.50 – 1.39 (m, 
1H), 1.36 – 1.28 (m, 1H).13C NMR (126 MHz, CDCl3) δ 150.4, 145.0, 137.0, 136.0, 129.7, 129.3, 
118.7, 76.5, 62.6, 58.8, 36.0, 34.0, 32.3, 21.8, 21.2. HRMS (ESI) m/z calculated for C17H24NO5S 
[M+H]+: 354.1375, found 354.1381. 
 
 
(±)-(4R,6R)-6-phenethyl-3-tosyl-4-vinyl-1,3-oxazinan-2-one (103). Racemic carbamate S70 
(77.5 mg, 0.2 mmol) was reacted according to the general procedure. Purification by flash 
chromatography (10 => 30% ethyl acetate/hexanes) afforded the syn- diastereomer as a white 
solid.  
Run 1 (crude: 84%, 6.1:1 dr; isolated: 53.4 mg, 0.139 mmol, 69.3%, >20:1 dr);  
Run 2 (crude: 83%, 6.2:1 dr; isolated: 51.4 mg, 0.133 mmol, 66.7%, >20:1 dr);  
Run 3 (crude: 81%, 6.7:1 dr; isolated: 51.2 mg, 0.133 mmol, 66.4%, >20:1 dr).  







1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 8.4 Hz, 2H), 7.32 – 7.27 (m, 4H), 7.24 – 7.19 
(m, 1H), 7.18 – 7.14 (m, 2H), 5.64 – 5.53 (m, 1H), 5.36 (app d, J = 17.0, 1H), 5.24 (app d, J = 
10.0, 1H), 4.96 – 4.87 (m, 1H), 4.23 (tdd, J = 8.0, 4.4, 2.4 Hz, 1H), 2.81 (ddd, J = 14.6, 9.6, 5.4 
Hz, 1H), 2.70 (ddd, J = 13.9, 9.3, 7.1 Hz, 1H), 2.44 (s, 3H), 2.32 (ddd, J = 14.3, 7.9, 2.4 Hz, 1H), 
2.06 – 1.96 (m, 1H), 1.85 (dddd, J = 14.2, 9.6, 7.1, 4.6 Hz, 1H), 1.74 (ddd, J = 14.3, 10.7, 9.5 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 150.4, 145.0, 140.6, 136.9, 136.0, 129.7, 129.3, 128.8, 128.5, 
126.4, 118.8, 75.7, 58.8, 36.0, 36.0, 31.0, 21.8. HRMS (ESI) m/z calculated for C21H24NO4S 




Racemic carbamate S71 (98.4 mg, 0.20 mmol) was reacted according to the general procedure. 
Purification by flash chromatography (10 => 20% ethyl acetate/hexanes) afforded the syn- 
diastereomer as a white solid (with 3% starting material).  
 
Run 1 (crude: 82%, 6.0:1 dr; isolated: 64.8 mg, 0.132 mmol, 66.1%, >20:1 dr);   
Run 2 (crude: 87%, 5.2:1 dr; isolated: 61.9 mg, 0.126 mmol, 63.2%, >20:1 dr);  
Run 3 (crude: 83%, 5.4:1 dr; isolated: 62.1 mg, 0.127 mmol, 63.4%, >20:1 dr).  
Average yield: 64%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.59 (ddd, 






J = 9.6, 7.9 Hz, 1H), 4.42 (dddd, J = 10.3, 7.5, 5.0, 2.3 Hz, 1H), 2.46 – 2.38 (m, 3H), 2.42 (s, 3H), 
1.92 (ddt, J = 14.2, 7.7, 6.5 Hz, 1H), 1.82 – 1.71 (m, 2H), 1.09 – 0.96 (m, 21H). 13C NMR (126 
MHz, CDCl3) δ 150.1, 145.0, 136.9, 135.9, 129.7, 129.3, 118.9, 106.7, 82.1, 75.3, 58.9, 35.7, 33.2, 





oxazinan-6-yl)ethyl)carbamate (105). Racemic carbamate S72 (111.4 mg, 0.20 mmol) was 
reacted according to the general procedure. Purification by flash chromatography (10 => 30% ethyl 
acetate/hexanes) afforded the syn- diastereomer as a white solid.  
Run 1 (crude: 92%, 4.4:1 dr; isolated: 79.8 mg, 0.144 mmol, 71.9%, >20:1 dr);  
Run 2 (crude: 95%, 4.1:1 dr; isolated: 85.7 mg, 0.154 mmol, 77.2%, >20:1 dr);  
Run 3 (crude: 91%, 4.1:1 dr; isolated: 78.0 mg, 0.141 mmol, 70.3%, >20:1 dr).  
Average yield: 73%, >20:1 d.r. (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 5.62 (ddd, 
J = 17.4, 10.1, 7.7 Hz, 1H), 5.34 (d, J = 17.0 Hz, 1H), 5.24 (d, J = 10.1 Hz, 1H), 4.94-4.90 (m, 
2H), 4.24 – 4.18 (m, 1H), 3.92 (dd, J = 10.4, 2.5 Hz, 1H), 3.77 – 3.68 (m, 1H), 3.62 (dd, J = 10.3, 
3.5 Hz, 1H), 2.42 (s, 3H), 2.42-2.37 (m, 1H), 1.92 (q, J = 11.0 Hz, 1H), 1.44 (s, 9H), 0.87 (s, 9H), 
0.04 (s, 3H), 0.02 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 155.4, 149.6, 144.9, 136.6, 135.8, 129.6, 











(+)-(4R,6S)-6-((R)-3-oxopentan-2-yl)-3-tosyl-4-vinyl-1,3-oxazinan-2-one (106). Racemic 
carbamate S73 (110.3 mg, 0.20 mmol) was reacted according to the general procedure. Purification 
by flash chromatography (5 => 25% acetone/hexanes) afforded the syn- diastereomer as a colorless 
oil.  
Run 1 (crude:88%, 4.9:1 dr; isolated: 48.3 mg, 0.132 mmol, 66.1%, >20:1 dr);  
Run 2 (crude:85%, 4.2:1 dr; isolated: 44.8 mg, 0.123 mmol, 61.3%, >20:1 dr);  
Run 3 (crude:87%, 4.4:1 dr; isolated: 45.7 mg, 0.125 mmol, 62.5%, >20:1 dr).  
Average yield: 63%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 5.54 (ddd, 
J = 17.1, 10.1, 8.0 Hz, 1H), 5.37 (app d, J = 17.0 Hz, 1H), 5.24 (app d, J = 10.1 Hz, 1H), 4.90 (dt, 
J = 10.0, 8.0 Hz, 1H), 4.39 (ddd, J = 10.3, 7.7, 2.1 Hz, 1H), 2.82 (app p, J = 7.2 Hz, 1H), 2.58 (dq, 
J = 18.4, 7.2 Hz, 1H), 2.50 – 2.40 (m, 1H), 2.42 (s, 3H), 2.33 (ddd, J = 14.1, 7.9, 2.1 Hz, 1H), 1.64 
(ddd, J = 14.1, 10.9, 9.8 Hz, 1H), 1.22 (d, J = 7.1 Hz, 3H), 1.03 (t, J = 7.2 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 211.8, 150.1, 145.1, 136.8, 135.9, 129.7, 129.3, 119.0, 77.2, 59.0, 49.0, 36.2, 33.9, 
21.8, 13.6, 7.6. HRMS (ESI) m/z calculated for C18H23NO5SNa [M+Na]+: 388.1195, found 








Streamlining the Synthesis of Chiral Amino Alcohol Motifs to Vitamin D3 Derivatives. 
Scheme 14. Synthesis of chiral N-tosyl carbamate. 
 
S74. A cooled (-78 °C) solution of (triisopropylsilyl)acetylene (11.6 mL, 51.9 mmol) in THF (60 
mL) was treated with n-BuLi (1.6 M in hexanes, 36.4 mL, 58.3 mmol) and the suspension was 
stirred for 30 min at -78 °C. After addition of boron trifluoride diethyl etherate (7.24 mL, 58.3 
mmol), the mixture was stirred for 30 min and treated with a solution of (R)-epichlorohydrin 
(3.00g, 32.4 mmol) in THF (50 mL) slowly. The reaction was stirred at -78 °C for 3 hours and 
quenched by addition of sat. aq. NH4Cl. The mixture was transferred into a separatory funnel with 
diethyl ether (100 mL) and layers were separated. The aqueous layer was extracted with diethyl 
ether (100 mL X 3). The combined organic layers were washed by sat. aq. NaHCO3, brine, dried 
over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude mixture was 
purified via flash column chromatography (ethyl acetate in hexanes) to afford the desired product  
in 88% yield (7.86 g, 28.6 mmol) as a colorless oil. 
 
S75. A cooled (0 °C) solution of S74 (7.86g, 28.6 mmol) in dichloromethane (200 mL) was treated 
with powdered NaOH (4.00 g, 100 mmol) and was stirred for 1 hour while warming to room 
temperature. The reaction was quenched by addition of ice cooled H2O (100 mL). The mixture 
was transferred into a separatory funnel and layers were separated. The aqueous layer was 
extracted with dichloromethane (100 mL X 3). The combined organic layers were washed with 





















The crude mixture was purified via flash column chromatography (ethyl acetate in hexanes) to 
afford the desired product  in 79% yield (5.40 g, 22.6 mmol) as a colorless oil. 
 
S76. To an oven-dried flask equipped with a stir bar was added  copper(I) cyanide (90 mg, 1.0 
mmol, 0.05 equiv.), THF (60 mL) and S75 (5.40 g , 22.6 mmol, 1.0 equiv.). The reaction flask was 
cooled to -78 °C and 3-butenylmagnesium bromide (0.5 M, 60 mL, 30 mmol, 1.0 equiv.) was 
added dropwise. The reaction was stirred at -78 °C for 1 hours and allowed to warm up to room 
temperature. The reaction was quenched by addition of sat. aq. NH4Cl. The mixture was transferred 
into a separatory funnel with diethyl ether (100 mL) and layers were separated. The aqueous layer 
was extracted with diethyl ether (100 mL X 3). The combined organic layers were washed by 
brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified via flash column chromatography (ethyl acetate in hexanes) to afford the 
desired homoallylic alcohol product  in 78% yield (4.96 g, 17.7 mmol) as a colorless oil. 
 
(-)-(S)-1-(triisopropylsilyl)oct-7-en-1-yn-4-yl tosylcarbamate (107) was synthesized following 
general procedure for making N-tosyl carbamate (vide supra) using homoallylic alcohol S76 
(4.96g, 17.7 mmol) in 81% yield (6.87 g, 14.4 mmol) as a colorless gel.  
 
44% overall yield over 4 steps. 
 
 
(-)-(S)-1-(triisopropylsilyl)oct-7-en-1-yn-4-yl tosylcarbamate (107). 1H NMR (500 MHz, 






16.9, 10.3, 6.6 Hz, 1H), 4.98 – 4.88 (m, 2H), 4.81 (ddd, J = 9.9, 7.3, 5.0 Hz, 1H), 2.56 – 2.44 (m, 
2H), 2.44 (s, 3H), 2.01-1.97 (m, 2H), 1.89 – 1.79 (m, 1H), 1.76-1.72 (m, 1H), 1.08 – 0.93 (m, 
21H). 13C NMR (126 MHz, CDCl3) δ 150.0, 145.2, 137.1, 135.6, 129.7, 128.5, 115.5, 102.5, 83.9, 
75.2, 32.0, 29.1, 25.2, 21.8, 18.7, 11.3. HRMS (ESI) m/z calculated for C25H40NO4SSi [M+H]+: 




(108a). N-tosyl carbamate 107 reacted following general procedure (vide supra) of Pd(II)/ (±)-
MeO SOX catalyzed allylic C-H amination for syn-1,3 oxazinanone on a 3 mmol scale.  
Run 1 (crude: 77%, 19:1 dr; isolated: 974.7 mg , 2.05 mmol, 68.3%, >20:1 dr);  
Run 2 (crude: 79%, 18:1 dr; isolated: 1.024 g, 2.15 mmol, 71.8%  >20:1 dr),  
Average yield: 70%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 5.89 (ddd, 
J = 16.9, 10.6, 4.6 Hz, 1H), 5.43 (dd, J = 10.6, 1.6 Hz, 1H), 5.39 (dd, J = 17.0, 1.7 Hz, 1H), 5.27-
5.23 (m, 1H), 4.55 – 4.45 (m, 1H), 2.71 (dd, J = 16.9, 4.3 Hz, 1H), 2.55 (dd, J = 16.9, 8.3 Hz, 1H), 
2.43 (s, 3H), 2.32-2.28 (m, 1H), 2.06 (ddd, J = 14.1, 12.0, 5.2 Hz, 1H), 1.04-0.96 (m, 21H).13C 
NMR (126 MHz, CDCl3) δ 148.0, 145.2, 135.6, 135.5, 129.5, 129.4, 118.8, 101.3, 85.1, 73.7, 56.2, 
31.9, 26.4, 21.8, 18.7, 11.2. HRMS (ESI) m/z calculated for C25H38NO4SiS [M+H]+: 476.2291, 












(+)- tert-butyl ((3S,5R)-5-hydroxyoct-1-en-7-yn-3-yl)carbamate (109a). To a 1 dram vial 
(equipped with Teflon cap) under argon was added 108a (475.7mg, 1.0 mmol), MeOH (0.5 mL), 
THF (0.2 mL) and Mg powder27 (120 mg, 5.0 mmol, 5.0 equiv.). The reaction was sonicated for 1 
hour under room temperature. The mixture was transferred into a separatory funnel with ethyl 
acetate (5 mL) and layers were separated. The aqueous layer was extracted with ethyl acetate (10 
mL X 3). The combined organic layers were washed by brine, dried over anhydrous MgSO4 
filtered and concentrated under reduced pressure into a 20 mL vial. The crude product S77 was 
carried through the next step without purification. 
 
To the 20 mL vial with the crude product S77 was added a stir bar, CH2Cl2 (5 mL), Boc2O (436.4 
mg, 2.0 mmol, 2.0 equiv.) and DMAP (24.4 mg, 0.2 mmol, 0.2 equiv.). The reaction was stirred 
at room temperature overnight. The reaction mixture was concentrated under reduced pressure and 





    Mg powder, 

















To a 20 mL vial was added a stir bar, the S78, Cs2CO328 (163mg, 0.5 mmol. 0.5 equiv.) and MeOH 
(10 mL, 0.1M). The reaction was stirred under room temperature overnight. The mixture was 
transferred into a separatory funnel with diethyl ether (5 mL) and layers were separated. The 
aqueous layer was extracted with diethyl ether (10 mL X 3). The combined organic layers were 
washed by brine, dried over anhydrous MgSO4 filtered and concentrated under reduced pressure 
into a 20 mL vial. The crude product S79 was carried through the next step without purification. 
 
To the 20 mL vial charged S79 was added a stir bar, THF (2 mL, 0.5M) and TBAF (1.0 M in THF, 
2.0 mL, 2.0 equiv.). The reaction was stirred under room temperature for 2 hours. Upon 
completion, the reaction mixture was transferred into a separatory funnel with diethyl ether (5 mL) 
and layers were separated. The aqueous layer was extracted with diethyl ether (10 mL X 3). The 
combined organic layers were washed by brine, dried over anhydrous MgSO4 filtered and 
concentrated under reduced pressure. The crude mixture was purified via flash column 
chromatography (ethyl acetate in hexanes) to afford the 109a  in 71% yield (Run 1: 73.9% yield 
(176.8 mg, 0.739 mmol); Run 2: 68.7% yield (164.4 mg, 0.687 mmol)) over 4 steps as a colorless 
oil. 
 
1H NMR (500 MHz, Chloroform-d) δ 5.76 (ddd, J = 17.3, 10.5, 5.0 Hz, 1H), 5.13 (ddd, J = 17.3, 
1.8, 0.9 Hz, 1H), 5.06 (app dt, J = 10.5, 1.3 Hz, 1H), 4.71 (d, J = 9.1 Hz, 1H), 4.37-4.33 (m, 1H), 
3.85 – 3.79 (m, 1H), 3.76 (d, J = 7.5 Hz, 1H), 2.39 (ddd, J = 16.6, 6.0, 2.7 Hz, 1H), 2.30 (ddd, J = 
16.6, 6.6, 2.7 Hz, 1H), 1.96 (t, J = 2.7 Hz, 1H), 1.67 (ddd, J = 13.9, 10.5, 3.5 Hz, 1H), 1.58 (ddd, 
J = 13.7, 10.4, 2.6 Hz, 1H), 1.38 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 156.9, 138.2, 114.9, 81.2, 
80.3, 70.6, 66.5, 49.3, 42.2, 28.5, 27.0. HRMS (ESI) m/z calculated for C13H21NO3Na [M+Na]+: 
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262.1419, found 262.1428. Optical rotation: [α]23D = +10.24 (c = 0.99, CHCl3). 1H NMR and 13C 




(108b). N-tosyl carbamate (-)-107 reacted following a modified general procedure of Pd(II)/ (±)-
CF3 SOX catalyzed allylic C-H amination for syn-1,3 oxazinanone using 2,5 
dimethylbenzoquinone (2,5 DMBQ) (1.2 equiv) in 3 mmol scale.  
Run 1 (crude: 83%, 4.0:1 dr; isolated: 900.5 mg, 1.89 mmol, 63.1 %, >20:1 dr);  
Run 2 (crude: 78%, 4.2:1 dr; isolated: 859.1 mg, 1.81 mmol, 59.5 %  >20:1 dr),  
Average yield: 61%, >20:1 dr (syn:anti).  
Slightly lower yield was achieved using the  general procedure (Pd(II) / (±)-CF3 SOX / BQ 
condition) with addition of 10% Ph2P(O)OH (0.2 mmol scale):  
(crude: 69%, 5.2:1 dr; isolated: 52.4 mg, 0.110 mmol, 55.1 %, >20:1 dr); 
 
1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.5 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 5.62 (ddd, 
J = 17.5, 10.2, 7.6 Hz, 1H), 5.37 (app d, J = 17.0 Hz, 1H), 5.26 (app d, J = 10.1 Hz, 1H), 4.99 (app 
q, J = 8.1 Hz, 1H), 4.38 (dddd, J = 10.1, 8.6, 4.6, 2.8 Hz, 1H), 2.75 (dd, J = 16.9, 4.6 Hz, 1H), 2.62 
– 2.51 (m, 2H), 2.42 (s, 3H), 1.93 (ddd, J = 14.2, 10.2, 8.9 Hz, 1H), 1.07-0.97 (m, 21H). 13C NMR 
(126 MHz, CDCl3) δ 149.7, 145.1, 136.7, 135.8, 129.7, 129.3, 118.8, 101.2, 85.2, 74.5, 58.4, 34.5, 
25.7, 21.8, 18.7, 11.3. HRMS (ESI) m/z calculated for C25H38NO4SiS [M+H]+: 476.2291, found 








(-)-tert-butyl ((3R,5R)-5-hydroxyoct-1-en-7-yn-3-yl)carbamate (109b) was synthesized 
following the same procedure of 109a using 108b in 68% yield (Run 1 66.2% yield (158.4 mg, 
0.662 mmol); Run 2 69.6% yield (166.6 mg, 0.696 mmol)) over 4 steps as a colorless oil. 
1H NMR (500 MHz, Chloroform-d) δ 5.77 (ddd, J = 16.8, 10.3, 6.1 Hz, 1H), 5.20 (app dt, J = 
17.2, 1.3 Hz, 1H), 5.12 (app dt, J = 10.4, 1.3 Hz, 1H), 4.75-4.71 (m, 1H), 4.26-4.22 (m, 1H), 3.87 
(dddd, J = 8.4, 5.8, 5.8, 4.1 Hz, 1H), 2.60-2.47 (m, 1H), 2.47 – 2.35 (m, 2H), 2.05 (t, J = 2.6 Hz, 
1H), 1.81-1.77 (m, 1H), 1.76 – 1.69 (m, 1H), 1.43 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 155.7, 
138.6, 115.3, 80.6, 79.8, 71.2, 67.9, 51.1, 41.4, 28.5, 27.7. HRMS (ESI) m/z calculated for 
C13H21NO3Na [M+Na]+: 262.1419, found 262.1423. Optical rotation: [α]23D = -18.8 (c = 1.01, 
CHCl3). 1H NMR and 13C NMR match literature report.17 
 
Stereodivergent Synthesis of Chiral Diamino Alcohol Motif in 8 Diastereomers 
Synthesis of amino ketones (110 and ent-110):  
 
 
(+)-tert-butyl (S)-(3-oxo-1-phenylhept-6-en-2-yl)carbamate (110) was synthesized via weinreb 
amide substitution with the Grignard reagent 3-butenylmagnesium bromide following a literature 
procedure for a similar compound29 using boc-(L)-phenylalanine (2.65g, 10 mmol) in 86% (2.62g, 








1H NMR (500 MHz, Chloroform-d) δ 7.29 (dd, J = 8.1, 6.5 Hz, 2H), 7.23 (app t, J = 7.5 Hz, 1H), 
7.14 (d, J = 7.0 Hz, 2H), 5.73 (ddt, J = 16.8, 10.2, 6.5 Hz, 1H), 5.11 (d, J = 7.8 Hz, 1H), 5.02 – 
4.93 (m, 2H), 4.53 (app q, J = 7.0 Hz, 1H), 3.05 (dd, J = 13.9, 6.8 Hz, 1H), 2.95 (dd, J = 13.9, 6.6 
Hz, 1H), 2.51 (ddd, J = 17.6, 8.5, 6.4 Hz, 1H), 2.43 (dd, J = 17.6, 7.2 Hz, 1H), 2.35 – 2.20 (m, 
2H), 1.41 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 208.6, 155.3, 136.9, 136.3, 129.4, 128.8, 127.1, 
115.6, 80.0, 60.2, 40.1, 38.0, 28.4, 27.4.  HRMS (ESI) m/z calculated for C18H26NO3 [M+H]+: 
304.1913, found 304.1901. Optical rotation: [α]23D = +54.1 (c = 0.99, CHCl3). 
 
 
(-)-tert-butyl (R)-(3-oxo-1-phenylhept-6-en-2-yl)carbamate (ent-110). 
1H NMR ,13C NMR match 110 . HRMS (ESI) m/z calculated for C18H26NO3 [M+H]+: 304.1913, 
found 304.1905. Optical rotation: [α]23D = -53.8 (c = 0.90, CHCl3). 
 
1. Synthesis of amino alcohols (111, ent-111, 112, ent-112):  
 
(-)-tert-butyl ((2S,3R)-3-hydroxy-1-phenylhept-6-en-2-yl)carbamate (111). 
Following literature procedure for diastereoselective reduction of a-amino ketone to anti 1,2 
amino alcohol.30 To a solution of LiAl(Ot-Bu)3H (1.017g, 4.0 mmol, 2.0 equiv.)  in EtOH (12 mL) 
at -78 °C was added dropwise an ice cooled solution of 110 (606.8 mg, 2.0 mmol, 1.0 equiv.) in 
EtOH (16 mL). After 2 hours, the reaction was quenched with 10% citric acid solution. The 









separated. The aqueous layer was extracted with ethyl acetate (25 mL X 3). The combined organic 
layers were dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The 
crude mixture was purified via a silica plug (ethyl acetate in hexanes) to afford the desired product 
33 in 92% yield (562.5 mg, 1.84 mmol) as a white solid (>20:1 anti : syn). Relative stereochemistry 
was confirmed by formation of cyclic carbamate (vide infra).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.32 – 7.27 (m, 2H), 7.24 – 7.18 (m, 3H), 5.85 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H), 5.07 (app d, J = 17.1, 1H), 4.99 (app d, J = 10.2 Hz, 1H), 4.66 – 4.55 (m, 
1H), 3.87 – 3.79 (m, 1H), 3.77 – 3.67 (m, 1H), 2.89 (dd, J = 14.2, 4.8 Hz, 1H), 2.79 – 2.70 (m, 
2H), 2.31 (dq, J = 14.4, 7.0 Hz, 1H), 2.21 – 2.10 (m, 1H), 1.66 – 1.51 (m, 2H), 1.35 (s, 9H).13C 
NMR (126 MHz, CDCl3) δ 156.4, 138.4, 138.3, 129.4, 128.6, 126.5, 115.3, 79.8, 73.8, 56.9, 35.7, 
32.7, 30.5, 28.4. HRMS (ESI) m/z calculated for C18H28NO3 [M+H]+: 306.2069, found 306.2056. 
Optical rotation: [α]23D = -28.5 (c = 0.99, CHCl3). 
 
 
(+)-tert-butyl ((2R,3S)-3-hydroxy-1-phenylhept-6-en-2-yl)carbamate (ent-111). 
Following the same procedure of 111 using ent-110. The desired product ent-111 was afforded in 
90% yield (550.9 mg, 1.80 mmol) as a white solid (>20:1 anti : syn). Relative stereochemistry was 
confirmed by formation of cyclic carbamate (vide infra).  
 
1H NMR ,13C NMR match 111. HRMS (ESI) m/z calculated for C18H28NO3 [M+H]+: 306.2069, 








(-)-tert-butyl ((2S,3S)-3-hydroxy-1-phenylhept-6-en-2-yl)carbamate (112). 
Following literature procedure for diastereoselective reduction of a-amino ketone to syn- 1,2 
amino alcohol.30 (S)-Alpine-Hydride solution was freshly prepared according to H. C. Brown’s 
procedure:31 To a flamed dried 100 mL round bottom flask with stir bar was added commercial 
(S)-Alpine-Borane solution (0.5 M in THF from Sigma Aldrich, 8.0 mL, 4.0 mmol). The flask was 
cooled to -78 °C and t-BuLi solution (1.7 M in pentane, 4.7 mL, 8.0 mmol) was added dropwise. 
The reaction was stirred at -78 °C for 5 min and allowed to warm up to room temperature until the 
reaction turned a homogenous and colorless solution from a bright yellow heterogeneous mixture. 
Freshly prepared (S)-Alpine-Hydride solution (cooled to -78 °C) was added dropwise to a solution 
of 110 (606.8 mg, 2.0 mmol, 1.0 equiv.) at -78 °C, and the reaction was stirred at 78 °C for 1 hour. 
The reaction was quenched with 10% citric acid solution. The mixture was transferred into a 
separatory funnel with diethyl ether (30 mL) and layers were separated. The aqueous layer was 
extracted with diethyl ether (25 mL X 3). The combined organic layers were dried over anhydrous 
MgSO4, filtered and concentrated under reduced pressure. The crude mixture was purified via flash 
column chromatography (ethyl acetate in hexanes) to afford the desired product 112 in 88% yield 
(545.4 mg, 1.79 mmol) as a white solid (>20:1 syn : anti). Relative stereochemistry was confirmed 
by formation of cyclic carbamate (vide infra). 
 
1H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.27 (m, 2H), 7.24 – 7.18 (m, 3H), 5.77 (ddt, J = 
16.9, 10.2, 6.7 Hz, 1H), 4.99 (app d, J = 17.1, 1H), 4.93 (app d, J = 10.2 Hz, 1H), 4.89-4.85 (m, 
1H), 3.76-3.72 (m, 1H), 3.59 (ddd, J = 7.9, 5.1, 2.3 Hz, 1H), 2.96 – 2.79 (m, 2H), 2.19 (s, 1H), 






156.3, 138.6, 138.3, 129.4, 128.6, 126.5, 115.2, 79.5, 71.4, 55.7, 38.7, 33.7, 30.2, 28.5. HRMS 
(ESI) m/z calculated for C18H28NO3 [M+H]+: 306.2069, found 306.2068. Optical rotation: [α]23D 
= -22.6 (c = 1.04, CHCl3). 
 
 
(+)-tert-butyl ((R,3R)-3-hydroxy-1-phenylhept-6-en-2-yl)carbamate (ent-112) was prepared 
following the same procedure as 112 using ent-110 and (R)-Alpine-Hydride solution (prepared 
using the same procedure31 as (S)-Alpine-Hydride using commercial (R)-Alpine-Borane solution 
(0.5 M in THF from Sigma Aldrich)) in 86% yield (524.7 mg, 1.72 mmol) as a white solid (>20:1 
syn : anti). Relative stereochemistry was confirmed by formation of cyclic carbamate (vide infra). 
 
1H NMR ,13C NMR match 112. HRMS (ESI) m/z calculated for C18H28NO3 [M+H]+: 306.2069, 
found 306.2056. Optical rotation: [α]23D = +22.8 (c = 0.89, CHCl3). 
 
Confirm relative stereochemistry of amino alcohols (111/ent-111/112/ent-112).  
Figure 17. Confirm relative stereochemistry of amino alcohols. 
 
To confirm the relative stereochistry of Boc protected amino alcohol (111/ent-111/112/ent-112). 
They were transformed into corresponding cyclic carbamates following literature procedure:32 To 












































was added a 0 °C solution of Boc protected amino alcohol (111/ent-111/112/ent-112) (152.7 mg, 
0.5 mmol,1.0 equiv.) in DMF (1 mL). After 2 hours, the reaction was quenched with 0.5 M HCl 
solution. The mixture was transferred into a separatory funnel with diethyl ether (10 mL) and 
layers were separated. The aqueous layer was extracted with diethyl ether (10 mL X 3). The 
combined organic layers were washed by brine, dried over anhydrous MgSO4, filtered and 
concentrated under reduced pressure. The crude reaction were analyzed by 1H NMR. The relative 
stereochemistry is confirmed according to literature report, based on coupling constant of 
oxazolidinone.33 
   
(J =7.4 Hz) 
S82. 1H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.31 (m, 2H), 7.29 – 7.25 (m, 1H), 7.18 – 7.14 
(m, 2H), 5.92 – 5.77 (m, 1H), 5.14 – 5.02 (m, 2H), 4.91 (s, 1H), 4.69 (ddd, J = 10.2, 7.4, 3.8 Hz, 
1H), 3.96 (ddd, J = 11.1, 7.4, 3.6 Hz, 1H), 2.87 (dd, J = 13.4, 3.6 Hz, 1H), 2.67 (dd, J = 13.4, 11.1 
Hz, 1H), 2.44 – 2.33 (m, 1H), 2.21 (ddtt, J = 14.3, 8.4, 7.0, 1.3 Hz, 1H), 1.98 (dddd, J = 14.0, 10.2, 
8.7, 5.2 Hz, 1H), 1.74 (dddd, J = 14.0, 9.1, 7.0, 3.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 158.6, 
136.9, 136.7, 129.2, 129.1, 127.3, 116.2, 79.2, 56.9, 36.5, 30.1, 28.9. HRMS (ESI) m/z calculated 
for C14H18NO2 [M+H]+: 232.1338, found 232.1335. 
 
(J =7.4 Hz) 









     
(J = 5.1-5.4 Hz) 
S83. 1H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.30 (m, 2H), 7.30 – 7.24 (m, 1H), 7.19 – 7.14 
(m, 2H), 5.72 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H), 5.67 (br s, 1H), 5.05 – 4.94 (m, 2H), 4.30 (dt, J = 
8.3, 5.1 Hz, 1H), 3.67 (tdd, J = 6.8, 5.4, 1.0 Hz, 1H), 2.84 (d, J = 6.9 Hz, 2H), 2.22 – 2.05 (m, 2H), 
1.77 (dtd, J = 14.1, 8.5, 5.7 Hz, 1H), 1.57 (dddd, J = 13.8, 9.0, 6.9, 4.6 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 158.8, 136.9, 136.1, 129.2, 129.1, 127.4, 115.9, 81.3, 59.2, 41.7, 33.9, 28.9. 
HRMS (ESI) m/z calculated for C14H18NO2 [M+H]+: 232.1338, found 232.1335. 
 
(J = 5.1-5.4 Hz) 
ent-S83. Spectra match S83.  
 
 
Synthesis of chiral diamino alcohol motifs 
General procedure for synthesizing N-tosyl carbamate from Boc protected amino alcohol (111/ent-
111/112/ent-112): A flame dried 100 mL round bottom flask under argon was charged with a stir 
bar, Boc protected amino alcohol (111/ent-111/112/ent-112) (1.0 mmol), and THF (3 mL). The 
flask was cooled to 0 °C and p-toluenesulfonyl isocyanate (0.15 mL, 1.0 mmol) was added 
dropwise. The reaction was stirred for 30 min and then quenched with sat. aq. NH4Cl. The mixture 











was dried over MgSO4, filtered, and concentrated in vacuo. Purification by flash silica plug (30% 




phenylethyl)carbamate (113a). N-tosyl carbamate was synthesized from (-)-111 in quantitative 
yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/MeO-SOX catalyzed 
allylic C-H amination for anti-1,3 oxazinanone to afford  (-)-113a. 
Run 1 (crude:86%, 9.3:1 dr; isolated: 70.4 mg, 0.141 mmol, 70.3%, >20:1 dr);  
Run 2 (crude:88%, 9.0:1 dr; isolated: 71.3 mg, 0.142 mmol, 71.2%, >20:1 dr);  
Run 3 (crude:90%, 8.9:1 dr; isolated: 72.8 mg, 0.145 mmol, 72.7%, >20:1 dr).  
Average yield: 71%, >20:1 dr (anti:syn).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.30 – 
7.25 (m, 2H), 7.24 – 7.19 (m, 1H), 7.13 (d, J = 7.0 Hz, 2H), 5.84 (ddd, J = 17.1, 10.5, 4.8 Hz, 1H), 
5.40 (dd, J = 10.6, 1.5 Hz, 1H), 5.36 (app d, J = 17.5 Hz, 1H), 5.22 (br s, 1H), 4.55 (br d, J = 9.4 
Hz, 1H), 4.36-4.32 (m, 1H), 3.94-3.90 (m, 1H), 2.98 (dd, J = 14.1, 4.6 Hz, 1H), 2.79 (dd, J = 14.1, 
8.7 Hz, 1H), 2.44 (s, 3H), 2.15 – 1.95 (m, 2H), 1.32 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 155.3, 
148.2, 145.3, 136.6, 135.5, 135.3, 129.5, 129.5, 129.4, 128.8, 126.9, 119.0, 80.1, 77.1 56.2, 53.7, 
35.6, 30.1, 28.3, 21.8. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 501.2059, found 











phenylethyl)carbamate (113b). N-tosyl carbamate was synthesized from (-)-111 in quantitative 
yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/CF3-SOX catalyzed allylic 
C-H amination for syn-1,3 oxazinanone to afford  (-)-113b. 
Run 1 (crude:70%, 6.3:1 dr; isolated: 56.8 mg, 0.113 mmol, 56.7%, >20:1 dr);  
Run 2 (crude:66%, 6.6:1 dr; isolated: 52.4 mg, 0.105 mmol, 52.3%, >20:1 dr);  
Run 3 (crude:68%, 6.6:1 dr; isolated: 53.6 mg, 0.107 mmol, 53.5%, >20:1 dr).  
Average yield: 54%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.99 (d, J = 8.4 Hz, 2H), 7.36 – 7.29 (m, 4H), 7.27 – 7.21 
(m, 1H), 7.20 – 7.15 (m, 2H), 5.67 – 5.54 (m, 1H), 5.38 (app d, J = 17.0 Hz, 1H), 5.28 (app d, J = 
10.1 Hz, 1H), 4.93 (app q, J = 8.3, 1H), 4.61 – 4.53 (m, 1H), 4.25-4.21 (m, 1H), 4.02-3.98 (m, 
1H), 3.01 (dd, J = 14.2, 4.4 Hz, 1H), 2.82 (dd, J = 14.3, 8.8 Hz, 1H), 2.46 (s, 3H), 2.38 (dd, J = 
14.1, 7.8 Hz, 1H), 1.84 (ddd, J = 14.3, 10.9, 9.6 Hz, 1H), 1.35 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 155.4, 150.1, 145.3, 136.7, 135.9, 129.9, 129.6, 129.4, 129.4, 128.9, 127.0, 119.2, 80.3, 
77.7, 59.0, 53.1, 35.6, 33.3, 28.5, 21.9. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 











phenylethyl)carbamate (114a). N-tosyl carbamate was synthesized from (-)-112 in quantitative 
yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/MeO-SOX catalyzed 
allylic C-H amination for anti-1,3 oxazinanone to afford  (+)-114a. 
 
Run 1 (crude:85%, 3.0:1 dr; isolated: 58.4 mg, 0.117 mmol, 58.3%, >20:1 dr);  
Run 2 (crude:85%, 3.5:1 dr; isolated: 60.7 mg, 0.121 mmol, 60.6%, >20:1 dr);  
Run 3 (crude:86%, 3.4:1 dr; isolated: 62.0 mg, 0.124 mmol, 71.9%, >20:1 dr).  
Average yield: 60%, >20:1 dr (anti:syn).  
1H NMR (500 MHz, Chloroform-d) δ 7.92 (d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.25 (d, 
J = 8.6 Hz, 2H), 7.22 – 7.18 (m, 1H), 7.18 – 7.14 (m, 2H), 5.77 (ddd, J = 16.9, 10.5, 5.0 Hz, 1H), 
5.30 (app d, J = 10.5 Hz, 1H), 5.23 (dd, J = 17.0, 1.5 Hz, 1H), 5.21 – 5.16 (m, 1H), 4.64 (br d, J = 
9.9 Hz, 1H), 4.34 (br d, J = 11.3 Hz, 1H), 3.90 (app q, J = 7.2 Hz, 1H), 2.88 (d, J = 8.0 Hz, 2H), 
2.44 (s, 3H), 2.16 – 2.03 (m, 1H), 1.89 (dt, J = 14.4, 2.6 Hz, 1H), 1.37 (s, 9H). 13C NMR (126 
MHz, CDCl3) δ 155.8, 148.6, 145.3, 137.0, 135.5, 135.4, 129.7, 129.6, 129.3, 128.7, 126.9, 118.7, 
80.1, 75.6, 55.8, 53.7, 38.3, 30.0, 28.4, 21.8. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 
















phenylethyl)carbamate (114b). N-tosyl carbamate was synthesized from (-)-112 in quantitative 
yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/CF3-SOX catalyzed allylic 
C-H amination for syn-1,3 oxazinanone to afford  (+)-114b. 
Run 1 (crude:89%, 12:1 dr; isolated: 73.6 mg, 0.147 mmol, 73.5%, >20:1 dr);  
Run 2 (crude:85%, 13:1 dr; isolated: 75.2 mg, 0.150 mmol, 75.1%, >20:1 dr);  
Run 3 (crude:85%, 13:1 dr; isolated: 70.3 mg, 0.140 mmol, 70.2%, >20:1 dr).  
Average yield: 73%, >20:1 dr (syn:anti).  
 
1H NMR (500 MHz, Chloroform-d) δ 7.94 (d, J = 8.3 Hz, 2H), 7.35 – 7.22 (m, 6H), 7.20 – 7.17 
(m, 2H), 5.54 (ddd, J = 17.6, 10.1, 8.0 Hz, 1H), 5.34 (app d, J = 17.0 Hz, 1H), 5.23 (app d, J = 
10.1 Hz, 1H), 4.83 (dt, J = 10.2, 8.0 Hz, 1H), 4.70 (d, J = 10.0 Hz, 1H), 4.19 – 4.12 (m, 1H), 3.98 
(q, J = 9.0 Hz, 1H), 2.95-2.84 (m, 2H), 2.45 (s, 3H), 2.21 (ddd, J = 14.5, 7.9, 2.1 Hz, 1H), 1.85 
(app dt, J = 14.4, 10.8 Hz, 1H), 1.36 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 155.7, 150.3, 145.1, 
136.9, 136.7, 135.9, 129.7, 129.4, 129.3, 128.9, 127.0, 119.1, 80.1, 75.7, 58.8, 53.3, 38.4, 33.2, 
28.4, 21.8. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 501.2059, found 501.2052. 












quantitative yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/MeO-SOX 
catalyzed allylic C-H amination for anti-1,3 oxazinanone to afford  (+)-115a. 
Run 1 (crude:86%, 9.1:1 dr; isolated: 72.0 mg, 0.144 mmol, 71.9%, >20:1 dr);  
Run 2 (crude:83%, 9.6:1 dr; isolated: 71.4 mg, 0.143 mmol, 71.3%, >20:1 dr);  
Run 3 (crude:83%, 9.3:1 dr; isolated: 68.0 mg, 0.136 mmol, 67.9%, >20:1 dr).  
Average yield: 70%, >20:1 dr (anti:syn).  
 
1H NMR ,13C NMR match 113a. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 501.2059, 




phenylethyl)carbamate (115b). N-tosyl carbamate was synthesized from (+)-ent-111 in 
quantitative yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/CF3-SOX 
catalyzed allylic C-H amination for syn-1,3 oxazinanone to afford  (+)-115b. 
Run 1 (crude:73%, 7.3:1 dr; isolated: 57.8 mg, 0.115 mmol, 57.7%, >20:1 dr);  
Run 2 (crude:70%, 7.7:1 dr; isolated: 56.2 mg, 0.112 mmol, 56.1%, >20:1 dr);  
Run 3 (crude:74%, 7.1:1 dr; isolated: 59.9 mg, 0.120 mmol, 59.8%, >20:1 dr).  
Average yield: 58%, >20:1 dr (syn:anti).  
 
1H NMR ,13C NMR match 113b. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 501.2059, 










phenylethyl)carbamate (116a). N-tosyl carbamate was synthesized from (+)-ent-112 in 
quantitative yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/MeO-SOX 
catalyzed allylic C-H amination for anti-1,3 oxazinanone to afford  (-)-116a. 
Run 1 (crude:80%, 3.4:1 dr; isolated: 52.0 mg, 0.104 mmol, 51.9%, >20:1 dr);  
Run 2 (crude:79%, 3.6:1 dr; isolated: 54.6 mg, 0.109 mmol, 54.5%, >20:1 dr);  
Run 3 (crude:79%, 3.6:1 dr; isolated: 54.9 mg, 0.110 mmol, 54.8%, >20:1 dr).  
Average yield: 54%, >20:1 dr (anti:syn).  
 
1H NMR ,13C NMR match 114a. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 501.2059, 




phenylethyl)carbamate (116b). N-tosyl carbamate was synthesized from (+)-ent-112 in 
quantitative yield. N-tosyl carbamate was reacted under general procedure of Pd(II)/CF3-SOX 
catalyzed allylic C-H amination for syn-1,3 oxazinanone to afford  (-)-116b. 













Run 2 (crude:84%, 14:1 dr; isolated: 69.7 mg, 0.139 mmol, 69.6%, >20:1 dr);  
Run 3 (crude:80%, 13:1 dr; isolated: 70.8 mg, 0.141 mmol, 70.7%, >20:1 dr).  
Average yield: 71%, >20:1 dr (syn:anti).  
 
1H NMR ,13C NMR match 114b. HRMS (ESI) m/z calculated for C26H33N2O6S [M+H]+: 501.2059, 
found 501.2050. Optical rotation: [α]23D = -18.6   (c = 1.01, CHCl3). 
 
Mechanistic Studies 
Reaction profile of Pd(OAc)2/(±)-MeO-SOX/2,5 DMBQ: 
Scheme 16. Pd(OAc)2/(±)-MeO SOX/2,5 DMBQ. 
 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-MeO SOX 
(6.9 mg, 0.02 mmol, 0.1 equiv), 2,5 DMBQ (2,5-dimethylbenzoquinone) (32.6 mg, 0.24 mmol, 
1.2 equiv), 2-methylhept-6-en-3-yl tosylcarbamate (S46) (0.2 mmol, 1.0 equiv), and 4-
nitroacetophenone (13.2 mg, 0.08 mmol, 0.4 equiv) as internal standard. Dichloroethane (0.3 
mmol, 0.67 M) was added and the vial was capped and heated to 45 °C. Aliquots (10 µL) were 
taken at the corresponding times from the reaction vial, and filtered through a silica plug with 
diethyl ether (0.6 mL) for HPLC analysis (Zorbax C-N, 3% isopropanol/hexanes, 1 mL/min, 35 
°C, 214 nm). The yields were determined by integration of the anti-(±)-62a (20.2 min) and syn-
(±)-62b (24.4 min) relative to the 4-nitroacetophenone internal standard peak (8.3 min) and 
corrected by a standard curve. Errors were calculated via propagation of the standard error of the 
mean for each set of rates. 
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Figure 18. Reaction profile for Pd(OAc)2/(±)-MeO-SOX/2,5 DMBQ condition. 
 
 
Reaction profile of Pd(OAc)2/(±)-CF3-SOX/BQ: 
Scheme 17. Pd(OAc)2/(±)-CF3-SOX/BQ. 
 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), (±)-CF3 SOX 
(7.6 mg, 0.02 mmol, 0.1 equiv), BQ (1,4-dibenzoquinone) (34./6 mg, 0.24 mmol, 1.6 equiv), 2-
methylhept-6-en-3-yl tosylcarbamate (S46) (0.2 mmol, 1.0 equiv), and 4-nitroacetophenone (13.2 
mg, 0.08 mmol, 0.4 equiv) as internal standard. Dichloroethane (0.3 mmol, 0.67 M) was added 
and the vial was capped and heated to 45 °C. Aliquots (10 µL) were taken at the corresponding 
times from the reaction vial, and filtered through a silica plug with diethyl ether (0.6 mL) for HPLC 
analysis (Zorbax C-N, 3% isopropanol/hexanes, 1 mL/min, 35 °C, 214 nm). The yields were 
determined by integration of the 62a (24.4) and 62b (20.2 min) relative to the 4-nitroacetophenone 
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internal standard peak (8.3 min) and corrected by a standard curve. Errors were calculated via 
propagation of the standard error of the mean for each set of rates. 
Figure 19. Reaction profile for Pd(OAc)2 /(±)-CF3-SOX/BQ condition. 
 
 








Pd(0) isomerization (Figure 12) 
To a ½ dram vial was added a stir bar, 62b (32.3 mg, 0.1 mmol, 1.0 equiv.), nitrobenzene (12.3 
mg, 1.0 equiv.) as internal standard. The vial was capped and placed on a heating aluminum block 
at  45 °C. SOX ligand + Pd2(dba)3 from a stock solution (1 mL, 0.01 mmol SOX ligand, 0.005 
mmol Pd2(dba)3 in 5 mL dichloroethane) was added through the cap. Aliquots (10 µL) were taken 
at the corresponding times from the reaction vial, and filtered through a silica plug with diethyl 
ether (0.6 mL) for HPLC analysis (Zorbax C-N, 3% isopropanol/hexanes, 1 mL/min, 35 °C, 214 
nm). The yield was determined by integration of the 62a (24.4 min) relative to the nitrobenzene 
internal standard peak (4.8 min) and corrected by a standard curve. Errors were calculated via 
propagation of the standard error of the mean for each set of rates.  
See Figure 12: 
Experiment 1 (blue triangle): (±)-MeO SOX was used; 
Experiment 2 (orange circle): (±)-CF3 SOX was used; 
Experiment 3 (purple square): No ligand is used (control experiment) 
 
Cross-over experiments (Figure 13) 
To a ½ dram vial was added a stir bar, Pd(OAc)2 (4.4 mg, 0.02 mmol, 0.1 equiv), SOX ligand 
(0.02 mmol, 0.1 equiv), quinone, S25 (0.2 mmol, 1.0 equiv), and 62b (6.5 mg, 0.02 mmol, 0.1 
equiv). Dichloroethane (0.3 mmol, 0.67 M) was added and the vial was capped and heated to 45 
°C. Aliquots (10 µL) were taken at the 24 hour from the reaction vial, and filtered through a silica 
plug with diethyl ether (0.6 mL) for HPLC analysis (Zorbax C-N, 2% isopropanol/hexanes, 1 
mL/min, 35 °C, 214 nm). The diastereomeric ratio was determined by ratio between integration of 





Experiment 1: (±)-MeO SOX and 2, 5 DMBQ were used.  
Dr(103:86) = 1:8.7 (syn : anti); dr (62b:62a) = 1:8.3 (syn : anti) 
Experiment 2: (±)-MeO SOX and BQ were used.  
dr (103:86) = 6.5:1 (syn : anti) (low conversion); dr (62b:62a) >20:1 (syn : anti) 
Experiment 3: (±)-CF3 SOX and BQ were used.  
dr (103:86) = 7.2:1 (syn : anti); dr (62b:62a) > 20:1 (syn : anti) 
Experiment 4: (±)-CF3 SOX and 2,5 DMBQ were used .  
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